Ste20-related protein kinases

ABSTRACT

The present invention relates to the novel kinase polypeptides STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

RELATED APPLICATIONS

[0001] The present application claims priority to U.S. Provisional Patent Application Serial No. 60/081,784 by Plowman and Martinez, entitled STE20-Related Protein kinases, filed Apr. 14, 1998 (Lyon & Lyon Docket No. 232/279), hereby incorporated by reference herein in its entirety, including any drawings, tables, or figures.

FIELD OF THE INVENTION

[0002] The present invention relates to novel kinase polypeptides, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

BACKGROUND OF THE INVENTION

[0003] The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to be or to describe prior art to the invention.

[0004] Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function.

[0005] The best characterized protein kinases in eukaryotes phosphorylate proteins on the hydroxyl moiety of serine, threonine and tyrosine residues. These kinases largely fall into two groups, those specific for phosphorylating serines and threonines, and those specific for phosphorylating tyrosines. Some kinases, referred to as “dual specificity” kinases, are able to phosphorylate on tyrosine as well as serine/threonine residues.

[0006] Protein kinases can also be characterized by their location within the cell. Some kinases are transmembrane receptor-type proteins capable of directly altering their catalytic activity in response to the external environment such as the binding of a ligand. Others are non-receptor-type proteins lacking any transmembrane domain. They can be found in a variety of cellular compartments from the inner surface of the cell membrane to the nucleus.

[0007] Many kinases are involved in regulatory cascades wherein their substrates may include other kinases whose activities are regulated by their phosphorylation state. Ultimately the activity of some downstream effector is modulated by phosphorylation resulting from activation of such a pathway.

[0008] Protein kinases are one of the largest families of eukaryotic proteins with several hundred known members. These proteins share a 250-300 amino acid domain that can be subdivided into 12 distinct subdomains that comprise the common catalytic core structure. These conserved protein motifs have recently been exploited using PCR-based cloning strategies leading to a significant expansion of the known kinases.

[0009] Multiple alignment of the sequences in the catalytic domain of protein kinases and subsequent parsimony analysis permits the segregation of related kinases into distinct branches or subfamilies including: tyrosine kinases, cyclic-nucleotide-dependent kinases, calcium/calmodulin kinases, cyclin-dependent kinases and MAP-kinases, serine-threonine kinase receptors, and several other less defined subfamilies.

SUMMARY OF THE INVENTION

[0010] Through the use of a targeted PCR cloning strategy and of a “motif extraction” bioinformatics script, mammalian members of the STE20-kinase family have been identified as part of the present invention. Multiple alignment and parsimony analysis of the catalytic domain of all of these STE20-family members reveals that these proteins cluster into 9 distinct subgroups. Classification in this manner has proven highly accurate not only in predicting motifs present in the remaining non-catalytic portion of each protein, but also in their regulation, substrates, and signaling pathways. The present invention includes the partial or complete sequence of new members of the STE20-family, their classification, predicted or deduced protein structure, and a strategy for elucidating their biologic and therapeutic relevance.

[0011] Thus, a first aspect of the invention features an isolated, enriched, or purified nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.

[0012] By “isolated” in reference to nucleic acid is meant a polymer of nucleotides conjugated to each other, including DNA and RNA, that is isolated from a natural source or that is synthesized. The isolated nucleic acid of the present invention is unique in the sense that it is not found in a pure or separated state in nature. Use of the term “isolated” indicates that a naturally occurring sequence has been removed from its normal cellular (i.e., chromosomal) environment. Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only nucleotide chain present, but that it is essentially free (about 90-95% pure at least) of non-nucleotide material naturally associated with it, and thus is distinguished from isolated chromosomes.

[0013] By the use of the term “enriched” in reference to nucleic acid is meant that the specific DNA or RNA sequence constitutes a significantly higher fraction (2-5 fold) of the total DNA or RNA present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. This could be caused by a person by preferential reduction in the amount of other DNA or RNA present, or by a preferential increase in the amount of the specific DNA or RNA sequence, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other DNA or RNA sequences present, just that the relative amount of the sequence of interest has been significantly increased. The term “significant” is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other nucleic acids of about at least 2 fold, more preferably at least 5 to 10 fold or even more. The term also does not imply that there is no DNA or RNA from other sources. The other source DNA may, for example, comprise DNA from a yeast or bacterial genome, or a cloning vector such as pUC19. This term distinguishes from naturally occurring events, such as viral infection, or tumor type growths, in which the level of one mRNA may be naturally increased relative to other species of mRNA. That is, the term is meant to cover only those situations in which a person has intervened to elevate the proportion of the desired nucleic acid.

[0014] It is also advantageous for some purposes that a nucleotide sequence be in purified form. The term “purified” in reference to nucleic acid does not require absolute purity (such as a homogeneous preparation). Instead, it represents an indication that the sequence is relatively more pure than in the natural environment (compared to the natural level this level should be at least 2-5 fold greater, e.g., in terms of mg/mL). Individual clones isolated from a cDNA library may be purified to electrophoretic homogeneity. The claimed DNA molecules obtained from these clones could be obtained directly from total DNA or from total RNA. The cDNA clones are not naturally occurring, but rather are preferably obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The construction of a cDNA library from mRNA involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection of the cells carrying the cDNA library. Thus, the process which includes the construction of a cDNA library from mRNA and isolation of distinct cDNA clones yields an approximately 10⁶-fold purification of the native message. Thus, purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

[0015] By a “kinase polypeptide” is meant 32 (preferably 40, more preferably 45, most preferably 55) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or the corresponding full-length amino acid sequence; 250 (preferably 255, more preferably 260, most preferably 270) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:105, or the corresponding full-length amino acid sequence; 27 (preferably 30, more preferably 40, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:18; 16 (preferably 20, more preferably 25, most preferably 35) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, or SEQ ID NO:103 or the corresponding full-length amino acid sequence; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99, 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101, or the corresponding full-length amino acid sequence; 78 (preferably 80, more preferably 85, most preferably 90) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:107 or functional derivatives thereof as described herein. For sequences for which the full-length sequence is not given, the remaining sequences can be determined using methods well-known to those in the art and are intended to be included in the invention. In certain aspects, polypeptides of 100, 200, 300 or more amino acids are preferred. The kinase polypeptide can be encoded by a full-length nucleic acid sequence or any portion of the full-length nucleic acid sequence, so long as a functional activity of the polypeptide is retained, not to include fragments containing only amino acids 1-22 of SEQ ID NO:13 or only amino acids 1-33 of SEQ ID NO:107.

[0016] The amino acid sequence will be substantially similar to the sequence shown in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequence, or fragments thereof, not to include fragments consisting only of the amino acid sequences 1-22 of SEQ ID NO:13 or 1-33 of SEQ ID NO:107. A sequence that is substantially similar to the sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107 will preferably have at least 90% identity (more preferably at least 95% and most preferably 99-100%) to the sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID N=:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107.

[0017] By “identity” is meant a property of sequences that measures their similarity or relationship. Identity is measured by dividing the number of identical residues by the total number of residues and gaps and multiplying the product by 100. “Gaps” are spaces in an alignment that are the result of additons or deletions of amino acids. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved, and have deletions, additions, or replacements, may have a lower degree of identity. Those skilled in the art will recognize that several computer programs are available for determining sequence identity using standard parameters, for example Blast (Altschul, et al. (1997) Nucleic Acids Res. 25:3389-3402), Blast2 (Altschul, et al. (1990) J. mol. biol. 215:403-410), and Smith-Waterman (Smith, et al. (1981) J. Mol. Biol. 147:195-197).

[0018] In preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding a kinase polypeptide comprising a nucleotide sequence that: (a) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide; (d) encodes a kinase polypeptide having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more, but not all, of the following segments of amino acid residues: 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489 or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 1-22, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 284-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-872, or 873-1227 of SEQ ID NO:105, or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (e) is the complement of the nucleotide sequence of (d); (f) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31; SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107 from amino acid residues 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489, or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-872, or 873-1227 of SEQ ID NO:105,or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (g) is the complement of the nucleotide sequence of (f);(h) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more of the domains selected from the group consisting of a N-terminal domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail; or (i) is the complement of the nucleotide sequence of (h).

[0019] The term “complement” refers to two nucleotides that can form multiple favorable interactions with one another. For example, adenine is complementary to thymine as they can form two hydrogen bonds. Similarly, guanine and cytosine are complementary since they can form three hydrogen bonds. A nucleotide sequence is the complement of another nucleotide sequence if all of the nucleotides of the first sequence are complementary to all of the nucleotides of the second sequence.

[0020] The term “domain” refers to a region of a polypeptide which contains a particular function. For instance, N-terminal or C-terminal domains of signal transduction proteins can serve functions including, but not limited to, binding molecules that localize the signal transduction molecule to different regions of the cell or binding other signaling molecules directly responsible for propagating a particular cellular signal. Some domains can be expressed separately from the rest of the protein and function by themselves, while others must remain part of the intact protein to retain function. The latter are termed functional regions of proteins and also relate to domains.

[0021] The term “N-terminal domain” refers to the extracatalytic region located between the initiator methionine and the catalytic domain of the protein kinase. The N-terminal domain can be identified following a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the N-terminal boundary of the catalytic domain. Depending on its length, the N-terminal domain may or may not play a regulatory role in kinase function. An example of a protein kinase whose N-terminal domain has been shown to play a regulatory role is PAK65, which contains a CRIB motif used for Cdc42 and rac binding (Burbelo, P.D. et al. (1995) J. Biol. Chem. 270, 29071-290740).

[0022] The N-terminal domain spans amino acid residues 1-21 of the sequence set forth in SEQ ID NO:5, amino acid residues 1-31 of the sequence set forth in SEQ ID NO:6, amino acid residues 1-22 of the sequence set forth in SEQ ID NO:13, amino acid residues 1-13 of the sequence set forth in SEQ ID NO:18, amino acid residues 1-21 of the sequence set forth in SEQ ID NO:22, amino acid residues 1-25 of the sequence set forth in SEQ ID NO:24, amino acid residues 1-51 of the sequence set forth in SEQ ID NO:29, amino acid residues 1-25 of the sequence set forth in SEQ ID NO:31, amino acid residues 1-57 of the sequence set forth in SEQ ID NO:99, amino acid residues 1-52 of the sequence set forth in SEQ ID NO:103, amino acid residues 1-24 of the sequence set forth in SEQ ID NO:105, or amino acid residues 1-33 of the sequence set forth in SEQ ID NO:107.

[0023] The term “catalytic domain” refers to a region of the protein kinase that is typically 25-300 amino acids long and is responsible for carrying out the phosphate transfer reaction from a high-energy phosphate donor molecule such as ATP or GTP to itself (autophosphorylation) or to other proteins (exogenous phosphorylation). The catalytic domain of protein kinases is made up of 12 subdomains that contain highly conserved amino acid residues, and are responsible for proper polypeptide folding and for catalysis. The catalytic domain can be identified following a Smith-Waterman alignment of the protein sequence against the non-redundant protein database.

[0024] The catalytic domain spans amino acid residues 22-274 of the sequence set forth in SEQ ID NO:5, residues 32-308 of the sequence set forth in SEQ ID NO:6, residues 1-178 of the sequence set forth in SEQ ID NO:7, residues 23-289 of the sequence set forth in SEQ ID NO:13, residues 1-255 of the sequence set forth in SEQ ID NO:14, residues 1-255 of the sequence set forth in SEQ ID NO:15, residues 14-273 of the sequence set forth in SEQ ID NO:18, residues 22-277 of the sequence set forth in SEQ ID NO:22, residues 1-66 of the sequence set forth in SEQ ID NO:23, residues 26-273 of the sequence set forth in SEQ ID NO:24, residues 394-658 of the sequence set forth in SEQ ID NO:29, residues 26-281 of the sequence set forth in SEQ ID NO:31, residues 1-278 of the sequence set forth in SEQ ID NO:97, residues 58-369 of the sequence set forth in SEQ ID NO:99, residues 1-103 of the sequence set forth in SEQ ID NO:101, residues 308-572 of the sequence set forth in SEQ ID NO:103, residues 25-289 of the sequence set forth in SEQ ID NO:105, or residues 34-294 of the sequence set forth in SEQ ID NO:107.

[0025] The term “catalytic activity”, as used herein, defines the rate at which a kinase catalytic domain phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a phosphorylated product as a function of time. Catalytic activity can be measured by methods of the invention by holding time constant and determining the concentration of a phosphorylated substrate after a fixed period of time. Phosphorylation of a substrate occurs at the active-site of a protein kinase. The active-site is normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

[0026] The term “substrate” as used herein refers to a molecule phosphorylated by a kinase of the invention. Kinases phosphorylate substrates on serine/threonine or tyrosine amino acids. The molecule may be another protein or a polypeptide.

[0027] The term “C-terminal domain” refers to the region located between the catalytic domain or the last (located closest to the C-terminus) functional domain and the carboxy-terminal amino acid residue of the protein kinase. By “functional” domain is meant any region of the polypeptide that may play a regulatory or catalytic role as predicted from amino acid sequence homology to other proteins or by the presence of amino acid sequences that may give rise to specific structural conformations (i.e. coiled-coils). The C-terminal domain can be identified by using a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the C-terminal boundary of the catalytic domain or of any functional C-terminal extracatalytic domain. Depending on its length and amino acid composition, the C-terminal domain may or may not play a regulatory role in kinase function. An example of a protein kinase whose C-terminal domain may play a regulatory role is PAK3 which contains a heterotrimeric Gb subunit-binding site near its C-terminus (Leeuw, T. et al (1998) Nature, 391, 191-195).

[0028] The C-terminal domain spans amino acid residues 275-416 of the sequence set forth in SEQ ID NO:5, residues 309-489 of the sequence set forth in SEQ ID NO:6, residues 179-414 of the sequence set forth in SEQ ID NO:7, residues 897-1239 of the sequence set forth in SEQ ID NO:13, residues 955-1297 of the sequence set forth in SEQ ID NO:14, residues 984-1326 of the sequence set forth in SEQ ID NO:15, residues 535-894 of the sequence set forth in SEQ ID NO:18, residues 752-898 of the sequence set forth in SEQ ID NO:22, residues 279-330 of the sequence set forth in SEQ ID NO:97, residues 370-418 of the sequence set forth in SEQ ID NO:99, or residues 873-1227 of the sequence set forth in SEQ ID NO:105.

[0029] The term “signal transduction pathway” refers to the molecules that propagate an extracellular signal through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The polypeptide molecules involved in signal transduction processes are typically receptor and non-receptor protein tyrosine kinases, receptor and non-receptor protein phosphatases, SRC homology 2 and 3 domains, phosphotyrosine binding proteins (SRC homology 2 (SH2) and phosphotyrosine binding (PTB and PH) domain containing proteins), proline-rich binding proteins (SH3 domain containing proteins), nucleotide exchange factors, and transcription factors.

[0030] The term “coiled-coil structure region” as used herein, refers to a polypeptide sequence that has a high probability of adopting a coiled-coil structure as predicted by computer algorithms such as COILS (Lupas, A. (1996) Meth. Enzymology 266:513-525). Coiled-coils are formed by two or three amphipathic α-helices in parallel. Coiled-coils can bind to coiled-coil domains of other polypeptides resulting in homo- or heterodimers (Lupas, A. (1991) Science 252:1162-1164). Coiled-coil-dependent oligomerization has been shown to be necessary for protein function including catalytic activity of serine/threonine kinases (Roe, J. et al. (1997) J. Biol. Chem. 272:5838-5845).

[0031] The coiled-coil structure region spans amino acid residues 290-526 of the sequence set forth in SEQ ID NO:13, residues 256-442 of the sequence set forth in SEQ ID NO:14, residues 256-476 of the sequence set forth in SEQ ID NO:15, residues 428-637 of the sequence set forth in SEQ ID NO:22, residues 216-425 or 540-786 of the sequence set forth in SEQ ID NO:23, residues 423-632 of the sequence set forth in SEQ ID NO:24, residues 431-640 or 755-901 of the sequence set forth in SEQ ID NO:31, residues 291-398 or 629-668 of the sequence set forth in SEQ ID NO:105, or residues 473-724 or 725-968 of the sequence set forth in SEQ ID NO:107.

[0032] The term “proline-rich region” as used herein, refers to a region of a protein kinase whose proline content over a given amino acid length is higher than the average content of this amino acid found in proteins(i.e., >10%). Proline-rich regions are easily discernable by visual inspection of amino acid sequences and quantitated by standard computer sequence analysis programs such as the DNAStar program EditSeq. Proline-rich regions have been demonstrated to participate in regulatory protein -protein interactions. Among these interactions, those that are most relevant to this invention involve the “PxxP” proline rich motif found in certain protein kinases (i.e., human PAK1) and the SH3 domain of the adaptor molecule Nck (Galisteo, M. L. et al. (1996) J. Biol. Chem. 271:20997-21000). Other regulatory interactions involving “PxxP” proline-rich motifs include the WW domain (Sudol, M. (1996) Prog. Biochys. Mol. Bio. 65:113-132).

[0033] The proline-rich region spans amino acid residues 527-640 of the sequence set forth in SEQ ID NO:13, residues 443-626 of the sequence set forth in SEQ ID NO:14, residues 477-680 of the sequence set forth in SEQ ID NO:15, residues 347-534 of the sequence set forth in SEQ ID NO:18,residues 398-628 of the sequence set forth in SEQ ID NO:105, or residues 338-472 of the sequence set forth in SEQ ID NO:107.

[0034] The term “spacer region” as used herein, refers to a region of the protein kinase located between predicted functional domains. The spacer region has no detectable homology to any amino acid sequence in the database, and can be identified by using a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the C- and N-terminal boundaries of the flanking functional domains. Spacer regions may or may not play a fundamental role in protein kinase function. Precedence for the regulatory role of spacer regions in kinase function is provided by the role of the src kinase spacer in inter-domain interactions (Xu, W. et al. (1997) Nature 385:595-602).

[0035] The spacer region spans amino acid residues 641-896 of the sequence set forth in SEQ ID NO:13, residues 627-954 of the sequence set forth in SEQ ID NO:14, residues 681-983 of the sequence set forth in SEQ ID NO:15, residues 274-346 of the sequence set forth in SEQ ID NO:18, residues 278-427 or 638-751 of the sequence set forth in SEQ ID NO:22, residues 67-215 or 426-539 of the sequence set forth in SEQ ID NO:23, residues 274-422 or 633-748 of the sequence set forth in SEQ ID NO:24, residues 225-393 of the sequence set forth in SEQ ID NO:29, residues 282-430 or 641-754 of the sequence set forth in SEQ ID NO:31, residues 174-307 of the sequence set forth in SEQ ID NO:103, residues 669-872 of the sequence set forth in SEQ ID NO:105, or residues 295-337 of the sequence set forth in SEQ ID NO:107.

[0036] The term “insert” as used herein refers to a portion of a protein kinase that is absent from a close homolog. Inserts may or may not by the product alternative splicing of exons. Inserts can be identified by using a Smith-Waterman sequence alignment of the protein sequence against the non-redundant protein database, or by means of a multiple sequence alignment of homologous sequences using the DNAStar program Megalign. Inserts may play a functional role by presenting a new interface for protein-protein interactions, or by interfering with such interactions. Inserts span amino acid residues 52-224 of the sequence set forth in SEQ ID NO:29 or residues 53-173 of the sequence set forth in SEQ ID NO:103.

[0037] The term “C-terminal tail” as used herein, refers to a C-terminal domain of a protein kinase, that by homology extends or protrudes past the C-terminal amino acid of its closest homolog. C-terminal tails can be identified by using a Smith-Waterman sequence alignment of the protein sequence against the non-redundant protein database, or by means of a multiple sequence alignment of homologous sequences using the DNAStar program Megalign. Depending on its length, a C-terminal tail may or may not play a regulatory role in kinase function.

[0038] The C-terminal tail spans amino acid residues 490-516 of the sequence set forth in SEQ ID NO:6, residues 787-887 of the sequence set forth in SEQ ID NO:23, residues 659-681 of the sequence set forth in SEQ ID NO:29, residues 994-1093 of the sequence set forth in SEQ ID NO:31, or residues 573-591 of the sequence set forth in SEQ ID NO:103.

[0039] Various low or high stringency hybridization conditions may be used depending upon the specificity and selectivity desired. These conditions are well-known to those skilled in the art. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides, more preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 50 contiguous nucleotides, most preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 100 contiguous nucleotides. In some instances, the conditions may prevent hybridization of nucleic acids having more than 5 mismatches in the full-length sequence.

[0040] By stringent hybridization assay conditions is meant hybridization assay conditions at least as stringent as the following: hybridization in 50% formamide, 5× SSC, 50 mM NaH₂PO₄, pH 6.8, 0.5% SDS, 0.1 mg/mL sonicated salmon sperm DNA, and 5× Denhart solution at 42° C. overnight; washing with 2× SSC, 0.1% SDS at 45° C.; and washing with 0.2× SSC, 0.1% SDS at 45° C. Under some of the most stringent hybridization assay conditions, the second wash can be done with 0.1× SSC at a temperature up to 70° C. (Berger et al. (1987) Guide to Molecular Cloning Techniques pg 421, hereby incorporated by reference herein including any figures, tables, or drawings.). However, other applications may require the use of conditions falling between these sets of conditions. Methods of determining the conditions required to achieve desired hybridizations are well-known to those with ordinary skill in the art, and are based on several factors, including but not limited to, the sequences to be hybridized and the samples to be tested.

[0041] In other preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding kinase polypeptides, further comprising a vector or promoter effective to initiate transcription in a host cell. The invention also features recombinant nucleic acid, preferably in a cell or an organism. The recombinant nucleic acid may contain a sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID N=:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102,SEQ ID NO:104, or SEQ ID NO:106, or a functional derivative thereof and a vector or a promoter effective to initiate transcription in a host cell. The recombinant nucleic acid can alternatively contain a transcriptional initiation region functional in a cell, a sequence complementary to an RNA sequence encoding a kinase polypeptide and a transcriptional termination region functional in a cell. Specific vectors and host cell combinations are discussed herein.

[0042] The term “vector” relates to a single or double-stranded circular nucleic acid molecule that can be transfected into cells and replicated within or independently of a cell genome. A circular double-stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes. An assortment of nucleic acid vectors, restriction enzymes, and the knowledge of the nucleotide sequences cut by restriction enzymes are readily available to those skilled in the art. A nucleic acid molecule encoding a kinase can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together.

[0043] The term “transfecting” defines a number of methods to insert a nucleic acid vector or other nucleic acid molecules into a cellular organism. These methods involve a variety of techniques, such as treating the cells with high concentrations of salt, an electric field, detergent, or DMSO to render the outer membrane or wall of the cells permeable to nucleic acid molecules of interest or use of various viral transduction strategies.

[0044] The term “promoter” as used herein, refers to nucleic acid sequence needed for gene sequence expression. Promoter regions vary from organism to organism, but are well known to persons skilled in the art for different organisms. For example, in prokaryotes, the promoter region contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5′-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

[0045] In preferred embodiments, the isolated nucleic acid comprises, consists essentially of, or consists of a nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100 SEQ ID NO:102, SEQ ID NO:104, or SEQ ID NO:106, or the corresponding full-length sequence, encodes the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequence, a functional derivative thereof, or at least 40, 45, 50, 60, 100, 200, or 300 contiguous amino acids of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or of the corresponding full-length amino acid sequence; at least 250, 255, 275, 300, or 400 contiguous amino acids of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or of the corresponding full-length amino acid sequence; at least 27, 30, 35, 40, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:18; at least 16, 25, 35, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, or SEQ ID NO:103, or of the corresponding full-length amino acid sequence; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99, or the corresponding full-length amino acid sequence; 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101, or the corresponding full-length amino acid sequence; or at least 80, 85, 90, 100, 200, or 300 contiguous amino acids of SEQ ID NO:107, or functional derivatives thereof. The kinase polypeptides, selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, comprise, consist essentially of, or consist of at least at least 40, 45, 50, 60, 100, 200, or 300 contiguous amino acids of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7; at least 250, 255, 275, 300, or 400 contiguous amino acids of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:105; at least 27, 30, 35, 40, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:18; at least 35, 40, 45, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31 or SEQ ID NO:103; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99; 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101; or at least 80, 85, 90, 100, 200, or 300 contiguous amino acids of SEQ ID NO:107, or the corresponding full-length sequences or derivatives thereof. The nucleic acid may be isolated from a natural source by cDNA cloning or by subtractive hybridization. The natural source may be mammalian, preferably human, blood, semen, or tissue, and the nucleic acid may be synthesized by the triester method or by using an automated DNA synthesizer.

[0046] The term “mammal” refers preferably to such organisms as mice, rats, rabbits, guinea pigs, sheep, and goats, more preferably to cats, dogs, monkeys, and apes, and most preferably to humans.

[0047] In yet other preferred embodiments, the nucleic acid is a conserved or unique region, for example those useful for: the design of hybridization probes to facilitate identification and cloning of additional polypeptides, the design of PCR probes to facilitate cloning of additional polypeptides, obtaining antibodies to polypeptide regions, and designing antisense oligonucleotides.

[0048] By “conserved nucleic acid regions”, are meant regions present on two or more nucleic acids encoding a kinase polypeptide, to which a particular nucleic acid sequence can hybridize under lower stringency conditions. Examples of lower stringency conditions suitable for screening for nucleic acid encoding kinase polypeptides are provided in Abe, et al. (J. Biol. Chem. 19:13361-13368, 1992), hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables. Preferably, conserved regions differ by no more than 5 out of 20 nucleotides, even more preferably 2 out of 20 nucleotides or most preferably 1 out of 20 nucleotides.

[0049] By “unique nucleic acid region” is meant a sequence present in a nucleic acid coding for a kinase polypeptide that is not present in a sequence coding for any other naturally occurring polypeptide. Such regions preferably encode 32 (preferably 40, more preferably 45, most preferably 55) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or the corresponding full-length amino acid sequence; 250 (preferably 255, more preferably 260, most preferably 270) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15, or SEQ ID NO:105, or the corresponding full-length amino acid sequence; 27 (preferably 30, more preferably 40, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:18; 16 (preferably 20, more preferably 25, most preferably 35) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, or SEQ ID NO:103, or the corresponding full-length amino acid sequence; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99, 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101, or the corresponding full-length amino acid sequence; or 78 (preferably 80, more preferably 85, most preferably 90) or more contiguous amino acids set forth in the amino acid sequence SEQ ID NO:107, or functional derivatives thereof. In particular, a unique nucleic acid region is preferably of mammalian origin.

[0050] A second aspect of the invention features a nucleic acid probe for the detection of nucleic acid encoding a kinase polypeptide in a sample, wherein said polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. Preferably, the nucleic acid probe encodes a kinase polypeptide that is a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequences, not to include fragments consisting only of amino acids 1-22 of SEQ ID NO:13 or amino acids 1-33 of SEQ ID NO:107. The nucleic acid probe contains a nucleotide base sequence that will hybridize to a sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, or SEQ ID NO:106, or the corresponding full-length sequence, or a functional derivative thereof.

[0051] In preferred embodiments, the nucleic acid probe hybridizes to nucleic acid encoding at least 6, 12, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous amino acids of the sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31 SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequence, or functional derivatives thereof.

[0052] Methods for using the probes include detecting the presence or amount of kinase RNA in a sample by contacting the sample with a nucleic acid probe under conditions such that hybridization occurs and detecting the presence or amount of the probe bound to kinase RNA. The nucleic acid duplex formed between the probe and a nucleic acid sequence coding for a kinase polypeptide may be used in the identification of the sequence of the nucleic acid detected (Nelson et al., in Nonisotopic DNA Probe Techniques, Academic Press, San Diego, Kricka, ed., p. 275, 1992, hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables). Kits for performing such methods may be constructed to include a container means having disposed therein a nucleic acid probe.

[0053] In a third aspect, the invention describes a recombinant cell or tissue comprising a nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. In such cells, the nucleic acid may be under the control of the genomic regulatory elements, or may be under the control of exogenous regulatory elements including an exogenous promoter. By “exogenous” it is meant a promoter that is not normally coupled in vivo transcriptionally to the coding sequence for the kinase polypeptides.

[0054] The polypeptide is preferably a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequence, not to include fragments consisting only of amino acids 1-22 of SEQ ID NO:13 or amino acids 1-33 of SEQ ID NO:107. By “fragment,” is meant an amino acid sequence present in a kinase polypeptide. Preferably, such a sequence comprises at least 32, 45, 50, 60, 100, 200, or 300 contiguous amino acids of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or of the corresponding full-length amino acid sequence; at least 250, 255, 275, 300, or 400 contiguous amino acids of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, OR SEQ ID NO:105, or of the corresponding full-length amino acid sequence; at least 27, 30, 35, 40, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:18; at least 16, 25, 35, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31 or SEQ ID NO:103, or of the corresponding full-length amino acid sequence; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99, 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101; at least 78, 85, 90, 100, 200, or 300 contiguous amino acids of SEQ ID NO:107, or the corresponding full-length amino acid sequence; or a functional derivative thereof.

[0055] In a fourth aspect, the invention features an isolated, enriched, or purified kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.

[0056] By “isolated” in reference to a polypeptide is meant a polymer of amino acids (2 or more amino acids) conjugated to each other, including polypeptides that are isolated from a natural source or that are synthesized. The isolated polypeptides of the present invention are unique in the sense that they are not found in a pure or separated state in nature. Use of the term “isolated” indicates that a naturally occurring sequence has been removed from its normal cellular environment. Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only amino acid chain present, but that it is essentially free (about 90-95% pure at least) of non-amino acid material naturally associated with it.

[0057] By the use of the term “enriched” in reference to a polypeptide is meant that the specific amino acid sequence constitutes a significantly higher fraction (2-5 fold) of the total amino acid sequences present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. This could be caused by a person by preferential reduction in the amount of other amino acid sequences present, or by a preferential increase in the amount of the specific amino acid sequence of interest, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other amino acid sequences present, just that the relative amount of the sequence of interest has been significantly increased. The term significant here is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other amino acid sequences of about at least 2-fold, more preferably at least 5- to 10-fold or even more. The term also does not imply that there is no amino acid sequence from other sources. The other source of amino acid sequences may, for example, comprise amino acid sequence encoded by a yeast or bacterial genome, or a cloning vector such as pUC19. The term is meant to cover only those situations in which man has intervened to increase the proportion of the desired amino acid sequence.

[0058] It is also advantageous for some purposes that an amino acid sequence be in purified form. The term “purified” in reference to a polypeptide does not require absolute purity (such as a homogeneous preparation); instead, it represents an indication that the sequence is relatively purer than in the natural environment. Compared to the natural level this level should be at least 2-5 fold greater (e.g., in terms of mg/mL). Purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. The substance is preferably free of contamination at a functionally significant level, for example 90%, 95%, or 99% pure.

[0059] In preferred embodiments, the kinase polypeptide is a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequences, not to include fragments consisting only of amino acids 1-22 of SEQ ID NO:13 or amino acids 1-33 of SEQ ID NO:107. Preferably, the kinase polypeptide contains at least 32, 45, 50, 60, 100, 200, or 300 contiguous amino acids of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or the corresponding full-length amino acid sequence; at least 250, 255, 275, 300, or 400 contiguous amino acids of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:105, or the corresponding full-length amino acid sequence; at least 27, 30, 35, 40, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:18; at least 16, 25, 35, 50, 100, 200, or 300 contiguous amino acids of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, or SEQ ID NO:103, or the corresponding full-length amino acid sequence; 6 (preferably 10, more preferably 15, most preferably 25) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:99, 22 (preferably 30, more preferably 35, most preferably 45) or more contiguous amino acids set forth in the amino acid sequence of SEQ ID NO:101, or the corresponding full-length amino acid sequence; or at least 78, 85, 90, 100, 200, or 300 contiguous amino acids of SEQ ID NO:107, or a functional derivative thereof.

[0060] In preferred embodiments, the kinase polypeptide comprises an amino acid sequence having (a) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107; (b) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more, but not all, of the following segments of amino acid residues: 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489 or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 1-22, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-668, 669-872, or 873-1227 of SEQ ID NO:105, or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (c) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107 from amino acid residues 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489, or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-273, 274-422, 423-632, 633-746, 747-993, or 994-1093 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-668, 669-872, or 873-1227 of SEQ ID NO:105, or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; or (d) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more, but not all, of the domains selected from the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a proline-rich region, a coiled-coil structure region, an insert, and a C-terminal tail.

[0061] The polypeptide can be isolated from a natural source by methods well-known in the art. The natural source may be mammalian, preferably human, blood, semen, or tissue, and the polypeptide may be synthesized using an automated polypeptide synthesizer. The isolated, enriched, or purified kinase polypeptide is preferably: a STLK2, STLK3, STLK4, STLK5, STLK6, or STLK7 polypeptide; a ZC1, ZC2, ZC3, or ZC4 polypeptide; a KHS2 polypeptide; a SULU1 or SULU3 polypeptide; a GEK2 polypeptide; or a PAK4 or PAK5 polypeptide.

[0062] In some embodiments the invention includes a recombinant kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. By “recombinant kinase polypeptide” is meant a polypeptide produced by recombinant DNA techniques such that it is distinct from a naturally occurring polypeptide either in its location (e.g., present in a different cell or tissue than found in nature), purity or structure. Generally, such a recombinant polypeptide will be present in a cell in an amount different from that normally observed in nature.

[0063] In a fifth aspect, the invention features an antibody (e.g., a monoclonal or polyclonal antibody) having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain or fragment where the polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. By “specific binding affinity” is meant that the antibody binds to the target kinase polypeptide with greater affinity than it binds to other polypeptides under specified conditions. Antibodies or antibody fragments are polypeptides that contain regions that can bind other polypeptides. The term “specific binding affinity” describes an antibody that binds to a kinase polypeptide with greater affinity than it binds to other polypeptides under specified conditions.

[0064] The term “polyclonal” refers to antibodies that are heterogenous populations of antibody molecules derived from the sera of animals immunized with an antigen or an antigenic functional derivative thereof. For the production of polyclonal antibodies, various host animals may be immunized by injection with the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species.

[0065] “Monoclonal antibodies” are substantially homogenous populations of antibodies to a particular antigen. They may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. Monoclonal antibodies may be obtained by methods known to those skilled in the art (Kohler et al., Nature 256:495-497, 1975, and U.S. Pat. No. 4,376,110, both of which are hereby incorporated by reference herein in their entirety including any figures, tables, or drawings).

[0066] The term “antibody fragment” refers to a portion of an antibody, often the hyper variable region and portions of the surrounding heavy and light chains, that displays specific binding affinity for a particular molecule. A hyper variable region is a portion of an antibody that physically binds to the polypeptide target.

[0067] Antibodies or antibody fragments having specific binding affinity to a kinase polypeptide of the invention may be used in methods for detecting the presence and/or amount of kinase polypeptide in a sample by probing the sample with the antibody under conditions suitable for kinase-antibody immunocomplex formation and detecting the presence and/or amount of the antibody conjugated to the kinase polypeptide. Diagnostic kits for performing such methods may be constructed to include antibodies or antibody fragments specific for the kinase as well as a conjugate of a binding partner of the antibodies or the antibodies themselves.

[0068] An antibody or antibody fragment with specific binding affinity to a kinase polypeptide of the invention can be isolated, enriched, or purified from a prokaryotic or eukaryotic organism. Routine methods known to those skilled in the art enable production of antibodies or antibody fragments, in both prokaryotic and eukaryotic organisms. Purification, enrichment, and isolation of antibodies, which are polypeptide molecules, are described above.

[0069] Antibodies having specific binding affinity to a kinase polypeptide of the invention may be used in methods for detecting the presence and/or amount of kinase polypeptide in a sample by contacting the sample with the antibody under conditions such that an immunocomplex forms and detecting the presence and/or amount of the antibody conjugated to the kinase polypeptide. Diagnostic kits for performing such methods may be constructed to include a first container containing the antibody and a second container having a conjugate of a binding partner of the antibody and a label, such as, for example, a radioisotope. The diagnostic kit may also include notification of an FDA approved use and instructions therefor.

[0070] In a sixth aspect, the invention features a hybridoma which produces an antibody having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain, where the polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. By “hybridoma” is meant an immortalized cell line that is capable of secreting an antibody, for example an antibody to a kinase of the invention. In preferred embodiments, the antibody to the kinase comprises a sequence of amino acids that is able to specifically bind a kinase polypeptide of the invention.

[0071] In a seventh aspect, the invention features a kinase polypeptide binding agent able to bind to a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK6, STLK7, STLK5, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. The binding agent is preferably a purified antibody that recognizes an epitope present on a kinase polypeptide of the invention. Other binding agents include molecules that bind to kinase polypeptides and analogous molecules that bind to a kinase polypeptide. Such binding agents may be identified by using assays that measure kinase binding partner activity, such as those that measure PDGFR activity.

[0072] The invention also features a method for screening for human cells containing a kinase polypeptide of the invention or an equivalent sequence. The method involves identifying the novel polypeptide in human cells using techniques that are routine and standard in the art, such as those described herein for identifying the kinases of the invention (e.g., cloning, Southern or Northern blot analysis, in situ hybridization, PCR amplification, etc.).

[0073] In an eighth aspect, the invention features methods for identifying a substance that modulates kinase activity comprising the steps of: (a) contacting a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5 with a test substance; (b) measuring the activity of said polypeptide; and (c) determining whether said substance modulates the activity of said polypeptide.

[0074] The term “modulates” refers to the ability of a compound to alter the function of a kinase of the invention. A modulator preferably activates or inhibits the activity of a kinase of the invention depending on the concentration of the compound exposed to the kinase.

[0075] The term “activates” refers to increasing the cellular activity of the kinase. The term inhibit refers to decreasing the cellular activity of the kinase. Kinase activity is preferably the interaction with a natural binding partner.

[0076] The term “modulates” also refers to altering the function of kinases of the invention by increasing or decreasing the probability that a complex forms between the kinase and a natural binding partner. A modulator preferably increases the probability that such a complex forms between the kinase and the natural binding partner, more preferably increases or decreases the probability that a complex forms between the kinase and the natural binding partner depending on the concentration of the compound exposed to the kinase, and most preferably decreases the probability that a complex forms between the kinase and the natural binding partner.

[0077] The term “complex” refers to an assembly of at least two molecules bound to one another. Signal transduction complexes often contain at least two protein molecules bound to one another. For instance, a protein tyrosine receptor protein kinase, GRB2, SOS, RAF, and RAS assemble to form a signal transduction complex in response to a mitogenic ligand.

[0078] The term “natural binding partner” refers to polypeptides, lipids, small molecules, or nucleic acids that bind to kinases in cells. A change in the interaction between a kinase and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of kinase/natural binding partner complex.

[0079] The term “contacting” as used herein refers to mixing a solution comprising the test compound with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as dimethyl sulfoxide (DMSO), which facilitates the uptake of the test compound or compounds into the cells of the methods. The solution comprising the test compound may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based device or syringe-based device.

[0080] In a ninth aspect, the invention features methods for identifying a substance that modulates kinase activity in a cell comprising the steps of: (a) expressing a kinase polypeptide in a cell, wherein said polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5; (b) adding a test substance to said cell; and (c) monitoring a change in cell phenotype or the interaction between said polypeptide and a natural binding partner.

[0081] The term “expressing” as used herein refers to the production of kinases of the invention from a nucleic acid vector containing kinase genes within a cell. The nucleic acid vector is transfected into cells using well known techniques in the art as described herein.

[0082] In a tenth aspect, the invention provides methods for treating a disease by administering to a patient in need of such treatment a substance that modulates the activity of a kinase selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5. Preferably, the disease is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer. Most preferably, the immune-related diseases and disorders include, but are not limited to, rheumatoid arthritis, artherosclerosis, and autoimmune disorders.

[0083] In preferred embodiments, the invention provides methods for treating or preventing a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase polypeptide selected from the group consisting of ZC1, ZC2, ZC3, ZC4, KHS2, PAK4, and PAK5. Preferably, the disease or disorder is selected from the group consisting of rheumatoid arthritis, artherosclerosis, autoimmune disorders, and organ transplantation. The invention also features methods of treating or preventing a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase polypeptide selected from the group consisting of STLK1, STLK2, STLK3, STLK4, STLK5, STLK6, and STLK7. Preferably the disease or disorder is selected from the group consisting of immune-related diseases and disorders, myocardial infarction, cardiomyopathies, stroke, renal failure, and oxidative stress-related neurodegenerative disorders. Most preferably, the immune-related diseases and disorders are selected from the group consisting of rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplantation.

[0084] The invention also features methods of treating or preventing a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase polypeptide selected from the group consisting of ZC1, ZC2, ZC3, and ZC4. Preferably the disease is selected from the group consisting of immune-related diseases and disorders, cardiovascular disease, and cancer. Most preferably, the immune-related diseases and disorders are selected from the group consisting of rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplantation.

[0085] Substances useful for treatment of kinase-related disorders or diseases preferably show positive results in one or more in vitro assays for an activity corresponding to treatment of the disease or disorder in question (Examples of such assays are provided in the references in section VI, below; and in Example 7, herein). Examples of substances that can be screened for favorable activity are provided and referenced in section VI, below. The substances that modulate the activity of the kinases preferably include, but are not limited to, antisense oligonucleotides and inhibitors of protein kinases, as determined by methods and screens referenced in section VI and Example 7, below.

[0086] The term “preventing” refers to decreasing the probability that an organism contracts or develops an abnormal condition.

[0087] The term “treating” refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

[0088] The term “therapeutic effect” refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of cells; (b) inhibition (i.e., slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.

[0089] The term “abnormal condition” refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, or cell survival.

[0090] Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

[0091] Abnormal differentiation conditions include, but are not limited to neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates.

[0092] Abnormal cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

[0093] The term “aberration”, in conjunction with the function of a kinase in a signal transduction process, refers to a kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

[0094] The term “administering” relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques, and carrier techniques.

[0095] The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig, or goat, more preferably a monkey or ape, and most preferably a human.

[0096] In an eleventh aspect, the invention features methods for detection of a kinase polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probe:target region hybrid as an indication of the disease.

[0097] In preferred embodiments of the invention, the disease or disorder is selected from the group consisting of rheumatoid arthritis, artherosclerosis, autoimmune disorders, organ transplantation, myocardial infarction, cardiomyopathies, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer. In other preferred embodiments, the kinase polypeptide is selected from the group consisting of PAK4 and PAK5, or the polypeptide is selected from the group consisting of ZC1, ZC2, ZC3, and ZC4, and the disease is cancer.

[0098] The kinase “target region” is the nucleotide base sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, or SEQ ID NO:106, or the corresponding full-length sequences, a functional derivative thereof, or a fragment thereof to which the nucleic acid probe will specifically hybridize. Specific hybridization indicates that in the presence of other nucleic acids the probe only hybridizes detectably with the kinase of the invention's target region. Putative target regions can be identified by methods well known in the art consisting of alignment and comparison of the most closely related sequences in the database.

[0099] In preferred embodiments the nucleic acid probe hybridizes to a kinase target region encoding at least 6, 12, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous amino acids of the sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or the corresponding full-length amino acid sequence, or a functional derivative thereof. Hybridization conditions should be such that hybridization occurs only with the kinase genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined supra.

[0100] The diseases for which detection of kinase genes in a sample could be diagnostic include diseases in which kinase nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By “amplification” is meant increased numbers of kinase DNA or RNA in a cell compared with normal cells. In normal cells, kinases are typically found as single copy genes. In selected diseases, the chromosomal location of the kinase genes may be amplified, resulting in multiple copies of the gene, or amplification. Gene amplification can lead to amplification of kinase RNA, or kinase RNA can be amplified in the absence of kinase DNA amplification.

[0101] “Amplification” as it refers to RNA can be the detectable presence of kinase RNA in cells, since in some normal cells there is no basal expression of kinase RNA. In other normal cells, a basal level of expression of kinase exists, therefore in these cases amplification is the detection of at least 1-2-fold, and preferably more, kinase RNA, compared to the basal level.

[0102] The diseases that could be diagnosed by detection of kinase nucleic acid in a sample preferably include cancers. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.

[0103] In a final aspect, the invention features a method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein the method comprises: (a) comparing a nucleic acid target region encoding the kinase polypeptide in a sample, where the kinase polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, or one or more fragments thereof, with a control nucleic acid target region encoding the kinase polypeptide, or one or more fragments thereof; and (b) detecting differences in sequence or amount between the target region and the control target region, as an indication of the disease or disorder. Preferably, the disease or disorder is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer. Immune-related diseases and disorders include, but are not limited to, those discussed previously.

[0104] The term “comparing” as used herein refers to identifying discrepancies between the nucleic acid target region isolated from a sample, and the control nucleic acid target region. The discrepancies can be in the nucleotide sequences, e.g. insertions, deletions, or point mutations, or in the amount of a given nucleotide sequence. Methods to determine these discrepancies in sequences are well-known to one of ordinary skill in the art. The “control” nucleic acid target region refers to the sequence or amount of the sequence found in normal cells, e.g. cells that are not diseased as discussed previously.

[0105] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. For example, in some instances the nucleotide sequence of the ZC4 kinase polypeptide may not be part of a preferred embodiment.

[0106] The summary of the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the invention, and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

[0107]FIG. 1 shows a multiple sequence alignment of the amino acid sequences of the STE20-STE20 family kinases.

[0108]FIG. 2 shows a multiple sequence alignment of the amino acid sequences of the STE20-STLK5 family kinases.

[0109]FIGS. 3A and 3B show a multiple sequence alignment of the amino acid sequences of STE20-ZC family kinases.

[0110]FIG. 4 shows a pairwise sequence alignment of STE20-KHS family kinases.

[0111]FIG. 5 shows a multiple sequence alignment of the amino acid sequences of STE20-SULU family kinases.

[0112]FIG. 6 shows a pairwise sequence alignment of STE20-GEK family kinases

[0113]FIG. 7 shows a multiple sequence alignment of the amino acid sequences of STE20-PAK family kinases.

[0114]FIGS. 8A, 8B, 8C, 8D, and 8E show the amino acid sequences of human STLK2, human STLK3, human STLK4, human STLK5, human ZC1, human ZC2, human ZC3, human ZC4, human KHS2, human SULU1, human SULU3, murine SULU3, human GEK2, human PAK4, and human PAK5.

[0115]FIGS. 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9I, 9J, 9K, 9L, 9M, 9N, 9O, and 9P show the nucleic acid sequences of human STLK2, human STLK3, human STLK4, human STLK5, human ZC1, human ZC2, human ZC3, human ZC4, human KHS2, human SULU1, human SULU3, murine SULU3, human GEK2, human PAK4, and human PAK5.

[0116]FIGS. 10A and 10B show the full-length amino acid sequences of human STLK5 (SEQ ID NO: 97), human PAKS (SEQ ID NO:103), and human ZC4 (SEQ ID NO:105), as well as the partial amino acid sequences of human full-length STLK6 (SEQ ID NO: 99) and human STLK7 (SEQ ID NO: 101).

[0117]FIGS. 11A, 11B, 11C, and 11D show the full-length nucleic acid sequences of human STLK5 (SEQ ID NO:96), human PAK5 (SEQ ID NO:102), and human ZC4 (SEQ ID NO:104), as well as the partial nucleic acid sequences of human STLK6 (SEQ ID NO: 98) and human STLK7 (SEQ ID NO: 100).

[0118]FIG. 12 shows a multiple sequence alignment among human SPAK, human STLK6, human STLK7 and full-length human STLK5.

[0119]FIG. 13 shows a multiple sequence alignment among human PAK1, human PAK4 and human PAK5.

[0120]FIGS. 14A and 14B show a pair-wise sequence alignment between human ZC1 and human ZC4.

[0121]FIG. 15 shows a pair-wise sequence alignment between LOK1 and full-length GEK2.

DETAILED DESCRIPTION OF THE INVENTION

[0122] The present invention relates in part to kinase polypeptides, nucleic acids encoding such polypeptides, cells containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. The present invention is based upon the isolation and characterization of new kinase polypeptides. The polypeptides and nucleic acids may be produced using well-known and standard synthesis techniques when given the sequences presented herein.

[0123] The recent elucidation of the DNA sequence of Saccharomyces cerevesiae has provided the first complete example of the genetic information contained in a simple eukaryotic organism. Analysis of this yeast genome revealed that it contains at least 113 protein kinases. These kinases were further subdivided into several structurally related groups. One of these newly defined groups was termed the STE20-family to represent its founding member STE20, which is a protein kinase involved in the yeast pheromone response pathway that initiates a protein kinase cascade in response to a G-protein mediated signal. S. cerevesiae has two additional members of this family, CLA4, and YOL113W (HRA655).

[0124] Several mammalian homologues have recently been identified that belong to the STE20-family, including SOK-1 (human STE20), GC-kinase, KHS, HPK1, NIK, SLK, GEK, PAK1, PAK65, MST1, and CDC7. Furthermore, the Drosophila and the C. elegans genome efforts have identified additional protein kinases which belong to the STE20-family, yet have structurally unique extracatalytic domains, including ZC504.4 and SULU kinases from C. elegans, and NINAC of Drosophila.

[0125] STE20-related protein kinases have been implicated as regulating a variety of cellular responses, including response to growth factors or cytokines, oxidative-, UV-, or irradiation-related stress pathways, inflammatory signals (i.e., TNFα), apoptotic stimuli (i.e., Fas), T and B cell costimulation, the control of cytoskeletal architecture, and cellular transformation. Typically, the STE20-related kinases serve as upstream regulators of MAPK cascades. Examples include: HPK1, a protein-serine/threonine kinase (STK) that possesses a STE20-like kinase domain that activates a protein kinase pathway leading to the stress-activated protein kinase SAPK/JNK; PAK1, an STK with an upstream CDC42-binding domain that interacts with Rac and plays a role in cellular transformation through the Ras-MAPK pathway; and murine NIK, which interacts with upstream receptor tyrosine kinases and connects with downstream STE11-family kinases.

[0126] The STE20-kinases possess a variety of non-catalytic domains that are believed to interact with upstream regulators. Examples include proline-rich domains for interaction with SH3-containing proteins, or specific domains for interaction with Rac, Rho, and Rab small G-proteins. These interactions may provide a mechanism for cross-talk between distinct biochemical pathways in response to external stimuli such as the activation of a variety of cell surface receptors, including tyrosine kinases, cytokine receptors, TNF receptor, Fas, T cell receptors, CD28, or CD40.

[0127] I. The Nucleic Acids of the Invention

[0128] Included within the scope of this invention are the functional equivalents of the herein-described isolated nucleic acid molecules. The degeneracy of the genetic code permits substitution of certain codons by other codons that specify the same amino acid and hence would give rise to the same protein. The nucleic acid sequence can vary substantially since, with the exception of methionine and tryptophan, the known amino acids can be coded for by more than one codon. Thus, portions or all of the kinase genes of the invention could be synthesized to give a nucleic acid sequence significantly different from that shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, and SEQ ID NO:106. The encoded amino acid sequence thereof would, however, be preserved.

[0129] In addition, the nucleic acid sequence may comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5′-end and/or the 3′-end of the nucleic acid formula shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, or SEQ ID NO:106, or a derivative thereof. Any nucleotide or polynucleotide may be used in this regard, provided that its addition, deletion or substitution does not alter the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, which is encoded by the nucleotide sequence. For example, the present invention is intended to include any nucleic acid sequence resulting from the addition of ATG as an initiation codon at the 5′-end of the inventive nucleic acid sequence or its derivative, or from the addition of TTA, TAG or TGA as a termination codon at the 3′-end of the inventive nucleotide sequence or its derivative. Moreover, the nucleic acid molecule of the present invention may, as necessary, have restriction endonuclease recognition sites added to its 5′-end and/or 3′-end.

[0130] Such functional alterations of a given nucleic acid sequence afford an opportunity to promote secretion and/or processing of heterologous proteins encoded by foreign nucleic acid sequences fused thereto. All variations of the nucleotide sequence of the kinase genes of the invention and fragments thereof permitted by the genetic code are, therefore, included in this invention.

[0131] Further, it is possible to delete codons or to substitute one or more codons with codons other than degenerate codons to produce a structurally modified polypeptide, but one which has substantially the same utility or activity as the polypeptide produced by the unmodified nucleic acid molecule. As recognized in the art, the two polypeptides are functionally equivalent, as are the two nucleic acid molecules that give rise to their production, even though the differences between the nucleic acid molecules are not related to the degeneracy of the genetic code.

[0132] Mammalian STLK2

[0133] The full-length human STLK2 cDNA (SEQ ID NO:1) is 3268 bp long and consists of a 1248 bp open reading frame (ORF) flanked by a 181 bp 5′ untranslated region (UTR; 1-181) and a 1784 bp 3′ UTR (1433-3216) that is followed by a 52 nucleotide polyadenylated region. A polyadenylation signal (AATAAA) is found at positions (3193-3198). The sequence flanking the first ATG conforms to the Kozak consensus (Kozak, M., Nucleic Acids Res. 15, 8125-8148 (1987)) for an initiating methionine, and is believed to be the translational start site for STLK2. Furthermore, human STLK2 and the related SOK-1 and MST3 proteins conserve the amino acid sequence immediately following this presumed initiating methionine.

[0134] Several EST fragments span the complete STLK2 sequence with AA191319 at the 5′ end and W16504 at the 3′ end.

[0135] Mammalian STLK3

[0136] The partial human STLK3 cDNA (SEQ ID NO:2) is 3030 bp long and consists of a 1548 bp ORF flanked by a 1476 bp 3′ UTR (1550-3025) and a 5 nucleotide polyadenylated region. A potential polyadenylation signal (AATAAA) begins at position 3004. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine.

[0137] Multiple EST fragments span the complete STLK3 sequence with AA278967 at the 5′ end and AA628477 and others at the 3′ end.

[0138] Mammalian STLK4

[0139] The partial human STLK4 cDNA (SEQ ID NO:3) is 3857 bp long and consists of a 1242 bp ORF flanked by a 2596 bp 3′ UTR (1244-3839) and an 18 nucleotide polyadenylated region. A potential polyadenylation signal (AATAAA) is found at positions 2181-3822. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. A near full-length murine STLK4 cDNA is represented in the 1773 bp EST AA117438. It extends an additional 21 nucleotides 5′ of the human STLK4 consensus, but since its coding region is open throughout the 5′ extent of the sequence, this is also apparently a partial cDNA clone lacking the N-terminal start methionine.

[0140] Several EST fragments span the complete STLK3 sequence with AA297759 at the 5′ end and AA100484 and others at the 3′ end.

[0141] Mammalian STLK5

[0142] The full-length human STLK5 cDNA (SEQ ID NO:96) is 2110 bp long and consists of a 1119 bp ORF flanked by a 229 bp 5′ UTR and a 762 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (supra) for an initiating methionine, and is believed to be the translational start site for STLK5. Several EST fragments span the complete STLK5 sequence with AA297059 and F07734 at the 5′ end, and R46686 and F03423 and others at the 3′ end.

[0143] Mammalian STLK6

[0144] The full-length human STLK6 cDNA (SEQ ID NO:98) is 2,001 bp long and consists of a 1,254 bp ORF flanked by a 75 bp 5′ UTR and a 673 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (supra) for an initiating methionine, and is believed to be the translational start site for STLK6.

[0145] Mammalian STLK7

[0146] The partial human STLK7 cDNA (SEQ ID NO:100) is 311 bp long and consists of a 309 bp ORF. Since the coding region is open throughout both the 5′ and 3′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine and C-terminal stop codon.

[0147] Mammalian ZC1

[0148] The full-length human ZC1 cDNA (SEQ ID NO:9) is 3798 bp long and consists of a 3717 bp ORF (7-3723) flanked by a 6 bp 5′ UTR and a 75 bp (3724-3798) 3′ UTR. No polyadenylation signal (AATAAA) or polyadenylated region are present in the 3′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human ZC1.

[0149] Multiple EST fragments (W81656) match the 3′ end of the human ZC1 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0150] Mammalian ZC2

[0151] The partial human ZC2 cDNA (SEQ ID NO:10) is 4055 bp long and consists of a 3891 bp ORF (1-3891) and a 164 bp (3892-4055) 3′ UTR. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. No polyadenylation signal (AATAAA) or polyadenylated region are present in the 3′UTR.

[0152] Multiple EST fragments (R51245) match the 3′ end of the human ZC2 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0153] Mammalian ZC3

[0154] The partial human ZC3 cDNA (SEQ ID NO:11) is 4133 bp long and consists of a 3978 bp ORF (1-3978) and a 152 bp (3979-4133) 3′UTR region. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. No polyadenylation signal (AATAAA) or polyadenylated region are present in the 3′UTR.

[0155] Multiple EST fragments (R54563) match the 3′end of the human ZC3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0156] Mammalian ZC4

[0157] The full-length human ZC4 cDNA (SEQ ID NO:104) is 3,684 bp long and was originally assembled from X chromosome genomic DNA sequence.

[0158] Multiple EST fragments (R98571) match the 3′end of the human ZC4 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end. ZC4 gene is also contained within the human genomic clone Z83850.

[0159] Mammalian KHS2

[0160] The full-length human KHS2 cDNA (SEQ ID NO:17) is 4023 bp long and consists of a 2682 bp ORF (6-2687) flanked by a 5 bp (1-5) 5′UTR and a 1336 bp (2688-4023) 3′ UTR. A potential polyadenylation signal (AATAAA) is found at positions 4008-4013. No polyadenylated region is present in the 3′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human KHS2.

[0161] Multiple EST fragments match the 5′end (AA446022) as well as the 3′ end (R37625) of the human KHS2 gene.

[0162] Mammalian SULU1

[0163] The full-length human SULU1 cDNA (SEQ ID NO:19) is 4177 bp long and consists of a 2694 bp ORF (415-3108) flanked by a 414 bp (1-414) 5′UTR and a 1069 bp (3109-4177) 3′ UTR followed by a 19 nucleotide polydenylated region. A potential polyadenylation signal (AATAAA) is found at positions 4164-4169. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human SULU1.

[0164] Multiple EST fragments match the 5′end (N27153) as well as the 3′ end (R90908) of the human SULU1 gene.

[0165] Mammalian (Murine) SULU3

[0166] The partial murine SULU3 cDNA (SEQ ID NO:21) is 2249 bp long and consists of a 2244 bp ORF (6-2249) flanked by a 5 bp (1-5) 5′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for murine SULU3. The 3′ end of the murine SULU3 cDNA shares 90% DNA sequence identity over 1620 nucleotides with human SULU3, suggesting that these two genes are functional orthologues.

[0167] One EST fragment (AA446022) matches the 3′ end of the partial murine SULU3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0168] Mammalian (Human) SULU3

[0169] The partial human SULU3 cDNA (SEQ ID NO:20) is 3824 bp long and consists of a 2358 bp ORF (2-2359) flanked by a 1465 bp (2360-3824) 3′UTR followed by a 19 nucleotide polydenylated region. A potential polyadenylation signal (AATAAA) is found at positions 2602-2607. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. The 5′ end of the human SULU3 cDNA shares 90% DNA sequence identity over 1620 nucleotides with murine SULU3, suggesting that these two genes are functional orthologues.

[0170] Multiple EST fragments (R02283) match the 3′end of the human SULU3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0171] Mammalian GEK2

[0172] The full-length human GEK2 cDNA (SEQ ID NO:106) is 2962 bp long and consists of a 2737 bp ORF (59-2795) flanked by a 58 bp (1-58) 5′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human GEK2.

[0173] Multiple EST fragments (AA465671) match the 5′end, but at the time of filing, the inventors believe that only one (AA380492) matches the 3′ end of the human GEK2 gene.

[0174] Mammalian PAK4

[0175] The full-length human PAK4 cDNA (SEQ ID NO:27) is 3604 bp long and consists of a 2043 bp ORF (143-2185) flanked by a 142 bp (1-142) 5′UTR and a 1419 3′ UTR followed by a 22 nucleotide polydenylated region. A potential polyadenylation signal (AATTAAA) is found at positions 3582-3588. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human PAK4.

[0176] Multiple EST fragments (AA535791) match the 3′end of the human PAK4 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0177] Mammalian PAK5

[0178] The full-length human PAK5 cDNA (SEQ ID NO:102) is 2806 bp long and consists of a 1773 bp ORF flanked by a 201 bp 5′ UTR and a 833 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (supra) for an initiating methionine, and is believed to be the translational start site for PAK5.

[0179] Multiple EST fragments (AA442867) match the 3′end of the human PAK5 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0180] II. Nucleic Acid Probes, Methods, and Kits for Detection of STE20-Related Kinases.

[0181] A nucleic acid probe of the present invention may be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain other nucleic acid molecules of the present invention. A chromosomal DNA or cDNA library may be prepared from appropriate cells according to recognized methods in the art (cf. “Molecular Cloning: A Laboratory Manual”, second edition, Cold Spring Harbor Laboratory, Sambrook, Fritsch, & Maniatis, eds., 1989).

[0182] In the alternative, chemical synthesis can be carried out in order to obtain nucleic acid probes having nucleotide sequences which correspond to N-terminal and C-terminal portions of the amino acid sequence of the polypeptide of interest. The synthesized nucleic acid probes may be used as primers in a polymerase chain reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to PCR Protocols, “A Guide to Methods and Applications”, Academic Press, Michael, et al., eds., 1990, utilizing the appropriate chromosomal or cDNA library to obtain the fragment of the present invention.

[0183] One skilled in the art can readily design such probes based on the sequence disclosed herein using methods of computer alignment and sequence analysis known in the art (“Molecular Cloning: A Laboratory Manual”, 1989, supra). The hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes may be visualized using known methods.

[0184] The nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art. The nucleic acid probe may be immobilized on a solid support. Examples of such solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.

[0185] The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample which is compatible with the method utilized.

[0186] One method of detecting the presence of nucleic acids of the invention in a sample comprises (a) contacting said sample with the above-described nucleic acid probe under conditions such that hybridization occurs, and (b) detecting the presence of said probe bound to said nucleic acid molecule. One skilled in the art would select the nucleic acid probe according to techniques known in the art as described above. Samples to be tested include but should not be limited to RNA samples of human tissue.

[0187] A kit for detecting the presence of nucleic acids of the invention in a sample comprises at least one container means having disposed therein the above-described nucleic acid probe. The kit may further comprise other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe. Examples of detection reagents include, but are not limited to radiolabelled probes, enzymatic labeled probes (horseradish peroxidase, alkaline phosphatase), and affinity labeled probes (biotin, avidin, or steptavidin).

[0188] In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and the like), and containers which contain the reagents used to detect the hybridized probe, bound antibody, amplified product, or the like. One skilled in the art will readily recognize that the nucleic acid probes described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

[0189] III. DNA Constructs Comprising a STE20-Related Nucleic Acid Molecule and Cells Containing These Constructs.

[0190] The present invention also relates to a recombinant DNA molecule comprising, 5′ to 3′, a promoter effective to initiate transcription in a host cell and the above-described nucleic acid molecules. In addition, the present invention relates to a recombinant DNA molecule comprising a vector and an above-described nucleic acid molecule. The present invention also relates to a nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complementary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide, and a transcriptional termination region functional in said cell. The above-described molecules may be isolated and/or purified DNA molecules.

[0191] The present invention also relates to a cell or organism that contains an above-described nucleic acid molecule and thereby is capable of expressing a polypeptide. The polypeptide may be purified from cells which have been altered to express the polypeptide. A cell is said to be “altered to express a desired polypeptide” when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or which the cell normally produces at lower levels. One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotic cells.

[0192] A nucleic acid molecule, such as DNA, is said to be “capable of expressing” a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are “operably linked” to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression. The precise nature of the regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5′-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

[0193] If desired, the non-coding region 3′ to the sequence encoding a kinase of the invention may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3′-region naturally contiguous to the DNA sequence encoding a kinase of the invention, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3′ region functional in the host cell may be substituted.

[0194] Two DNA sequences (such as a promoter region sequence and a sequence encoding a kinase of the invention) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of a gene sequence encoding a kinase of the invention, or (3) interfere with the ability of the gene sequence of a kinase of the invention to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence. Thus, to express a gene encoding a kinase of the invention, transcriptional and translational signals recognized by an appropriate host are necessary.

[0195] The present invention encompasses the expression of a gene encoding a kinase of the invention (or a functional derivative thereof) in either prokaryotic or eukaryotic cells. Prokaryotic hosts are, generally, very efficient and convenient for the production of recombinant proteins and are, therefore, one type of preferred expression system for kinases of the invention. Prokaryotes most frequently are represented by various strains of E. coli. However, other microbial strains may also be used, including other bacterial strains.

[0196] In prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors may include pBR322, pUC118, pUC119 and the like; suitable phage or bacteriophage vectors may include γgt10, γgt11 and the like; and suitable virus vectors may include pMAM-neo, PKRC and the like. Preferably, the selected vector of the present invention has the capacity to replicate in the selected host cell.

[0197] Recognized prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, and the like. However, under such conditions, the polypeptide will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

[0198] To express a kinase of the invention (or a functional derivative thereof) in a prokaryotic cell, it is necessary to operably link the sequence encoding the kinase of the invention to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Examples of constitutive promoters include the int promoter of bacteriophage λ, the bla promoter of the β-lactamase gene sequence of pBR322, and the cat promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P_(L) and P_(R)), the trp, recA, λacZ, λacI, and gal promoters of E. coli, the α-amylase (Ulmanen et al., J. Bacteriol. 162:176-182, 1985) and the ζq-28-specific promoters of B. subtilis (Gilman et al., Gene Sequence 32:11-20, 1984), the promoters of the bacteriophages of Bacillus (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY, 1982), and Streptomyces promoters (Ward et al., Mol. Gen. Genet. 203:468-478, 1986). Prokaryotic promoters are reviewed by Glick (Ind. Microbiot. 1:277-282, 1987), Cenatiempo (Biochimie 68:505-516, 1986), and Gottesman (Ann. Rev. Genet. 18:415-442, 1984).

[0199] Proper expression in a prokaryotic cell also requires the presence of a ribosome-binding site upstream of the gene sequence-encoding sequence. Such ribosome-binding sites are disclosed, for example, by Gold et al. (Ann. Rev. Microbiol. 35:365-404, 1981). The selection of control sequences, expression vectors, transformation methods, and the like, are dependent on the type of host cell used to express the gene. As used herein, “cell”, “cell line”, and “cell culture” may be used interchangeably and all such designations include progeny. Thus, the words “transformants” or “transformed cells” include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. However, as defined, mutant progeny have the same functionality as that of the originally transformed cell.

[0200] Host cells which may be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the kinase polypeptide of interest. Suitable hosts may often include eukaryotic cells. Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture. Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin and their derivatives. Preferred mammalian host cells include SP2/0 and J558L, as well as neuroblastoma cell lines such as IMR 332, which may provide better capacities for correct post-translational processing.

[0201] In addition, plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the cauliflower mosaic virus 35S and 19S, and nopaline synthase promoter and polyadenylation signal sequences. Another preferred host is an insect cell, for example the Drosophila larvae. Using insect cells as hosts, the Drosophila alcohol dehydrogenase promoter can be used (Rubin, Science 240:1453-1459, 1988). Alternatively, baculovirus vectors can be engineered to express large amounts of kinases of the invention in insect cells (Jasny, Science 238:1653, 1987; Miller et al., In: Genetic Engineering, Vol. 8, Plenum, Setlow et al., eds., pp. 277-297, 1986).

[0202] Any of a series of yeast expression systems can be utilized which incorporate promoter and termination elements from the actively expressed sequences coding for glycolytic enzymes that are produced in large quantities when yeast are grown in mediums rich in glucose. Known glycolytic gene sequences can also provide very efficient transcriptional control signals. Yeast provides substantial advantages in that it can also carry out post-translational modifications. A number of recombinant DNA strategies exist utilizing strong promoter sequences and high copy number plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences on cloned mammalian genes and secretes peptides bearing leader sequences (i.e., pre-peptides). Several possible vector systems are available for the expression of kinases of the invention in a mammalian host.

[0203] A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, cytomegalovirus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, and the like, may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.

[0204] Expression of kinases of the invention in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer et al., J. Mol. Appl. Gen. 1:273-288, 1982); the TK promoter of Herpes virus (McKnight, Cell 31:355-365, 1982); the SV40 early promoter (Benoist et al., Nature (London) 290:304-31, 1981); and the yeast gal4 gene sequence promoter (Johnston et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975, 1982; Silver et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955, 1984).

[0205] Translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes a kinase of the invention (or a functional derivative thereof) does not contain any intervening codons which are capable of encoding a methionine (i.e., AUG). The presence of such codons results either in the formation of a fusion protein (if the AUG codon is in the same reading frame as the kinase of the invention coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the kinase of the invention coding sequence).

[0206] A nucleic acid molecule encoding a kinase of the invention and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a nonreplicating DNA or RNA molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced DNA sequence into the host chromosome.

[0207] A vector may be employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama (Mol. Cell. Biol. 3:280-, 1983).

[0208] The introduced nucleic acid molecule can be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to “shuttle” the vector between host cells of different species.

[0209] Preferred prokaryotic vectors include plasmids such as those capable of replication in E. coli (such as, for example, pBR322, ColEl, pSC101, pACYC 184, πVX; “Molecular Cloning: A Laboratory Manual”, 1989, supra). Bacillus plasmids include pCl94, pC221, pT127, and the like (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, NY, pp. 307-329, 1982). Suitable Streptomyces plasmids include p1J101 (Kendall et al., J. Bacteriol. 169:4177-4183, 1987), and streptomyces bacteriophages such as φC31 (Chater et al., In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary, pp. 45-54, 1986). Pseudomonas plasmids are reviewed by John et al. (Rev. Infect. Dis. 8:693-704, 1986), and Izaki (Jpn. J. Bacteriol. 33:729-742, 1978).

[0210] Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives. Such plasmids are well known in the art (Botstein et al., Miami Wntr. Symp. 19:265-274, 1982; Broach, In: “The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance”, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 445-470, 1981; Broach, Cell 28:203-204, 1982; Bollon et al., J. Clin. Hematol. Oncol. 10:39-48, 1980; Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608, 1980).

[0211] Once the vector or nucleic acid molecule containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate-precipitation, direct microinjection, and the like. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene(s) results in the production of a kinase of the invention, or fragments thereof. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like). A variety of incubation conditions can be used to form the peptide of the present invention. The most preferred conditions are those which mimic physiological conditions.

[0212] IV. The Proteins of the Invention

[0213] A variety of methodologies known in the art can be utilized to obtain the polypeptides of the present invention. The polypeptides may be purified from tissues or cells that naturally produce the polypeptides. Alternatively, the above-described isolated nucleic acid fragments could be used to express the kinases of the invention in any organism. The samples of the present invention include cells, protein extracts or membrane extracts of cells, or biological fluids. The samples will vary based on the assay format, the detection method, and the nature of the tissues, cells or extracts used as the sample.

[0214] Any eukaryotic organism can be used as a source for the polypeptides of the invention, as long as the source organism naturally contains such polypeptides. As used herein, “source organism” refers to the original organism from which the amino acid sequence of the subunit is derived, regardless of the organism the subunit is expressed in and ultimately isolated from.

[0215] One skilled in the art can readily follow known methods for isolating proteins in order to obtain the polypeptides free of natural contaminants. These include, but are not limited to: size-exclusion chromatography, HPLC, ion-exchange chromatography, and immuno-affinity chromatography.

[0216] Mammalian STLK2

[0217] Analysis of the deduced amino acid sequence predicts STLK2 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. STLK2 contains a 21 amino acid N-terminal domain, a 253 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, followed by a 142 amino acid C-terminal domain.

[0218] STLK2 is most closely related to human STE20-subfamily kinases, MST3 (GB:AF024636) and SOK-1 (GB:X99325) and a C. elegans kinase yk34b11.5 (GB:U53153) sharing 72.7%, 68.7%, and 69.3% amino acid identity, respectively.

[0219] The 21 amino acid N-terminal domain of human STLK2 is 71.4% identical to the N-terminus of MST3 (GB:AF024636). Human STLK2 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0220] The 253 amino acid catalytic domain of human STLK2 is most related to human SOK-1 (X99325), MST3 (GB:AF024636), C. elegans yk32b11.5 (GB:U53153), and STLK3 (SEQ ID NO:6) sharing 88.9%, 87.4%, 78.3%, and 49% amino identity respectively, placing it in the STLK-subfamily of STE20-related kinases. The STLK2 kinase domain displayed lesser homology to other STE20-related kinases including: 55.9% to human MST2 (GB:U26424), 49.2% to human GCK (GB:U07349), 49.2% to human KHS1 (GB:U77129), and 44.2% to human HPKl (GB:U66464). The activation loop of human STLK2 catalytic domain is identical to that of human SOK-1 and MST3 including the presence of four potential threonine phosphorylation sites that could serve an autoregulatory role on kinase activity.

[0221] The 142 amino acid C-terminal domain of human STLK2 is most related to human SOK-1 (X99325), MST3 (GB:AF024636), and C. elegans yk32b11.5 (GB:U53153), sharing 39.9%, 39.9%, and 33.3% amino acid identity, respectively. This C-terminal domain shares some significant amino acid similarity to the C-terminal domains of the related human STLK3 (SEQ ID NO:6) and STLK4 (SEQ ID NO:7).

[0222] The C-terminus of the related human SOK-1 (GB:X99325) kinase has been shown to be inhibitory to the catalytic activity of this kinase (Pombo, C. M., Bonventre, J. V., Molnar, A., Kyriakis, J. and Force, T. EMBO J. 15, 4537-4546 (1996)). Based on the sequence identity between the C-termini of human SOK-1 (GB:X99325) and human STLK2 (39.2%), the C-terminus of human STLK2 may also function as an inhibitory domain for its kinase.

[0223] Mammalian STLK3

[0224] The 3030 bp human STLK3 nucleotide sequence of the partial cDNA clone encodes a polypeptide of 516 amino acids (SEQ ID NO:6) with a predicted molecular mass of 56,784 daltons. Analysis of the deduced amino acid sequence predicts STLK3 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain, however the cDNA clone lacks an initiating ATG, so the full extent of it N-termius is not known. STLK3 contains a 31 amino acid N-terminal domain, a 277 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, followed by a 181 amino acid C-terminal domain containing a 25 amino acid insert and a 27 amino acid tail relative to the sequence of human STLK2.

[0225] STLK3 is most closely related to human STE20-subfamily kinases, STLK4 (SEQ ID. NO:7), MST3 (GB:AF024636), SOK-1 (GB:X99325) and STLK2 (SEQ ID NO:5) sharing 71.1%, 37.6%, 38.1%, and 38.4% amino acid identity respectively.

[0226] The 31 amino acid N-terminal domain of human STLK3 lacked any significant amino acid sequence homologies using a Smith-Waterman search of the nonredundant protein database, other than sequence similarity to proline-alanine repeats.

[0227] The 277 amino acid catalytic domain of human STLK3 is most related to human STLK4 (SEQ ID NO:7), SOK-1 (GB:X99325), MST3 (GB:AF024636), and STLK2 (SEQ ID NO:5) sharing 88.2%, 49.2%, 49%, and 49% amino acid identity, respectively. It also shares strong homology to other STKs from lower organisms including 51.7% to A. thaliana (GB: AC002343), 43.1% to A. thaliana (GB: Z97336), 42.1% to A. thaliana (GB: U96613), and 43.3% to C. elegans (GB: U53153). The activation loop of the human STLK3 catalytic domain conserves three potential threonine phosphorylation sites with other members of the STLK-subfamily of STE20-related kinases (human STE20, MST3, STLK2, STLK4) that could serve an autoregulatory role on kinase activity.

[0228] The 181 amino acid C-terminal domain of human STLK3 shares 55.5% amino acid identity to human STLK4 (SEQ ID NO:7), and is 100% identical to a partial human cDNA DCHT (GB:AF017635). The C-terminal domain of human STLK3 contains a 26 amino acid insert relative to human STE20. A similar (87.5% amino acid identity) 26 amino acid insert is also present in human STLK4.

[0229] The 27 amino acid C-terminal tail of human STLK3 shares 77.8% amino acid identity to human STLK4, but is absent from other STLK-family members. This high degree of homology between the C-tail of two STLK-family members suggests they may be involved in an as yet unidentified protein-protein interaction.

[0230] The weak sequence homology between the C-termini of human STLK3 and STE20, suggests it may also function as an inhibitory domain for its kinase.

[0231] Mammalian STLK4

[0232] The 3857 bp human STLK4 nucleotide sequence of the partial cDNA clone encodes a polypeptide of 414 amino acids (SEQ ID NO:7) with a predicted molecular mass of 45,451 daltons. Analysis of the deduced amino acid sequence predicts STLK4 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain, however the cDNA clone lacks an initiating ATG, so the full extent of it N-terminus is not known. The partial STLK4 protein sequence contains a 178 amino acid catalytic domain corresponding to the C-terminal motifs VI-XI of a serine/threonine kinase, followed by a 236 amino acid C-terminal domain containing two inserts of 25 and 41 amino acids each, relative to the sequence of human STLK2.

[0233] STLK4 is most closely related to human STE20-subfamily kinases, STLK3 (SEQ ID. NO 6), MST3 (GB:AF024636), STLK2 (SEQ ID NO:5), and SOK-1 (GB:X99325) sharing 71.0%, 46.8%, 43.9%, and 37.7% amino acid identity, respectively.

[0234] The 178 amino acid catalytic domain of human STLK4 is most related to human STLK3 (SEQ ID NO. 7), SOK-1 (GB:X99325), MST3 (GB:AF024636), STLK2 (SEQ ID NO:5), and MST1 (GB:U18297), sharing 88.2%, 54.2%, 54.0%, 53.7 and 45.7% amino acid identity, respectively. It also shares strong homology to other STKs from lower organisms including 56.9% to A. thaliana (GB: AC002343), 52.5% to C. elegans (GB: U53153), 46.2% to A. thaliana (GB: Z97336) and 45.7% to A. thaliana (GB: U96613). The activation loop of the human STLK4 catalytic domain conserves three potential threonine phosphorylation sites with other members of the STLK-subfamily of STE20-related kinases (human STE20, MST3, STLK2 and STLK3) that could serve an autoregulatory role on kinase activity.

[0235] The 236 amino acid C-terminal domain of human STLK4 shares 58.1% amino acid identity to both human STLK3 (SEQ ID NO:6) and to a partial human cDNA, DCHT (GB:AF017635). The C-terminal domain of human STLK4 contains a 25 amino acid insert relative to human SOK-1 and shares 87.5% amino acid identity to an insert present in human STLK3.

[0236] The weak sequence homology between the C-termini of human STLK4 and STE20, suggests it may also function as an inhibitory domain for its kinase.

[0237] Mammalian STLK5

[0238] The full-length 2110 bp human STLK5 cDNA encodes a polypeptide of 373 amino acids (SEQ ID NO:97) with a predicted molecular mass of 41,700 daltons. Analysis of the deduced amino acid sequence predicts STLK5 to be an intracellular STE20-subfamily kinase, lacking both a signal sequence and transmembrane domain. STLK5 contains a 10 amino acid N-terminal domain, a 311 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, and a 52 amino acid C-terminal domain.

[0239] STLK5 is most closely related to the human STE20-subfamily kinases STLK6 (SEQ ID No. 99) and SPAK (AFO99989), sharing 51% and 33% amino acid identity, respectively, over its full extent. It also shares significant homology to database entries from Arabidopsis thaliana (GB:AC002343) and C.elegans (GB:AL023843, GB:AL023843).

[0240] The 10 amino acid N-terminal domain of human STLK5 does not reveal any significant homologies to the protein database.

[0241] The 311 amino acid catalytic domain of human STLK5 shares 51% and 34% identity to STLK6 and SPAK, respectively. The catalytic domain of STLK5 contains a 45 amino acid insert between kinase subdomains X and XI relative to human STE20. Multiple human EST fragments as well as a murine EST (GB:AA575647) contain this insert providing evidence that this region is an integral part of STLK5.

[0242] The 52 amino acid C-terminal tail of human STLK5 shares 41.3% amino acid identity to human SOK-1 (GB:X99325). The weak sequence homology between the C-termini of human STLK5 and STE20, suggests it may also function as an inhibitory domain for its kinase.

[0243] Mammalian STLK6

[0244] The 2,001 bp human STLK6 nucleotide sequence of the complete cDNA encodes a polypeptide of 418 amino acids (SEQ ID NO:99) with a predicted molecular mass of 47,025 daltons. Analysis of the deduced amino acid sequence predicts STLK6 to be an intracellular STE20-subfamily kinase, lacking both a signal sequence and transmembrane domain. STLK6 contains a 57 amino acid N-terminal domain, a 312 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, followed by a 49 amino acid C-terminal domain.

[0245] STLK6 is most closely related to human STE20-subfamily kinases STLK5 (SEQ ID NO:97), STLK7 (SEQ ID NO:101), and SPAK (AF099989), sharing 50%, 35%, and 30% amino acid identity over its full extent. It also shares significant homology to database entries from Arabidopsis thaliana (GB:AC002343) and C.elegans (GB:U53153). The 57 amino acid N-terminal domain of human STLK6 does not reveal any significant homologies in the protein database.

[0246] The 312 amino acid catalytic domain of human STLK6 shares 51 and 30% identity to human STLK5 and SPAK, respectively.

[0247] The 49 amino acid C-terminal tail of human STLK6 shares low amino acid sequence identity (29%) with STLK5 and SPAK.

[0248] Mammalian STLK7

[0249] The 311 bp human STLK7 nucleotide sequence of the partial cDNA encodes a polypeptide of 103 amino acids (SEQ ID NO:101). Analysis of the deduced amino acid sequence predicts STLK7 to be an internal fragment of an intracellular STE20-family kinase. This sequence lacks the N- and C-terminal portions of STLK7 and contains only the N-terminal 103 amino acids of the predicted catalytic domain.

[0250] Human STLK7 is most closely related to human STE20-subfamily kinases SPAK (AF099989), STLK5 (SEQ ID NO:97), and STLK6 (SEQ ID NO:99), sharing 86%, 38%, and 35% amino acid identity within this region of the kinase domain. It also shares significant homology to database entries from Arabidopsis thaliana (GB:AC002343) and Drosophila melanogaster (GB:AF006640).

[0251] Mammalian ZC1

[0252] The 3798 bp human ZC1 nucleotide sequence encodes a polypeptide of 1239 amino acids (SEQ ID NO:13) with a predicted molecular mass of 142,140 daltons. Analysis of the deduced amino acid sequence predicts ZC1 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The full-length ZC1 protein contains a 22 amino acid N-terminus, a 267 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 237 amino acid region predicted to form a coiled-coil structure, a 114 amino acid proline-rich region, a 256 amino acid spacer region, followed by a 343 amino acid C-terminal domain containing a potential Rab/Rho-binding region.

[0253] ZC1 is most closely related to the human STE20-subfamily kinases ZC2 (SEQ ID NO:14), ZC3 (SEQ ID NO:15), and ZC4 (SEQ ID NO:16), sharing 61.7%, 60.9%, and 43.8% amino acid identity, respectively. ZC1 also shares 45.5% amino acid identity to a C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029). ZC1 exhibits 90.0% amino acid homology to murine NIK (GB:U88984), suggesting it may be the human orthologue of this STK.

[0254] The 22 amino acid N-terminal domain of human ZC1 is 58.8% identical to the C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029), and 100% identical to murine NIK (GB: U88984). Human ZC1 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0255] The 267 amino acid catalytic domain of human ZC1 is most related to human STE20-subfamily kinases, ZC3 (SEQ ID NO:15), ZC2 (SEQ ID NO:14), KHS2 (SEQ ID NO:18), SOK-1 (GB:X99325), GCK (GB:U07349), and GEK2 (SEQ ID NO:107), and to the C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029) sharing 90.6%, 90.2%, 50.6%, 47.4%, 45.4%, 42.5% and 82.6% amino acid identity, respectively. The ZC1 kinase domain shares 98.1% identity to murine NIK (GB:U88984). ZC1 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3, PAK4 and PAK5.

[0256] Immediately C-terminal to the kinase domain of human ZC1 is a 237 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm (Lupas, A. Meth. Enzymol. 266, 513-525 (1996)). This region of ZC1 is most related to human STE20-subfamily kinases, ZC3 (SEQ ID NO:15), ZC2 (SEQ ID NO:14), and GEK2 (SEQ ID NO:107), as well as to human PITSLRE (GB:U04824) sharing 65.5%, 65.4%, 25.3%, and 29.0% amino acid identity, respectively. The ZC1 coiled-coil domain also shares 90.6% amino acid homology to murine NIK. The C. elegans homologue ZC504.4 shares 32.2% sequence identity over this region.

[0257] Within the predicted coiled-coil domain of human ZC1, and the related ZC3, is a region predicted to form a leucine zipper (Leu-X6-Leu-X6-Leu-X6-Leu-X20-Leu-X6-Leu). The fact that this leucine repeat exists within a predicted coiled-coil structure suggests that the leucine zipper may have a high probability of serving as a dimerization interface (Hirst, J. D. et al Protein Engineering 9 657-662 (1996)) mediating a potential inter- or intra-molecular dimerization of human ZC1.

[0258] The 114 amino acid proline-rich region of human ZC1 is most related to human STE20-subfamily kinases, ZC2 (SEQ ID NO:14) and ZC3 (SEQ ID NO:15), sharing 35.8%, and 24.9%, respectively. The ZC1 proline-rich domain shares 36.4% amino acid homology to murine NIK (GB:U88984). Three potential “PxxP” SH3 domain-binding motifs (I, II and III) are found within the proline-rich region of human ZC1. Motif I is conserved in human ZC1 and C. elegans ZC504.4 (GB:Z50029). Motif II is conserved in ZC1, ZC2, ZC3, ZC4 and C. elegans ZC504.4. Motif III is conserved in ZC1, ZC2, ZC3 and ZC4. Motifs II and III of murine NIK have been shown to bind the SH3 motif of the adaptor molecule Nck (Su, Y-C. et al, EMBO J. 16, 1279-1290 (1997)). From this evidence, human ZC1 may have the potential to bind to Nck or other SH3 or WW domain-containing proteins and participate in growth factor-induced signaling pathways.

[0259] The 256 amino acid spacer region of human ZC1 is most related to human STE20-subfamily kinases, ZC2 (SEQ ID NO:14) and ZC3 (SEQ ID NO:15), as well as to human PITSLRE (GB:U04824), sharing 59.9%, 33.1%, 29.6%, and 26.4% amino acid identity, respectively. It also shares 59.9% amino acid homology to murine NIK. The C. elegans homologue ZC504.4 has only limited sequence similarity in this spacer region.

[0260] The 343 amino acid C-terminal of human ZC1 is most related to human STE20-subfamily kinases, ZC3 (SEQ ID NO:15), ZC2 (SEQ ID NO:14), and ZC4 (SEQ ID NO:16), sharing 89.2%, 88.9%, and 42.3%, amino acid identity, respectively. The ZC1 C-terminal domain also shares 98.8% amino acid identity to murine NIK. The C. elegans homologue ZC504.4 also shares 68.7% amino acid identity with the C-tail of human ZC1. A lower, yet significant, homology is also evident to human KHS2 (SEQ ID NO:18), GCK (GB:U07349), and murine citron (GB:U07349) with 26.6%, 23.1% and 36.2% amino acid identity, respectively. GCK is a STE20-family kinase whose C-terminal domain has been shown to bind the small G-protein Rab8 (Ren, M. et al., Proc. Natl. Acad. Sci. 93, 5151-5155 (1996)). Citron is a non-kinase Rho-binding protein (Madaule, P. et al., FEBS Lett. 377, 243-238 (1995)).

[0261] The sequence similarity of the C-terminal region of ZC1 to proteins that have potential Rab- or Rho-binding domains suggests that ZC1 may signal through a small G-protein-dependant pathway.

[0262] Mammalian ZC2

[0263] The 4055 bp human ZC2 nucleotide sequence of the partial cDNA encodes a polypeptide of 1297 amino acids (SEQ ID NO:14) with a predicted molecular mass of 147,785 daltons. Analysis of the deduced amino acid sequence predicts ZC2 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain, however the cDNA clone lacks an initiating ATG, so the full extent of it N-terminus is not known. The N-terminally truncated ZC2 protein contains a 255 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 187 amino acid region predicted to form a coiled-coil structure, a 184 amino acid proline-rich region, a 328 amino acid spacer region, followed by a 343 amino acid C-terminal domain containing a potential Rab/Rho-binding region.

[0264] ZC2 is most closely related to the human STE20-subfamily kinases ZC3 (SEQ ID NO:15), ZC1 (SEQ ID NO:13), and ZC4 (SEQ ID NO:16), sharing 88.3%, 61.7%, and 41.9% amino acid identity, respectively, and shares 41.7% amino acid identity to a C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029).

[0265] The 255 amino acid catalytic domain of human ZC2 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15), SOK-1 (GB:X99325), KHS2 (SEQ ID NO:18), MST1 (GB:U18297), and GCK (GB:U07349), and to the C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029) sharing 90.2%, 89.8%, 49.0%, 48.6%, 47.9%, 45.0 and 76.7% amino acid identity, respectively. ZC2 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3, PAK4 and PAK5.

[0266] Immediately C-terminal to the kinase domain of human ZC2 is a 187 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm (supra). This region of ZC2 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15), and GEK2 (SEQ ID NO:107), as well as to human PITSLRE (GB:U04824), sharing 65.8%, 61.5%, 29.7% and 29.6% amino acid identity, respectively. The C. elegans homologue ZC504.4 shares 30.8% sequence identity over this region. Human ZC2 lacks the potential leucine zipper found in ZC1 as a consequence of a 29 amino acid deletion relative to ZC1 and ZC3.

[0267] The 184 amino acid proline-rich region of human ZC2 is most related to human STE20-subfamily kinases, ZC3 (SEQ ID NO:15) and ZC1 (SEQ ID NO:13), sharing 35.9% and 28.6%,amino acid identity, respectively. Significant homology is also evident to the murine WW domain-binding protein WBP7 (GB:U92455), and to the human SH3 domain-binding protein 3BP-1 (GB:X87671), with 27.7% and 25.3% amino acid identity, respectively.

[0268] ZC2 contains two of the potential “PxxP” SH3 domain-binding motifs (II and III) found within the proline-rich region of human ZC1. Motif II is conserved in ZC1, ZC3, ZC4 and C. elegans ZC504.4, and Motif III is conserved in ZC1, ZC3 and ZC4. Motifs II and III of murine NIK have been shown to bind the SH3 motif of the adaptor molecule Nck. From this evidence, human ZC1 may have the potential to bind to Nck or other SH3 or WW domain-containing proteins, and to participate in growth factor-induced signaling pathways.

[0269] The 328 amino acid spacer region of human ZC2 is most related to human STE20-subfamily kinases ZC1 (SEQ ID NO:13) and ZC3 (SEQ ID NO:15), and to murine NIK (GB:U88984), sharing 31.6%, 26.9% and 25.9% amino acid identity, respectively. The C. elegans homologue ZC504.4 has only limited sequence similarity in this spacer region.

[0270] The 343 amino acid C-terminal of human ZC2 is most related to human STE20-subfamily kinases ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15) and ZC4 (SEQ ID NO:16), and to murine NIK (GB:U88984), sharing 88.9%, 88.3%, 41.9%, and 88.0%, amino acid identity, respectively. The C. elegans homologue, ZC504.4, also shares 67.2% amino acid identity with the C-tail of human ZC2. A lower, yet significant, homology is also evident to human GCK (GB:U07349), murine citron (GB:U07349), and the S. cerevisiae ROM2 protein (GB:U19103), a Rhol GDP/GTP exchange factor, with 22.3%, 22.2% and 21.9% amino acid identity, respectively.

[0271] The sequence similarity of the C-terminal region of ZC2 to proteins that have potential Rab- or Rho-binding domains suggests that ZC2, like ZC1, may also signal through a small G-protein-dependant pathway.

[0272] Mammalian ZC3

[0273] The 4133 bp human ZC3 nucleotide sequence of the partial cDNA encodes a polypeptide of 1326 amino acids (SEQ ID NO:15) with a predicted molecular mass of 149,906 daltons. Analysis of the deduced amino acid sequence predicts ZC3 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain, however the cDNA clone lacks an initiating ATG, so the full extent of it N-termius is not known. The N-terminally truncated ZC3 protein contains a 255 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase: a 221 amino acid region predicted to form a coiled-coil structure, a 204 amino acid proline-rich region, and a 303 amino acid spacer region followed by a 343 amino acid C-terminal domain containing a potential Rab/Rho-binding region.

[0274] ZC3 is most closely related to the human STE20-subfamily kinases ZC1 (SEQ ID NO:13), ZC2 (SEQ ID NO:14), and ZC4 (SEQ ID NO:16), sharing 62.0%, 61.0%, and 42.5% amino acid identity, respectively and shares 46.7% amino acid identity to a C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029).

[0275] The 255 amino acid catalytic domain of human ZC3 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13), ZC2 (SEQ ID NO:14), SOK-1 (GB:X99325), KHS2 (SEQ ID NO:18), GCK (GB:U07349), SULU1 (SEQ ID NO:22), and GEK2 (SEQ ID NO:107), and to the C. elegans kinase encoded by the cosmid ZC504.4 (GB:Z50029) sharing 90.6%, 89.3%, 49.0%, 48.3%, 45.0%, 43.1%, 42.3% and 76.7% amino acid identity, respectively. ZC1 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC2, GEK2, KHS2, SULU1, SULU3, PAK4 and PAK5.

[0276] Immediately C-terminal to the kinase domain of human ZC3 is a 221 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm (supra). This region of ZC3 is most homologous to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13), ZC2 (SEQ ID NO:14), and GEK2 (SEQ ID NO:107), sharing 66.9%, 61.5%, and 27.5% identity, as well as to rat PLC-beta (GB:A45493) and human PITSLRE (GB:H54024) sharing 29.6% and 25.9% amino acid identity, respectively. The C. elegans homologue ZC504.4 shares 26.8% sequence identity over this region.

[0277] Within the predicted coiled-coil domain of human ZC3, and the related ZC1, is a region predicted to form a leucine zipper (Leu-X6-Leu-X6-Leu-X6-Leu-X20-Leu-X6-Leu). The fact that this leucine repeat exists within a predicted coiled-coil structure suggests that the leucine zipper may have a high probability of serving as a dimerization interface (Hirst, J. D. et al Protein Engineering 9 657-662 (1996)) mediating a potential inter- or intra-molecular dimerization of human ZC3.

[0278] The 204 amino acid proline-rich region of human ZC3 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13) and ZC2 (SEQ ID NO:14), sharing 66.9% and 61.5% amino acid identity, respectively.

[0279] ZC3 contains two of the potential “PxxP” SH3 domain-binding motifs (II and III) found within the proline-rich region of human ZC1. Motif II is conserved in ZC1, ZC2, ZC4 and C. elegans ZC504.4; Motif III is conserved in ZC1, ZC2 and ZC4. Motifs II and III of murine NIK have been shown to bind the SH3 motif of the adaptor molecule Nck. From this evidence, human ZC3 may have the potential to bind to Nck or other SH3 or WW domain-containing proteins and participate in growth factor-induced signaling pathways.

[0280] The 303 amino acid acid spacer region of human ZC3 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13) and ZC2 (SEQ ID NO:14) sharing 30.1%, and 27.1% amino acid identity, respectively. The C. elegans homologue ZC504.4 lacks nearly the entire spacer region of ZC3.

[0281] The 343 amino acid C-terminal of human ZC3 is most related to human STE20-subfamily kinases, ZC1 (SEQ ID NO:13), ZC2 (SEQ ID NO:14) and ZC4 (SEQ ID NO:16), sharing 89.2%, 88.9%, and 42.5%, amino acid identity, respectively. The C. elegans homologue ZC504.4 also shares 67.2% amino acid identity with the C-tail of human ZC3. A lower, yet significant, homology is also evident to human GCK (GB:U07349), as well as to the non-kinases murine citron (GB:U07349) and the S. cerevisiae ROM2 protein (GB:U19103), a Rhol GDP/GTP exchange factor, with 21.6%, 32.4% and 22.9% amino acid identity, respectively.

[0282] The sequence similarity of the C-terminal region of ZC3 to proteins that have potential Rab- or Rho-binding domains suggests that ZC3, like ZC1 and ZC2, may signal through a small G-protein-dependant pathway.

[0283] Mammalian ZC4

[0284] The 3,684 bp human ZC4 nucleotide sequence of the complete cDNA encodes a polypeptide of 1,227 amino acids (SEQ ID NO:105) with a predicted molecular mass of 138,205 Daltons. Analysis of the deduced amino acid sequence predicts ZC4 to be an intracellular STE20-subfamily kinase, lacking both a signal sequence and a transmembrane domain. The full-length ZC4 protein contains a 25 amino acid N-terminus, a 265 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 108 amino acid region predicted to form a coiled-coil structure, a 231 amino acid proline-rich region, a 40 amino acid region predicted to form a coiled-coil structure spacer region, a 204 amino acid spacer region (domain B), followed by a 355 amino acid C-terminal domain containing a potential Rab/Rho-binding region (domain C).

[0285] ZC4 is most closely related to human ZC1 (SEQ ID NO:13, also known as human HGK, human KIAA0687, murine NIK, human AC005035, human NIK, and C. elegans MIG-15), ZC2 (SEQ ID NO:14, similar to partial sequence human KIAA0551), and ZC3 (SEQ ID NO:15). An assembled genomic fragment in the database (Z83850) is identical to ZC4, except for inappropriate identification of the exon boundaries. (Abo et al. (1998) EMBO J. 17: 6527-6540.)

[0286] The 25 amino acid N-terminal domain of human ZC4 shares weak homology to human ZC1 in its C-terminal extent, but otherwise does not reveal any significant homologies to the protein database.

[0287] The 265 amino acid catalytic domain of human ZC4 is most related to human ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15), and ZC2 (SEQ ID NO:14), sharing 63%, 64% and 62% amino acid identity, respectively.

[0288] Immediately C-terminal to the kinase domain of human ZC4 is a 108 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm (supra). This region is most related to human ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15), and ZC2 (SEQ ID NO:14), sharing 29%, 25% and 20% amino acid identity, respectively.

[0289] The 231 amino acid proline-rich region of human ZC4 does not reveal any significant homologies to the protein database. This region of ZC4 contains two “PxxP” motifs that could potentially bind to proteins containing SH3 or WW domains and allow ZC4 to participate in growth factor activated signaling pathways. In addition, within the pro-rich domain of human ZC4 is a region predicted to form a leucine zipper (Leu-X6-Leu-X6-Leu-X6-Leu-X20-Leu-X6-Leu) which may serve as a dimerization interface. The ZC STE20 subfamily kinases (ZC1, ZC2 and ZC3) have similarly located “PxxP’ motifs and potential Leu zippers.

[0290] Immediately C-terminal to the proline-rich region of human ZC4 is a 40 amino acid region also predicted to form a coiled-coil structure based on the Lupas algorithm. This region of human ZC4 does not reveal any significant homologies to the protein database.

[0291] The 204 amino acid acidic- and serine-rich domain “B” of ZC4 does not reveal any significant homologies to the protein database.

[0292] The 355 amino acid C-terminal of human ZC4 is most related to human ZC1 (SEQ ID NO:13), ZC3 (SEQ ID NO:15), and ZC2 (SEQ ID NO:14), sharing 43%, 42% and 42% amino acid identity, respectively.

[0293] The sequence similarity of the C-terminal region of ZC4 to proteins that have potential Rab- or Rho-binding domains suggests that ZC4, like other ZC-subfamily STE20 kinases, may signal through a small G-protein-dependant pathway.

[0294] Mammalian KHS2

[0295] The 4023 bp human KHS2 nucleotide sequence encodes a polypeptide of 894 amino acids (SEQ ID NO:18) with a predicted molecular mass of 101,327 daltons. Analysis of the deduced amino acid sequence predicts KHS2 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The full-length KHS2 protein contains a 13 amino acid N-terminus, a 260 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 73 amino acid spacer region, a 188 proline-rich region, followed by a 360 amino acid C-terminal domain containing a potential Rab/Rho-binding site.

[0296] KHS2 is most closely related to the human STE20-subfamily kinases KHS1 (GB:U177129), GCK (GB:U07349), and HPKl (GB:U07349), sharing 65.5%, 51.9%, and 44.9% amino acid identity, respectively and shares 38.5% amino acid identity to a C. elegans STK (GB:U55363).

[0297] The 13 amino acid N-terminal domain of human KHS2 does not reveal any significant homologies that might suggest a potential function for this domain when examined by a Smith-Waterman alignment to the nonredundant protein database. Human KHS2 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristylation.

[0298] The 260 amino acid catalytic domain of human KHS2 is most related to human STE20-subfamily kinases KHS1 (GB:U177129), GCK (GB:U07349), HPK1 (GB:U66464), SOK-1 (GB:X99325), MST1 (GB:U18297), ZC1 (SEQ ID NO:13), and to the C. elegans kinase (GB:U55363), sharing 85.4%, 75.1%, 67.7%, 51.4%, 48.1%, 49.8% and 72.0% amino acid identity, respectively. KHS2 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC2, ZC3, ZC4, GEK2, SULU1, SULU3, PAK4 and PAK5.

[0299] The 73 amino acid acid spacer region of human KHS2 is most related to human STE20-subfamily kinases, KHS1 (GB:U177129), HPKl (GB:U66464) and GCK (GB:U07349), sharing 60.3%, 43.5% and 44.0%, amino acid identity, respectively.

[0300] The 188 amino acid proline-rich region of human KHS2 is most related to human STE20-subfamily kinases, HPK1 (GB:U66464), GCK (GB:U07349) and KHS1 (GB:U177129), sharing 33.3%, 31.9% and 31.4%, amino acid identity, respectively.

[0301] Two potential “PxxP” SH3 domain-binding motifs (I and II) are found within the proline-rich region of human KHS2. Motif I is conserved with human KHS1 and HPK1; motif II is conserved with GCK and KHS2. A 192 amino acid region of human HPKl containing motif II has been shown to bind to the C-terminal SH3 motif of the adaptor molecule Grb2 (Anafi, M et al, J. Biol. Chem. J. 272, 27804-27811 (1997)). Human KHS2 may bind SH3 or WW domain-containing proteins through this proline-rich region.

[0302] The 360 amino acid C-terminal of human KHS2 is most related to KHS1 (GB:U177129), GCK (GB:U07349) and HPK1 (GB:U66464), and to the C. elegans kinase (GB:U55363), sharing 74.9%, 54.8%, 42.9%, and 31.0%, amino acid identity, respectively. GCK is a STE20-family kinase whose C-terminal domain has been shown to bind the small G-protein Rab8 (Ren, M. et al., Proc. Natl. Acad. Sci. 93, 5151-5155 (1996)).

[0303] Mammalian SULU1

[0304] The 4196 bp human SULU1 nucleotide sequence encodes a polypeptide of 898 amino acids (SEQ ID NO:22) with a predicted molecular mass of 105,402 daltons. Analysis of the deduced amino acid sequence predicts SULU1 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The full-length SULU1 protein contains a 21 amino acid N-terminus, a 256 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 150 amino acid spacer region, a 210 amino acid region predicted to form a coiled-coil structure, a 114 amino acid spacer region and a 147 amino acid C-terminal domain predicted to form a coiled-coil structure.

[0305] SULU1 is most closely related to the STE20-subfamily kinases murine SULU3 (SEQ ID NO:24), human SULU3 (SEQ ID NO:23), and to the C. elegans kinase SULU (GB:U11280), sharing 68.9%, 72.2% and 38.2% amino acid identity, respectively.

[0306] The 21 amino acid N-terminal domain of human SULU1 is most related to murine SULU3 (SEQ ID NO:24) and to the C. elegans kinase SULU (GB:U11280), sharing 86.3% and 62.3% amino acid identity. Human SULU1 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristoylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0307] The 256 amino acid catalytic domain of human SULU1 is most related to murine SULU3 (SEQ ID NO:24), and to human SOK-1 (GB:X99325), STLK2 (SEQ ID NO:5), MST1 (GB:U18297), PAK1 (GB:U24152), ZC2 (SEQ ID NO:14), and KHS2 (SEQ ID NO:18) sharing 86.3%, 48.1%, 46.9%, 45.2%, 43.3%, 43.1% and 42.0% amino acid identity, respectively. The C. elegans SULU STK (GB:U11280) shares 62.3% sequence identity over this region. SULU1 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC2, ZC3, ZC4, GEK2, KHS2, SULU3, PAK4 and PAK5.

[0308] The 150 amino acid spacer region of human SULU1 is most related to human SULU3 (SEQ ID NO:23) and to the C. elegans kinase (GB:U11280), sharing 53.5% and 10.4% amino acid identity, respectively.

[0309] Immediately C-terminal to the spacer region of human SULU1 is a 210 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of SULU1 is most related to SULU3 (SEQ ID NO:23), the C. elegans SULU kinase (GB:U11280), GEK 2 (SEQ ID NO:107) and ZC1 (SEQ ID NO:13), sharing 68.6%,26.8%,23.2%, and 22.8% amino acid identity, respectively.

[0310] The 114 amino acid spacer region human SULU1 is most related to human SULU3 (SEQ ID NO:24) with 73.7% amino acid sequence identity. A lower, yet significant, homology is also evident to murine PITSLRE (GB:U04824) and DLK (GB:A55318), human ZC1 (SEQ ID NO:13) and GEK 2 (SEQ ID NO:107), as well as to the C. elegans SULU STK (GB:U11280), sharing 39.7%, 35.4%, 29.5%, 23.6% and 37.6% amino acid identity, respectively.

[0311] Immediately C-terminal to the second spacer region of human SULU1 is a 147 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of SULU1 is most related to human SULU3 (SEQ ID NO:24), ZC1 (SEQ ID NO:13) and GEK 2 (SEQ ID NO:107), as well as to the C. elegans SULU STK (GB:U11280), sharing 73.3%, 28.4%, 26.1% and 39.5%, amino acid identity, respectively.

[0312] Mammalian (Human) SULU3

[0313] The 3824 bp partial cDNA human SULU3 nucleotide sequence encodes a polypeptide of 786 amino acids (SEQ ID NO:23) with a predicted molecular mass of 92,037 daltons. Analysis of the deduced amino acid sequence predicts SULU3 to be an intracellular serine/threonine kinase lacking a transmembrane domain. The N-terminally truncated human SULU3 protein contains a 66 amino acid partial catalytic domain followed by a 149 amino acid spacer region, a 210 amino acid region predicted to form a coiled-coil structure, a second spacer region of 114 amino acids, a 247 amino acid C-terminal region predicted to form a second coiled-coil structure and a 100 amino acid C-terminal tail.

[0314] Human SULU3 is most closely related murine SULU3 (SEQ ID NO:24), human SULU1 (SEQ ID NO:22), and to the C. elegans SULU kinase (GB:U11280), sharing 66.3%, 68.9% and 32.9% amino acid identity, respectively. The high sequence homology between murine and human SULU3 suggests that these two proteins are orthologs of each other.

[0315] The 66 amino acid partial catalytic domain of human SULU3 is most related to murine SULU3 (SEQ ID NO:24), and to the human STE20 subfamily kinases ZC1 (SEQ ID NO:13), STE20 (GB:X99325), KHS1(GB:U177129) and GEK 2 (SEQ ID NO:107), as well as to the C. elegans SULU kinase (GB:U11280), sharing 83.3%, 47.0%, 45.5%, 43.5%,41.8% and 55.6% amino acid identity, respectively.

[0316] The 149 amino acid spacer region of human SULU3 is most related to murine SULU3 (SEQ ID NO:24), human STE20 (GB:X99325), MST1 (GB:U18297), and to the C.elegans SULU kinase (GB:U11280) sharing 98.7%, 21.9% and 21.8% amino acid identity, respectively.

[0317] Immediately C-terminal to the first spacer region of human SULU3 is a 210 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of SULU3 is most related to murine SULU3 (SEQ ID NO:24), and to human SULU1 (SEQ ID NO:22), ZC1 (SEQ ID NO:13) and GEK 2 (SEQ ID NO:107), as well as to the C. elegans SULU kinase (GB:U11280), sharing 99. 5%, 68.6%, 27.4% and 22.5% amino acid identity, respectively.

[0318] The 114 amino acid second spacer region of human SULU3 is most related to murine SULU3 (SEQ ID NO:24), and to human SULU1 (SEQ ID NO:22) GEK 2 (SEQ ID NO:107), and ZC1 (SEQ ID NO:13), as well as to the C. elegans SULU kinase (GB:U11280), sharing 99.1%, 73.7%, 24.6%,24.1% and 41.2% amino acid identity, respectively.

[0319] Immediately C-terminal to the second spacer region of human SULU3 is a 247 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm (supra). This region of SULU3 is most related to human SULU1 (SEQ ID NO:22) and ZC1 (SEQ ID NO:13) as well as to rat PKN-(GB:D26180) murine pl60 ROCK1 (GB:U58512), and the C. elegans SULU kinase (GB:U11280), sharing 73.7%, 26.7%, 24.0% and 21.0% amino acid identity, respectively.

[0320] The 100 amino acid C-tail of human SULU3 is most related to a human prion protein (GB:L38993), with 45.0% amino acid identity.

[0321] Mammalian (Murine) SULU3

[0322] The 2249 bp murine, partial cDNA SULU3 nucleotide sequence encodes a polypeptide of 748 amino acids (SEQ ID NO:24) with a predicted molecular mass of 87,520 daltons. Analysis of the deduced amino acid sequence predicts SULU3 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The partial murine SULU3 protein contains a 25 amino acid N-terminus, a 248 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 149 amino acid spacer region, a 210 amino acid region predicted to form a coiled-coil structure, and a 116 amino acid spacer region.

[0323] Murine SULU3 is most closely related to human SULU3 (SEQ ID NO:23) and SULU1 (SEQ ID NO:22), as well as to the C. elegans SULU kinase (GB:U112 80), sharing 97.0%, 72.3% and 38.4% amino acid identity, respectively. The high sequence homology between murine and human SULU3 suggests that these two proteins are orthologs.

[0324] The 25 amino acid N-terminal domain of murine SULU3 is most related to human SULU1 (SEQ ID NO:22) and to the C. elegans SULU kinase (GB:U11280), sharing 70.0% and 44.4% amino acid identity, respectively.

[0325] Murine SULU3 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristoylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0326] The 248 amino acid catalytic domain of murine SULU3 is most related to human SULU1 (SEQ ID NO:22), STE20 (GB:X99325), ZC1 (SEQ ID NO:13), and KHS1 (GB:U77129), as well as to the C. elegans SULU kinase (GB:U11280), sharing 86.7%, 46.6%, 43.3%, 59.4% amino acid identity, respectively. Murine SULU3 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3, PAK4 and PAK5.

[0327] The 149 amino acid spacer of murine SULU3 is most related to human SULU3 (SEQ ID NO:23), SULU1 (SEQ ID NO:22), and STE20 (GB:X99325), as well as to the C. elegans SULU (GB:U11280) and the S. cerevisiae STE20 (GB:L04655) kinases, sharing 98.7%, 53.4%, 21.9%, 59.4% and 21.9% amino acid identity, respectively.

[0328] Immediately C-terminal to the spacer region of murine SULU3 is a 210 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of murine SULU3 is most related to human SULU3 (SEQ ID NO:23), ZC1 (SEQ ID NO:13), and GEK 2 (SEQ ID NO:107), as well as to the C. elegans SULU kinase (GB:U11280), sharing 99.5%, 27.4%, 22.5% and 29.2% amino acid identity, respectively.

[0329] The 116 amino acid C-terminal spacer region of murine SULU3 is most related to human SULU3 (SEQ ID NO:23), GEK 2 (SEQ ID NO:107), and ZC1 (SEQ ID NO:13), well as to the C. elegans SULU kinase (GB:U11280), sharing 98.3%, 24.6%, 24.1% and 40.5% amino acid identity, respectively.

[0330] Mammalian (Murine/Human) SULU3

[0331] The 2249 bp murine SULU3 and the 3824 bp human SULU3 cDNAs contain a 1620 nucleotide overlap (541 amino acids) with 90% and 98% DNA and amino acid sequence identity, respectively. Owing to the high degree of sequence identity in this extended overlap, we propose that these are functional orthologues of a single gene. The combined murine/human 4492 bp SULU3 sequence encodes a polypeptide of 1001 amino acids (SEQ ID NO:31) with a predicted molecular mass of 116,069 daltons. Analysis of the deduced amino acid sequence predicts SULU3 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. SULU3 contains a 25 amino acid N-terminus, a 248 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 149 amino acid spacer region, a 210 amino acid region predicted to form a coiled-coil structure and a second spacer region of 114 amino acids, a 247 amino acid C-terminal region predicted to form a second coiled-coil structure and a 100 amino acid C-terminal tail. The murine SULU3 clone lacks the region from the second C-terminal coiled-coil to the C-terminus, whereas the human clone lacks the N-terminal domain, and all but 66 amino acids of the 248 amino acid kinase domain.

[0332] SULU3 is most closely related to SULU1 (SEQ ID NO:22) and the C. elegans SULU kinase (GB:U11280) sharing 72.3% and 38.4% amino acid identity, respectively.

[0333] The 25 amino acid N-terminal domain of SULU3 is most related to human SULU1 (SEQ ID NO:22) and to the C. elegans SULU kinase (GB:U11280), sharing 70.0% and 44.4% amino acid identity, respectively. SULU3 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0334] The 248 amino acid catalytic domain of SULU3 is most related to human SULU1 (SEQ ID NO:22), SOK-1 (GB:X99325), ZC1 (SEQ ID NO:13), KHS1 (GB:U77129) and the C. elegans SULU kinase (GB:U11280), sharing 86.7%, 46.6%, 43.3%, 42.0% and 59.4% amino acid identity, respectively. SULU3 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, PAK4 and PAK5.

[0335] The 149 amino acid spacer of SULU3 is most related to SULU1 (SEQ ID NO:22) and SOK-1 (GB:X99325), and to the C. elegans SULU (GB:U11280), and S. cerevisiae STE20 (GB:L04655) kinases, sharing 53.4%, 21.9%, 59.4% and 21.9% amino acid identity, respectively.

[0336] Immediately C-terminal to the spacer region of SULU3 is a 210 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region is most related to ZC1 (SEQ ID NO:13), GEK 2 (SEQ ID NO:107), and the C. elegans SULU kinase (GB:U11280), sharing 27.4% 22.5% and 29.2% amino acid identity, respectively.

[0337] The 114 amino acid spacer region of SULU3 is most related to human SULU1 (SEQ ID NO:22), GEK 2 (SEQ ID NO:107), ZC1 (SEQ ID NO:13), and to the C. elegans SULU kinase (GB:U11280), sharing 73.7%, 24.6%, 24.1% and 41.2% amino acid identity, respectively.

[0338] Immediately C-terminal to the second spacer region of SULU3 is a 247 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of SULU3 is most related to human SULU1 (SEQ ID NO:22) and ZC1 (SEQ ID NO:13), as well as to rat PKN (GB:D26180), murine p160 ROCK1 (GB:U58512) and the C. elegans SULU kinase (GB:U11280), sharing 73.7%, 26.7%, 24.0%, 21.0% and 37.6% amino acid identity, respectively.

[0339] The 100 amino acid C-tail of SULU3 is most related to a human prion protein (GB:L38993) with 45.0% amino acid identity.

[0340] Mammalian GEK2

[0341] The 2926 bp human GEK2 nucleotide sequence of the complete cDNA encodes a polypeptide of 968 amino acids (SEQ ID NO:107) with a predicted molecular mass of 112,120 daltons. Analysis of the deduced amino acid sequence predicts GEK2 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The complete GEK2 protein contains a 33 amino acid N-terminus, a 261 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase, a 43 amino acid spacer region, a 135 amino acid proline-rich region, a 252 amino acid region predicted to form a coiled-coil structure followed by a 244 amino acid region also predicted to form a coiled-coil structure.

[0342] GEK2 is most closely related to rat AT1-46 (GB:U33472) (a partial cDNA that extends from the middle of the first potential coiled-coil domain of GEK2 to the C-terminus), murine LOK (GB:D89728), Xenopus laevis polo-like kinase 1 (GB:AF100165), and human SLK (GB:AB002804), sharing 91.3%, 88.5%, 65.0%, and 44.7% amino acid identity, respectively. The high sequence homology between human GEK2, murine LOK and rat AT1-46 suggests that human GEK2 is a highly related protein to the rodent forms, or alternatively, its orthologue. Recently, a full-length version of GEK2 was reported (STK10 or human LOK AB015718). The 968 amino acid sequence is 99% identical to GEK2 (SEQ ID NO:107).

[0343] The 33 amino acid N-terminal domain of human GEK2 is most related to murine LOK (GB:D89728) and to human SLK (GB:AB002804), sharing 100% and 54.5% amino acid identity, respectively.

[0344] Human GEK2 lacks a glycine residue at position 2, and is therefore unlikely to undergo myristylation. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this domain.

[0345] The 261 amino acid catalytic domain of human GEK2 is most related to murine LOK (GB:D89728), rat AT1-46 (GB:D89728) and human SLK (GB:AB002804) as well as to a C. elegans kinase (GB:Z81460), sharing 97.7%, 90.8%, 54.5% and 55.9% amino acid identity, respectively. GEK2 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3, PAK4 and PAK5.

[0346] The 43 amino acid spacer region of human GEK2 is most related to murine LOK (GB:D89728) and to human SLK, sharing 83.7% and 77.6% amino acid identity, respectively.

[0347] The 135 amino acid proline-rich region of human GEK2 is most related to murine LOK (GB:D89728) with 66.2% amino acid identity, respectively. Within the proline-rich region of human GEK2 is a potential “PxxP” SH3-binding domain conserved with murine LOK.

[0348] Immediately C-terminal to the proline-rich region of human GEK2 is a 252 amino acid region predicted to form a coiled-coil structure based on the Lupas algorithm. This region of human GEK2 is most related to rat AT1-46 (GB:D89728), murine LOK (GB:D89728) and human SLK (GB:AB002804), and ZC2 (SEQ ID NO:14), sharing 90.8%, 86.9%, 42.2%, and 29.7% amino acid identity, respectively.

[0349] Immediately C-terminal to the predicted coiled-coil structure of human GEK2 is a second potential coiled-coil structure of 244 amino acids predicted based on the Lupas algorithm. This region of human GEK2 is most related to rat AT1-46 (GB:D89728) and murine LOK (GB:D89728) as well as to human SLK (GB:AB002804) and ZC1 (SEQ ID NO:13), sharing 91.8%, 92.6%, 70.4% and 26.7% amino acid identity, respectively. The C. elegans kinase (GB:Z81460) shares 31.5% amino acid sequence identity over this region.

[0350] Mammalian PAK4

[0351] The 3604 bp human PAK4 nucleotide sequence encodes a polypeptide of 681 amino acids (SEQ ID NO:29) with a predicted molecular mass of 74,875 daltons. Analysis of the deduced amino acid sequence predicts PAK4 to be an intracellular serine/threonine kinase, lacking both a signal sequence and transmembrane domain. The full-length PAK4 protein contains a 51 amino acid N-terminus predicted to contain a rac-binding motif, a 173 amino acid insert relative to the known mammalian PAK proteins, a 169 amino acid spacer region, a 265 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase and a 23 amino acid C-terminal tail.

[0352] PAK4 is most closely related to human PAK5 (SEQ ID NO:30), PAK1 (GB: U24152), and PAK65 (GB:U25975), as well as to a C. elegans kinase (GB: Z74029), sharing 76.8%, 49.5%, 49.8%, and 34.6% amino acid identity, respectively.

[0353] The 51 amino acid N-terminal domain of human PAK4 is most related to human PAK1 (GB:U24152), and PAK65 (GB:U25975), as well as to a C.elegans kinase (GB: Z74029), sharing 50.0%, 50.0% and 49.0% amino acid identity, respectively.

[0354] The 11 amino acid region at positions 13-23 of human PAK4 fits the consensus for a Cdc42/Rac-binding motif (SXPX4-6HXXH) (Burbelo, P.D., Dreschel, D. and Hall, A. J. Bio. Chem. 270, 29071-29074 (1995)).

[0355] The 173 amino acid insert of human PAK4, relative to the known mammalian PAK proteins, is most related to a C. elegans kinase (GB: Z74029) with 39.0% amino acid identity. A Smith-Waterman search of the nonredundant protein database does not reveal any significant homologies that might suggest a potential function for this region.

[0356] The 169 amino acid spacer of human PAK4 does not reveal any significant homologies that might suggest a potential function for this region. The equivalent spacer region in PAK1 binds to the guanine nucleotide exchange factor PIX (Manser, E. et al (1998) Molecular Cell, 1, 183-192). Since PAK4 differs substantially from PAK1 over this region, the spacer domain of PAK4 may differ in its guanine nucleotide exchange factor binding specificity, relative to PAK1.

[0357] The 265 amino acid catalytic domain of human PAK4 is most related to human PAK5 (SEQ ID NO:30), PAK1 (GB:U24152), GCK (GB:U07349), SOK-1 (GB:X99325), and SLK (GB:AB002804), as well as to the C. elegans (GB: Z74029), and S. cerevisiae STE20-related kinases (GB:L04655), sharing 95.9%, 51.7%, 41.3%, 39.8%, 37.4%, 60.2% and 47.9% amino acid identity, respectively. PAK4 contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3 and PAK5.

[0358] The 23 amino acid C-tail of human PAK4 contains a sequence that is homologous to a G-protein beta subunit binding site (Leeuw, T. et al. Nature, 391, 191-195 (1998)). PAK4 has, therefore, the potential to be activated by both Cdc42- as well as G-protein-dependant pathways.

[0359] Mammalian PAK5

[0360] The 2,806 bp human PAK5 nucleotide sequence of the complete cDNA encodes a polypeptide of 591 amino acids (SEQ ID NO:103) with a predicted molecular mass of 64,071 Daltons. Analysis of the deduced amino acid sequence predicts PAK5 to be an intracellular STE20-subfamily kinase, lacking both a signal sequence and transmembrane domain. The full-length PAKS protein contains a 52 amino acid N-terminus predicted to contain a p21 (small G-protein) binding domain (PDB or CRIB), a 121 amino acid -insert relative to the known mammalian PAK proteins, a 134 amino spacer region, a 265 amino acid catalytic domain with all the motifs characteristic of a serine/threonine kinase and a 19 amino acid C-terminal tail.

[0361] PAK5 is most closely related to Human PAK4 (SEQ ID NO:29), Drosophila melanogaster PAK (also known as “mushroom bodies tiny”) (AJ011578), C45B11.1b from C. elegans (Z74029), and human PAK3 (Q13177) sharing 48% (327/674 aa), 50% (330/651 aa), 43% (234/435 aa excluding gap), and 47% (190/405 aa excluding gap) amino acid identity, respectively. Recently, a full length version of PAK5 was reported (PAK4 AF005046) whose 591 amino acid sequence is identical to PAK5 (SEQ ID NO:103). (Abo, et al. (1998) EMBO J. 17:6527-6540).

[0362] The 52 amino acid N-terminal domain of human PAK5 is most related to human PAK4 (SEQ ID NO:29), Drosophila melanogaster PAK (AJ011578), C45B11.1b from C. elegans (Z74029), and human PAK3 (Q13177), sharing 65%, 57%, 54%, and 53% amino acid identity, respectively.

[0363] The 11 amino acid region at positions 12-22 of human PAK5 (FIG. 18) fits the consensus for a small G-protein binding domain (PDB or CRIB) (SXPX4-6HXXH) (Burbelo, P. D., Dreschel, D. and Hall, A. J. Bio. Chem. 270, 29071-29074 (1995), hereby incorporated by reference herein in its entirety including any figures, tables, or drawings.).

[0364] The 121 amino acid insert of human PAK5 shares 43% amino acid identity with a similar domain from PAK4 (SEQ ID NO:29), but that is absent from other known PAKs.

[0365] The equivalent spacer region in PAK1 binds to the guanine nucleotide exchange factor PIX (Manser, E. et al (1998) Molecular Cell, 1, 183-192 hereby incorporated by reference herein in its entirety including any drawings, figures, or tables.). Since PAK5 differs substantially from PAK1 over this region, the spacer domain of PAK5 may differ in its guanine nucleotide exchange factor binding specificity, relative to PAK1.

[0366] The 134 amino acid collagen-like region of human PAK5 shares 34% amino acid identity to pro-α I type collagen from several species and is not present in other known PAKs.

[0367] The 265 amino acid catalytic domain of human PAK5 is most related to human PAK4 (SEQ ID NO:29), Drosophila melanogaster PAK (AJ011578), C45B11.1b from C. elegans (Z74029), and human PAK3 (Q13177), sharing 78%, 80%, 61%, and 55% amino acid identity, respectively. PAK5 also contains the potential “TPY” regulatory phosphorylation site in its activation loop. This “TPY” motif is conserved in other STE20-related kinases, including ZC1, ZC2, ZC3, ZC4, GEK2, KHS2, SULU1, SULU3 and PAK4.

[0368] The 19 amino acid C-tail shares 80% amino acid identity to a PAK-like homologue identified from genomic DNA (AL031652). Furthermore, this C-terminal region of human PAK5 contains a sequence that is homologous to a G-protein beta subunit binding site (Leeuw, T. et al. Nature, 391, 191-195 (1998) hereby incorporated by reference herein in its entirety including any figures, tables, or drawings). PAK5 has, therefore, the potential to be activated by both, Cdc42 as well as G-protein-dependant pathways.

[0369] V. Antibodies, Hybridomas, Methods of Use and Kits for Detection of STE20-Related Kinases

[0370] The present invention relates to an antibody having binding affinity to a kinase of the invention. The polypeptide may have the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, or a functional derivative thereof, or at least 9 contiguous amino acids thereof (preferably, at least 20, 30, 35, or 40 or more contiguous amino acids thereof).

[0371] The present invention also relates to an antibody having specific binding affinity to a kinase of the invention. Such an antibody may be isolated by comparing its binding affinity to a kinase of the invention with its binding affinity to other polypeptides. Those which bind selectively to a kinase of the invention would be chosen for use in methods requiring a distinction between a kinase of the invention and other polypeptides. Such methods could include, but should not be limited to, the analysis of altered kinase expression in tissue containing other polypeptides.

[0372] The STE20-Related kinases of the present invention can be used in a variety of procedures and methods, such as for the generation of antibodies, for use in identifying pharmaceutical compositions, and for studying DNA/protein interaction.

[0373] The kinases of the present invention can be used to produce antibodies or hybridomas. One skilled in the art will recognize that if an antibody is desired, such a peptide could be generated as described herein and used as an immunogen. The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies, and humanized forms. Humanized forms of the antibodies of the present invention may be generated using one of the procedures known in the art such as chimerization or CDR grafting.

[0374] The present invention also relates to a hybridoma which produces the above-described monoclonal antibody, or binding fragment thereof. A hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.

[0375] In general, techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell, “Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology,” Elsevier Science Publishers, Amsterdam, The Netherlands, 1984; St. Groth et al., J. Immunol. Methods 35:1-21, 1980). Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art. Such methods include subcutaneous or intraperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection.

[0376] The polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity. Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or β-galactosidase) or through the inclusion of an adjuvant during immunization.

[0377] For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Agl4 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al., Exp. Cell Res. 175:109-124, 1988). Hybridomas secreting the desired antibodies are cloned and the class and subclass are determined using procedures known in the art (Campbell, “Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology”, supra, 1984).

[0378] For polyclonal antibodies, antibody-containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures. The above-described antibodies may be detectably labeled. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horse radish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see Stemberger et al., J. Histochem. Cytochem. 18:315, 1970; Bayer et al., Meth. Enzym. 62:308-, 1979; Engval et al., Immunol. 109:129-, 1972; Goding, J. Immunol. Meth. 13:215-, 1976. The labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ assays to identify cells or tissues which express a specific peptide.

[0379] The above-described antibodies may also be immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., “Handbook of Experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10, 1986; Jacoby et al., Meth. Enzym. 34, Academic Press, N.Y., 1974). The immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as in immunochromotography.

[0380] Furthermore, one skilled in the art can readily adapt currently available procedures, as well as the techniques, methods and kits disclosed herein with regard to antibodies, to generate peptides capable of binding to a specific peptide sequence in order to generate rationally designed antipeptide peptides (Hurby et al., “Application of Synthetic Peptides: Antisense Peptides”, In Synthetic Peptides, A User's Guide, W.H. Freeman, NY, pp. 289-307, 1992; Kaspczak et al., Biochemistry 28:9230-9238, 1989).

[0381] Anti-peptide peptides can be generated by replacing the basic amino acid residues found in the peptide sequences of the kinases of the invention with acidic residues, while maintaining hydrophobic and uncharged polar groups. For example, lysine, arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine.

[0382] The present invention also encompasses a method of detecting a STE20-related kinase polypeptide in a sample, comprising: (a) contacting the sample with an above-described antibody, under conditions such that immunocomplexes form, and (b) detecting the presence of said antibody bound to the polypeptide. In detail, the methods comprise incubating a test sample with one or more of the antibodies of the present invention and assaying whether the antibody binds to the test sample. Altered levels of a kinase of the invention in a sample as compared to normal levels may indicate disease.

[0383] Conditions for incubating an antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the antibody used in the assay. One skilled in the art will recognize that any one of the commonly available immunological assay formats (such as radioimmunoassays, enzyme-linked immunosorbent assays, diffusion based Ouchterlony, or rocket immunofluorescent assays) can readily be adapted to employ the antibodies of the present invention. Examples of such assays can be found in Chard (“An Introduction to Radioimmunoassay and Related Techniques” Elsevier Science Publishers, Amsterdam, The Netherlands, 1986), Bullock et al. (“Techniques in Immunocytochemistry,” Academic Press, Orlando, Fla. Vol. 1, 1982; Vol. 2, 1983; Vol. 3, 1985), Tijssen (“Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology,” Elsevier Science Publishers, Amsterdam, The Netherlands, 1985).

[0384] The immunological assay test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as blood, serum, plasma, or urine. The test samples used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is testable with the system utilized.

[0385] A kit contains all the necessary reagents to carry out the previously described methods of detection. The kit may comprise: (i) a first container means containing an above-described antibody, and (ii) second container means containing a conjugate comprising a binding partner of the antibody and a label. In another preferred embodiment, the kit further comprises one or more other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound antibodies.

[0386] Examples of detection reagents include, but are not limited to, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the chromophoric, enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. The compartmentalized kit may be as described above for nucleic acid probe kits. One skilled in the art will readily recognize that the antibodies described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

[0387] VI. Isolation of Compounds Which Interact With STE20-Related Kinases

[0388] The present invention also relates to a method of detecting a compound capable of binding to a STE20-related kinase of the invention comprising incubating the compound with a kinase of the invention and detecting the presence of the compound bound to the kinase. The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts.

[0389] The present invention also relates to a method of detecting an agonist or antagonist of kinase activity or kinase binding partner activity comprising incubating cells that produce a kinase of the invention in the presence of a compound and detecting changes in the level of kinase activity or kinase binding partner activity. The compounds thus identified would produce a change in activity indicative of the presence of the compound. The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts. Once the compound is identified it can be isolated using techniques well known in the art.

[0390] The present invention also encompasses a method of agonizing (stimulating) or antagonizing kinase associated activity in a mammal comprising administering to said mammal an agonist or antagonist to a kinase of the invention in an amount sufficient to effect said agonism or antagonism. A method of treating diseases in a mammal with an agonist or antagonist of STE20-related kinase activity comprising administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize STE20-related kinase associated functions is also encompassed in the present application.

[0391] In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples of molecules that have been reported to inhibit the function of protein kinases include, but are not limited to, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published Nov. 26, 1992 by Maguire et al.), vinylene-azaindole derivatives (PCT WO 94/14808, published Jul. 7, 1994 by Ballinari et al.), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Pat. No. 5,330,992), styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Pat. No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published Feb. 17, 1994 by Denny et al.), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published Dec. 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published Oct. 17, 1991 by Dow et al).

[0392] Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In addition, many inhibit a variety of protein kinases and will cause multiple side-effects as therapeutics for diseases.

[0393] Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. wO 96/22976 (published Aug. 1, 1996 by Ballinari et al.) describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindole ring. These bicyclic substituents are in turn substituted with polar moieties including hydroxylated alkyl, phosphate, and ether moieties. U.S. patent application Ser. No. 08/702,232, filed Aug. 23, 1996, entitled “Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 221/187) and Ser. No. 08/485,323, filed Jun. 7, 1995, entitled “Benzylidene-Z-Indoline Compounds for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published Aug. 1, 1996 by Ballinari et al., all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. application Ser. No. 08/702,232, filed Aug. 23, 1996, entitled “Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 221/187), Ser. No. 08/485,323, filed Jun. 7, 1995, entitled “Benzylidene-Z-Indoline Compounds for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 223/298), and WO 96/22976, published Aug. 1, 1996 by Ballinari et al. teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives.

[0394] Other examples of substances capable of modulating kinase activity include, but are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker et al., EPO Publication No. 0 520 722 A1; Jones et al., U.S. Pat. No. 4,447,608; Kabbe et al., U.S. Pat. No. 4,757,072; Kaul and Vougioukas, U.S. Pat. No. 5,316,553; Kreighbaum and Corner, U.S. Pat. No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker et al., Proc. of Am. Assoc. for Cancer Research 32:327 (1991); Bertino, J. R., Cancer Research 3:293-304 (1979); Bertino, J. R., Cancer Research 9(2 part 1):293-304 (1979); Curtin et al., Br. J. Cancer 53:361-368 (1986); Fernandes et al., Cancer Research 43:1117-1123 (1983); Ferris et al. J. Org. Chem. 44(2):173-178; Fry et al., Science 265:1093-1095 (1994); Jackman et al., Cancer Research 51:5579-5586 (1981); Jones et al. J. Med. Chem. 29(6):1114-1118; Lee and Skibo, Biochemistry 26(23):7355-7362 (1987); Lemus et al., J. Org. Chem. 54:3511-3518 (1989); Ley and Seng, Synthesis 1975:415-522 (1975); Maxwell et al., Magnetic Resonance in Medicine 17:189-196 (1991); Mini et al., Cancer Research 45:325-330 (1985); Phillips and Castle, J. Heterocyclic Chem. 17(19):1489-1596 (1980); Reece et al., Cancer Research 47(11):2996-2999 (1977); Sculier et al., Cancer Immunol. and Immunother. 23:A65 (1986); Sikora et al., Cancer Letters 23:289-295 (1984); Sikora et al., Analytical Biochem. 172:344-355 (1988); all of which are incorporated herein by reference in their entirety, including any drawings.

[0395] Quinoxaline is described in Kaul and Vougioukas, U.S. Pat. No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

[0396] Quinolines are described in Dolle et al., J. Med. Chem. 37:2627-2629 (1994); MaGuire, J. Med. Chem. 37:2129-2131 (1994); Burke et al., J. Med. Chem. 36:425-432 (1993); and Burke et al. BioOrganic Med. Chem. Letters 2:1771-1774 (1992), all of which are incorporated by reference in their entirety, including any drawings.

[0397] Tyrphostins are described in Allen et al., Clin. Exp. Immunol. 91:141-156 (1993); Anafi et al., Blood 82:12:3524-3529 (1993); Baker et al., J. Cell Sci. 102:543-555 (1992); Bilder et al., Amer. Physiol. Soc. pp. 6363-6143:C721-C730 (1991); Brunton et al., Proceedings of Amer. Assoc. Cancer Rsch. 33:558 (1992); Bryckaert et al., Experimental Cell Research 199:255-261 (1992); Dong et al., J. Leukocyte Biology 53:53-60 (1993); Dong et al., J. Immunol. 151(5):2717-2724 (1993); Gazit et al., J. Med. Chem. 32:2344-2352 (1989); Gazit et al., “J. Med. Chem. 36:3556-3564 (1993); Kaur et al., Anti-Cancer Drugs 5:213-222 (1994); Kaur et al., King et al., Biochem. J. 275:413-418 (1991); Kuo et al., Cancer Letters 74:197-202 (1993); Levitzki, A., The FASEB J. 6:3275-3282 (1992); Lyall et al., J. Biol. Chem. 264:14503-14509 (1989); Peterson et al., The Prostate 22:335-345 (1993); Pillemer et al., Int. J. Cancer 50:80-85 (1992); Posner et al., Molecular Pharmacology 45:673-683 (1993); Rendu et al., Biol. Pharmacology 44(5):881-888 (1992); Sauro and Thomas, Life Sciences 53:371-376 (1993); Sauro and Thomas, J. Pharm. and Experimental Therapeutics 267(3):119-1125 (1993); Wolbring et al., J. Biol. Chem. 269(36):22470-22472 (1994); and Yoneda et al., Cancer Research 51:4430-4435 (1991); all of which are incorporated herein by reference in their entirety, including any drawings.

[0398] Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Ser. No. 08/702,232 filed Aug. 23, 1996, incorporated herein by reference in its entirety, including any drawings.

[0399] VII. Biological Significance, Applications and Clinical Relevance of Novel STE20-Related Kinases Human STLK2, STLK3, STLK4, STLK5, STLK6, and STLK7

[0400] STLK2, STLK4, STLK5, STLK6 and STLK7 belong to an expanding family of intracellular STKs that have varying degrees of sequence homology to SOK-1, a kinase implicated in oxidative stress agents (Pombo, CM et al, EMBO J. (17) 4537-4546, 1996). Our data shows that STLK2 is expressed highly in hematopoietic cells. Therefore, STLK2 may participate in the oxidative response pathway during inflammation. In addition, STLK2 could also be a possible component in the signaling pathways leading to T cell activation. High levels of STLK2 in several tumor cell lines could also imply that STLK2 might be involved in tumorigenesis.

[0401] STLK2 is most closely related to two human STE20-subfamily kinases: MST3 and SOK-1. MST3 is a 52,000 daltons cytoplasmic kinase that is ubiquitously expressed with its highest levels of expression found in heart, skeletal muscle and pancreas. The serine/threonine kinase activity of MST3 is activated by phosphorylation. Unlike SOK-1, MST3 prefers Mn++over Mg++and can use both GTP and ATP as phosphate donors. MST3 may undergo dimerization. No agonists have yet been identified that activate MST3. The downstream signaling mechanism of this kinase is unknown (Schinkmann, K and Blenis, J. (1997) J. Biol. Chem. 272, 28695-28703).

[0402] SOK-1 is a 50,000 daltons cytoplasmic kinase expressed predominantly in testis, large intestine, brain and stomach and to a lesser extent in heart and lung. SOK-1 is also expressed in the germinal center B-cell line (RAMOS) and in a mature B cell line (HS Sultan). The serine/threonine kinase activity of SOK-1 is activated by phosphorylation. The C-terminus of SOK-1 has been shown to be inhibitory to the catalytic activity of this kinase. The only agonists known to activate SOK-1 are oxidant agents, like H₂O₂ and menadione, a quinone that is a potent intracellular generator of reactive oxygen species (Pombo, C. M. et al. EMBO J. 15, 4537-4546). SOK-1 is also activated by chemical anoxia through the generation of reactive oxygen species and release of calcium into the cytoplasm from intracellular stores. SOK-1, therefore, may play an important role in ischemia, the cause of myocardial infarction, stroke and acute renal failure (Pombo, C. M. et al. J. Biol. Chem. 272, 29372-29379 (1997)). The activity of SOK-1 in the response to oxidant stress is inversely correlated with the activity of the stress-activated protein kinases (SAPKs) elevated SOK-1 activity correlates with absent SAPK activity and vice-versa. SOK-1 does not activate any of the four MAP kinase pathways, SAPKs, p38, ERK-1 or MEK-5/ERK-5 (Pombo, C. M. et al. EMBO J. 15, 4537-4546). The downstream signaling mechanism of this kinase remains unknown.

[0403] STLK2 is expressed in a wide variety of immune cell types and tissues including thymus, dendrocytes, mast cells, monocytes, B cells (primary, Jurkat, RPMI, SR), T cells (CD8/CD4+, TH1, TH2, CEM, MOLT4) and megakaryocytes (K562), whereas STLK3 is restricted to thymus and STLK4 is predominately expressed in thymus, T cells (CD4/CD8+, TH1, CEM) and B cells (Jurkat, RPMI). Consequently, these STKs might participate in the oxidative response pathway during inflammation, reperfusion injury (stroke, surgery, shock), TNFa-mediated signaling, insulin desensitization, atherogenesis, vascular injury, T or B cell costimulation, or alternatively, participate in other MAPK-related signal transduction processes.

[0404] STLK5 is more distantly related to this STE20-subfamily including SOK-1 and STLK2, STLK3 and STLK4. STLK5, may therefore mediate a signaling pathway that is distinct from the oxidative stress response pathway.

[0405] The high degree of sequence homology in the C-termini of SOK-1, STLK2, STLK3, STLK4, STLK5, and STLK6 raises the possibility that these novel STKs, like SOK-1, may be subject to autoinhibition through a conserved C-terminal motif.

[0406] Human ZC1, ZC2, ZC3 and ZC4

[0407] ZC1 is a good candidate for any disease in which tyrosine kinase, cytokine, or heterotrimeric G-protein coupled receptors have been implicated. The mouse homologue binds to NCK, and is recruited to activated PDGF (Su et al., EMBO 16: 1279-1290, 1997). The Drosophila homolog has been shown to bind to TRAF2, implicating it in TNF-α signaling (Liu et al., (1999) Curr. Biol. 9:101-104, 1999)). While ZC1 does not contain the exact NCK- and TRAF2-binding domains, it is likely to bind to related proteins.

[0408] Of the ZC subfamily of STE20-related protein kinases, ZC1 has very broad over-expression in many tumor types, suggesting that it may be involved in cellular growth, transformation, or tumor progression. A truncated form of ZC1 containing only the C-terminal putative MEKK1-binding domain was found to reduce the number of foci generated by H-Ras-V12 in Rat Intestinal Epithelial cells (RIE-1). These data indicate that ZC1 may play a role in the ability for these cells to overcome contact inhibition and anchorage-dependent growth.

[0409] The ZC1 homolog, Misshapen (msn) in Drosophila melanogaster was cloned as a result of complementing a mutation in a developmental pathway required for dorsal closure, a process involving changes in cell shape and position in the embryo (Treisman et al. Gene 186 119-125, 1997). A D. melanogaster homolog of the JNK1/JNK2 kinases from mammals was shown to function downstream of msn in the dorsal-closure signaling pathway (Su et al. Genes Dev. 12:2371-2380, 1998).

[0410] While ZC1 could be involved in multiple aspects of tumorigenesis, by analogy with Drosophila, the role of misshapen in dorsal closure suggests a critical role in the regulation of the cytoskeleton for the processes of cell attachment, cell movement and perhaps migration.

[0411] The association of the ZC1 family members msn and NIK with TRAF2 may indicate a role for this kinase in cell survival and/or in apoptosis. The ZC1 family contains a highly conserved domain that in the mouse homolog, NIK, has been shown to bind to MEKK1 (Mitogen-activated/Extracellular-regulated Kinase Kinase 1) (Su et al., (1997) EMBO 16(6): 1279-90). MEKK1 is involved in cell survival and/or apoptosis in several systems (Schlesinger et al., Front. Biosci.3:D1181-6, 1998). Depending on the context, MEKK1 appears to be upstream of either the ERK1/MAPK or the JNK/SAPK pathway [Schlesinger et al., (1998 Front. Biosci. 3:D1181-6). Three homologues of ZC1: murine NIK (NCK-interacting kinase)(Su et al. EMBO 16:1279-90, 1997), Drosophila msn (Liu et al. Curr. Biol. 9:101-104, 1999) and human HGK (HPK/GCK-like kinase)(Yao et al., J. Biol. Chem. 274:2118-25, 1999) have all been shown to activate the JNK pathway when over-expressed in 293T cells.

[0412] ZC1 shares a high degree of homology with these other family members in both the kinase domain and the “MEKK”-binding domains, yet it differs in the intervening region, which contains several putative binding domains for upstream signaling adapter molecules (e.g. NCK, TRAF2). Unlike the other family members, ZC1 does not appear to activate the JNK pathway in 293T cells as seen by its ability to induce expression of either a JUN or ATF2-driven luciferase gene. Upon co-transfection into these cells with HA-tagged JNK, modest activation of JNK was detected. ZC1 also modestly activated co-transfected ERKI. Both the ERK and the JNK activation were very slight compared with the positive controls in the assay (activated forms of MEK1 and MEKK1, respectively). In both cases, activation required the full-length kinase. While the kinase domain alone is up to 5× more active in autophosphorylation and in phosphorylation of MBP, it does not lead to activation of these potential downstream kinases. Based on the strong sequence homology of ZC1 with the other family members, it is very likely that ZC1 will be important for either JNK or ERK activation once the proper context is found.

[0413] ZC1 profoundly inhibits ERK1 kinase expression in co-transfection assays. This effect is dependent on ZC1 kinase activity, occurring with the wild-type and the kinase domain alone, but not with the kinase-dead mutant even though all three forms of ZC1 are expressed at similar levels. This may suggest a role for this kinase in transcriptional or post-transcriptional regulation.

[0414] ZC1 may be an important component in the signaling pathways mediated by the co-stimulatory receptor CD28 in T cells and/or by the pro-inflammatory cytokine TNFα, since co-transfection of the wild-type ZC1 activated the RE/AP-luciferase and NFκB-luciferase reporter genes. While our data showed that ZC1 strongly activates NFθB in T-cells, no activation of NFκB driven luciferase was detectable in NIH 3T3 cells. A recent paper (J. Biol. Chem. 274:2118-25; 1999.) has shown that a human ZC1 splicing isoform, HGK, is involved in the TNFα-signaling pathways.

[0415] Given the importance of T cell activation in autoimmunity and transplantation, as well as the key role that TNFα plays in inflammatory diseases, it is possible that ZC1 could be a therapeutic target for immunological diseases which include but are not limited to: rheumatoid arthritus, chronic inflammatory bowel diseases (ie Crohn's disease), chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, and autoimmunity as well as organ transplantation and cardiovascular diseases.

[0416] ZC1 appears to be the human orthologue of murine NIK and possibly an orthologue of a C. elegans STE20-subfamily kinase encoded by the ZC504.4 cosmid.

[0417] Murine NIK is a 140,000 daltons kinase that is most highly expressed in brain and heart. NIK interacts with the SH3 domains of the adaptor molecule Nck through its proline-rich regions found in the C-terminal extra-catalytic region. The specific regions that mediate this interaction are two PxxP motifs that are nearly uniformly conserved between NIK, ZC1,2,3 and the C. elegans STE20 ZC504.4 kinase. In addition, NIK binds MEKK1 through its 719 amino acid C-terminal (Su, Y-C. et al. (1997) EMBO J. 16, 1279-1290). MEKK1 is a membrane-associated kinase responsible for activating MKK4 (also known as SEK1), which in turn activates SAPK (Yan, M et al. (1994) Nature, 372, 798-800). NIK may function as a kinase that links growth factor activated pathways and the stress-response pathway mediated by SAPKs. According to this hypothesis, activation of growth factor receptors leads to receptor tyrosine phosphorylation, Nck binding to the phosphorylated tyrosines via its SH2 domain, NIK redistribution to a membrane compartment via binding to the SH3 domain of Nck, and juxtaposition to the membrane-associated MEKK1. The NIK-MEKK1 interaction would, in this fashion, turn on the SAPK pathway in response to growth factor stimulation (Su, Y-C. et al. (1997) EMBO J. 16, 1279-1290).

[0418] Given the high homology between ZC1, ZC2, ZC3, and ZC4 STKs and NIK, it is conceivable that these kinases may each function to connect growth factor- and stress-activated signaling pathways. The heterogeneity that the ZC kinases exhibit within their putative SH3-binding domain could provide signaling specificity in terms of the nature of the adaptor molecule that they bind. The high level of sequence conservation in the C-termini of the ZC1, ZC2 and ZC3 strongly suggests that these human kinases, like murine NIK, also may bind to MEKK1 and activate SAPKs. The ZC kinases also display strong homology at their C-termini to protein domains that bind small GTPase proteins such as Rab, Rho and Rac. For example, the C-termini of ZC1 is 36.2% identical to citron, a murine Rho-binding protein, and 23.1% identical to the rab-binding region of GC kinase. This suggests that, in addition to adaptor molecules, small GTPase proteins may also mediate membrane association and activation of the ZC kinases. The presence of a potential coiled-coil region located immediately C-terminal to the catalytic region strongly suggests that the ZC kinases may also be subject to regulation via homo or heterodimerization events.

[0419] The C. elegans STE20 ZC504.4 kinase is the product of the mig-15 gene. The product of this gene has been implicated in several developmental processes such as epidermal development, Q neuroblast migrations and muscle arm targeting in the developing worm (Zhu, X. and Hedgecock E. (1997) Worm Breeder's Gazette 14, 76). The high level of sequence conservation between the ZC kinases and the ZC504.4 C. elegans kinase will make C. elegans a valuable model organism to study, through epistatic analysis, the signaling properties of the human ZC kinases.

[0420] Human KHS2

[0421] KHS1 (kinase homologous to SPS1/STE20) is a 100,000 dalton cytoplasmic STK that is expressed ubiquitously. KHS1 has been implicated in the mechanism of SAPK activation in response to inflammatory cytokines such as TNFα as well as to ultraviolight light, which also uses the TNF signaling pathway. TNFα binding to its receptors (TNFR1 and TNFR2) results in the sequential association with the receptor C-tail of multiple signaling molecules including TNFR1-associated death domain protein (TRADD), Fas-associated death domain protein (FADD or MORT1), TNFR-associated factor 2 (TRAF2), and the STK RIP (receptor interacting protein). The TRADD-TRAF2 interaction is mediated by a conserved region present at the C-terminus of TRAF2, the TRAF domain. Activation of the NFθB and SAPK pathways is mediated by the ring finger motif present at the N-terminus of TRAF2 (Curr. Opinion in Cell. Biol. (1997) 9:247-251). KHS1 is activated by TNFα stimulation in a TRAF2-dependant manner and inhibition of KHS1 blocks TNFα-induced SAPK activation but not NFκB activation. The mechanism by which TRAF2 activates KHS1 is not known. Cotransfection of TRAF2- and KHS1-expressing constructs in 293T cells failed to reveal a direct association between these two molecules. KHS1 activates the SAPK pathway by a direct association with the constitutively active kinase MEKK1. MEKK1 subsequently activates SEK1, which in turn activates SAPK. Neither the MAPK nor the p38 kinase pathways are activated by KHS1 (Shi, C-S and Kehrl. J. H. (1997) J. Biol. Chem. 272, 32102-32107). In addition to its catalytic domain, downstream signaling of KHS1 requires its conserved C-terminus (Diener, K. et al (1997) Proc. Natl. Acad. Sci. 94, 9687-9692).

[0422] GCK (germinal center kinase) is a constitutively active 97,000 dalton STK that is broadly expressed. GCK may participate in B-cell differentiation since its expression is localized to the germinal center within lymphoid follicles. GCK activates the SAPK pathway in response to TNFα via activation of SEK1. The upstream activators of GCK in response to cytokines as well as the immediate downstream target of this kinase are unknown. The C-terminus of GCK is sufficient to activate SEK1 (Pombo, C. M. et al (1995) Nature, 377, 750-754).

[0423] The murine orthologue of GCK, rab8ip (rab8-interacting protein), is a 97,000 dalton protein that fractionates with both the soluble cytoplasmic fraction as well as with a salt-sensitive fraction associated with the basolateral membrane of the trans-Golgi region in polarized MDCK epithelial cells. The C-terminus of rab8ip binds to rab8, a small GTP-binding protein required for vesicular transport from the Golgi apparatus (Ren, M. et al. (1996) Proc. Natl. Acad. Sci. 93, 5151-5155). In addition to inducing the transcriptional activation of cytokines like IL2 via SAPK, GCK may also promote the rab-dependent release of secretory proteins in response to TNFα (Buccione, R. et al (1995) Mol. Bio. Cell 6, 291).

[0424] HPK1 (hematopoietic protein kinase) is a constitutively active 90,000 dalton STK restricted to hematopoietic cells. HPKl activates the SAPK pathway by directly binding to and activating MEKK1 (Hu, M. et al (1996) Genes and Dev. 10:2251-2264) as well as the ubiquitously expressed mixed-lineage kinase MLK-3 (Kiefer, F. et al (1996) EMBO J. 15:7013-7025). This function of HPK1 requires, in contrast to GCK, both its kinase domain as well as its C-terminus. The upstream activators of HPK1 remain unknown. HPK1 also plays a key role as a mediator of transforming growth factor-β (TGFβ) signaling. HPK1 activates the TGFb-activated kinase (TAK), which in turn stimulates the SAPK pathway by phosphorylating SEK1 (Wang W. et al (1997) J. Biol. Chem. 272:22771-22775).

[0425] KHS2 is expressed in thymus, dendrocytes and monocytes. KHS2 could have a complementary function to that of KHS1 as a mediator of SAPK activation in the cellular response to inflammatory cytokines. KHS2 could have the potential to interact directly with TRAF2 since a STK with the predicted molecular weight of KHS2 (approximately 101,000 daltons) is found in the TNFR-TRAF2 complex upon TNFα stimulation (VanArsdale, T. and Ware, C. F. (1994) J. Immunol. 153, 3043-3050). The presence of a putative binding domain for Rab or a Rab-like molecule at the C-terminus of KHS2 indicates that KHS2, in addition to having a potential role in the TRAF2-dependant TNFα cytokine response, could also mediate signaling events that utilize small GTPase proteins. Alternatively, the binding of a small GTPase protein to the C-terminus of KHS2 may be required for its potential TRAF2-dependant signaling to a downstream kinase such as MEKK1.

[0426] Human GEK2, SULU1 and SULU3

[0427] A recent report (Y-W Qian et al., Science 282:1701-1704,1998) described xPlkkl as the activator of Plx1 (the Xenopus Polo kinase). In Xenopus oocytes, the STK Plkk1 can phosphorylate and activate Plx1 STK (the mammalian Polo kinase or PLK). A dominant-negative (kinase-dead) form of xPlkkl prevents Plx1 activation and delays germinal vesicle breakdown. Yet another unidentified kinase is probably responsible for xPlkk1 activation during mitosis.

[0428] The homology through the entire length of the xPlkk1 protein with GEK2 suggests that GEK2 might represent the human homologue for xPlkk1. Based on this, GEK2 might be upstream of PLK in mammalian cells. In addition, based on the phage display screen results using the SULU1 coiled-coil2 domain as bait, SULU1 might also interact in vivo with GEK2 and therefore regulate GEK2 (and/or SLK through the coiled-coil domain) activation leading to PLK activation and mitosis.

[0429] If such a cascade of events is required for mitosis in mammalian cells, interruption of this signaling cascade at any point might block mitosis and could be beneficial for cancer treatment.

[0430] A recently cloned STE20-subfamily kinase, rat TAO1, is most likely the rodent orthologue of human SULU3 (Hutchinson, M. et al. J. Biol. Chem 273:28625-28632, 1998). TAO1 activates MEK3, 4 and 6 in vitro, while in transfected cells it associates and activates only MEK3, resulting in phosphorylation and activation of p38. These results implicate TAO1 (SULU3) in the regulation of the p38 containing stress-responsive MAP kinase pathway.

[0431] Human SULU1 is weakly expressed in hematopoietic sources whereas SULU3 is found in B-cells and TH1-restricted T cells. These mammalian SULU STKs display strong homology to the C. elegans SULU kinase. The role that this kinase plays in nematode development is unknown. The strong sequence homology between the catalytic domain of mammalian SULU kinases and other STE20-subfamily kinases such as SOK-1 (human STE20) and KHS2 suggests that the mammalian kinases may participate in the stress-response pathway. The potential coiled-coil domains found at the C-terminus of the SULU kinases may play a role in the regulation of this kinase.

[0432] Murine LOK (lymphocyte-oriented kinase) is a constitutively activated STK of approximately 130,000 daltons that is predominantly expressed in spleen, thymus and bone marrow (Kuramochi, S. et al (1997) J. Biol. Chem. 272: 22679-22684) as well as in meiotic testicular and primordial germ cells. The LOK1 gene is located in chromosome 11 of the mouse near the wr locus, a region that is associated with reproductive and neurological defects (Yanagisawa, M. et al (1996) Mol. Reprod. and Dev. 45:411-420). LOK does not activate any of the known MAPK pathways (ERK, JNK and p38) nor the NFκB pathway. The upstream signaling elements of LOK as well as the extracellular stimuli that utilize this kinase to elicit a biological response are also unknown (Kuramochi, S. et al (1997) J. Biol. Chem. 272: 22679-22684).

[0433] Human GEK2 is highly related to murine LOK, but based on sequence divergence in the non-catalytic domain, it appears to be a distinct member of this STE20-subfamily. GEK2 may signal through a pathway that remains to be defined. The presence of potential coiled-coil regions at the C-terminus of GEK2 could play a key role in regulating the functions of this kinase.

[0434] Human PAK4 and PAK5

[0435] The p21 activated protein kinases (PAK) are a closely related subgroup of the STE20 family of serine/threonine kinases. Extensive genetic and biochemical analysis of the budding yeast STE20 has shown the critical role this serine/threonine kinase plays at the juncture of several important intracellular pathways required to appropriately respond to extracellular signals. STE20 links the transcriptional response by mediating the activation of the appropriate downstream MAPK pathway as well as coupling changes in cellular morphology via its control of the actin cytoskeleton.

[0436] A hallmark of the PAK subgroup is their small G protein-binding domain (PBD) that confers G protein-dependent activation upon this group of kinases. Via the PBD, PAKs bind to activated small G proteins resulting in the derepression of the PAK's intrinsic kinase activity.

[0437] Until recently, there were three known PAK kinases: PAK1, a 68 kD protein whose expression is restricted expression to brain, muscle, and spleen; PAK2 (PAKI, PAK65), a 62 kD protein whose expression is ubiquitous; and PAK3, a 65 kD protein whose expression is restricted to the brain. Similar to STE20, the mammalian PAKs (1,2, and 3) have been shown to respond to extracellular signals (growth factors, mitogens, cytokines and a variety of cellular stresses) (Bagrodia, et al. (1995). J. Biol. Chem. 270: 22731-22737; Zhang, S., et al. (1995). J. Biol. Chem. 270: 23934-23936, Frost, J. et al. (1998) J. Biol. Chem. 273: 28191-28198; Galisteo, M. et al. (1996) J. Biol. Chem. 271: 20997-21000), and are linked to TCR activation (Yablonski, D., et al. (1998) EMBO J. 17: 5647-5657), and heterotrimeric G protein-coupled receptors (Knaus, U. et al. (1995) Science 269: 221-223) The PAKs were originally identified as effectors for members of the Rho family of small G proteins (such as Rac and Cdc42), hence their name, p21-activated kinases (PAK) (Manser et al Nature 367:40-46). The recruitment of the PAKs to the appropriate intracellular location is critical to their function. Attempts to elucidate the role played by PAKs in intracellular signaling and morphological changes is complicated due to the complex interactions by which they can be recruited by such factors as activated small G proteins (rac, cdc42), adaptors (nck) and exchange proteins (PIX, Cool).

[0438] The adaptor molecule, Nck, is constitutively bound via its SH3 domain to the proline-rich motif in the N-terminal portion of PAK1. Binding of the Nck-PAK complex to activated growth factor receptors in response to growth factor stimulation provides a mechanism to link growth factor-stimulated and stress-response pathways (Galisteo, M. et al. (1996) J. Biol. Chem. 271:20997-21000).

[0439] The PBD found at the N-terminus of PAK1 is responsible for its high-affinity interaction with the GTP-bound forms of Cdc42 and Rac (Burbelo, P. et al. (1995) J. Biol. Chem. 270:29071-29074). The exact mechanism through which the small GTPases activate PAKs may involve, in part, association of the kinase with activated growth factor receptors through guanine nucleotide exchange factors (GEFs). GEFs activate small GTPases by catalyzing the formation of their GTP-bound state, thereby promoting their association with, and activation of, PAKs. The known mammalian PAK kinases, as well as Drosophila and C. elegans PAKs, all conserve an N-terminal extracatalytic motif responsible for a high-affinity interaction with the GEF, PIX. The PAK-Cdc42 interaction and subsequent PAKs occurs as a PIX/PAK complex (Manser, E. et al. (1998) Molecular Cell, 1, 183-192).

[0440] PAK signaling stimulated by heterotrimeric G proteins is mediated through the interaction between a short conserved amino acid region located at the C-terminus of PAK1 with the G-protein P-subunit (Leeuw, T. et al. (1998) Nature, 391: 191-195).

[0441] A variety of studies have indicated that the human PAKs are involved in mediating the activation of stress-activated protein kinase pathways (JNK and to lesser extent p38). PAKs are also potential mediators in the crosstalk between the pathways regulated by the Rho family of small G proteins and the signaling pathways directly downstream of Ras leading to the activation of the ERK pathway (Bagrodia, et al. (1995). J. Biol. Chem. 270: 22731-22737; Zhang, S., et al. (1995). J. Biol. Chem. 270: 23934-23936; Brown, J., et al. (1996) Curr Biol. 6:598-60596; Frost, J., et al. (1996). Mol. Cell. Biol. 16: 3707-3713).

[0442] PAK1 has been implicated in phosphorylating a regulatory site in MEK1 that is necessary for MEK1's ability to interact with Rafl (Frost, et al. (1997) EMBO J. 16:6426-6438). PAK3 has been shown to phosphorylate Rafl on a site that is important for Rafl activity (King, A., et al. (1998). Nature 396: 180-183).

[0443] PAKs play an important role in controlling morphological changes in cell shape mediated by the actin cytoskeleton. Such morphological changes are required for cellular functions ranging from cell division and proliferation to cell motility and vesicle transport. PAK activity has been implicated in the localized assembly (leading edge) and disassembly (retracting edge) of focal adhesions necessary for cell motility (Frost J. et al (1998) J. Biol. Chem. 273:28191-28198).

[0444] PAK2 may have a role in the morphological changes induced during apoptosis (Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. (Rudel, T. (1997) Science. 276:1571-4)), and PAK1 may be important in preventing apoptosis (Faure S, et al. (1997) EMBO J. (1997) 16:5550-61). In addition to overcoming mitogen- and anchorage-independent growth, tumor cells need to escape the programmed cell death that accompanies deregulated cell growth. Thus, inhibition of PAKs may be effective in triggering apoptosis in tumors.

[0445] A direct requirement for PAKs in the transformation of mammalian cells has been shown for PAK1 and PAK2. Kinase-dead alleles of PAK1 block ras transformation of RAT1 and Schwann cells (Tang, Y., et al. (1997) Mol. Cell. Biol. 17, 4454-4464). Dominant-negative alleles of PAK2 have been shown to interfere with ras-mediated transformation of mammalian cells (Osada, S., (1997) FEBS Lett 404:227-233) Mutations in PAK3 have been implicated in nonsyndromic X-linked mental retardation suggesting a role for PAK3 in cognitive function (Allen, K. et al. (1998) Nat. Genet. 20: 25-30). PAK1 has been implicated in neurite outgrowth in PC12 cells (Daniels, R. et al. (1998) EMBO J. 17: 754-764; Nikolic, M. et al. (1998) Nature 395:194-198).

[0446] Finally, PAK-like STKs may also play a role in AIDS pathogenesis since the myristoylated 27 kD membrane-associated HIV Nef gene product directly interacts with and activates these kinases via cdc42 and Rac. The Nef-mediated activation of PAK-like STKs correlates with the induction of high viral titers and the development of AIDS in infected hosts (Cullen, B. R. (1996) Curr. Biol. 6:1557-1559).

[0447] Our results show that PAK4 is expressed in thymus, dendrocytes, mast cells, monocytes, as well as in T cells (TH2-restricted cells and MOLT4) and the B cell line RPMI. PAK5 is found in mast cells and in the T cell line MOLT4. These data suggest potential roles for PAK4 and PAKS in the immune system.

[0448] PAK4 and PAK5 share with the known PAKs a potential cdc42-binding motif at their N-termini. Both PAK4 and PAK5 display sequence homology in their C-termini to a motif responsible for an interaction between PAK1 and the β-subunit of heterotrimic G-proteins (amino acid residues 665-676 in PAK 4, and amino acid residues 386-398 in PAK5). Consequently, PAK4, and possibly PAK5, could mediate signaling events originating from growth factors as well as from ligands that stimulate G-protein-linked receptors.

[0449] PAK4 conserves a leucine (leu 44), that when mutated to a phenylalanine renders the kinase activity of human PAK1 constitutively active, bypassing its cdc42-binding requirement for activation (Brown J. et al (1996) Current Biol. 6:598-605). PAKS contains an isoleucine at the equivalent position. Therefore, the mechanism by which cdc42 potentially activates human PAK1, PAK4, and possibly PAK5, may be very similar.

[0450] PAK4 and PAK5 however, lack the PIX-binding motif, and consequently cdc42-activating GEFs other than PIX (for example Dbl and Cool) must be responsible for the activation of these kinases. Alternatively, PAK4 and PAK5 may be activated by another GTPase, such as Racl which uses the Tiaml GEF for its activation to the GTP-bound state.

[0451] PAK4 and PAK5 also lack the PxxP motif responsible for the Nck-PAK1 association. Between the PBD or cdc42-binding N-terminal motifs and the putative GEF-binding regions, PAK4 and PAK5 have long insertions (185 and 123 amino acids for PAK4 and PAK5, respectively) relative to PAK1. This region probably confers different binding characteristics to adaptor molecules and/or GEFs from those exhibited by known mammalian PAKs.

[0452] PAKs have been shown to be upstream in pathways leading to activation of both the JNK (Bagrodia, S., et al. (1995) J. Biol. Chem. 270: 22731-22737) and ERK kinase pathways (Brown, J., et al. (1996). Curr Biol. 6:598-605). PAK1 was shown to synergize with ras in activation of the ERK pathway through phosphorylation of MEK1 (Frost, J. et al. (1997). EMBO J. 16:6426-6438). Our data shows that MEK1 serves as an in vitro substrate for PAK4, suggesting a potential role for PAK4 in the activation of the ERK pathway and mitogenesis.

[0453] PAK5 may also have a mitogenic role, and be linked to cancer, based on its expression profile (elevated RNA and protein levels in a wide variety of tumor cell lines), its interaction with cdc42 via its PBD, and the ability of a kinase-dead allele (Lys350, 351 Ala) to block ras transformation of NIH3T3 cells. Thus, a screen for small molecule inhibitors of PAK5 kinase activity may yield compounds with therapeutic potential for intervention in cancer derived from a wide variety of tissue types.

[0454] PAK4 and PAK5 may also play a role in HIV pathogenesis as potential mediators of Nef signaling, since none of the known PAKs correspond to the PAK-like kinase shown to interact with, and be activated by, the HIV nef protein (Lu, X. et al. (1996) Current Biology 6:1677-1684) The 3′ untranslated region of PAK4 contains a CA repeat that is prone to undergo expansion. CA dinucleotide repeat instability has been associated with disease (Toren, M.Z. et al (1998) Am. J. Hematol. 57: 148-152), and expansion of such repeat in the 3′ untranslated region of PAK4 could implicate this kinase in as yet unknown pathologies.

[0455] Clinical Applications

[0456] Human STLK2, STLK3, STLK4, STLK5, STLK6, and STLK7

[0457] STLK3, STLK5, STLK6 and STLK7, as well as other homologues of the STLK subfamily of STE20 protein kinases such as STLK4, may play an important role as mediators of the immune response. Thus, they are targets for the development of specific small molecule inhibitors to treat immunological diseases, including, but not limited to, rheumatoid arthritis, chronic inflammatory bowel diseases (e.g. Crohn's disease), chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis and autoimmunity, as well as in organ transplantation. Other diseases include cardiovascular diseases.

[0458] The human STLKs may also play an important role in cell growth regulation. Thus, they are targets for developing small molecule kinase inhibitors for the treatment of cancer and metastases. STLK5 maps to a chromosomal region frequently amplified in a variety of tumors including those from non-small cell lung cancer, breast cancer and peripheral nerve tumors. This suggests that STLK5 could play a role in the development, maintenance, or progression of human tumors.

[0459] The potential role of human STLKs 2,3, and 4 in mediating oxidative stress strongly suggests that drugs targeting these kinases could prove useful in the treatment of myocardial infarction, arrhythmia and other cardiomyopathies, stroke, renal failure, oxidative stress-related neurodegenerative disorders such amyotrophic lateral sclerosis, Parkinson's disease and Leigh syndrome, a necrotizing mitochondrial encephalopathy, as well.

[0460] Human ZC1, ZC2, ZC3, and ZC4

[0461] ZC1 may be a component of the CD28-signaling pathway and therefore important in T cell activation. As such, ZC1 as well as other ZC subfamily kinases, are targets for the development of specific small molecule inhibitors to treat immunological diseases, including, but not limited to, rheumatoid arthritis, chronic inflammatory bowel diseases (e.g. Crohn's disease), chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis and autoimmunity, as well as organ transplantation. Other diseases include cardiovascular diseases.

[0462] ZC1 and ZC2 are also implicated in cell growth regulation. Thus, ZC subfamily kinases are targets for developing small molecule inhibitors for the treatment of cancer and metastases. ZC2 maps to a chromosomal region frequently amplified in a variety of tumors including those from non-small cell lung cancer, small cell lung cancer, and cervical cancer. This suggests that ZC2 could play a role in the development, maintenance, or progression of human tumors.

[0463] The role of human ZC1, ZC2, ZC3, and ZC4 in the inflammatory and stress-response pathways, strongly suggests that drugs targeting these kinases could have strong immunosuppressive actions. These drugs can prove valuable for the treatment of rheumatoid arthritis, artherosclerosis, autoimmune disorders and organ transplantation among others. At least one very important class of immunosuppresants, corticosteroids, functions by blocking SAPK activation at an as yet undefined site on this pathway (Swantek, J.L. et al (1997) Mol. Cell. Biol. (1997) 6274-6282). Other immunosuppresive drugs like the pyridinylimidazoles specifically target the p38 kinases (Kumar, S. et al (1997) Biochem. Biophys. Res. Commun. 235: 533-528). Drug targeting of the MAPK and p38 pathways could lead to the development of novel immunosuppresants.

[0464] Human SULU and GEK

[0465] The potential role of these novel STE20-related protein kinases in the control of mitosis strongly suggests that agents that specifically inhibit these kinases could be useful for cancer and metastases treatment.

[0466] The close homology of human STLK5, GEK2, SULU1 and SULU3 to STE20-subfamily kinases involved in the stress and oxidative response pathway strongly suggests that drugs targeting these kinases may also be useful as immunosuppressants as well as to treat ischemic disorders.

[0467] Human KHS2

[0468] The role of human KHS2 in the inflammatory and stress-response pathways, strongly suggests that drugs targeting this and related kinases could have strong immunosuppressive actions. These drugs can prove valuable for the treatment of rheumatoid arthritis, artherosclerosis, autoimmune disorders and organ transplantation among others. At least one very important class of immunosuppresants, corticosteroids, functions by blocking SAPK activation at an as yet undefined site on this pathway (Swantek, J.L. et al (1997) Mol. Cell. Biol. (1997) 6274-6282). Other immunosuppresive drugs like the pyridinylimidazoles specifically target the p38 kinases (Kumar, S. et al (1997) Biochem. Biophys. Res. Commun. 235: 533-528). Drug targeting of the MAPK and p38 pathways could lead to the development of novel immunosuppressants.

[0469] Human PAK Family

[0470] PAK5 has a role in cancer based on its expression profile (elevated RNA and protein levels in wide variety of tumor lines), its interaction with Cdc42 via its PBD, and the ability of the kinase-dead allele of PAK5 (Lys350, 351Ala) to block ras transformation of NIH3T3 cells. Thus, a screen for small molecule inhibitors of PAK5 kinase activity may yield compounds with therapeutic potential for intervention in cancers and metastases derived from a wide range of tissue types.

[0471] PAK5 maps to a chromosomal region frequently amplified in a variety of tumors including those from non-small cell lung cancer, and small cell lung cancer. These findings suggest that PAK5 could play a role in the development, maintenance, or progression of human tumors and/or metastases.

[0472] The role of human PAK4, and PAK5 in the inflammatory and stress-response pathways also strongly suggests that drugs targeting these kinases could have strong immunosuppressive actions. These drugs can prove valuable for the treatment of rheumatoid arthritis, artherosclerosis, autoimmune disorders and organ transplantation among others. At least one very important class of immunosuppresants, corticosteroids, functions by blocking SAPK activation at an as yet undefined site on this pathway (Swantek, J. L. et al (1997) Mol. Cell. Biol. (1997) 6274-6282). Other immunosuppresive drugs like the pyridinylimidazoles specifically target the p38 kinases (Kumar, S. et al (1997) Biochem. Biophys. Res. Commun. 235: 533-528). Drug targeting of the MAPK and p38 pathways could lead to the development of novel immunosuppresants. In addition, drugs targeting PAK4 or PAK5 could prove useful as immunosuppresants as well as in AIDS treatment.

[0473] VIII. Transgenic Animals.

[0474] A variety of methods are available for the production of transgenic animals associated with this invention. DNA can be injected into the pronucleus of a fertilized egg before fusion of the male and female pronuclei, or injected into the nucleus of an embryonic cell (e.g., the nucleus of a two-cell embryo) following the initiation of cell division (Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442, 1985). Embryos can be infected with viruses, especially retroviruses, modified to carry inorganic-ion receptor nucleotide sequences of the invention.

[0475] Pluripotent stem cells derived from the inner cell mass of the embryo and stabilized in culture can be manipulated in culture to incorporate nucleotide sequences of the invention. A transgenic animal can be produced from such cells through implantation into a blastocyst that is implanted into a foster mother and allowed to come to term. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, Mass.), Taconic (Germantown, N.Y.), Harlan Sprague Dawley (Indianapolis, Ind.), etc.

[0476] The procedures for manipulation of the rodent embryo and for microinjection of DNA into the pronucleus of the zygote are well known to those of ordinary skill in the art (Hogan et al., supra). Microinjection procedures for fish, amphibian eggs and birds are detailed in Houdebine and Chourrout (Experientia 47: 897-905, 1991). Other procedures for introduction of DNA into tissues of animals are described in U.S. Pat. No. 4,945,050 (Sandford et al., Jul. 30, 1990).

[0477] By way of example only, to prepare a transgenic mouse, female mice are induced to superovulate. Females are placed with males, and the mated females are sacrificed by CO₂ asphyxiation or cervical dislocation and embryos are recovered from excised oviducts. Surrounding cumulus cells are removed. Pronuclear embryos are then washed and stored until the time of injection. Randomly cycling adult female mice are paired with vasectomized males. Recipient females are mated at the same time as donor females. Embryos then are transferred surgically. The procedure for generating transgenic rats is similar to that of mice (Hammer et al., Cell 63:1099-1112, 1990).

[0478] Methods for the culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection also are well known to those of ordinary skill in the art (Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press, 1987).

[0479] In cases involving random gene integration, a clone containing the sequence(s) of the invention is co-transfected with a gene encoding resistance. Alternatively, the gene encoding neomycin resistance is physically linked to the sequence(s) of the invention. Transfection and isolation of desired clones are carried out by any one of several methods well known to those of ordinary skill in the art (E.J. Robertson, supra).

[0480] DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination (Capecchi, Science 244: 1288-1292, 1989). Methods for positive selection of the recombination event (i.e., neo resistance) and dual positive-negative selection (i.e., neo resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described by Capecchi, supra and Joyner et al. (Nature 338: 153-156, 1989), the teachings of which are incorporated herein in their entirety including any drawings. The final phase of the procedure is to inject targeted ES cells into blastocysts and to transfer the blastocysts into pseudopregnant females. The resulting chimeric animals are bred and the offspring are analyzed by Southern blotting to identify individuals that carry the transgene. Procedures for the production of non-rodent mammals and other animals have been discussed by others (Houdebine and Chourrout, supra; Pursel et al., Science 244:1281-1288, 1989; and Simms et al., Bio/Technology 6:179-183, 1988).

[0481] Thus, the invention provides transgenic, nonhuman mammals containing a transgene encoding a kinase of the invention or a gene effecting the expression of the kinase. Such transgenic nonhuman mammals are particularly useful as an in vivo test system for studying the effects of introduction of a kinase, or regulating the expression of a kinase (i.e., through the introduction of additional genes, antisense nucleic acids, or ribozymes).

[0482] A “transgenic animal” is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. The transgenic DNA may encode human STE20-related kinases. Native expression in an animal may be reduced by providing an amount of anti-sense RNA or DNA effective to reduce expression of the receptor.

[0483] IX. Gene Therapy

[0484] STE20-related kinases or their genetic sequences will also be useful in gene therapy (reviewed in Miller, Nature 357:455-460, 1992). Miller states that advances have resulted in practical approaches to human gene therapy that have demonstrated positive initial results. The basic science of gene therapy is described in Mulligan (Science 260:926-931, 1993).

[0485] In one preferred embodiment, an expression vector containing STE20-related kinase coding sequence is inserted into cells, the cells are grown in vitro and then infused in large numbers into patients. In another preferred embodiment, a DNA segment containing a promoter of choice (for example a strong promoter) is transferred into cells containing an endogenous gene encoding kinases of the invention in such a manner that the promoter segment enhances expression of the endogenous kinase gene (for example, the promoter segment is transferred to the cell such that it becomes directly linked to the endogenous kinase gene).

[0486] The gene therapy may involve the use of an adenovirus containing kinase cDNA targeted to a tumor, systemic kinase increase by implantation of engineered cells, injection with kinase-encoding virus, or injection of naked kinase DNA into appropriate tissues.

[0487] Target cell populations may be modified by introducing altered forms of one or more components of the protein complexes in order to modulate the activity of such complexes. For example, by reducing or inhibiting a complex component activity within target cells, an abnormal signal transduction event(s) leading to a condition may be decreased, inhibited, or reversed. Deletion or missense mutants of a component, that retain the ability to interact with other components of the protein complexes but cannot function in signal transduction may be used to inhibit an abnormal, deleterious signal transduction event.

[0488] Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, several RNA viruses, or bovine papilloma virus, may be used for delivery of nucleotide sequences (e.g., cDNA) encoding recombinant kinase of the invention protein into the targeted cell population (e.g., tumor cells). Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors containing coding sequences (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y., 1989). Alternatively, recombinant nucleic acid molecules encoding protein sequences can be used as naked DNA or in a reconstituted system e.g., liposomes or other lipid systems for delivery to target cells (e.g., Felgner et al., Nature 337:387-8, 1989). Several other methods for the direct transfer of plasmid DNA into cells exist for use in human gene therapy and involve targeting the DNA to receptors on cells by complexing the plasmid DNA to proteins (Miller, supra).

[0489] In its simplest form, gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection (Capecchi, Cell 22:479-88, 1980). Once recombinant genes are introduced into a cell, they can be recognized by the cell's normal mechanisms for transcription and translation, and a gene product will be expressed. Other methods have also been attempted for introducing DNA into larger numbers of cells. These methods include: transfection, wherein DNA is precipitated with CaPO₄ and taken into cells by pinocytosis (Chen et al., Mol. Cell Biol. 7:2745-52, 1987); electroporation, wherein cells are exposed to large voltage pulses to introduce holes into the membrane (Chu et al., Nucleic Acids Res. 15:1311-26, 1987); lipofection/liposome fusion, wherein DNA is packaged into lipophilic vesicles which fuse with a target cell (Felgner et al., Proc. Natl. Acad. Sci. USA. 84:7413-7417, 1987); and particle bombardment using DNA bound to small projectiles (Yang et al., Proc. Natl. Acad. Sci. 87:9568-9572, 1990). Another method for introducing DNA into cells is to couple the DNA to chemically modified proteins.

[0490] It has also been shown that adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells. The admixture of adenovirus to solutions containing DNA complexes, or the binding of DNA to polylysine covalently attached to adenovirus using protein crosslinking agents substantially improves the uptake and expression of the recombinant gene (Curiel et al., Am. J. Respir. Cell. Mol. Biol., 6:247-52, 1992).

[0491] As used herein “gene transfer” means the process of introducing a foreign nucleic acid molecule into a cell. Gene transfer is commonly performed to enable the expression of a particular product encoded by the gene. The product may include a protein, polypeptide, anti-sense DNA or RNA, or enzymatically active RNA. Gene transfer can be performed in cultured cells or by direct administration into animals. Generally gene transfer involves the process of nucleic acid contact with a target cell by non-specific or receptor mediated interactions, uptake of nucleic acid into the cell through the membrane or by endocytosis, and release of nucleic acid into the cytoplasm from the plasma membrane or endosome. Expression may require, in addition, movement of the nucleic acid into the nucleus of the cell and binding to appropriate nuclear factors for transcription.

[0492] As used herein “gene therapy” is a form of gene transfer and is included within the definition of gene transfer as used herein and specifically refers to gene transfer to express a therapeutic product from a cell in vivo or in vitro. Gene transfer can be performed ex vivo on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

[0493] In another preferred embodiment, a vector having nucleic acid sequences encoding a STE20-related kinase polypeptide is provided in which the nucleic acid sequence is expressed only in specific tissue. Methods of achieving tissue-specific gene expression are set forth in International Publication No. WO 93/09236, filed Nov. 3, 1992 and published May 13, 1993.

[0494] In all of the preceding vectors set forth above, a further aspect of the invention is that the nucleic acid sequence contained in the vector may include additions, deletions or modifications to some or all of the sequence of the nucleic acid, as defined above.

[0495] In another preferred embodiment, a method of gene replacement is set forth. “Gene replacement” as used herein means supplying a nucleic acid sequence which is capable of being expressed in vivo in an animal and thereby providing or augmenting the function of an endogenous gene which is missing or defective in the animal.

[0496] X. Administration of Substances

[0497] Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. application Ser. No. 08/702,282, filed Aug. 23, 1996 and International patent publication number WO 96/22976, published Aug. 1, 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures, or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

[0498] The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used, and the size and physiological condition of the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially takes into account the ICso as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

[0499] Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors, and major organs can be also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan, and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

[0500] Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition, and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

[0501] At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 202:229-249, 1993). Representative animals from each treatment group can then be examined by gross necropsy for immediate evidence of metastasis, unusual illness, or toxicity. Gross abnormalities in tissue are noted, and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

[0502] For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness.

[0503] Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

EXAMPLES

[0504] The examples below are not limiting and are merely representative of various aspects and features of the present invention. The examples below demonstrate the isolation and characterization of the STE20-related kinases of the invention.

Example 1 Isolation of cDNAs Encoding Mammalian STE20-related Protein Kinases

[0505] Materials and Methods

[0506] Identification of Novel Clones

[0507] Total RNAs were isolated using the Guanidine Salts/Phenol extraction protocol of Chomczynski and Sacchi (P. Chomczynski and N. Sacchi, Anal. Biochem. 162, 156 (1987)) from primary human tumors, normal and tumor cell lines, normal human tissues, and sorted human hematopoietic cells. These RNAs were used to generate single-stranded cDNA using the Superscript Preamplification System (GIBCO BRL, Gaithersburg, Md.; Gerard, G F et al. (1989), FOCUS 11, 66) under conditions recommended by the manufacturer. A typical reaction used 10 μg total RNA with 1.5 μg oligo(dT)₁₂₋₁₈ in a reaction volume of 60 1L. The product was treated with RNaseH and diluted to 100 μL with H₂O. For subsequent PCR amplification, 1-4 μL of this sscDNA was used in each reaction.

[0508] Degenerate oligonucleotides were synthesized on an Applied Biosystems 3948 DNA synthesizer using established phosphoramidite chemistry, precipitated with ethanol and used unpurified for PCR. The sequence of some of the degenerate oligonucleotide primers and the amino acid motif they encode is as follows: TRK1 5′-CTGAATTCGGNGCNTTYGGNAARGT-3′ GAFGKV (sense) TRK4 5′-GCTGGATCCYTCNGGNGGCATCCA-3′ WMPPE (antisense) ROS1 5′-GCNTTYGGNGARGTNTAYGARGG-3′ AFGEVYEG (sense) CCK4b 5′-GCTGGATCCYTCNGGNSWCATCCA-3′ WMSPE (antisense) CCK4c 5′-GAGTTYGGNGARGTNTTYYTNGC-3′ EFGEVYEG (sense)

[0509] These primers were derived from the sense and antisense strands of conserved motifs within the catalytic domain of several protein kinases. Degenerate nucleotide residue designations are: N=A, C, G, or T; R=A or G; Y=C or T; H=A, C or T not G; D=A, G or T not C; S=C or G; and W=A or T.

[0510] PCR reactions were performed using degenerate primers applied to multiple single-stranded cDNAs. The primers were added at a final concentration of 5 μM each to a mixture containing 10 mM TrisHCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 200 μM each deoxynucleoside triphosphate, 0.001% gelatin, 1.5 U AmpliTaq DNA Polymerase (Perkin-Elmer/Cetus), and 1-4 μL cDNA. Following 3 min denaturation at 95° C., the cycling conditions were 94° C. for 30 s, 50° C. for 1 min, and 72° C. for 1 min 45 s for 35 cycles. PCR fragments migrating between 300-350 bp were isolated from 2% agarose gels using the GeneClean Kit (Bio101), and T-A cloned into the pCR11 vector (Invitrogen Corp. U.S.A.) according to the manufacturer's protocol.

[0511] Colonies were selected for mini plasmid DNA-preparations using Qiagen columns and the plasmid DNA was sequenced using a cycle sequencing dye-terminator kit with AmpliTaq DNA Polymerase, FS (ABI, Foster City, Calif.). Sequencing reaction products were run on an ABI Prism 377 DNA Sequencer, and analyzed using the BLAST alignment algorithm (Altschul, S. F. et al., J.Mol.Biol. 215: 403-10).

[0512] Additional PCR strategies were employed to connect various PCR fragments or ESTs using exact or near exact oligonucleotide primers as detailed in the results section for each cDNA. PCR conditions were as described above except the annealing temperatures were calculated for each oligo pair using the formula: Tm=4(G+C)+2(A+T).

[0513] Isolation of cDNA Clones:

[0514] Human cDNA libraries were probed with PCR or EST fragments corresponding to STE20-related genes. Probes were ³²P-labeled by random priming and used at 2×10⁶ cpm/mL following standard techniques for library screening. Pre-hybridization (3 h) and hybridization (overnight) were conducted at 42° C. in 5× SSC, 5× Denhart's solution, 2.5% dextran sulfate, 50 mM Na₂PO₄/NaHPO₄, pH 7.0, 50% formamide with 100 mg/mL denatured salmon sperm DNA. Stringent washes were performed at 65° C. in 0.1× SSC and 0.1% SDS. DNA sequencing was carried out on both strands using a cycle sequencing dye-terminator kit with AmpliTaq DNA Polymerase, FS (ABI, Foster City, Calif.). Sequencing reaction products were run on an ABI Prism 377 DNA Sequencer.

[0515] Makegene Bioinformatics EST assembler

[0516] The EST reports were downloaded from ncbi (www.ncbi.nlm.nih.gov). After uncompressing the files, the program ‘report2est’ was scripted to extract the following information: 1) EST names, 2) GenBank Accession numbers, 3) GenBank gi numbers, 4) Clone Id numbers, 5) the nucleotide sequences of the ESTs 6) the organism, 7) the library name, 8) the name of the lab, and 9) the institution. The output of ‘report2est’ is a file in FASTA format with all of the information listed above in the first line of each entry except the sequence, which is listed in the second line of each entry. The resulting file is formatted for BLAST using ‘pressdb’ (available as part of the ncbi tool kit).

[0517] To build a gene or part of a gene from ESTs, the program ‘makegene’ was developed. Input to this program is a query sequence and the organism/species for which a gene is to be built. An initial search of the formatted EST database described above is performed using BLAST (blastn). Any results that contain warnings, such as polyA tails or other repeat elements, are eliminated from future queries. The program ‘blast_parse_reports’ was developed to extract the FASTA header line from the search results and the output is then filtered to extract only FASTA header lines for the desired species.

[0518] The initial results, having been filtered for warnings and species, go into a loop in which searches against the database are repeated until no new ESTs are found. The loop consists of the following steps: 1) when possible the names of both ends of the ESTs are extracted from the database by searching using the ‘Clone Id’ field or the part of the ‘EST name’ field before the .r or s postscript, 2) any ESTs that have been used as queries in previous loops are removed from the current query by the program ‘subtract’, 3) the resulting list of ESTs is used to extract the sequences from the database by the program batch_parse_fasta, 4) BLAST is run against the database using each sequence, 5) the output files from BLAST containing warnings are removed, 6) the results are filtered by species, and 7) the loop is reentered if there were new ESTs found in the previous pass through the loop.

[0519] The ESTs chosen by ‘makegene’ are used as input for the program ‘mpd2 cluster’ (Hide, W., Burke, J, and Davison, D. U. of Houston, unpublished) which clusters overlapping sequences. The programs ‘contig’ (Kerlavage, T., TIGR, unpublished), ‘gde2mult’ and ‘gde2sing’ (Smith, S. W., et al., CABIOS 10, 671-675 (1994)), are used to make an alignment and consensus sequence of the overlapping ESTs.

Results

[0520] cDNA Cloning and Characterization of STLK2

[0521] The human STLK2 cDNA sequence is composed of two overlapping EST fragments, AA191319 and W16504, that were identified using a Smith-Waterman search of the EST database with STLK1 (MST3 GB:AF024636) as a query. The complete sequence of both clones was determined and used to generate the full-length human STL2 sequence.

[0522] EST clone AA191319 contains a 1327 bp insert and an ORF of 1146 bp (382 amino acids). EST clone W16504 contains a 2474 bp insert (not including the poly-A tail) and an ORF of 687 bp (382 amino acids).

[0523] The full-length human STLK2 cDNA (SEQ ID NO. 1) is 3268 bp long. AA191319 spans positions 1-1327 and W16504 positions 743-3216. The overlap between these two clones exhibits 100% sequence identity. The human STLK2 cDNA constains a 1248 bp ORF flanked by a 181 bp 5′ UTR (1-181) and a 1784 bp 3′ UTR (1433-3216) that is followed by a 52 nucleotide polyadenylated region. A polyadenylation signal (AATAAA) is found at positions 3193-3198. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for STLK2. Furthermore, human STLK2, and the related SOK-1 and MST3 proteins, conserve the amino acid sequence immediately following this presumed initiating methionine.

[0524] Several EST fragments span the complete STLK2 sequence with AA191319 at the 5′ end and W16504 at the 3′ end.

[0525] All searches against the public nucleic acid database (NRN) and protein database (NRP) were conducted using the Smith-Waterman gap alignment program ((Smith, T F and Waterman, M S (1981) J. Mol. Biol, 147, 195-197).) with the PAM100 matrix and gap open and extension penalties of 14:1, respectively.

[0526] cDNA Cloning and Characterization of STLK3

[0527] A mammalian STLK3 clone, 135-31-19, was first identified from a PCR screen with the degenerate oligos, TRK1 and TRK4, applied to a sscDNA generated from adult rat brain substantia nigra. Sequence analysis of the 457 bp insert indicated that it represented a novel member of the STE20-subfamily of STKs.

[0528] A Smith-Waterman search of the EST database with the rat STLK3 fragment and human STLK1 (MST3 GB:AF024636) as queries identified several overlapping ESTs spanning most of the human STLK3 cDNA sequence. A Makegene analysis generated a 3037 bp contig from approximately 44 EST sequences. Since the 3′ ESTs were not commercially available, a pair of primers (5′-CACAGAAACGGTCAGATTCAC-3′ and 5′-GATCAGGGTGACATCAAGGGAC-3′) were derived from this region to generate PCR clone 3R21-20-6 from human fetal liver sscDNA. This clone and EST AA278967 were fully sequenced to generate the full-length STLK2 cDNA sequence.

[0529] AA278967 is a 837 bp EST isolated by the IMAGE consortium from cDNA made from CD20+/IgD-germinal center B cells sorted from human tonsillar cells.

[0530] PCR clone 3R21-20-6 was isolated from human fetal sscDNA and contains a 1116 bp insert, including a 1086 bp ORF encoding the 362 C-terminal amino acids of STLK3.

[0531] The full-length human STLK3 cDNA (SEQ ID NO. 2) is 3030 bp long. AA278967 spans positions 1-814 and 3R21-20-6 spans positions 464-1579. The overlap between these two clones exhibits 100% sequence identity. The remaining 1452 bp of 3′ UTR is derived from an assembly of multiple unconfirmed EST fragments.

[0532] The near full-length human STLK3 cDNA (SEQ ID NO.2) is 3030 bp long and consists of a 1548 bp ORF flanked by a 1476 bp 3′ UTR (1550-3025) and a 5 nucleotide polyadenylated region. A polyadenylation signal (AATAAA) begins at position 3004. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. Six copies of a “GGCCCC” repeat were observed in positions 21-67. Five independent ESTs (AA150838, AA286879, AA251679, AA252004, AA278967) showed the same repeat, suggesting that this sequence may be an integral region of the human STLK3 gene. Stronger evidence for this being the case is provided by the sequence of the murine orthologue of STLK3 represented by a 876 bp EST W20737.

[0533] Multiple EST fragments span the complete STLK3 sequence with AA278967 at the 5′ end and AA628477 and others at the 3′ end.

[0534] cDNA Cloning and Characterization of STLK4

[0535] The human STLK4 cDNA sequence is composed of two overlapping EST fragments, AA297759 and AA100484, that were identified using a Smith-Waterman search of the EST database with STLK1 (MST3 GB:AF024636) as a query. The complete sequence of both clones was determined and used to generate the near full-length human STLK4 sequence.

[0536] AA100484 is an IMAGE consortium cDNA clone isolated from the T-84 colonic epithelium cell line. It has an insert of 3694 bp and a coding region of 1146 bp (382 amino acids). A Smith-Waterman sequence alignment against the NRN database showed this EST to be 71.4% identical to the human STE20-like kinase (GB:X99325).

[0537] W16504 is an IMAGE consortium clone isolated from a human fetal heart cDNA library. It has an insert length of 2474 bp (not including the poly-A tail) and a coding region of 687 bp (229 amino acids). A Smith-Waterman sequence alignment of W16504 against the NRN database showed this EST to be 69.2% identical to the human STE20-like kinase (GB:X99325).

[0538] The full-length human STLK2 cDNA (SEQ ID NO. 1) is 3268 bp long. AA191319 spans positions 1-1327, and W16504 positions 743-3216. The overlap between these two clones is 585 bp long with 100% sequence identity.

[0539] AA100484 is an IMAGE consortium cDNA clone isolated from the T-84 colonic epithelium cell line. AA100484 covers the bulk of Human STLK4 with its 3694 bp, which spans positions 146-3839 of SEQ ID NO:3. A second EST, AA297759, isolated from a Jurkat T cell cDNA library, spans positions 1-271 of the human STLK4 contig. The two ESTs overlap over a 126 bp stretch that has only one nucleotide discrepancy at position 149 (G in AA297759 and T in AA100484). A T at this position was chosen for the SEQ ID NO:3 based on sequence data generated from A100484. The 5′ 145 bp of human STLK4 contains three sequencing ambiguities (N's in SEQ ID NO:3) arising from sequence errors in the GenBank entry for AA297759. Three amino acid sequence ambiguities in the N-terminus of human STLK4 are present also in SEQ ID NO:7 as a consequence of the sequence inaccuracies from the EST entry.

[0540] The coding region of human STLK4 is 1242 bp long (2-1243), capable of encoding a 414 amino acid polypeptide, and is followed by a 2596 nucleotide 3′ UTR (1244-3839). Human STLK4 ends in a polyadenylated stretch that has 18 adenines (3840-3857). A polyadenylation signal (AATAAA) is found between positions 3822-3827. Targeted-PCR cloning identified one rat orthologue of human STLK4, clone 135-31-19. In addition, one murine orthologue of human STLK4 was recognized in the EST database as AA117483. None of these orthologues add additional N-terminal sequence to the human STLK4.

[0541] The near full-length human STLK4 cDNA (SEQ ID NO.3) is 3857 bp long and consists of a 1242 bp ORF flanked by a 2596 bp 3′ UTR (1244-3839) and an 18 nucleotide polyadenylated region. Polyadenylation signals (AATAAA) begin at positions 2181 and 3822. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine. A near full-length murine STLK4 cDNA is represented in the 1773 bp EST AA117438. It extends an additional 21 nucleotides 5′ of the human STLK4 consensus, but since its coding region is open throughout the 5′ extent of the sequence, this is also probably a partial cDNA clone lacking the N-terminal start methionine.

[0542] Several EST fragments span the complete STLK3 sequence with AA297759 at the 5′ end and AA100484 and others at the 3′ end.

[0543] cDNA Cloning and Characterization of STLK5

[0544] The human STLK5 cDNA sequence is composed of four overlapping sequences, AI418298, 2R96-13-1, 3R25-45-3 and R46685. A human STLK5 clone, F07734, was first identified using a Smith-Waterman search of the EST database with SPS_sc (U33057) as a query.

[0545] AI418298 is an IMAGE consortium cDNA clone with an 895 bp insert.

[0546] PCR clone 2R96-13-1 was isolated from human brain sscDNA using primers 5′-CTCATCTGTACACACTTCATGG and 5′-GATTCCCACACTGTAGATGTC derived from F07734. 2R96-13-1 contains a 330 bp insert and an ORF of 330 bp (110 amino acids).

[0547] EST clone R46685 was identified using a Smith-Waterman search of the EST database with the C-terminus of SPS_sc (GB:U33057) as query. Sequence analysis of the 1047 bp insert identified this EST to contain an ORF of 285 bp (95 amino acids) encoding the C-terminus of human STLK5.

[0548] PCR clone 3R25-45-3 was isolated from human fetal brain sscDNA using primers 5′- GGCCCTCGACTACATCCACCACAT and 5′- CAACGAAACTAACACAGCATAAGG derived from 2R96-13-1 and R46685, respectively. 3R25-45-3 contains a 330 bp insert and an ORF of 750 bp (250 amino acids).

[0549] The full-length human STLK5 cDNA (SEQ ID NO:96) is 2110 bp long and consists of a 1119 bp ORF flanked by a 229 bp 5′ UTR and a 762 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (supra) for an initiating methionine, and is believed to be the translational start site for STLK5.

[0550] Several EST fragments span the complete STLK5 sequence with AA297059 and F07734 at the 5′ end and R46686 and F03423 and others at the 3′ end.

[0551] STLK5 displays a 100% match over a 41 bp stretch (position 2-42, SEQ ID NO. 97) to a human CpG island repeat (Z61277).

[0552] cDNA Cloning and Characterization of STLK6

[0553] Human STLK6 was first identified in the translated EST database (AA219667) as a novel serine threonine kinase.

[0554] The partial human STLK6 cDNA (SEQ ID NO:98) is 2,001 bp long and consists of a 1,254 bp ORF flanked by a 75 bp 5′ UTR and a 673 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (Kozak, M., Nucleic Acids Res. 15, 8125-8148 (1987)) for an initiating methionine, and is believed to be the translational start site for STLK6.

[0555] At the time of filing, inventors believe that STLK6 does not have any significant match in the nucleic acid database.

[0556] cDNA Cloning and Characterization of STLK7

[0557] Human STLK7 was first identified in the translated EST database (AA988954) as a novel serine threonine kinase. The original clone was not available through public sources, so a PCR fragment amplified from the sequence of AA988954 yielded 5R54-21-2.

[0558] The partial human STLK7 cDNA (SEQ ID NO:100) is 311 bp long and consists of a 309 bp ORF. Since the coding region is open throughout the 5′ and 3′ extent of this sequence, this appears to be a partial cDNA clone lacking the N-terminal start methionine and C-terminal stop codon.

[0559] STLK7 shares 80% sequence identity to human SPAK (AF099989) over a 167 bp region and 50% nucleotide sequence identity to SLTK7 (SEQ ID NO. 101) over 391 nucleotides.

[0560] cDNA Cloning and Characterization of ZC1

[0561] The human ZC1 cDNA sequence is composed of two overlapping PCR clones, 3R25-24-2 and R65-12-2.

[0562] A human ZC1 clone, 125-33-5, was first identified from a PCR screen with degenerate oligos, TRK1 and TRK4, applied to sscDNA generated from human small airway epithelial cells (Clontech). Sequence analysis of the 503 bp insert identified a 501 bp ORF (167 amino acids) with the potential to encode a novel human STK related to the C. elegans ZC504.4 gene product.

[0563] PCR clone 3R25-24-2 was isolated from human SNB19 glioblastoma sscDNA using primers 5′-ATGGCGAACGACTCTCCCGCGAA and 5′-ACACCAAAATCAACAAGTTTCACCTC derived from the N-terminus of a murine orthologue of ZC1 (NIK, GB:U88984) and the original human ZC1 clone 125-33-5, respectively. 3R25-24-2 contains a 527 bp insert and an ORF of 519 bp (173 amino acids).

[0564] PCR clone R65-12-2 was isolated as follows: A Smith-Waterman search of the EST database with the C. elegans ZC504.4 gene (GB:Z50029) as a query identified a human EST (W81656) whose ORF is related to the C. elegans gene and terminates in an identical residue (Trp). A primer was designed 3′ to this stop codon (5′-AGTTACAAGGAATTCCAAGTTCT) and used in a PCR reaction with a primer derived from the original human ZC1 clone 125-33-5 (5′-ATGAAGAGGAAGAAATCAAACTG) using sscDNA from human SNB19 glioblastoma as a template. PCR clone R65-12-2 was identified and was found to contain a 3611 bp insert with a 3534 bp ORF encoding the C-terminal portion of human ZC1 (1178 amino acids).

[0565] The full-length human ZC1 cDNA (SEQ ID NO. 9) is 3798 bp long. Clone 3R25-24-2 spans positions 1-527, and clone R65-12-2 spans positions 188-3798. The overlap between these two clones exhibits 100% sequence identity. The human ZC1 contains a 3717 bp ORF (17-3723) flanked by a 6 bp 5′ UTR and a 75 bp (3724-3798) 3′ UTR. No polyadenylation signal (AATAAA) or polyadenylated region are present in the 3′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human ZC1.

[0566] Multiple EST fragments (W81656) match the 3′ end of the human ZC1 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0567] cDNA Cloning and Characterization of ZC2

[0568] The human ZC2 cDNA sequence is composed of four overlapping PCR clones, G75-31-17, R65-24-6, 2R28-8-1, and R99-6-10.

[0569] A human ZC2 clone, G75-31-17, was first identified from a PCR screen with degenerate oligos, ROS1 (5′-GCNTTYGGNGARGTNTAYGARGG) and CCK4b (5′-GCTGGATCCYTCNGGNSWCATCCA), applied to sscDNA generated from the human HLT383 primary non-small cell lung cancer tissue. Sequence analysis of the 492 bp insert identified a 492 ORF (164 amino acids) with the potential to encode a novel human STK related to the C. elegans ZC504.4 gene product.

[0570] PCR clone R99-6-10 was isolated as follows: A Smith-Waterman search of the EST database with C. elegans ZC504.4 gene (GB:Z50029) as a query identified two overlapping human EST fragments (AA115844 and R51245) whose ORFs were related to the C. elegans gene and terminate in an identical residue (Trp). A primer was designed 3′ to the stop codon found in R51245 (5′-AGATGGACTGTACTGGGAGG) and used in a PCR reaction with a primer derived from AA115844 (5′-ACTTTGTGCAGCTCTGTGGG) using human fetal brain sscDNA as a template. PCR clone R99-6-10 was identified and was found to contain a 1095 bp insert with a 930 bp ORF encoding the C-terminal portion of human ZC2 (310 amino acids).

[0571] PCR clone R65-24-6 was isolated from human HT29 colon cancer cell line sscDNA using primers 5′-AAGGTTATGGATGTCACAGGG and 5′-AGATGGACTGTACTGGGAGG derived from G75-31-17 and R51245, respectively. The 3′ primer used in this PCR reaction misprimed between positions 1634-1653 of this gene leading to the formation of a truncated product. R65-24-6 contains a 1593 bp insert and an ORF of 1593 bp (531 amino acids).

[0572] PCR clone 2R28-8-1 was isolated from human colon cancer cell line HT29 sscDNA using primers 5′-CTCACAAGGTTGCCAACAGG and 5′-AGTCCCCACCAGAAGGTTTAC derived from R65-24-6 and R99-6-10, respectively. 2R28-8-1 contains a 1538 bp insert and an ORF of 1536 bp (512 amino acids).

[0573] The partial human ZC2 cDNA (SEQ ID NO. 10) is 4055 bp long. Clone G75-31-17 spans positions 1-492, clone R65-24-6 spans positions 58-1650, clone 2R28-8-1 spans positions 1466-3003 and clone R99-6-10 spans positions 2961-4055. The overlaping regions between these clones exhibit 100% sequence identity except for a single guanine (G75-31-17) to adenosine (R65-24-6) mismatch at position 280 resulting in a Glu to Lys change. Based on the presence of an acidic residue in this position in human ZC1 and ZC3 and C. elegans ZC504.4, the sequence encoding the Glu is probably correct. The human ZC2 gene contains a 3891 bp ORF (1-3891) flanked by 164 bp (3892-4055) 3′ UTR. No polyadenylation signal (AATAAA) or polyadenylated region is present in the 3′UTR.

[0574] Multiple EST fragments (R51245) match the 3′ end of the human ZC2 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0575] cDNA Cloning and Characterization of ZC3

[0576] The human ZC3 cDNA sequence is composed of four overlapping PCR clones, G75-30-30, 3R33-5-3, 3R19-17-6, and R99-43-11.

[0577] A human ZC3 clone, G75-30-30, was first identified from a PCR screen with degenerate oligos, ROS1 and CCK4b, applied to sscDNA generated from a human HLT370 primary non-small cell lung cancer tissue. Sequence analysis of the 492 bp insert identified a 492 ORF (164 amino acids) with the potential to encode a novel human STK related to the C. elegans ZC504.4 gene product.

[0578] PCR clone R99-43-11 was isolated as follows: A Smith-Waterman search of the EST database with the C. elegans ZC504.4 gene (GB:Z50029) as a query identified a human EST (R54563) whose ORF is related to the C. elegans gene and terminates in an identical residue (Trp). A primer was designed 3′ to the stop codon found in R54563 (5′-TCAGGGGTCAGAGGTCACG) and used in a PCR reaction with a primer derived from the 5′ end of R54563 (5′-CCCAAACCCTACCACAAATTC) using sscDNA from human fetal brain as a template. PCR clone R99-43-11 was identified and was found to contain a 719 bp insert with a 564 bp ORF encoding the C-terminal portion of human ZC3 (188 amino acids).

[0579] PCR clone 3R19-17-6 was isolated from human A549 lung cancer cell line sscDNA using primers 5′-CCCCCGGGAAACGATGACCA and 5′-AGCCGCTGCCCCTCCTCTACTGT derived from G75-30-30 and R99-43-11, respectively. The 3′ primer used in this PCR reaction misprimed leading to the formation of a truncated product. 3R19-17-6 contains a 1172 bp insert and an ORF of 1170 bp (390 amino acids).

[0580] PCR clone 3R33-5-3 was isolated from human A549 lung cancer cell line sscDNA using primers 5′-ACCGCAACATCGCCACCTACTAC and 5′-CTCGACGTCGTGGACCACC derived from G75-30-30 and 3R19-17-6, respectively. 3R33-5-3 contains a 2465 bp insert and an ORF of 2463 bp (821 amino acids).

[0581] The full-length human ZC3 cDNA (SEQ ID NO. 11) is 4133 bp long. Clone G75-30-30 spans positions 1-483, clone 3R33-5-3 spans positions 134-2598, clone 3R19-17-6 spans positions 2356-3512 and clone R99-43-11 spans positions 3415-4133. The overlaps between these clones exhibit 100% sequence identity. The human ZC3 gene contains a 3978 bp ORF (1-3978) flanked by a 152 bp 3′ UTR (3979-4133). No polyadenylation signal (AATAAA) or polyadenylated region is present in the 3′UTR.

[0582] Multiple EST fragments (R54563) match the 3′end of the human ZC3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0583] cDNA Cloning and Characterization of ZC4

[0584] The human ZC4 cDNA sequence, represented by PCR fragment 3R25-27-1, was first identified in the human genomic cosmid 82J11 (GB:Z833850) containing exon sequences that displayed strong homology to the ZC504.4 C. elegans gene.

[0585] PCR clone 3R25-27-1 was isolated from human fetal liver sscDNA and primers 5′-CAATGTTAACCCACTCTATGTCTC and 5′-AGTTTGCCGATGTTTTTCTTTTC derived from a potential ORF (positions 25729-25852) from the 82J11 cosmid and from an EST (R98571) encoding the C-terminus of the human ZC4 gene, respectively.

[0586] The partial human ZC4 cDNA (SEQ ID NO.12) is 1459 bp long and consists of a 1047 bp ORF (2-1048) flanked by a 411 bp (1049-1459) 3′UTR region. No polyadenylation signal (AATAAA) or polyadenylated region is present in the 3′UTR.

[0587] The N-terminal coding sequence for ZC4_h was extended by building a contiguous DNA sequence of 233,137 bp containing Z83850 and four other sequences: cU84B10 and cU230B10 (from the Sanger Human Genome Sequencing Project, http://www.sanger.ac.uk/HGP/) and Z97356 and Z69734 (available from the National Institute for Biotechnology Information, http://www.ncbi.nlm.nih.gov/Entrez/nucleotide.html). The position of each sequence in the contig is represented in the table below. Accession Length Start End cU84B10 43273   0  43273 Z97356 21848 43171  65018 Z69734 37077 63073 100149 cU230B10 11841 88416 100256 Z83850 132981  100156  233137

[0588] The 233,137 bp contig was analyzed for exons using the programs FGENES 1.5 and FGENESH, human gene structure prediction software available from The Sanger Centre (http://genomic.sanger.ac.uk/gf/gf.shtml).

[0589] The resulting human ZC4 coding sequence (SEQ ID NO:104) is 3,681 bp long (excluding the stop codon) and encodes for a STE20 kinase of 1227 amino acids.

[0590] cDNA Cloning and Characterization of KHS2

[0591] The human KHS2 cDNA sequence is composed of four overlapping clones, 3R25-51-2, 3R16-34-2, 3R16-31-2, and T79916.

[0592] A human KHS2 clone, AA250855, was first identified using a Smith-Waterman search of the EST database with KHS1 (GB:U77129) as a query. Sequence analysis of the 1112 bp insert identified a 618 bp ORF (206 amino acids) with the potential to encode a novel STK related to the human KHS1 gene product. Using AA250855 as a query, a second EST (AA446022) was found whose sequence was shown to contain the initiator methionine for human KHS2 based on a comparison with KHS1.

[0593] PCR clone 3R25-51-2 was isolated from human testicular cancer sscDNA using primers 5′-CCGCCATGAACCCCGGCTT and 5′-CGATTGCCAAAGACCGTGTCA derived from AA446022 and AA250855, respectively. 3R25-51-2 contains an 850 bp insert and an ORF of 849 bp (283 amino acids).

[0594] EST clone, T79916, was identified using a Smith-Waterman search of the EST database with the C-terminus of KHS1 (GB:U77129) as a query. Sequence analysis of the 2107 bp insert identified this EST to contain an ORF of 345 bp (115 amino acids disrupted by a single stop codon) encoding the C-terminus of human KHS2, followed by 1762 bp 3′UTR.

[0595] PCR clone 3R16-34-2 was isolated from human testis sscDNA using primers 5′-AGAAGTTGCAGCTGTTGAGAGGA and 5′-TATGGCCCGTGTAAGGATTTC derived from AA250885 and T79916, respectively. 3R16-34-2 contains an 1516 bp insert and an ORF of 1128 bp (376 amino acids).

[0596] PCR clone 3R16-31-2 was isolated from normal human colon sscDNA using primers 5′- GTGCCAGAAGTGTTGTGTTGTAA and 5′-TATGGCCCGTGTAAGGATTTC derived from EST T79916. 3R16-31-2 contains a 728 bp insert and an ORF of 669 bp (223 amino acids). This clone lacked the stop codon present within EST T79916 (postion 2662 in the KHS2 sequence).

[0597] The full-length human KHS2 cDNA (SEQ ID NO.17) is 4023 bp long. Clone 3R25-51-2 spans positions 1-855, clone AA250885 spans positions 336-923, clone 3R16-34-2 spans positions 545-2061, and clone T79916 spans positions 1917-4023. The overlaping regions between these clones exhibit 100% sequence identity, except for 4 nucleotide differences, two of which are silent, a third corrects the internal stop codon at position 2662, and the fourth at position 247 (T to C change) results in a Pro to Leu change. The human KHS2 cDNA contains a 2682 bp ORF (6-2687) flanked by a 5 bp (1-5) 5′UTR and a 1336 bp (2688-4023) 3′ UTR. A potential polyadenylation signal (AATAAA) is found at positions 4008-4013. No polyadenylated region is present in the 3′UTR. The sequence flanking the first ATG is in a poor context for translational initiation, however, a 134 bp 5′UTR sequence from EST AA446022 did not reveal any additional ATG's and displayed two in-frame stop codons 5′ to the putative start ATG for human KHS2.

[0598] Multiple EST fragments match the 5′end (AA446022) as well as the 3′ end (R37625) of the human KHS2 gene. cDNA Cloning and Characterization of SULU1 The human SULU1 cDNA sequence is composed of three overlapping clones, N40091, 2R90-1-1 and R90907.

[0599] A human SULU1 clone, N40091, was first identified using a Smith-Waterman search of the EST database with the C. elegans SULU gene (GB: U32275) as a query. Sequence analysis of the 1321 bp insert identified a 906 bp ORF (302 amino acids) with the potential to encode a novel human STK related to the C. elegans SULU gene product.

[0600] EST clone R90907 was first identified using a Smith-Waterman search of the EST database with the 3′ end of the C. elegans SULU gene (GB: U32275) as a query. Sequence analysis of the 1647 bp insert identified a 578 bp ORF (192 amino acids) with the potential to encode the C-terminus of the human SULU1 gene product.

[0601] PCR clone 2R90-1-1 was isolated from human HT29 colon cancer cell sscDNA using primers 5′- TATTGAATTGGCGGAACGGAAG and 5′- TTGTTTTGTGCTCATTCTTTGGAG derived from N40091 and R90907, respectively. 2R90-1-1 contains a 1625 bp insert and an ORF of 1623 bp (541 amino acids).

[0602] The full-length human SULU1 cDNA (SEQ ID NO.19) is 4177 bp long Clone N40091 spans positions 1-1321, clone 2R90-1-1 spans positions 1048-2671, and clone R90907 spans positions 2531-4177. The overlaping regions between these clones exhibit 100% sequence identity. The human SULU1 cDNA contains a 2694 bp ORF (415-3108) flanked by a 414 bp (1-414) 5′UTR and a 1069 bp (3109-4177) 3′ UTR followed by a 19 nucleotide polydenylated region. A potential polyadenylation signal (AATAAA) is found at positions 4164-4169. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human SULU1.

[0603] Multiple EST fragments match the 5′end (N27153) as well as the 3′ end (R90908) of the human SULU1 gene.

[0604] cDNA Cloning and Characterization of Murine SULU3

[0605] The murine SULU3 cDNA sequence is represented by PCR fragment 2R92-1-6.

[0606] A murine SULU3 clone, G83-4-5, was first identified from a PCR screen with degenerate oligos, CCK4c and CCK4b, applied to sscDNA generated from murine day-12 embryos. Sequence analysis of the 473 bp insert identified a 471 ORF (157 amino acids) with the potential to encode a novel human STK related to the C. elegans SULU gene (GB: U32275) product. The antisense strand of G83-4-5 is identical at the nucleic acid level to the 5′UTR of the murine etsl protooncogenic transcription factor (GB:X53953). This homology is likely the result of a cloning artifact attached to the 5′-end of the database entry for murine etsl.

[0607] PCR clone 3R19-17-6 was isolated from human A549 cell sscDNA using primers 5′-CCCCCGGGAAACGATGACCA and 5′-AGCCGCTGCCCCTCCTCTACTGT derived from G75-30-30 and R99-43-11, respectively. The 3′ primer used in this PCR reaction misprimed leading to the formation of a truncated product. 3R19-17-6 contains a 1172 bp insert and an ORF of 1170 bp (390 amino acids).

[0608] PCR clone 2R92-1-6 was isolated from murine d8 embryo sscDNA using primers 5′-ACCGCAACATCGCCACCTACTAC and 5′-GATTGCTTTGTGCTCATTCTTTGG derived from the 5′ UTR of the etsl gene and the human EST AA234623, respectively. The latter (shown herein) encodes the C-terminus of human SULU3. 2R92-1-6 contains a 2249 bp insert and an ORF of 2244 bp (748 amino acids).

[0609] The partial murine SULU3 cDNA (SEQ ID NO.21) is 2249 bp long and consists of a 2244 bp ORF (6-2249) flanked by a 5 bp (1-5) 5′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for murine SULU3.

[0610] One EST fragment (AA446022) matches the 3′ end of the partial murine SULU3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0611] cDNA Cloning and Characterization of Human SULU3

[0612] The human SULU3 cDNA sequence is composed of two overlapping clones, 2R90-22-1 and AA234623.

[0613] A human SULU3 clone, AA234623, was first identified using a Smith-Waterman search of the EST database with the C. elegans SULU gene (GB: U32275) as a query. Sequence analysis of the 2652 bp insert identified a 1185 bp ORF (395 amino acids) with the potential to encode the C-terminus of a novel human STK related to the C. elegans SULU gene product.

[0614] PCR clone 2R90-22-1 was isolated from human SKMell28 melanoma cell line sscDNA using primers 5′-TATTGAATTGGCGGAACGGAAG and 5′- TTGTTCTAAGAGTGCCCTCCG derived from the murine SULU3 2R92-1-6 clone and from AA234623, respectively. 2R92-1-6 contains a 1897 bp insert and an ORF of 1896 bp (632 amino acids).

[0615] The partial human SULU3 cDNA (SEQ ID NO.20) is 3824 bp long. Clone 2R90-22-1 spans positions 1-1897 and clone AA234623 spans positions 1173. The overlaping region between these clones exhibits 100% sequence identity. The human SULU3 cDNA contains a 2358 bp ORF (2-2359) flanked by a 1465 bp (2360-3824) 3′UTR followed by a 19 nucleotide polydenylated region. A potential polyadenylation signal (AATAAA) is found at positions 2602-2607. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine.

[0616] Multiple EST fragments (R02283) match the 3′end of the human SULU3 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0617] cDNA Cloning and Characterization of GEK2

[0618] The human GEK2 cDNA sequence is composed of three overlapping clones, AA459448, 3R25-48-1 and GEK2_h#3.

[0619] A human GEK2 clone, AA459448, was first identified using a Smith-Waterman search of the EST database with the human SLK gene (GB: AB002804) as a query. Sequence analysis of the 1286 bp insert identified a 1227 bp ORF (409 amino acids) with the potential to encode the N-terminus of a novel human STK related to the human SLK gene product. An additional Smith-Waterman search using the C-terminus of the SLK gene as a query yielded three additional EST's, AA323687, AA380492 and AA168869, that encode the C-terminal region of human GEK2.

[0620] PCR clone 2R98-41-17 was isolated from human testis sscDNA using primers 5′- AAGACCATGCCGTGCGCCG and 5′-ATTCCTTCAGGTTCTGGTTATGG derived from AA323687 and from AA380492, respectively. 2R98-41-17 contains a 851 bp insert and an ORF of 849 bp (283 amino acids).

[0621] PCR clone GEK2_h#3 was isolated from human sscDNA made from the H23 tumor cell line using primers 5′-GCAGCAAGTGGAGAAGATGG and 5′- GGAAGCATCCCCAGAGCTGTAG derived from the sequence of clone 3R25-48-1 and from the 3′ end of murine LOK (GB:D89728), respectively. GEK2_h#3 contains a 1042 bp insert and an ORF of 1041 bp (347 amino acids).

[0622] The full-length human GEK2 cDNA (SEQ ID NO:106) is 2962 bp long. Clone AA459448 spans positions 1-1286, clone 3R25-48-1 spans positions 1100-2449 and clone GEK2_h#3 spans positions 1920-2962. The overlapping regions between these clones exhibit 100% sequence identity.

[0623] The human GEK2 cDNA contains a 2904 bp ORF (59-2962) flanked by a 58 bp (1-58) 5′UTR. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human GEK2.

[0624] Multiple EST fragments (AA465671) match the 5′end of the sequence, but only one (AA380492) matches the 3′ end of the human GEK2 gene.

[0625] cDNA Cloning and Characterization of PAK4

[0626] The human PAK4 cDNA sequence is represented by clone SNB2#1.

[0627] A human PAK4 clone, R88460, was first identified using a Smith-Waterman search of the EST database with the human PAK gene (GB: U24152) as a query. Sequence analysis of the 2332 bp insert identified a 930 bp ORF (310 amino acids) with the potential to encode the C-terminus of a novel human STK related to the human PAK gene product. cDNA clone SNB2#1 was isolated from human glioblastoma cell line SNB75 cDNA library using a probe derived from R88460. SNB2#1 contains a 3604 bp insert and an ORF of 2043 bp (681 amino acids).

[0628] The full-length human PAK4 cDNA (SEQ ID NO.27) is 3604 bp long and consists of a 2043 bp ORF (143-2185) flanked by a 142 bp (1-142) 5′UTR and a 1419 3′ UTR followed by a 22 nucleotide polydenylated region. A potential polyadenylation signal (AATTAAA) is found at positions 3582-3588. The sequence flanking the first ATG conforms to the Kozak consensus for an initiating methionine, and is believed to be the translational start site for human PAK4. The 3′ UTR of the PAK4 gene contains a GT dinucleotide repeat prone to undergo expansion based on the number of repeats found in clones SNB#1 and R88460, 32 and 23, respectively. Several neurologic disorders have been correlated with the expansion of di- or tri-nucleotide repeats similar to those found in the PAK4 sequence, suggesting PAK 4 may also be a disease target and that this repeat in its 3′UTR may serve as a diagnostic marker.

[0629] Multiple EST fragments (AA535791) match the 3′end of the human PAK4 gene, but at the time of filing, the inventors believe that none exist in GenBank or the EST database that match its 5′ end.

[0630] cDNA Cloning and Characterization of PAK5

[0631] The full-length human PAK5 cDNA sequence is composed of two overlapping clones, H450#1-1 and SNB8#5.

[0632] A human PAK5 clone, R18825, was first identified using a Smith-Waterman search of the EST database with the human PAK4 gene as a query. Sequence analysis of the 1248 bp insert identified a 420 bp ORF (140 amino acids) with the potential to encode the C-terminus of a novel human STK related to the human PAK4 gene product.

[0633] cDNA clone SNB8#5 was isolated from human SNB75 cDNA library using a probe derived from R18825. SNB2#1 contains a 2028 bp insert and an ORF of 1194 bp (398 amino acids).

[0634] The partial human PAK5 cDNA (SEQ ID NO.28) is 2028 bp long and consists of a 1194 bp ORF (2-1195) flanked by an 833 bp (1196-2028) 3′UTR followed by a 22 nucleotide polydenylated region. A potential polyadenylation signal (AATTAAA) is found at positions 2004-2010. Since the coding region is open throughout the 5′ extent of this sequence, this is apparently a partial cDNA clone lacking the N-terminal start methionine.

[0635] Clone H460#1-1 was isolated from a human lung H460 cDNA library using a probe derived from the partial SNB2#1 cDNA clone described above. Sequence analysis of the 2526 bp insert identified a 1773 bp ORF (592 amino acids) with the potential to encode a full-length PAK5.

[0636] The human PAK5 cDNA (SEQ ID NO:102) is 2,806 bp long and consists of a 1,773 bp ORF flanked by a 201 bp 5′ UTR and a 833 bp 3′ UTR. The sequence flanking the first ATG conforms to the Kozak consensus (Kozak, M., Nucleic Acids Res. 15, 8125-8148 (1987)) for an initiating methionine, and is believed to be the translational start site for PAKS.

[0637] PAK5 shares 99% sequence identity over 2795 bp to a recent database entry, AF005046. These sequences are presumed to be from the same gene, with minor polymorphic variations.

EXAMPLE 2 Expression Analysis of Mammalian STE20-Related Protein Kinases

[0638] Materials and Methods

[0639] Northern Blot Analysis

[0640] Northern blots were prepared by running 10 □g total RNA isolated from 60 human tumor cell lines (HOP-92, EKVX, NCI-H23, NCI-H226, NCI-H322M, NCI-H460, NCI-H522, A549, HOP-62, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, IGROV1, SK-OV-3, SNB-19, SNB-75, U251, SF-268, SF-295, SF-539, CCRF-CEM, K-562, MOLT-4, HL-60, RPMI 8226, SR, DU-145, PC-3, HT-29, HCC-2998, HCT-116, SW620, Colo 205, HTC15, KM-12, UO-31, SN12C, A498, CaKil, RXF-393, ACHN, 786-0, TK-10, LOX IMVI, Malme-3M, SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257, M14, MCF-7, MCF-7/ADR RES, Hs578T, MDA-MB-231, MDA-MB-435, MDA-N, BT-549, T47D), from 22 human adult tissues (thymus, lung, duodenum, colon, testis, brain, cerebellum, cortex, salivary gland, liver, pancreas, kidney, spleen, stomach, uterus, prostate, skeletal muscle, placenta, mammary gland, bladder, lymph node, adipose tissue), and 2 human fetal normal tissues (fetal liver, fetal brain ), on a denaturing formaldehyde 1.2% agarose gel and transferring to nylon membranes.

[0641] Filters were hybridized with random primed [α³²P]dCTP-labeled probes synthesized from the inserts of several of the STE20-related kinase genes. Hybridization was performed at 42° C. overnight in 6× SSC, 0.1% SDS, 1× Denhardt's solution, 100 μg/mL denatured herring sperm DNA with 1-2×10⁶ cpm/mL of ³²P-labeled DNA probes. The filters were washed in 0.1× SSC/0.1% SDS, 65° C., and exposed on a Molecular Dynamics phosphorimager.

[0642] Quantitative PCR Analysis

[0643] RNA was isolated from a variety of normal human tissues and cell lines. Single stranded cDNA was synthesized from 10 μg of each RNA as described above using the Superscript Preamplification System (GibcoBRL). These single strand templates were then used in a 25 cycle PCR reaction with primers specific to each clone. Reaction products were electrophoresed on 2% agarose gels, stained with ethidium bromide and photographed on a UV light box. The relative intensity of the STK-specific bands were estimated for each sample.

[0644] DNA Array Based Expression Analysis

[0645] Plasmid DNA array blots were prepared by loading 0.5 μg denatured plasmid for each STE20-related kinase on a nylon membrane. The [α³²P]dCTP labeled single stranded DNA probes were synthesized from the total RNA isolated from several human immune tissue sources or tumor cells (thymus, dendrocytes, mast cells, monocytes, B cells (primary, Jurkat, RPMI8226, SR), T cells (CD8/CD4+, TH1, TH2, CEM, MOLT4), K562 (megakaryocytes). Hybridization was performed at 42° C. for 16 hours in 6× SSC, 0.1% SDS, 1× Denhardt's solution, 100 μg/mL denatured herring sperm DNA with 10⁶ cpm/mL of [α³²P]dCTP labeled single stranded probe. The filters were washed in 0.1× SSC/0.1% SDS, 65° C., and exposed for quantitative analysis on a Molecular Dynamics phosphorimager.

Results

[0646] Distribution of STE20-Related Gene Transcripts in Normal Tissues and Tumor Cell Lines

[0647] ZC1, ZC2, and ZC3 RNA expression was analyzed by quantitative PCR from multiple human normal tissues, cultured primary epithelial and endothelial cells, and tumor cell lines. The results are summarized in Tables 1 and 2, with relative expression values ranging from 0 (undetectable) to 23 (very strong). An “x” refers to sample not tested. ZC1, ZC2, and ZC3 were all expressed at very low levels in most normal human tissues, however ZC1 and ZC2 were more abundant in cultured epithelial cells and ZC3 in normal kidney and breast tissue.

[0648] Expression of these 3 genes was also examined in a panel of human tumor cell lines representing a diverse sampling of tumor types (Table 2). ZC1 and ZC2 showed strong expression in cell lines from most melanomas and renal tumors and from some non-small cell lung cancers and colon tumors. ZC3 expression was consistently lower in the tumor cell lines except for high expression in most breast cancers and leukemias. The robust overexpression ZC1, ZC2, and ZC3 in tumor cells versus normal tissues may provide an attractive target for oncology drug development.

[0649] Expression of all the novel STE20-related kinases was examined in a panel of human immune tissues/cells by hybridization to a DNA array blot containing plasmids encoding each of these genes. STLK2 was broadly expressed in all 14 immune samples, whereas STLK4 and PAK4 were highly expressed in a subset of 6-7 of the samples (Table 3). Several other kinases (SULU3, ZC4, KHS2) had more restricted expression, while others were expressed in only a single immune source (STLK3, thymus; ZC1, dendrocytes; ZC3, monocytes; PAK5, mast cells and MOLT4), and several more were absent from all the immune sources assayed (GEK2, SULU1, ZC2, STLK5). These expression patterns were quite distinct among members of the same subfamily (i.e., ZC1, ZC2, ZC3 and ZC4, or PAK1, PAK2, PAK3, PAK4, PAK5). This analysis suggests that some of these kinases may be candidate targets for various immune disorders, and that some, which are more broadly expressed, may mediate functions vital to the basic biology of most proliferating cells. TABLE 1 ZC1, ZC2 and ZC3 Expression in Normal Human Tissues and Cells Sample NORMAL ZC1 ZC2 ZC3 Brain Tiss 2.8 0.6 0.9 Duod Tiss 3.8 1.5 0.3 Heart Tiss 1.2 0.3 0.0 Kidney Tiss 0.7 0.0 7.0 Lung Tiss 1.6 0.2 0.0 Pancreas Tiss 2.0 0.4 2.5 Placenta Tiss 1.4 0.0 0.0 Sal gl. Tiss 3.0 0.3 3.2 Sk mus. Tiss 2.3 0.1 0.1 Spleen Tiss 0.4 0.0 x Stomach Tiss 0.8 0.0 0.0 Thymus Tiss 3.5 0.4 1.5 Cereb Tiss 2.8 1.1 4.4 Liver Tiss 1.8 0.0 0.4 Uterus Tiss 1.6 0.0 1.4 Prostate Tiss 1.4 0.0 1.6 Testis Tiss x x 5.8 f Brain Tiss x x 3.1 Mam gl Tiss x x 7.2 HCAEC ENDO 1.0 0.0 0.0 HMVEC-d ENDO 0.7 0.0 0.4 HMVEC-L ENDO 2.2 1.6 1.8 HPAEC ENDO 9.3 5.3 6.4 HMEC EPI 4.1 2.3 1.9 RPTEC EPI 3.6 2.2 0.2 HRCE EPI 5.3 3.5 1.3 HSAE EPI 0.9 3.3 4.8

[0650] TABLE 2 ZC1, ZC2 and ZC3 Expression in Tumor Cell lLnes Sample Origin ZC1 ZC2 ZC3 Sample Origin ZC1 ZC2 ZC3 HOP-92 Lung 9.3 7.2 3.3 HCC-2998 Colon 2.4 3.8 3.0 EKVX Lung 10.7 3.7 3.5 HCT 116 Colon 2.2 2.1 5.4 NCI-H23 Lung 5.8 6.3 4.1 SW-620 Colon 7.8 12.1 3.1 NCI-H226 Lung 6.5 6.8 3.3 COLO 205 Colon 9.1 16.2 3.0 NCI-H322M Lung 3.5 5.8 4.9 HCT-15 Colon 13.8 4.9 2.5 NCI-H460 Lung 4.5 3.7 2.9 KM-12 Colon 7.0 13.2 3.1 NCI-H522 Lung 4.7 3.3 4.6 UO-31 Colon 10.4 10.6 0.9 A549/ATCC Lung 3.8 3.6 4.1 SN12C Renal 8.1 3.4 2.8 HOP-62 Lung 4.3 3.8 4.2 A498 Renal 6.2 3.1 2.9 OVCAR-3 Ovary 2.9 3.1 1.5 Caki-1 Renal 9.2 14.4 2.3 OVCAR-4 Ovary 3.3 1.0 3.8 RXF 393 Renal 10.6 4.8 2.8 OVCAR-5 Ovary 2.6 3.6 2.2 ACHN Renal 9.3 6.0 3.9 OVCAR-8 Ovary 3.6 2.0 4.7 786-0 Renal 8.8 15.6 5.6 IGROV1 Ovary 3.8 1.7 3.2 TK-10 Renal 20.9 21.2 5.0 SK-OV-3 Ovary 4.9 0.0 3.5 LOX IMVI Mel 2.3 2.4 3.3 SNB-19 CNS 5.1 5.4 4.2 Malme-3M Mel x x 2.2 SNB-75 CNS 2.5 0.9 0.7 SK-MEL-2 Mel 15.7 14.1 2.9 U251 CNS 1.5 1.2 0.6 SK-MEL-5 Mel 7.9 7.0 0.0 SF-268 CNS 5.8 2.7 3.0 SK-MEL-28 Mel 16.5 23.1 0.0 SF-295 CNS 6.4 1.1 3.2 UACC-62 Mel 12.1 18.3 5.3 SF-539 CNS 5.1 2.9 4.3 UACC-257 Mel 10.8 9.4 6.2 CCRF-CEM Leuk 3.4 2.7 3.1 M14 Mel 4.4 0.9 7.9 K-562 Leuk 4.1 6.3 4.3 MCF7 Breast 4.8 1.3 7.7 MOLT-4 Leuk 7.1 3.4 4.2 MCF-7/ADR Breast 8.8 3.4 7.7 HL-60 Leuk x x 0.4 Hs 578T Breast 6.9 2.6 5.7 RPMI 8226 Leuk 0.5 0.2 1.4 MDA-MB-231 Breast 5.7 1.9 6.4 SR Leuk 3.5 7.2 5.4 MDA-MB-435 Breast 4.8 6.7 9.1 DU-145 Pro x x 3.4 MDA-N Breast 7.3 6.3 9.1 PC-3 Pro x x 3.4 BT-549 Breast 3.6 1.9 8.0 HT-29 Colon 2.4 5.9 6.6 T-47D Breast 0.4 12.3 9.3

[0651] TABLE 3 STE20-related kinase expression in a human immune panel Dendro- Mast Mono- B CD8+ CEM MOLT4 JURKAT RPMI8226 SR K562 KINASE thymus cytes cells cytes cells CD4+ TH1 TH2 (T cell) (T cell) (B cell) (B cell) (B cell) (MO) GEK2 350 350 350 350 350 350 350 350 350 350 350 350 350 350 SULU1 350 350 350 350 350 350 350 350 350 350 350 350 350 350 SULU3 350 350 350 350 12149 350 5115 350 350 350 350 350 350 350 STLK2 117770 13771 27620 92036 18305 39109 5408 3564 47236 53262 47605 22560 65936 30390 STLK3 8624 350 350 350 350 350 350 350 350 350 350 350 350 350 STLK4 8524 350 350 350 350 8685 5642 350 3648 350 26772 1570 350 350 STLK5 xxx xxx xxx xxx 350 350 350 xxx 350 350 350 xxx 350 350 ZC1 350 3377 350 350 350 350 350 350 350 350 350 350 350 350 ZC2 350 350 350 350 350 350 350 350 350 350 350 350 350 350 ZC3 350 350 350 20156 350 350 350 350 350 350 350 350 350 350 ZC4 xxx xxx xxx xxx 350 350 350 xxx 1094 7813 14945 xxx 350 6385 KHS2 8766 2508 350 56575 350 350 350 350 350 350 350 350 350 350 PAK4 32658 7684 3729 100948 350 350 350 1604 350 10246 350 3229 350 350 PAK5 350 350 4905 350 350 350 350 350 350 12672 350 350 350 350

[0652] Transcript size from Northern data Kinase (kb) STLK2 3.8 STLK4 5.0 ZC1 6.9/4.7 ZC2 6.0/8.0 ZC4 5 KHS2 4.4 SULU1 4.5 SULU3 10.0 GEK2 5.5 PAK4 4.8 PAK5 3.5

[0653] STLK2 is widely expressed; the highest expression levels were found in placenta, spleen and PBL.

[0654] STLK4 is also widely expressed in normal tissues including heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood lymphocytes. STLK4 was also detected in Jurkat T cells.

[0655] ZC1 is highly overexpressed in the following human cancer cell lines: HOP-92, EKVX, NCI-H23, NCI-H226, NCI-H322M, NCI-H522, A549, HOP-62 (lung); OVCAR-3, OVCAR-4, OVCAR-5 (ovary); SNB-19, U251, SF-268, SF-295, SF-539 (CNS); K-562, RPMI-8226 (leukemia); DU-145, PC-3 (prostate); HT-29, HCC-2998, HCT-116, SW620, COLO-205, HCT-15, KM-12 (colon); UO-31, CAKi-1, RXF-393, 786-0, TK-10 (renal); LOXIMVI, Malme-3M, SK-MEL-2, SK-MEL-28, UACC-62, UACC-257, M14 (melanoma); and MCF-7, MCF-7/ADR, HIS 578T, MDA-MB-231, MDA-MB-431, MDA-N, BT-549, T-47D (breast).

[0656] ZC2 is expressed in brain and testis. It is highly overexpressed in the following human cancer cell lines: TK-10 (renal); SK-MEL-28, UACC-62 (melanoma); T47D (breast).

[0657] Moderate expression in HOP92 (lung); OVCAR4, IGROV1 (ovary); DNB75, U251 (brain); K-562 (leukemia); and COL0205 (colon).

[0658] SULU1 is overexpressed in the following human cancer cell lines: HOP-92, EKVX, NCI-H23, NCI-H226, NCI-H322M, NCI-H522, A549, HOP-62 (lung); OVCAR-3, OVCAR-4, OVCAR-5, SK-OV-3 (ovary); SNB-19, U251, SF-268, SF-295, SF-539 (CNS); K-562, RPMI-8226 (leukemia); DU-145, PC-3 (prostate); HT-29, HCC-2998, HCT-116, SW620,. COLO-205, HCT-15, KM-12 (colon); UO-31, CAKi-1, RXF-393, 786-0, TK-10 (renal); LOX, IMVI, Malme-3M, SK-MEL-2, SK-MEL-28, UACC-62, UACC-257, M14 (melanoma); MCF-7, MCF-7/ADR, HIS 578T, MDA-MB-231, MDA-MB-431, MDA-N, BT-549, T-47D (breast) SULU3 showed a broad pattern of expression in the normal tissue panel of RNAs.

[0659] GEK2 was expressed in spleen, thymus and testis. Expression was high in the cell lines RBL-2H3 and H441.

[0660] PAK4 was expressed in the normal tissues: brain, testis and prostate, and in the human cancer cell lines: HNCI-H23 (lung); OVCAR-3 (ovary); SNB-19, U251 (CNS); RPMI-8226 (leukemia); DU-145 (prostate); COLO-205, HCT-15 (colon).

[0661] PAK5 showed weak expression levels in the normal tissues: brain, testes, bladder, colon, adrenal medulla, spleen, fetal liver, breast, cerebral cortex, cerebellum, thymus, salivary gland, lung, stomach, duodenum, uterus, prostate, skeletal muscle and placenta. PAK5 was overexpressed in the human cancer cell lines: HOP-92, EKVX, NCI-H23, NCI-H226, NCI-H322M, NCI-H522, A549, HOP-62 (lung); OVCAR-3, OVCAR-4, OVCAR-5, SK-OV-3 (ovary); SNB-19, U251, SF-268, SF-295, SF-539 (CNS); K-562, RPMI-8226 (leukemia); DU-145, PC-3 (prostate); HT-29, HCC-2998, HCT-116, SW620,. COLO-205, HCT-15, KM-12 (colon); UO-31, CAKi-1, RXF-393, 786-0, TK-10 (renal); LOXIMVI, Malme-3M, SK-MEL-2, SK-MEL-28, UACC-62, UACC-257, M14 (melanoma); MCF-7, MCF-7/ADR, HIS 578T, MDA-MB-231, MDA-MB-431, MDA-N, BT-549, T-47D (breast).

Example 3 STE20-Related Protein Kinase Gene Expression Vector Construction

[0662] Materials and Methods

[0663] Expression Vector Construction

[0664] Several expression constructs were generated for some of the human STE20-related cDNAs including: a) full-length clones in a PcDNA expression vector; b) a GST-fusion construct containing the catalytic domain of the novel STE20-related kinase fused to the C-terminal end of a GST expression cassette; and c) a full-length clone containing a Lys to Ala (K to A) mutation at the predicted ATP binding site within the kinase domain, inserted in the pcDNA vector.

[0665] The “K to A” mutants of the STE20-related kinase might function as dominant negative constructs, and will be used to elucidate the function of these novel STKs.

Results

[0666] Constructs for ZC1, ZC2, ZC3, SULU1, SULU3, PAK4 and PAK5 have been generated.

[0667] Numerous additional constructs have been generated for the various STE20-subfamily kinases, including full length, kinase inactive and tagged versions. In addition, the following three constructs were designed for specific applications based on their unique domain structure:

[0668] Construct 1: SULU1-coiled-coil2

[0669] Vector: pGEX-4T

[0670] Insert: Coiled-coil2

[0671] Sequence: Amino acids 752-898

[0672] Purpose: phage display

[0673] Result: Interacts with GEK2 CC1

[0674] Construct 2: SULU3-coiled-coil2

[0675] Vector: pGEX4T

[0676] Insert: coiled-coil 2 domain fused to GST

[0677] Sequence range of insert: amino acids 802-898 of SEQ

[0678] Purpose: phage display

[0679] Result: Interacts with coiled-coiled region of human SLK

[0680] Construct 3: PAK5 Dominant Negative

[0681] Vector: pCAN5

[0682] Insert: Full length coding sequence of human PAK5

[0683] containing the following mutation: K350,351A (Lys at aa positions 350 and 351 changed to Ala).

[0684] Purpose: to determine role of human PAK5 kinase activity in cell growth and transformation.

[0685] Result: Interferes with Ras transformation.

Example 4 Generation of Specific Immunoreagents to STE20-Related Protein Kinases

[0686] Materials and Methods

[0687] Specific immunoreagents were raised in rabbits against KLH- or MAP-conjugated synthetic peptides corresponding to the human STE20-related kinases. C-terminal peptides were conjugated to KLH with glutaraldehyde, leaving a free C-terminus. Internal peptides were MAP-conjugated with a blocked N-terminus. Additional immunoreagents can also be generated by immunizing rabbits with the bacterially expressed GST-fusion proteins containing the cytoplasmic domains of each novel STK.

[0688] The various immune sera are first tested for reactivity and selectivity to recombinant protein, prior to testing for endogenous sources.

[0689] Western Blots

[0690] Proteins in SDS PAGE are transferred to immobilon membrane. The washing buffer is PBST (standard phosphate-buffered saline pH 7.4+0.1% triton×100). Blocking and antibody incubation buffer is PBST +5% milk. Antibody dilutions varied from 1:1000 to 1:2000.

Results

[0691] Three SULU1 antisera (against both 539A and 540A) and two SULU3 antisera (542A) reacted specifically with the peptide antigens. Antisera binding was competable with peptide. Experiments with extracts from cells transfected with epitope-tagged SULU1 and SULU3 genes are underway.

[0692] Antisera against the PAK4 C-terminal peptide 554A reacted with purified Gst-PAK4 and detected a protein of the correct molecular weight from tissue culture cells. Specific immunoprecipitation experiments are ongoing to determine the reactivity with native protein.

[0693] Similar immunization and antisera testing experiments are underway for each of the other novel STE20-kinases. STE20-related protein kinase peptide immunogens and their specificity in recognizing endogenous protein by Western blots or immunoprecipitations. Aa Protein Sequence positions Conj West. IP STLK2 EKFQKCSADESP 405-416 KLH Y Y STLK4 SISNSELFPTTDPVGT 252-267 KLH Y Y SULU1 LDFPKEDYR 890-898 KLH Y Y SULU1 HGDPRPEPRPTQ 409-420 KLH Y Y SULU3 PSTNRAGSLKDPEC  2-14 KLH N ND SULU3 DPRTRASDPQSPPQVSRHK 411-429 KLH ND ND PAK4 CLVPLIQLYRKQTSTC 666-680 KLH ND Y PAK5 PLMRQNRTR 390-398 KLH Y Y PAK5 SGDRRRAGPEKRPKSS 148-163 KLH Y Y PAK5 (C) RRKSLVGTPYWMAPE 471-485 KLH Y ND

[0694] STE20-related protein kinase GST fusion protein immunogens and their specificity in recognizing endogenous protein by Western blots or immunoprecipitations. Aa Protein domain positions West. IP ZC1 Coiled-coil/pro/B/C 350-867 Y Y ZC1 B 615-732 Y Y ZC2 Coiled-coil/pro/B 348-762 ND ND ZC2 B 658-762 Y Y PAK4 Nterm 252-426 ND ND PAK4 Kinase/Cterm 350-681 ND Y PAK5 A/Nterm  53-330 ND ND PAK5 A/Nterm  53-309 ND ND

[0695] The 50 kD STLK2 protein was expressed highly in several hematopoietic cell lines including Jurkat, pGL10, Ramos, A20, WEHI-231, K562, HEL and freshly isolated thymocytes from C57/BL6 mice. High levels of STLK2 expression were also detected in several tumor cell lines including Calu6, Colo205, LS180, MDAM231 and A549.

[0696] The 160 kD ZC1 protein was detected in Jurkat T cells, Colo205, HCT116, RIE-1, 293T, MDAMB231, and SK-MEL28.

[0697] The 170 kD ZC2 protein was detected in SK-Mel28 and UACC-62.

[0698] Elevated levels of the 64 kD PAK5 protein were confirmed in the breast cancer cell lines MDA-231 and MCF-7, and in the lung cancer cell line A549.

Example 5 Recombinant Expression and Biological Assays for STE20-related Protein Kinases

[0699] Materials and Methods

[0700] Transient Expression of the Ste20-related Kinases in Mammalian Cells

[0701] The pcDNA expression plasmids (10 μg DNA/100 mm plate) containing the STE20-related kinase constructs are introduced into 293 cells with lipofectamine (Gibco BRL). After 72 hours, the cells are harvested in 0.5 mL solubilization buffer (20 mM HEPES, pH 7.35, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 2 mM phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin). Sample aliquots were resolved by SDS polyacrylamide gel electrophoresis (PAGE) on 6% acrylamide/0.5% bis-acrylamide gels and electrophoretically transferred to nitrocellulose. Non-specific binding was blocked by preincubating blots in Blotto (phosphate buffered saline containing 5% w/v non-fat dried milk and 0.2% v/v nonidet P-40 (Sigma)), and recombinant protein was detected using the various anti-peptide or anti-GST-fusion specific antisera.

[0702] In Vitro Kinase Assays

[0703] Three days after transfection with the STE20-related kinase expression contructs, a 10 cm plate of 293 cells was washed with PBS and solubilized on ice with 2 mL PBSTDS containing phosphatase inhibitors (10 mM NaHPO₄, pH 7.25, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 0.2% sodium azide, 1 mM NaF, 1 mM EGTA, 4 mM sodium orthovanadate, 1% aprotinin, 5 μg/mL leupeptin). Cell debris was removed by centrifugation (12000× g, 15 min, 4° C.) and the lysate was precleared by two successive incubations with 50 μL of a 1:1 slurry of protein A sepharose for 1 hour each. One-half mL of the cleared supernatant was reacted with 10 μL of protein A purified kinase-specific antisera (generated from the GST fusion protein or antipeptide antisera) plus 50 μL of a 1:1 slurry of protein A-sepharose for 2 hr at 4° C. The beads were then washed 2 times in PBSTDS, and 2 times in HNTG (20 mM HEPES, pH 7.5/150 mM NaCl, 0,1% Triton X-100, 10% glycerol).

[0704] The immunopurified kinases on sepharose beads were resuspended in 20 μL HNTG plus 30 mM MgCl₂, 10 mM MnCl₂, and 20 μCi [α³²P]ATP (3000 Ci/mmol). The kinase reactions were run for 30 min at room temperature, and stopped by addition of HNTG supplemented with 50 mM EDTA. The samples were washed 6 times in HNTG, boiled 5 min in SDS sample buffer and analyzed by 6% SDS-PAGE followed by autoradiography. Phosphoamino acid analysis was performed by standard 2D methods on ³²P-labeled bands excised from the SDS-PAGE gel.

[0705] Similar assays were performed on bacterially expressed GST-fusion constructs of the kinases.

[0706] ZC1 Assay buffer:

[0707] 20 mM Tris pH 7.4, 200 mM NaCl, 0.5 mM DTT, 3 mM MgCl2, 0.3 mM MnCl2, 100 μM ³²PγATP.

[0708] Substrates: myelin basic protein (MBP) at 0.28 mg/mL and phosphorylated ZC1 peptide RTVGRRNTFIGT-PPYWMAPE at 17 μM (bold underlined residue shows site of phosphorylation).

[0709] At higher concentrations of MgCl₂ (3 mM), the activity of ZC1 (both full-length and recombinant kinase domain) is up to 10-fold greater towards exogenous substrate MBP. In contrast, the autophosphorylation and the phosphorylation of the activation loop peptide substrate are both inhibited. Mn++does not inhibit the autophosphorylation and the peptide phosphorylation by the truncated kinase domain form. However, both the MBP phosphorylation, Mn++-preferring activity AND the autophosphorylating, Mg++-preferring activity are eliminated with mutation of the ATP-binding lysine in ZC1 (Lys54Ala) indicating that both activities are attributable to the ZC1 kinase domain.

[0710] SULU1 Assay Buffer:

[0711] This buffer is identical to that for ZC1, except for 5 mM MgCl2. Under these conditions, other STE20 family members (PAK4, ZC1) were inhibited for autophosphorylation and required reducing the [Mn] to <0.3 mM for an efficient autophosphorylation reaction.

[0712] Substrates: MBP, phosvitin, or α-casein at 0.28 mg/mL.

[0713] PAK4, PAK5 Assay Buffer:

[0714] 20 mM Hepes pH 7.2, 130 mM KCl, 10 mM MgCl2, 1 mM NaF, 20 mM B-glycerolphosphate, 0.5 mM DTT, 50 μM ATP, 0.5 μCi ³²PyATP.

[0715] Substrates: MBP at 0.28 mg/mL and peptide substrates derived from PAK5 activation loop at 2.5 μM.

[0716] STLK2 Assay Buffer:

[0717] Similar to that described above, except for the inclusion of 5 mM MgCl₂, 5 mM MnCl₂ and 5 μCi ³²PγATP.

[0718] Transformation (PAK Experiments)

[0719] Low-passage NIH3T3 fibroblasts displaying normal morphology (flat, non-refractile cellular morphology), as well as low rates of spontaneous transformation, were used in transformation assays. NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum, penicillin (100 U/mL) and streptomycin (100 U/mL) and kept in an humidified incubator at 37° C. and 5% CO₂.

[0720] Cells were transfected with DNA-lipid complexes. As per manufacturer instructions, lipofectamine was utilized to transfect NIH3T3 cells. All transfections were with equal amounts of plasmid DNA (DNA from the appropriate expression vector without insert was used to give equivalent amounts of DNA per transfection). 1 μg of activated allele of H-Ras was co-transfected with increasing amounts of various alleles of PAK5.

[0721] Foci were scored after 3 weeks by fixing 10 min in 10% methanol, 10% acetic acid for 10 min, followed by staining with 0.4% (w/v) crystal violet in 10% methanol for 10 min, and washing with deionized water and drying at room temperature.

[0722] Transfections, Stimulations, and Luciferase Assays (ZC1 Experiments)

[0723] Cells (10⁷) were transiently transfected by electroporation using a Gene Pulser (Bio-Rad Labs) with the setting of 960_F and 250 V. 20-40 hours later, transfected cells (about 10⁵) were stimulated with various stimuli. After a 6-hour stimulation, cells were lysed, and luciferase activities were measured using the MicroLumatPlus (EG&G Berthold). (J. Exp. Med. 183:611-620, 1996, hereby incorporated by reference herein in its entirety including any drawings, tables, or figures.)

Results

[0724] Protein expression and kinase activity of novel STE20- related protein kinases Observed In vitro Endogenous size Predicted Kinase Kinase Protein (kD) Size (kD) activity activity STLK2  50  46 y y STLK4  55  50 y ND ZC1 160 140 y y ZC2 170 150 y y KHS2 ND 101 ND ND SULU1 119 105 y y SULU3 140 115 ND y PAK4  80  75 y y PAK5  64  64 y y

[0725] ZC1: Regulation of Kinase Activity

[0726] ZC1 is constitutively active as a full-length kinase when expressed either in vitro (TNT rabbit reticulocyte system) or in NIH 3T3, 293T, or H1299 tissue culture cells. The endogenously expressed kinase is also active when immunoprecipitated from carcinoma cell lines.

[0727] ZC1 Signaling Pathways

[0728] Using human leukemic T cell line Jurkat as a model system, the impact of cotransfected wild-type ZC1 on the activation of two reporter genes, RE/AP-luciferase and NFκB luciferase, was examined. RE/AP is a composite in the IL-2 gene promoter containing both a NFκB-like site and an AP-1 site.

[0729] Optimal activation of both RE/AP-luciferase and NFκB-luciferase reporter genes in Jurkat T cells requires signals generated from stimulation of both T cell receptor and the costimulator receptor CD28. Cotransfection of wild-type ZC1 with either the RE/AP-luciferase or the NFκB-luciferase reporter results in the activation of RE/AP or NFκB when costimulated with the anti-T cell receptor monoclonal antibody or the pharmacological reagents PMA and ionomycin that bypass proximal T cell receptor. No activation was seen when costimulated with an anti-CD28 monoclonal antibody.

[0730] These results suggest that wild-type ZC1, when overexpressed, was replacing a CD28-specific signal to activate RE/AP or NFκB. These results imply that ZC1 is involved in the CD28 signaling pathway. Since NFκB is one of the major pathways also activated by the pro-inflammatory cytokine TNF-α signaling, it is also likely that ZC1 may be a component in the TNF-α signaling pathways.

[0731] PAK5: Design of Specific Peptide Substrates

[0732] To aid in the development of in vitro kinase assays for screening small molecule libraries to identify specific inhibitors, the search for specific peptide substrates for PAK5 was undertaken.

[0733] The rationale used to design such peptides is based on the hypothesis that upon binding activated small G protein, PAK5 undergoes a conformational change that results in derepression of its kinase activity followed by autophosphorylation on the activation loop resulting in a fully active kinase. The site of autophosphorylation for related family members has been identified by biochemical and/or genetic means (e.g. Wu, C, et al. J.Biol.Chem 270:15984-15992 and Szczepanowska, et al. Proc.Natl.Acad.Sci 94, 8503-8508, 1997). Specific peptide substrates for PAKS were designed from the sequence of the activation loop of this kinase.

[0734] An activation loop PAK5 peptide phosphorylated on the Thr residue of the TPY motif served as a high-affinity substrate for PAK5. PAK5 activation loop peptides as kinase substrates Peptide SEQ # Kinase Sequence Aa ID Kinase substrate 1 PAK5 (C) RRKSLVGTPYWMAPE 471-485 102 PAK5 yes 2 PAK5 (C) RRKSLVG T PYWMAPE 471-485 102 PAK5 yes 3 PAK5 (C) RRK S LVGTPYWMAPE 471-485 102 PAK5 no 4 KHS1 KRKSFIGTPYWMAPE 171-185 U77129 PAK5 yes 5 STLK2 KRNTFVGTPFWMAPE 175-189  5 PAK5 poor 6 SULU1 PANSFVGTPYWMAPE 174-188  22 PAK5 poor 7 ZC1 RRNTFIGTPYWMAPE 184-198  13 PAK5 poor 8 ZC1 RRNTFIG T PYWMAPE 184-198  13 PAK5 poor 9 STLK4 RNKVRKTFVGTPCWMAPE 66-83  7 PAK5 poor 10  PAK5 (C) RRKSLVGTPYWMAPE 471-485 102 PAK4 yes

[0735] Peptide # Kinase Notes 1 PAK5 Equally well as MBB 2 PAK5 High Km for PAK5 (1-10 μM) 3 PAK5 S is the site of phosphorylation 4 KHS1 Similar to peptide 1 5 STLK2 6 SULU1 7 ZC1 8 ZC1 Better than 7 9 STLK4 10  PAK5 Same Km as phosph. by PAK5

[0736] PAK5: Transformation

[0737] Transformation of low-passage NIH3T3 cells by ras in the presence or absence of various alleles of PAK5 showed that the dominant negative, kinase-dead allele of PAK5 was able to block ras transformation of NIH3T3 cells. Thus, PAK5 activity is required for ras transformation of NIH3T3 cells. Inhibition of PAK5 activity may have therapeutic value as an anti-proliferative agent for treating cancer.

[0738] PAK4 and PAK5: Interaction with Cdc42

[0739] PAK 4 interacts with CDC42 small G-protein but not Rac, RhoA, or Ras as determined by co-transfection of recombinant genes and detection by kinase assays. PAK5 also interacts with Cdc42. Coding sequences of activated alleles of small G proteins (ras, Cdc42, Rac, Rho) tagged with a Myc epitope were transiently expressed in 293T cells, various alleles of ³⁵S-labeled PAK5 tagged with HA epitope were expressed in vitro with the reticulocyte (TNT) system.

Example 6 Chromosomal Localization of Ste2O-Related Protein Kinases

[0740] Materials and Methods

[0741] STE20 protein kinases STLK3, STLK4, ZC1, ZC2, ZC3, KHS2, SULU1, PAK4, and PAK5 were mapped using the GeneBridge 4 Radiation Hybrid Panel, RHO2.05 (Research Genetics). The GeneBridge 4 Panel consists of 91 hybrid panel samples, in addition to one human positive control (HFL), and one hamster negative control (A23). The standard reaction conditions used to test and conduct PCR reactions using the GeneBridge 4 Panel are available from Research Genetics.

[0742] Oligonucleotide sequences (all 5′ to 3′) used for PCR mapping were: STLK3: CTCCCATTTCCTAGCAAAATCA, AGAGGCAGTATTGTCAGATGTA STLK4: CCACACATGCGTATCTCTGTTG, TTGCTAGAATTCACATCAGGTACA ZC1: ATCCCTGGATCACACTGCTTCT, CAAGGTGTTCTTTGCCTCTGTT ZC2: AGATGGACTGTACTGGGAGGG, AGAAGAGCACTTGGCACTTATC ZC3: CATCATGAACTGGTGACGGG, CCAGTGAAATCAAACCAGTAAAA SULU1: CAAAACCTGGCCGTCTCTTCTATT, ATTTGTGCTACTGGGATTCTGTG KHS2: GAATAGCGGTACCATGATAGAATA, TACCAAAAAGAGCCAAAAGTGTG PAK4: CTCAGTATTCTCTCCAAAGATTG, GATGTTCTCTCCATTCTGTAAAG PAK5: CATCACTGGAAGTCTGCAGTG, CAGGTGCAGTAGTCATTTGC

[0743] Positive reactions were assigned a score of “1”, negative reactions are assigned a score of “0”, and ambiguous reactions are assigned a score of “2”. Results were submitted to the Whitehead Institute (www@genome.wi.mit.edu) for position analysis. Chromosomal localizations for ZC4, SULU3, STLK2, STLK5 and STLK6 were available publicly (for example, from Unigene). The chromosomal locations of GEK2 and STLK7 have not been determined. STLK2_h Xq25-27.1 (Public) STLK3 2q31.3 (Sugen) STLK4_h 3p22.3-p22.2 (Sugen) STLK5_h 17q23.2-24.2 (Public) STLK6_h 2g32.2-q33.3 (Public) STLK7_h NA ZC1_h 2p11.2 (Sugen) ZC2_h 3q26.31-3q26.32 (Sugen) ZC3_h 17p13.2-13.3 (Sugen) ZC4_h Xq22 (Public) KHS2_h 2p22-2p22.2 (Sugen) SULU1_h 12q24.21 (Sugen) SULU3_h 17p11.2 (Public) GEK2_h NA PAK4_h 15q14 (Sugen) PAK5_h 19q13.2-q13.3 (Sugen)

[0744] Many of the STE 20 kinases were mapped to regions associated with various human cancers, as shown below.

[0745] The regions were also cross-checked with the Mendalian Inheritance in Man database, which tracks genetic information for many human diseases, including cancer. References for association of the mapped sites with chromosomal abnormalities found in human cancer can be found in: Knuutila, et al., Am J Pathol, 1998, 152:1107-1123, hereby incorporated herein be reference in its entirety including any figures, tables, or drawings.

[0746] Association of these mapped regions with other diseases is documented in the Online Mendalian Inheritance in Man (OMIM)(http://www.ncbi.nlm.nih.gov/htbin-post/Omim).

[0747] STLK2 h, Xq25-27.1, (Public)

[0748] Osteosarcoma, Xq25-qter, 2 of 31.

[0749] Lymphoproliferative syndrome, X-linked (OMIM No. 308240) human STLK3, 2q31.3, (Sugen)

[0750] Squamous cell carcinoma of Head and Neck, 3 of 30.

[0751] STLK4 h, 3p22.3-p22.2, (Sugen)

[0752] Mantle cell lymphoma 3pl4-p22 1 of 27

[0753] Squamous cell carcinoma of Head and Neck 3p22-p24 1 of 14

[0754] Cardiomyopathy, dilated (OMIM 601154)

[0755] STLK5 h, 17q23.2-24.2, (Public)

[0756] Cervical cancer, 17q, 1 of 30

[0757] Gastroesophageal junction adenocarcinoma xenograft, 17q, 1 of 5

[0758] Breast carcinoma, 17ql2-qter, 1 of 16

[0759] Bladder carcinoma, 17q22-q23, 1 of 14

[0760] Breast carcinoma, 17q22-q25, 8 of 101

[0761] Non-small cell lung cancer, 17q24-q25, 6 of 50

[0762] Testis, 17q24-qter, 2 of 11

[0763] Malignant peripheral nerve sheath tumors, 17q24-qter, 5 of 7

[0764] Alzheimer disease, susceptibility to (OMIM 106180)

[0765] STLK6 h, 2q32.2-q33.3, (Public)

[0766] Non-small cell lung cancer, 2q31-q32, 1 of 50

[0767] Squamous cell carcinoma of Head and Neck, 2q31-q33, 3 of 30

[0768] Small cell lung cancer, 2q32-q35, 1 of 22

[0769] ZC1 h, 2pll.2, (Sugen)

[0770] non-small cell lung cancer, 2pter-ql3, 1 of 10

[0771] non-small cell lung cancer, 2pter-q21, 1 of 10

[0772] Pulmonary alveolar proteinosis, congenital (OMIM 178640).

[0773] ZC2 h, 3q26.31-3q26.32, (Sugen)

[0774] Non-small cell lung cancer, 3q26.1-q26.3, 26 of 103

[0775] Cervical cancer, 3q26.1-q27, 4 of 30

[0776] Small cell lung cancer, 3q26.3-qter, 3 of 35

[0777] Squamous cell carcinoma of Head and Neck, 3q26.3-qter, 3 of 13

[0778] Marginal zone B-cell lymphoma, 3q26-q27, 1 of 25

[0779] Parosteal osteosarcoma, 3q26-q28, 1 of 1

[0780] Gastrointestinal stromal tumor, 3q26-q29, 1 of 16

[0781] Mantle cell lymphoma, 3q26-q29, 1 of 5

[0782] ZC3 h 17pl3.2-13.3 (Sugen)

[0783] Malignant fibrous histiocytoma of soft tissue, 17p, 2 of 58

[0784] Leiomyosarcoma, 17p, 7 of 29

[0785] Non-small cell lung cancer, 17p, 1 of 50

[0786] ZC4 h, Xq22, (Public)

[0787] Diffuse large cell lymphoma, Xq22-ter, 1 of 32

[0788] Deafness, X-linked 1, progressive. (OMIM 304700).

[0789] KHS2 h, 2p22-2p22.2, (Sugen)

[0790] Synovial sarcoma, 2p21-q14, 1_of_(—)67

[0791] Follicular lymphoma, 2p22-p24, 1_of_(—)46

[0792] Colorectal cancer, hereditary, nonpolyposis, type 1,

[0793] Ovarian cancer (MSH2, COCA1, FCC1). (OMIM 120435).

[0794] SULU1 h, 12q24.21 (Sugen)

[0795] Neuroglial tumors, 12q22-qter, 1_of_(—)15

[0796] Gastroesophageal junction adenocarcinoma, 12q23-qter, 1 of 5.

[0797] Non-small cell lung cancer, 12q24.1-24.3, 2 of 50.

[0798] SULU3 h 17pll.2 (Public)

[0799] Malignant fibrous histiocytoma of soft tissue, 17p, 2_of_(—)58

[0800] Leiomyosarcoma, 17p, 7_of_(—)29

[0801] non-small cell lung cancer, 17p, 1_of_(—)50

[0802] Diffuse large cell lymphoma, 17pll.2, 1_of_(—)32

[0803] Osteosarcoma, 17p11.2-pl2, 4_of_(—)31

[0804] PAK4 h: 15ql4 (Sugen)

[0805] Schizophrenia, (OMIM 118511).

[0806] PAK5 h: 19ql3.2-ql3.3 (Sugen)

[0807] Follicular lymphoma, 19ql3, 1 of 46*

[0808] Mantle cell lymphoma, 19ql3, 1 of 5

[0809] Hepatocellular carcinoma, 19ql3.1, 2 of 50

[0810] Small cell lung cancer, 19ql3.1, 10 of 35

[0811] Breast carcinoma, 19ql3.1-qter, 1 of 33

[0812] cervical cancer, 19ql3.1-qter, 1 of 30

[0813] Testis, 19ql3.1-qter, 1 of 11

[0814] Chondrosarcoma, 19ql3.2, 1 of 29

[0815] Malignant fibrous histiocytoma of soft tissue, 19q13.2-qter, 2 of 58

[0816] Non-small cell lung cancer, 19qcen-q13.3, 6 of 104

Example 7 Demonstration of Gene Amplification by Southern Blotting

[0817] Materials and Methods

[0818] Nylon membranes were purchased from Boehringer Mannheim. Denaturing solution contains 0.4 M NaOH and 0.6 M NaCl. Neutralization solution contains 0.5 M Tris-HCL, pH 7.5 and 1.5 M NaCl. Hybridization solution contains 50% formamide, 6× SSPE, 2.5× Denhardt's solution, 0.2 mg/mL denatured salmon DNA, 0.1 mg/mL yeast tRNA, and 0.2% sodium dodecyl sulfate. Restriction enzymes were purchased from Boehringer Mannheim. Radiolabeled probes were prepared using the Prime-it II kit by Stratagene. The beta actin DNA fragment used for a probe template was purchased from Clontech.

[0819] Genomic DNA was isolated from 20 different tumor cell lines: MCF-7, MDA-MB-231, Calu-6, A549, HCT-15, HT-29, Colo 205, LS-180, DLD-1, HCT-116, PC3, CAPAN-2, MIA-PaCa-2, PANC-1, AsPc-1, BxPC-3, OVCAR-3, SKOV3, SW 626 and PA-1, and from two normal cell lines: human mammary epithelial cells and human umbilical vein endothelial cells.

[0820] A 10 μg aliquot of each genomic DNA sample was digested with EcoR I restriction enzyme and a separate 10 μg sample was digested with Hind III restriction enzyme. The restriction-digested DNA samples were loaded onto a 0.7% agarose gel and, following electrophoretic separation, the DNA was capillary-transferred to a nylon membrane by standard methods (Sambrook, J. et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory).

[0821] PAK5 Amplicon:

[0822] A 600 base pair fragment (EcoR 1- Sac I) of the PAK5 gene was used as a template for a radiolabeled DNA probe which was hybridized to the blots at 42° C. for 48 hours in hybridization solution using standard methods (supra). The blots were exposed to a phosphorimager screen for 4 days, then scanned and analyzed using a Molecular Dynamics Storm 840 phosphorimager. The relative mass and gene copy number values of the PAKS DNA fragments were calculated from the band density values obtained. The blots were re-hybridized with a radiolabeled probe copied from a fragment of human beta actin DNA and developed as above to confirm the sample mass loading equivalency.

Results

[0823] The PAK5 gene was determined to exhibit 3-fold amplification compared to the normal DNA copy number in PANC-1 (pancreatic epithelioid carcinoma) and OVCAR-3 (ovarian adenocarcinoma) human cell lines, and approximately 2 times the normal copy number in the BxPC-3 (primary pancreatic adenocarcinoma) human cell line.

[0824] Similar Southern analyses can be performed for other STE20 kinases.

Example 8 Detection of Protein-Protein Interaction through Phage Display

[0825] Materials and Methods

[0826] Phage display provides a method for isolating molecular interactions based on affinity for a desired bait. cDNA fragments cloned as fusions to phage coat proteins are displayed on the surface of the phage. Phage(s) interacting with a bait are enriched by affinity purification and the insert DNA from individual clones is analyzed.

[0827] T7 Phage Display Libraries

[0828] All libraries were constructed in the T7Selectl-lb vector (Novagen) according to the manufacturer's directions.

[0829] Bait Presentation

[0830] Protein domains to be used as baits were generated as C-terminal fusions to GST and expressed in E. coli. Peptides were chemically synthesized and biotinylated at the N-terminus using a long chain spacer biotin reagent.

[0831] Selection

[0832] Aliquots of refreshed libraries (10¹⁰-10¹² pfu) supplemented with PanMix and a cocktail of E. coli inhibitors (Sigma P-8465) were incubated for 1-2 hrs at room temperature with the immobilized baits. Unbound phage was extensively washed (at least 4 times) with wash buffer.

[0833] After 3-4 rounds of selection, bound phage was eluted in 100 μL of 1% SDS and plated on agarose plates to obtain single plaques.

[0834] Identification of Insert DNAs

[0835] Individual plaques were picked into 25 μL of 10 mM EDTA and the phage was disrupted by heating at 70° C. for 10 min. 2 μL of the disrupted phage were added to 50 μL PCR reaction mix. The insert DNA was amplified by 35 rounds of thermal cycling (94° C., 50 sec; 50° C., 1 min; 72° C., 1 min).

[0836] Composition of Buffer

[0837] 10× PanMix

[0838] 5% Triton X100

[0839] 10% non-fat dry milk (Carnation)

[0840] 10 mM EGTA

[0841] 250 mM NaF

[0842] 250 μg/mL Heparin (sigma)

[0843] 250 μg/mL sheared, boiled salmon sperm DNA (sigma)

[0844] 0.05% Na azide

[0845] Prepared in PBS

[0846] Wash Buffer

[0847] PBS supplemented with:

[0848] 0.5% NP-40

[0849] 25 μl g/mL heparin PCR reaction mix 1.0 mL 10x PCR buffer (Perkin-Elmer, with 15 mM Mg) 0.2 mL each dNTPs (10 mM stock) 0.1 mL T7UP primer (15 pmol/μL) GGAGCTGTCGTATTCCAGTC 0.1 mL T7DN primer (15 pmol/μL) AACCCCTCAAGACCCGTTTAG 0.2 mL 25 mM MgCl₂ or MgSO₄ to compensate for EDTA Q.S. to 10 mL with distilled water Add 1 unit of Taq polymerase per 50 μL reaction

[0850] LIBRARY: T7 Selectl-H441

Results

[0851] Phage display baits and interactors Sequence Patent CDNA Range Bait Domain Aa SEQ ID library Interactor & SEQ ID SULU1 Coiled- 752-898 22 H441 GEK2 cc 677-820 coil2 dom (1) SEQ #26 SULU3 Coiled- 755-898 23 H441 SLK M83780 coil2 isoform

[0852] The phage display data suggest potential interactions of SULU3 with SLK and SULU1 with GEK2 through their coiled-coil domains. Therefore two members of the SULU subfamily of STE20 kinases interact with two members of a separate STE20 family, the prototype being SLK.

[0853] These results suggest a specificity in the interaction, and imply that these STE20 kinases may interact with each other through homo- and hetero-dimerization. Alternatively SULU-related kinases could act immediately up- or down-stream of the SLK-related kineses in a signaling cascade.

[0854] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.

[0855] It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[0856] All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains.

[0857] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

[0858] In particular, although some formulations described herein have been identified by the excipients added to the formulations, the invention is meant to also cover the final formulation formed by the combination of these excipients. Specifically, the invention includes formulations in which one to all of the added excipients undergo a reaction during formulation and are no longer present in the final formulation, or are present in modified forms.

[0859] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

[0860] Other embodiments are within the following claims.

1 155 1 3268 DNA Homo sapiens 1 taacagccca cctcctagcc ccgggctacg cgccgccagc ccagtaaccc cacttttgtg 60 tgtcctccca ggccccgatc gaaaagcctg ggagggccgc cgaactaccc ccggagggag 120 gagccagtcc gaacccaagg cgccaccgcc gcagaagcgg agcgaggcag cattcgcctc 180 catggcccac tcgccggtgg ctgtccaagt gcctgggatg cagaataaca tagctgatcc 240 agaagaactg ttcacaaaat tagagcgcat tgggaaaggc tcatttgggg aagttttcaa 300 aggaattgat aaccgtaccc agcaagtcgt tgctattaaa atcatagacc ttgaggaagc 360 cgaagatgaa atagaagaca ttcagcaaga aataactgtc ttgagtcaat gtgacagctc 420 atatgtaaca aaatactatg ggtcatattt aaaggggtct aaattatgga taataatgga 480 atacctgggc ggtggttcag cactggatct tcttcgagct ggtccatttg atgagttcca 540 gattgctacc atgctaaagg aaattttaaa aggtctggac tatctgcatt cagaaaagaa 600 aattcaccga gacataaaag ctgccaatgt cttgctctca gaacaaggag atgttaaact 660 tgctgatttt ggagttgctg gtcagctgac agatacacag attaaaagaa atacctttgt 720 gggaactcca ttttggatgg ctcctgaagt tattcaacag tcagcttatg actcaaaagc 780 tgacatttgg tcattgggaa ttactgctat tgaactagcc aagggagagc cacctaactc 840 cgatatgcat ccaatgagag ttctgtttct tattcccaaa aacaatcctc caactcttgt 900 tggagacttt actaagtctt ttaaggagtt tattgatgct tgcctgaaca aagatccatc 960 atttcgtcct acagcaaaag aacttctgaa acacaaattc attgtaaaaa attcaaagaa 1020 gacttcttat ctgactgaac tgatagatcg ttttaagaga tggaaggcag aaggacacag 1080 tgatgatgaa tctgattccg agggctctga ttcggaatct accagcaggg aaaacaatac 1140 tcatcctgaa tggagcttta ccaccgtacg aaagaagcct gatccaaaga aagtacagaa 1200 tggggcagag caagatcttg tgcaaaccct gagttgtttg tctatgataa tcacacctgc 1260 atttgctgaa cttaaacagc aggacgagaa taacgctagc aggaatcagg cgattgaaga 1320 actcgagaaa agtattgctg tggctgaagc cgcctgtccc ggcatcacag ataaaatggt 1380 gaagaaacta attgaaaaat ttcaaaagtg ttcagcagac gaatccccct aagaaactta 1440 ttattggctt ctgtttcata tggacccaga gagccccacc aaacctacgt caagattaac 1500 aatgcttaac ccatgagctc catgtgcctt ttggatcttt gcaacactga agatttggaa 1560 gaagctatta aactattttg tgatggcgtt tatcatttta tattttgaaa ggattatttt 1620 gtaaggaata acttttaata ctatagtttc acctgtattc tagtaaatgt tgagacaccg 1680 ttttgctttt aagtatccct atttcttaag ttacgaggat gaataccttt cacattttga 1740 tctttagttg actctacagt catgaaacat acaggtcttt caaagtcatt ctcaatattc 1800 agcttttgta aattatcaag cttcaaaaag ctttttttta aaaaaaaaaa catgcatatt 1860 ctaaaaatga ctattggtgg ggaggtgtaa ataagtcata ccttcttaaa acagaaaatt 1920 taagtaaagt cttttaaatg aaacctgtaa aagtattgac tcttctacca agttggtatg 1980 atattccagg cagctcaatg attatcacat ttgagaccct gtgtttgaag catttacagg 2040 caatgtacag caacagaggt acctcttggt gtatagtatt tacattctct tttaggtaga 2100 agaggcaatt ttacccttat ttcacatggt tagaaattta aagcaagatc atttacccaa 2160 ggataggtgt ttggtaatgt tgaaggagtt agtctggctt catgttttac atcttcaact 2220 aaaatcccat actatctgct tggatttgga gagccaaaaa ataaagctga ttgtcatgtg 2280 attaaatatc tgatcaacag gtatgaatat aacttaaatc agcatatttt tgccatggta 2340 ataaattgtc ctataaacta tttatatatt tttgttcttc ataattatca ctaataagca 2400 tcagtttgtt gtttttaaaa ggatatttaa gtgagcattt tctagttcat atgaaaataa 2460 ccatagtaca ggatgatttc tgtccacaca aaggttaaat tagattgcac agttaatttt 2520 cacttatatt tatggtacta ttatgtgggt gatgcctttt tcttttaagc ccagtacata 2580 tattatgcct gcctaagttc tgaactgggg ctgtatttca gtagttgtag aattattgat 2640 atttagtttt gatagctaat gtttaattgt ttggatctgc acagtttggt ttttgcacaa 2700 aagtcattta aaaaaatctg agtaattgtc aaatattaaa agaaagatat tcttcctgta 2760 aggaatacag tttttagtca aagtggccat tacatcctct ttttaattta cataatacag 2820 atacttgaga aagttgttgt ggtgttgtat gccaagaaaa ttctttttat tggtgcctat 2880 attgtaacaa ttatttttaa tgcattgtat tttgaagtaa cggttcagtt aaatttttca 2940 cctgctgtgt aactgaaaca caattacagt ttataatcat ctgtagaagt ctggagataa 3000 ttttgcaact catgttatgg gttaaatgaa tatttttgta aaagtaaaag caacaaattt 3060 ataaattgat tatttgaaac tttacaacac aattgcatcc caaatacaaa ttgtattgct 3120 tattcattat agctattcgt cctgtaatct gtttctaggt gaagcatact ccagtgtttt 3180 aggggttttg aaaataaata tttaaatttc acagtcaaaa aaaaaaaaaa aaaaaaaaaa 3240 aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3268 2 3030 DNA Homo sapiens 2 gacagcagcg ccggccccgg cagctcccgc ggccccggcc ccggccccgg ccccggcccc 60 ggcggcacag gctgtcggct ggcccatctg cagggacgcg tacgagctgc aggaggttat 120 cggcagtgga gctactgctg tggttcaggc agccctatgc aaacccaggc aagaacgtgt 180 agcaataaaa cggatcaact tggaaaaatg ccagaccagt atggatgaac tattaaaaga 240 aattcaagcc atgagtcagt gcagccatcc caacgtagtg acctattaca cctcttttgt 300 ggtcaaagat gaactttggc tggtcatgaa attactaagt ggaggttcaa tgttggatat 360 cataaaatac attgtcaacc gaggagaaca caagaatgga gttctggaag aggcaataat 420 agcaacaatt cttaaagagg ttttggaagg cttagactat ctacacagaa acggtcagat 480 tcacagggat ttgaaagctg gtaatattct tctgggtgag gatggttcag tacaaatagc 540 agattttggg gtaagtgcgt tcctagcaac agggggtgat gttacccgaa ataaagtaag 600 aaaaacattc gttggcaccc catgttggat ggctcctgaa gtcatggaac aggtgagagg 660 ctatgacttc aaggctgaca tgtggagttt tggaataact gccattgaat tagcaacagg 720 agcagcgcct tatcacaaat atcctcccat gaaagtgtta atgttgactt tgcaaaatga 780 tccacccact ttggaaacag gggtagagga taaagaaatg atgaaaaagt acggcaagtc 840 ctttagaaaa ttactttcac tgtgtcttca gaaagatcct tccaaaaggc ccacagcagc 900 agaactttta aaatgcaaat tcttccagaa agccaagaac agagagtacc tgattgagaa 960 gctgcttaca agaacaccag acatagccca aagagccaaa aaggtaagaa gagttcctgg 1020 gtcaagtggt caccttcata aaaccgaaga cggggactgg gagtggagtg acgacgagat 1080 ggatgagaag agcgaagaag ggaaagcagc tttttctcag gaaaagtcac gaagagtaaa 1140 agaagaaaat ccagagattg cagtgagtgc cagcaccatc cccgaacaaa tacagtccct 1200 ctctgtgcac gactctcagg gcccacccaa tgctaatgaa gactacagag aagcttcttc 1260 ttgtgccgtg aacctcgttt tgagattaag aaactccaga aaggaactta atgacatacg 1320 atttgagttt actccaggaa gagatacagc agatggtgta tctcaggagc tcttctctgc 1380 tggcttggtg gatggtcacg atgtagttat agtggctgct aatttacaga agattgtaga 1440 tgatcccaaa gctttaaaaa cattgacatt taagttggct tctggctgtg atgggtcgga 1500 gattcctgat gaagtgaagc tgattgggtt tgctcagttg agtgtcagct gatgtatgtc 1560 ccttgatgtc accctgatct gtcatgcccc accgccaccc ctactccctt caaccctccc 1620 tctttctgcc catttcctcc caccccctca ctcccatttc ctagcaaaat cagaagattg 1680 tgaagaggcc ggcttcaaca aaatgggata aaaaaataat tttttaaaac ttacaacact 1740 ccgagttctg ctttattctc tagcaatcca cagtacaaga acaagcaaat gccacagctg 1800 cacgactgtt gctcattttt ccaaaagcta tttaatattc ttagcaatca atttggatat 1860 cccttaagtg aaaagaatct gaaatacact caggtggtct tatttattgg caacaaaagg 1920 aattttctat ccagaagcct atttctcctt tcattgttgt tatttctgtt ataatacttt 1980 aattgtacat ctgacaatac tgcctctttt atgttgtatt tagaaattaa tatacttata 2040 aaattaagat ttattagcca aacttgaatt ctagttttaa aactgactgt gaattttatt 2100 tttcatatat ttatgcatta cacaccttag ctataagaaa aaaagggttt tgattatatg 2160 cttcttgcag ttaatctcgt tatttaaaca aaaagttttg ggtctatctt tggagtattt 2220 gtaacttcta aattttgaaa tgactgaatt aggaatttgg atgcttattc ttttagtctg 2280 tttgcctaaa aaccaattta caatctgact gtctcttggg agagggaggt gccttgcaaa 2340 ctttcacatt aagaatgtgc ctgaggctgc tttactctgg aatagtctca gatctaaaat 2400 ttcctctata taaggtggca tatgttaagt tttgcttcat tggaccgttt agaatgctat 2460 gtaaaatgtt gccattctgt tagattgcta actatatacc catctctgat ttggctctcc 2520 ttaagtgata ggatttgtta ttctaaaggt gataaacttg aaaatatcag aatctgagtt 2580 ttacttgaaa ttttgcagaa tacccaggtg gagtgaaaat tggaagggtt ttgtgcaatg 2640 actaaaaggt aaaacgctgt taaggttcaa gaatcaatac tttcaaccca agtagccctc 2700 tgcttgactg tatattatgg aactagtaaa ccttaggatt ttgaaaattg gagtctaatc 2760 tttcaaggag gtgggctccc aggatggtac cattgctctt tcctagctaa ccctagatat 2820 ggcagctctt taatgtactt caaaaagcaa atatatatta ctaaggaaaa aaagttattt 2880 ataattgcct tgtcataatt gttaaggtgt tctagagcca tttgcataca atttaatgta 2940 atttcattcc attctattgt ttacacaacg attactcgaa gatgactgca aaggtaaaag 3000 gaaaataaaa gtgtattgca caatgaaaaa 3030 3 3857 DNA Homo sapiens modified_base (22) a, t, c, g, other or unknown 3 caaaagtgga gtcctagatg antctaccat tgctacgata ctccgagaag tactggaagg 60 gctggaatat ctgcataaaa ntggacagat ccacagagat gtgaaagctg gaaacattct 120 tnttggagaa gatggctcag tacagatttc agactttggg gttagtgctt ttttagcaac 180 tggtggtgat attacccgaa ataaagtgag aaagaccttt gttggcaccc cttgttggat 240 ggcacctgaa gttatggaac aggtccgtgg ttatgatttc aaagctgata tttggagttt 300 tggaattaca gcaattgaat tggctacagg ggcggctcct tatcataaat atccaccaat 360 gaaggtttta atgctgacac tgcagaacga tcctccttct ttggaaactg gtgttcaaga 420 taaagaaatg ctgaaaaaat atggaaaatc atttagaaaa atgatttcat tgtgccttca 480 aaaagatcca gaaaaaagac caacagcagc agaactatta aggcacaaat ttttccagaa 540 agcaaagaat aaagaatttc ttcaagaaaa aacattgcag agagcaccaa ccatttctga 600 aagagcaaaa aaggttcgga gagtaccagg ttccagtggg cgtcttcata agacagagga 660 tggaggctgg gagtggagtg atgatgaatt tgatgaagaa agtgaggaag ggaaagcagc 720 aatttcacaa ctcaggtctc cccgagtgaa agaatcaata tcaaattctg agctctttcc 780 aacaactgat cctgtgggta ctttgctcca agttccagaa cagatctctg ctcatctacc 840 tcagccagct gggcagattg ctacacagcc aactcaagtc tctctcccac ccaccgcaga 900 gccagcaaaa acagctcagg ctttgtcttc aggatcaggt tcacaagaaa ccaagatccc 960 aatcagtcta gtactaagat taaggaattc caaaaaagaa ctaaatgata ttcgatttga 1020 atttactcct gggagagata cagcagaggg tgtctctcag gaactcattt ctgctggcct 1080 ggtcgacgga agggatttag taatagtggc agctaatttg cagaaaattg tggaagaacc 1140 tcagtcaaat cgatctgtca ctttcaaact ggcatctggt gtcgaaggct cagatattcc 1200 tgatgatggt aaactgatag gatttgccca gctcagcatc agctaaacca caaccctgga 1260 agaggcggcc taaggagatt ccacacatgc gtatctctgt tgcttctatt ggcctaaacc 1320 cactactgcc aaagaaccca gcaacaaacc tcccggctag gagctttaga agtctttatg 1380 ttcttcctgc catcattcct ccttttccca cagggaaaga aaagttggat cactagtggc 1440 cagcatcccc agagttccgt tagtaaactt acttcatatg tcccctgtct tcctccatct 1500 gagaagtggc ccatgtgctt caaggcccag gagggagatc tgtcagctca ttcttgcctt 1560 actccaatga tggcccaggt ggaaaagtag cagctgtatc gggcttcctc atcctgcctg 1620 ttcccccaca cctgccagga tatggacatc ttgggatatc tctttaccac tgaagtagaa 1680 ttgattgttc agctggagcc cagagaattt aatttaatgt tttttctttg tacctgatgt 1740 gaattctagc aacctttgtt aggaaaaagc acagcctcag atggaggcag cctaaactgt 1800 gttcttgttt tgttcatggt gtttctaagc gttttgctga agctgctctc aggcaccccc 1860 ttcttcattg ctctctccag aaagggttgc tagccttaac ttcagctggt gcaaaacatc 1920 tgactgtagc cgaacttcag ccatcagatc cttcaaagtg gaactttgga ttgtttttac 1980 agacaacatc gagtaatggc ttgtaaatgt gaattttgcc agaggtggtt tttgaacagg 2040 aaaatcataa ttcatatcat tggagaagta tttattttca aatatcaaat tgaagaaaaa 2100 ctcaatcctc ccatgaaaat cagttcgcct ggcctccaag tcgtgaggaa atgggtatgc 2160 aaggctgaga tttctacagc aataaaggag acacacactg ggccagagag gcctgccttc 2220 tgcctgctct cctgcactga ccctttggag ggggtctctg tgtgctgaag ctaactcaag 2280 atggaaagtg aaaccacatg tgccgtgacc tttaggtttt atgagtagac agtgttcatt 2340 tgattttcta cagaaataat ataaattatt ctttaggttt aaaaaagagc actcataatg 2400 caatatgtga ataatcagtg aggttgattt ttcttttttc ctaccgtttc atagtctttg 2460 tctaactgct agtaacccta ccgagtttta tatatgagtg ggatactcaa tctggcctta 2520 aaaagataca caaagatggg ctgtgggtcc ctggaaaggg ggagagttgc cctttacaga 2580 atcactcgag ccctttccag cactgttggt ctgatgaaca aggttgtttt accttatttt 2640 ctcttggaac atatctgaaa accttcccca caaataactt gtcacacctt ttgtttcatt 2700 ctgagtcttt agttttagtc atgggctttc ttcacctgct ctaggtgcaa aggcatgttg 2760 ggaaagagat ggatgttggg gaggaagaga ggagatggat ttcagttggg agttaggagg 2820 agagtaggtg agatgatcag acaccggagt tcaacgtccc agcagtcttg gtaaaaggag 2880 ggagcctgct gagccaggag ggagaaaaga agattgacca gcttgctaga aaaatactta 2940 gcttttcttt ttcttttttt gtggaggggg gacggagagg aacaaggatg gggaggtagg 3000 aatgaggtat agaaaagaga tagcatcttc tttggcacaa gactagtggc ttaccgctta 3060 ccttagagtt ttgttttttt tttttcaaac ccatcaaaat ctacttattt atgaatccaa 3120 ggggtggcag catcactctg ttctagcatt ctttgtggag atggtctggt gcctagctgg 3180 gagtgagcag cagcccatcc cctgttcact ttctctagcc catcattacc tgtgaactgc 3240 agtggggcag tcatggcaaa tagaattggg ctggggtttc tccttctttt cagttcattg 3300 tttgccctgc taggaattag aagacagaca ccatgtccca ggacagtgtt acttcttctg 3360 catgatgtgt ggtagactcc ctttgctggc ttgtgcagtg atactgagaa aatacatgaa 3420 cagaaactgc ccaggtggaa cagcacgtaa cctagtgagt gactgtactc ctttctagga 3480 atgctgattc agagtgcacc tctttgacta ggtcccagga tccccttgtc cctggagtag 3540 ggactaacta tagcacaaag taatatgtgc caatgctatt tgtgaaatgt ttggtctttc 3600 taaacgacta aaggatttgt tgggtttttg cttaagtttt gaaccaaatc ctagagccag 3660 ctgataatat ttaataatct ggaggagaga ataatgatgt accaataagt ggagattcct 3720 ccttatgatg tatgctaggt tatggaagat gtaaaatatt caactttttc ctcctttttt 3780 tggactttgt attttactgc atgttttctt catttttaat caataaagag taaattgtca 3840 aaaaaaaaaa aaaaaaa 3857 4 1584 DNA Homo sapiens 4 ctcatctgta cacacttcat ggatggcatg aatgagctgg cgattgctta catcctgcag 60 ggggtgctga aggccctcga ctacatccac cacatgggat atgtacacag gagtgtcaaa 120 gccagccaca tcctgatctc tgtggatggg aaggtctacc tgtctggttt gcgcagcaac 180 ctcagcatga taagccatgg gcagcggcag cgagtggtcc acgattttcc caagtacagt 240 gtcaaggttc tgccgtggct cagccccgag gtcctccagc agaatctcca gggttatgat 300 gccaagtctg acatctacag tgtgggaatc acagcctgtg aactggccaa cggccatgtc 360 ccctttaagg atatgcctgc cacccagatg ctgctagaga aactgaacgg cacagtgccc 420 tgcctgttgg ataccagcac catccccgct gaggagctga ccatgagccc ttcgcgctca 480 gtggccaact ctggcctgag tgacagcctg accaccagca ccccccggcc ctccaacggt 540 gactcgccct cccaccccta ccaccgaacc ttctcccccc acttccacca ctttgtggag 600 cagtgccttc agcgcaaccc ggatgccagg cccagtgcca gcaccctcct gaaccactct 660 ttcttcaagc agatcaagcg acgtgcctca gaggctttgc ccgaattgct tcgtcctgtc 720 acccccatca ccaattttga gggcagccag tctcaggacc acagtggaat ctttggcctg 780 gtaacaaacc tggaagagct ggaggtggac gattgggagt tctgagcctc tgcaaactgt 840 gcgcattctc cagccaggga tgcagaggcc acccagaggc ccttcctgag ggccggccac 900 attcccgccc tcctgggcag attgggtaga aaggacattc ttccaggaaa gttgactgct 960 gactgattgg gaaagaaaat cctggagaga tacttcactg ctccaaggct tttgagacac 1020 aagggaatct caacaaccag ggatcaggag ggtccaaagc cgacattccc agtcctgtga 1080 gctcaggtga cctcctccgc agaagagaga tgctgctctg gccctgggag ctgaattcca 1140 agcccagggt ttggctcctt aaacccgagg accgccacct cttcccagtg cttgcgacca 1200 gcctcattct atttaacttt gctctcagat gcctcagatg ctataggtca gtgaaagggc 1260 aagtagtaag ctgcctgcct cccttccctc agacctctcc ctcataattc cagagaaggg 1320 catttctgtc tttttaagca cagactaagg ctggaacagt ccatccttat ccctcttctg 1380 gcttgggccc tgacacctaa gtctttccca cggtttatgt gtgtgcctca ttcctttccc 1440 accaagaatc catcttagcg cctcctgcca gctgccctgg tgctttctcc aagggccatc 1500 agtgtcttgc ctagcttgag ggcttaagtc cttatgctgt gttagtttcg ttgtcagaac 1560 aaattaaaat tttcagagac gctg 1584 5 416 PRT Homo sapiens 5 Met Ala His Ser Pro Val Ala Val Gln Val Pro Gly Met Gln Asn Asn 1 5 10 15 Ile Ala Asp Pro Glu Glu Leu Phe Thr Lys Leu Glu Arg Ile Gly Lys 20 25 30 Gly Ser Phe Gly Glu Val Phe Lys Gly Ile Asp Asn Arg Thr Gln Gln 35 40 45 Val Val Ala Ile Lys Ile Ile Asp Leu Glu Glu Ala Glu Asp Glu Ile 50 55 60 Glu Asp Ile Gln Gln Glu Ile Thr Val Leu Ser Gln Cys Asp Ser Ser 65 70 75 80 Tyr Val Thr Lys Tyr Tyr Gly Ser Tyr Leu Lys Gly Ser Lys Leu Trp 85 90 95 Ile Ile Met Glu Tyr Leu Gly Gly Gly Ser Ala Leu Asp Leu Leu Arg 100 105 110 Ala Gly Pro Phe Asp Glu Phe Gln Ile Ala Thr Met Leu Lys Glu Ile 115 120 125 Leu Lys Gly Leu Asp Tyr Leu His Ser Glu Lys Lys Ile His Arg Asp 130 135 140 Ile Lys Ala Ala Asn Val Leu Leu Ser Glu Gln Gly Asp Val Lys Leu 145 150 155 160 Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg 165 170 175 Asn Thr Phe Val Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Gln 180 185 190 Gln Ser Ala Tyr Asp Ser Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr 195 200 205 Ala Ile Glu Leu Ala Lys Gly Glu Pro Pro Asn Ser Asp Met His Pro 210 215 220 Met Arg Val Leu Phe Leu Ile Pro Lys Asn Asn Pro Pro Thr Leu Val 225 230 235 240 Gly Asp Phe Thr Lys Ser Phe Lys Glu Phe Ile Asp Ala Cys Leu Asn 245 250 255 Lys Asp Pro Ser Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys His Lys 260 265 270 Phe Ile Val Lys Asn Ser Lys Lys Thr Ser Tyr Leu Thr Glu Leu Ile 275 280 285 Asp Arg Phe Lys Arg Trp Lys Ala Glu Gly His Ser Asp Asp Glu Ser 290 295 300 Asp Ser Glu Gly Ser Asp Ser Glu Ser Thr Ser Arg Glu Asn Asn Thr 305 310 315 320 His Pro Glu Trp Ser Phe Thr Thr Val Arg Lys Lys Pro Asp Pro Lys 325 330 335 Lys Val Gln Asn Gly Ala Glu Gln Asp Leu Val Gln Thr Leu Ser Cys 340 345 350 Leu Ser Met Ile Ile Thr Pro Ala Phe Ala Glu Leu Lys Gln Gln Asp 355 360 365 Glu Asn Asn Ala Ser Arg Asn Gln Ala Ile Glu Glu Leu Glu Lys Ser 370 375 380 Ile Ala Val Ala Glu Ala Ala Cys Pro Gly Ile Thr Asp Lys Met Val 385 390 395 400 Lys Lys Leu Ile Glu Lys Phe Gln Lys Cys Ser Ala Asp Glu Ser Pro 405 410 415 6 516 PRT Homo sapiens 6 Thr Ala Ala Pro Ala Pro Ala Ala Pro Ala Ala Pro Ala Pro Ala Pro 1 5 10 15 Ala Pro Ala Pro Ala Ala Gln Ala Val Gly Trp Pro Ile Cys Arg Asp 20 25 30 Ala Tyr Glu Leu Gln Glu Val Ile Gly Ser Gly Ala Thr Ala Val Val 35 40 45 Gln Ala Ala Leu Cys Lys Pro Arg Gln Glu Arg Val Ala Ile Lys Arg 50 55 60 Ile Asn Leu Glu Lys Cys Gln Thr Ser Met Asp Glu Leu Leu Lys Glu 65 70 75 80 Ile Gln Ala Met Ser Gln Cys Ser His Pro Asn Val Val Thr Tyr Tyr 85 90 95 Thr Ser Phe Val Val Lys Asp Glu Leu Trp Leu Val Met Lys Leu Leu 100 105 110 Ser Gly Gly Ser Met Leu Asp Ile Ile Lys Tyr Ile Val Asn Arg Gly 115 120 125 Glu His Lys Asn Gly Val Leu Glu Glu Ala Ile Ile Ala Thr Ile Leu 130 135 140 Lys Glu Val Leu Glu Gly Leu Asp Tyr Leu His Arg Asn Gly Gln Ile 145 150 155 160 His Arg Asp Leu Lys Ala Gly Asn Ile Leu Leu Gly Glu Asp Gly Ser 165 170 175 Val Gln Ile Ala Asp Phe Gly Val Ser Ala Phe Leu Ala Thr Gly Gly 180 185 190 Asp Val Thr Arg Asn Lys Val Arg Lys Thr Phe Val Gly Thr Pro Cys 195 200 205 Trp Met Ala Pro Glu Val Met Glu Gln Val Arg Gly Tyr Asp Phe Lys 210 215 220 Ala Asp Met Trp Ser Phe Gly Ile Thr Ala Ile Glu Leu Ala Thr Gly 225 230 235 240 Ala Ala Pro Tyr His Lys Tyr Pro Pro Met Lys Val Leu Met Leu Thr 245 250 255 Leu Gln Asn Asp Pro Pro Thr Leu Glu Thr Gly Val Glu Asp Lys Glu 260 265 270 Met Met Lys Lys Tyr Gly Lys Ser Phe Arg Lys Leu Leu Ser Leu Cys 275 280 285 Leu Gln Lys Asp Pro Ser Lys Arg Pro Thr Ala Ala Glu Leu Leu Lys 290 295 300 Cys Lys Phe Phe Gln Lys Ala Lys Asn Arg Glu Tyr Leu Ile Glu Lys 305 310 315 320 Leu Leu Thr Arg Thr Pro Asp Ile Ala Gln Arg Ala Lys Lys Val Arg 325 330 335 Arg Val Pro Gly Ser Ser Gly His Leu His Lys Thr Glu Asp Gly Asp 340 345 350 Trp Glu Trp Ser Asp Asp Glu Met Asp Glu Lys Ser Glu Glu Gly Lys 355 360 365 Ala Ala Phe Ser Gln Glu Lys Ser Arg Arg Val Lys Glu Glu Asn Pro 370 375 380 Glu Ile Ala Val Ser Ala Ser Thr Ile Pro Glu Gln Ile Gln Ser Leu 385 390 395 400 Ser Val His Asp Ser Gln Gly Pro Pro Asn Ala Asn Glu Asp Tyr Arg 405 410 415 Glu Ala Ser Ser Cys Ala Val Asn Leu Val Leu Arg Leu Arg Asn Ser 420 425 430 Arg Lys Glu Leu Asn Asp Ile Arg Phe Glu Phe Thr Pro Gly Arg Asp 435 440 445 Thr Ala Asp Gly Val Ser Gln Glu Leu Phe Ser Ala Gly Leu Val Asp 450 455 460 Gly His Asp Val Val Ile Val Ala Ala Asn Leu Gln Lys Ile Val Asp 465 470 475 480 Asp Pro Lys Ala Leu Lys Thr Leu Thr Phe Lys Leu Ala Ser Gly Cys 485 490 495 Asp Gly Ser Glu Ile Pro Asp Glu Val Lys Leu Ile Gly Phe Ala Gln 500 505 510 Leu Ser Val Ser 515 7 414 PRT Homo sapiens MOD_RES (7) Any amino acid 7 Lys Ser Gly Val Leu Asp Xaa Ser Thr Ile Ala Thr Ile Leu Arg Glu 1 5 10 15 Val Leu Glu Gly Leu Glu Tyr Leu His Lys Xaa Gly Gln Ile His Arg 20 25 30 Asp Val Lys Ala Gly Asn Ile Leu Xaa Gly Glu Asp Gly Ser Val Gln 35 40 45 Ile Ala Asp Phe Gly Val Ser Ala Phe Leu Ala Thr Gly Gly Asp Ile 50 55 60 Thr Arg Asn Lys Val Arg Lys Thr Phe Val Gly Thr Pro Cys Trp Met 65 70 75 80 Ala Pro Glu Val Met Glu Gln Val Arg Gly Tyr Asp Phe Lys Ala Asp 85 90 95 Ile Trp Ser Phe Gly Ile Thr Ala Ile Glu Leu Ala Thr Gly Ala Ala 100 105 110 Pro Tyr His Lys Tyr Pro Pro Met Lys Val Leu Met Leu Thr Leu Gln 115 120 125 Asn Asp Pro Pro Ser Leu Glu Thr Gly Val Gln Asp Lys Glu Met Leu 130 135 140 Lys Lys Tyr Gly Lys Ser Phe Arg Lys Met Ile Ser Leu Cys Leu Gln 145 150 155 160 Lys Asp Pro Glu Lys Arg Pro Thr Ala Ala Glu Leu Leu Arg His Lys 165 170 175 Phe Phe Gln Lys Ala Lys Asn Lys Glu Phe Leu Gln Glu Lys Thr Leu 180 185 190 Gln Arg Ala Pro Thr Ile Ser Glu Arg Ala Lys Lys Val Arg Arg Val 195 200 205 Pro Gly Ser Ser Gly Arg Leu His Lys Thr Glu Asp Gly Gly Trp Glu 210 215 220 Trp Ser Asp Asp Glu Phe Asp Glu Glu Ser Glu Glu Gly Lys Ala Ala 225 230 235 240 Ile Ser Gln Leu Arg Ser Pro Arg Val Lys Glu Ser Ile Ser Asn Ser 245 250 255 Glu Leu Phe Pro Thr Thr Asp Pro Val Gly Thr Leu Leu Gln Val Pro 260 265 270 Glu Gln Ile Ser Ala His Leu Pro Gln Pro Ala Gly Gln Ile Ala Thr 275 280 285 Gln Pro Thr Gln Val Ser Leu Pro Pro Thr Ala Glu Pro Ala Lys Thr 290 295 300 Ala Gln Ala Leu Ser Ser Gly Ser Gly Ser Gln Glu Thr Lys Ile Pro 305 310 315 320 Ile Ser Leu Val Leu Arg Leu Arg Asn Ser Lys Lys Glu Leu Asn Asp 325 330 335 Ile Arg Phe Glu Phe Thr Pro Gly Arg Asp Thr Ala Glu Gly Val Ser 340 345 350 Gln Glu Leu Ile Ser Ala Gly Leu Val Asp Gly Arg Asp Leu Val Ile 355 360 365 Val Ala Ala Asn Leu Gln Lys Ile Val Glu Glu Pro Gln Ser Asn Arg 370 375 380 Ser Val Thr Phe Lys Leu Ala Ser Gly Val Glu Gly Ser Asp Ile Pro 385 390 395 400 Asp Asp Gly Lys Leu Ile Gly Phe Ala Gln Leu Ser Ile Ser 405 410 8 274 PRT Homo sapiens 8 Leu Ile Cys Thr His Phe Met Asp Gly Met Asn Glu Leu Ala Ile Ala 1 5 10 15 Tyr Ile Leu Gln Gly Val Leu Lys Ala Leu Asp Tyr Ile His His Met 20 25 30 Gly Tyr Val His Arg Ser Val Lys Ala Ser His Ile Leu Ile Ser Val 35 40 45 Asp Gly Lys Val Tyr Leu Ser Gly Leu Arg Ser Asn Leu Ser Met Ile 50 55 60 Ser His Gly Gln Arg Gln Arg Val Val His Asp Phe Pro Lys Tyr Ser 65 70 75 80 Val Lys Val Leu Pro Trp Leu Ser Pro Glu Val Leu Gln Gln Asn Leu 85 90 95 Gln Gly Tyr Asp Ala Lys Ser Asp Ile Tyr Ser Val Gly Ile Thr Ala 100 105 110 Cys Glu Leu Ala Asn Gly His Val Pro Phe Lys Asp Met Pro Ala Thr 115 120 125 Gln Met Leu Leu Glu Lys Leu Asn Gly Thr Val Pro Cys Leu Leu Asp 130 135 140 Thr Ser Thr Ile Pro Ala Glu Glu Leu Thr Met Ser Pro Ser Arg Ser 145 150 155 160 Val Ala Asn Ser Gly Leu Ser Asp Ser Leu Thr Thr Ser Thr Pro Arg 165 170 175 Pro Ser Asn Gly Asp Ser Pro Ser His Pro Tyr His Arg Thr Phe Ser 180 185 190 Pro His Phe His His Phe Val Glu Gln Cys Leu Gln Arg Asn Pro Asp 195 200 205 Ala Arg Pro Ser Ala Ser Thr Leu Leu Asn His Ser Phe Phe Lys Gln 210 215 220 Ile Lys Arg Arg Ala Ser Glu Ala Leu Pro Glu Leu Leu Arg Pro Val 225 230 235 240 Thr Pro Ile Thr Asn Phe Glu Gly Ser Gln Ser Gln Asp His Ser Gly 245 250 255 Ile Phe Gly Leu Val Thr Asn Leu Glu Glu Leu Glu Val Asp Asp Trp 260 265 270 Glu Phe 9 3798 DNA Homo sapiens 9 gagaccatgg cgaacgactc tcccgcgaaa agtctggtgg acatcgacct ctcctccctg 60 cgggatcctg ctgggatttt tgagctggtg gaagtggttg gaaatggcac ctatggacaa 120 gtctataagg gtcgacatgt taaaacgggt cagttggcag ccatcaaagt tatggatgtc 180 actgaggatg aagaggaaga aatcaaactg gagataaata tgctaaagaa atactctcat 240 cacagaaaca ttgcaacata ttatggtgct ttcatcaaaa agagccctcc aggacatgat 300 gaccaactct ggcttgttat ggagttctgt ggggctgggt ccattacaga ccttgtgaag 360 aacaccaaag ggaacacact caaagaagac tggatcgctt acatctccag agaaatcctg 420 aggggactgg cacatcttca cattcatcat gtgattcacc gggatatcaa gggccagaat 480 gtgttgctga ctgagaatgc agaggtgaaa cttgttgact ttggtgtgag tgctcagctg 540 gacaggactg tggggcggag aaatacgttc ataggcactc cctactggat ggctcctgag 600 gtcatcgcct gtgatgagaa cccagatgcc acctatgatt acagaagtga tctttggtct 660 tgtggcatta cagccattga gatggcagaa ggtgctcccc ctctctgtga catgcatcca 720 atgagagcac tgtttctcat tcccagaaac cctcctcccc ggctgaagtc aaaaaaatgg 780 tcgaagaagt tttttagttt tatagaaggg tgcctggtga agaattacat gcagcggccc 840 tctacagagc agcttttgaa acatcctttt ataagggatc agccaaatga aaggcaagtt 900 agaatccagc ttaaggatca tatagatcgt accaggaaga agagaggcga gaaagatgaa 960 actgagtatg agtacagtgg gagtgaggaa gaagaggagg aagtgcctga acaggaagga 1020 gagccaagtt ccattgtgaa cgtgcctggt gagtctactc ttcgccgaga tttcctgaga 1080 ctgcagcagg agaacaagga acgttccgag gctcttcgga gacaacagtt actacaggag 1140 caacagctcc gggagcagga agaatataaa aggcaactgc tggcagagag acagaagcgg 1200 attgagcagc agaaagaaca gaggcgacgg ctagaagagc aacaaaggag agagcgggaa 1260 gctagaaggc agcaggaacg tgaacagcga aggagagaac aagaagaaaa gaggcgtcta 1320 gaggagttgg agagaaggcg caaagaagaa gaggagagga gacgggcaga agaagaaaag 1380 aggagagttg aaagagaaca ggagtatatc aggcgacagc tagaagagga gcagcggcac 1440 ttggaagtcc ttcagcagca gctgctccag gagcaggcca tgttactgga gtgccgatgg 1500 cgggagatgg aggagcaccg gcaggcagag aggctccaga ggcagttgca acaagaacaa 1560 gcatatctcc tgtctctaca gcatgaccat aggaggccgc acccgcagca ctcgcagcag 1620 ccgccaccac cgcagcagga aaggagcaag ccaagcttcc atgctcccga gcccaaagcc 1680 cactacgagc ctgctgaccg agcgcgagag gtggaagata gatttaggaa aactaaccac 1740 agctcccctg aagcccagtc taagcagaca ggcagagtat tggagccacc agtgccttcc 1800 cgatcagagt ctttttccaa tggcaactcc gagtctgtgc atcccgccct gcagagacca 1860 gcggagccac aggttcctgt gagaacaaca tctcgctccc ctgttctgtc ccgtcgagat 1920 tccccactgc agggcagtgg gcagcagaat agccaggcag gacagagaaa ctccaccagt 1980 attgagccca ggcttctgtg ggagagagtg gagaagctgg tgcccagacc tggcagtggc 2040 agctcctcag ggtccagcaa ctcaggatcc cagcccgggt ctcaccctgg gtctcagagt 2100 ggctccgggg aacgcttcag agtgagatca tcatccaagt ctgaaggctc tccatctcag 2160 cgcctggaaa atgcagtgaa aaaacctgaa gataaaaagg aagttttcag acccctcaag 2220 cctgctgatc tgaccgcact ggccaaagag cttcgagcag tggaagatgt acggccacct 2280 cacaaagtaa cggactactc ctcatccagt gaggagtcgg ggacgacgga tgaggaggac 2340 gacgatgtgg agcaggaagg ggctgacgag tccacctcag gaccagagga caccagagca 2400 gcgtcatctc tgaatttgag caatggtgaa acggaatctg tgaaaaccat gattgtccat 2460 gatgatgtag aaagtgagcc ggccatgacc ccatccaagg agggcactct aatcgtccgc 2520 cggactcagt ccgctagtag cacactccag aaacacaaat cttcctcctc ctttacacct 2580 tttatagacc ccagattact acagatttct ccatctagcg gaacaacagt gacatctgtg 2640 gtgggatttt cctgtgatgg gatgagacca gaagccataa ggcaagatcc tacccggaaa 2700 ggctcagtgg tcaatgtgaa tcctaccaac actaggccac agagtgacac cccggagatt 2760 cgtaaataca agaagaggtt taactctgag attctgtgtg ctgccttatg gggagtgaat 2820 ttgctagtgg gtacagagag tggcctgatg ctgctggaca gaagtggcca agggaaggtc 2880 tatcctctta tcaaccgaag acgatttcaa caaatggacg tacttgaggg cttgaatgtc 2940 ttggtgacaa tatctggcaa aaaggataag ttacgtgtct actatttgtc ctggttaaga 3000 aataaaatac ttcacaatga tccagaagtt gagaagaagc agggatggac aaccgtaggg 3060 gatttggaag gatgtgtaca ttataaagtt gtaaaatatg aaagaatcaa atttctggtg 3120 attgctttga agagttctgt ggaagtctat gcgtgggcac caaagccata tcacaaattt 3180 atggccttta agtcatttgg agaattggta cataagccat tactggtgga tctcactgtt 3240 gaggaaggcc agaggttgaa agtgatctat ggatcctgtg ctggattcca tgctgttgat 3300 gtggattcag gatcagtcta tgacatttat ctaccaacac atatccagtg tagcatcaaa 3360 ccccatgcaa tcatcatcct ccccaataca gatggaatgg agcttctggt gtgctatgaa 3420 gatgaggggg tttatgtaaa cacatatgga aggatcacca aggatgtagt tctacagtgg 3480 ggagagatgc ctacatcagt agcatatatt cgatccaatc agacaatggg ctggggagag 3540 aaggccatag agatccgatc tgtggaaact ggtcacttgg atggtgtgtt catgcacaaa 3600 agggctcaaa gactaaaatt cttgtgtgaa cgcaatgaca aggtgttctt tgcctctgtt 3660 cggtctggtg gcagcagtca ggtttatttc atgaccttag gcaggacttc tcttctgagc 3720 tggtagaagc agtgtgatcc agggattact ggcctccaga gtcttcaaga tcctgagaac 3780 ttggaattcc ttgtaact 3798 10 4055 DNA Homo sapiens 10 gctttcgggg aggtctatga gggtcgtcat gtcaaaacgg gccagcttgc agccatcaag 60 gttatggatg tcacagggga tgaagaggaa gaaatcaaac aagaaattaa catgttgaag 120 aaatattctc atcaccggaa tattgctaca tactatggtg cttttatcaa aaagaaccca 180 ccaggcatgg atgaccaact ttggttggtg atggagtttt gtggtgctgg ctctgtcacc 240 gacctgatca agaacacaaa aggtaacacg ttgaaagagg agtggattgc atacatctgc 300 agggaaatct tacgggggct gagtcacctg caccagcata aagtgattca tcgagatatt 360 aaagggcaaa atgtcttgct gactgaaaat gcagaagtta aactagtgga ctttggagtc 420 agtgctcagc ttgatcgaac agtgggcagg aggaatactt tcattggaac tccctactgg 480 atggcaccag aagttattgc ctgtgatgaa aacccagatg ccacatatga tttcaagagt 540 gacttgtggt ctttgggtat caccgccatt gaaatggcag aaggtgctcc ccctctctgt 600 gacatgcacc ccatgagagc tctcttcctc atcccccgga atccagcgcc tcggctgaag 660 tctaagaagt ggtcaaaaaa attccagtca tttattgaga gctgcttggt aaagaatcac 720 agccagcgac cagcaacaga acaattgatg aagcatccat ttatacgaga ccaacctaat 780 gagcgacagg tccgcattca actcaaggac catattgata gaacaaagaa gaagcgagga 840 gaaaaagatg agacagagta tgagtacagt ggaagtgagg aagaagagga ggagaatgac 900 tcaggagagc ccagctccat cctgaatctg ccaagggagt cgacgctgcg gagggacttt 960 ctgaggctgc agctggccaa caaggagcgt tctgaggccc tacggaggca gcagctggag 1020 cagcagcagc gggagaatga ggagcacaag cggcagctgc tggccgagcg tcagaagcgc 1080 atcgaggagc agaaagagca gaggcggcgg ctggaggagc aacaaaggcg agagaaggag 1140 ctgcggaagc agcaggagag ggagcagcgc cggcactatg aggagcagat gcgccgggag 1200 gaggagagga ggcgtgcgga gcatgaacag gaatataagc gcaaacaatt ggaagaacag 1260 agacaagcag aaagactgca gaggcagcta aagcaagaaa gagactactt agtttccctt 1320 cagcatcagc ggcaggagca gaggcctgtg gagaagaagc cactgtacca ttacaaagaa 1380 ggaatgagtc ctagtgagaa gccagcatgg gccaaggagg tagaagaacg gtcaaggctc 1440 aaccggcaaa gttcccctgc catgcctcac aaggttgcca acaggatatc tgaccccaac 1500 ctgcccccaa ggtcggagtc cttcagcatt agtggagttc agcctgctcg aacacccccc 1560 atgctcagac cagtcgatcc ccagatccca catctggtag ctgtaaaatc ccagggacct 1620 gccttgaccg cctcccagtc agtgcacgag cagcccacaa agggcctctc tgggtttcag 1680 gaggctctga acgtgacctc ccaccgcgtg gagatgccac gccagaactc agatcccacc 1740 tcggaaaatc ctcctctccc cactcgcatt gaaaagtttg accgaagctc ttggttacga 1800 caggaagaag acattccacc aaaggtgcct caaagaacaa cttctatatc cccagcatta 1860 gccagaaaga attctcctgg gaatggtagt gctctgggac ccagactagg atctcaaccc 1920 atcagagcaa gcaaccctga tctccggaga actgagccca tcttggagag ccccttgcag 1980 aggaccagca gtggcagttc ctccagctcc agcaccccta gctcccagcc cagctcccaa 2040 ggaggctccc agcctggatc acaagcagga tccagtgaac gcaccagagt tcgagccaac 2100 agtaagtcag aaggatcacc tgtgctcccc catgagcctg ccaaggtgaa accagaagaa 2160 tccagggaca ttacccggcc cagtcgacca gctagctaca aaaaagctat agatgaggat 2220 ctgacggcat tagccaaaga actaagagaa ctccggattg aagaaacaaa ccgcccaatg 2280 aagaaggtga ctgattactc ctcctccagt gaggagtcag aaagtagcga ggaagaggag 2340 gaagatggag agagcgagac ccatgatggg acagtggctg tcagcgacat acccagactg 2400 ataccaacag gagctccagg cagcaacgag cagtacaatg tgggaatggt ggggacgcat 2460 gggctggaga cctctcatgc ggacagtttc agcggcagta tttcaagaga aggaaccttg 2520 atgattagag agacgtctgg agagaagaag cgatctggcc acagtgacag caatggcttt 2580 gctggccaca tcaacctccc tgacctggtg cagcagagcc attctccagc tggaaccccg 2640 actgagggac tggggcgcgt ctcaacccat tcccaggaga tggactctgg gactgaatat 2700 ggcatgggga gcagcaccaa agcctccttc accccctttg tggaccccag agtataccag 2760 acgtctccca ctgatgaaga tgaagaggat gaggaatcat cagccgcagc tctgtttact 2820 ggcgaacttc ttaggcaaga acaggccaaa ctcaatgaag caagaaagat ttcggtggta 2880 aatgtaaacc caaccaacat tcggcctcat agcgacacac cagaaatcag aaaatacaag 2940 aaacgattca actcagaaat actttgtgca gctctgtggg gtgtaaacct tctggtgggg 3000 actgaaaatg gcctgatgct tttggaccga agtgggcaag gcaaagtcta taatctgatc 3060 aaccggaggc gatttcagca gatggatgtg ctagagggac tgaatgtcct tgtgacaatt 3120 tcaggaaaga agaataagct acgagtttac tatctttcat ggttaagaaa cagaatacta 3180 cataatgacc cagaagtaga aaagaaacaa ggctggatca ctgttgggga cttggaaggc 3240 tgtatacatt ataaagttgt taaatatgaa aggatcaaat ttttggtgat tgccttaaag 3300 aatgctgtgg aaatatatgc ttgggctcct aaaccgtatc ataaattcat ggcatttaag 3360 tcttttgcag atctccagca caagcctctg ctagttgatc tcacggtaga agaaggtcaa 3420 agattaaagg ttatttttgg ttcacacact ggtttccatg taattgatgt tgattcagga 3480 aactcttatg atatctacac accatctcat attcagggca atatcactcc tcatgctatt 3540 gtcatcttgc ctaaaacaga tggaatggaa atgcttgttt gctatgagga tgagggggtg 3600 tatgtaaaca cctatggccg gataactaag gatgtggtgc tccaatgggg agaaatgccc 3660 acgtctgtgg cctacattca ttccaatcag ataatgggct ggggcgagaa agctattgag 3720 atccggtcag tggaaacagg acatttggat ggagtattta tgcataagcg agctcaaagg 3780 ttaaagtttc tatgtgaaag aaatgataag gtattttttg catccgtgcg atctggagga 3840 agtagccaag tgtttttcat gaccctcaac agaaattcca tgatgaactg gtaacagaag 3900 agcacttggc acttatcttc atggcgttat ttctaattta aaagaacata actcatgtgg 3960 acttatgcca gtctagaggc agaatcagaa ggcttggttg aacatatcgc tttccctttt 4020 tcctctccct ccgcccctcc cagtacagtc catct 4055 11 4133 DNA Homo sapiens 11 gcatttgggg aggtgtatga gggtcggcat gtcaagacgg ggcagctggc tgccatcaag 60 gtcatggatg tcacggagga cgaggaggaa gagatcaaac aggagatcaa catgctgaaa 120 aagtactctc accaccgcaa catcgccacc tactacggag ccttcatcaa gaagagcccc 180 ccgggaaacg atgaccagct ctggctggtg atggagttct gtggtgctgg ttcagtgact 240 gacctggtaa agaacacaaa aggcaacgcc ctgaaggagg actgtatcgc ctatatctgc 300 agggagatcc tcaggggtct ggcccatctc catgcccaca aggtgatcca tcgagacatc 360 aaggggcaga atgtgctgct gacagagaat gctgaggtca agctagtgga ttttggggtg 420 agtgctcagc tggaccgcac cgtgggcaga cggaacactt tcattgggac tccctactgg 480 atggctccag aggtcatcgc ctgtgatgag aaccctgatg ccacctatga ttacaggagt 540 gatatttggt ctctaggaat cacagccatc gagatggcag agggagcccc ccctctgtgt 600 gacatgcacc ccatgcgagc cctcttcctc attcctcgga accctccgcc caggctcaag 660 tccaagaagt ggtctaagaa gttcattgac ttcattgaca catgtctcat caagacttac 720 ctgagccgcc cacccacgga gcagctactg aagtttccct tcatccggga ccagcccacg 780 gagcggcagg tccgcatcca gcttaaggac cacattgacc gatcccggaa gaagcggggt 840 gagaaagagg agacagaata tgagtacagc ggcagcgagg aggaagatga cagccatgga 900 gaggaaggag agccaagctc catcatgaac gtgcctggag agtcgactct acgccgggag 960 tttctccggc tccagcagga aaataagagc aactcagagg ctttaaaaca gcagcagcag 1020 ctgcagcagc agcagcagcg agaccccgag gcacacatca aacacctgct gcaccagcgg 1080 cagcggcgca tagaggagca gaaggaggag cggcgccgcg tggaggagca acagcggcgg 1140 gagcgggagc agcggaagct gcaggagaag gagcagcagc ggcggctgga ggacatgcag 1200 gctctgcggc gggaggagga gcggcggcag gcggagcgcg agcaggaata tattcgtcac 1260 aggctagagg aggagcagcg acagctcgag atccttcagc aacagctgct ccaggaacag 1320 gccctgctgc tggaatacaa gcggaagcag ctggaggagc agcggcagtc agaacgtctc 1380 cagaggcagc tgcagcagga gcatgcctac ctcaagtccc tgcagcagca gcaacagcag 1440 cagcagcttc agaaacaaca gcagcagcag ctcctgcctg gggacaggaa gcccctgtac 1500 cattatggtc ggggcatgaa tcccgctgac aaaccagcct gggcccgaga ggtagaagag 1560 agaacaagga tgaacaagca gcagaactct cccttggcca agagcaagcc aggcagcacg 1620 gggcctgagc cccccatccc ccaggcctcc ccagggcccc caggacccct ttcccagact 1680 cctcctatgc agaggccggt ggagccccag gagggaccgc acaagagcct ggtggcacac 1740 cgggtcccac tgaagccata tgcagcacct gtaccccgat cccagtccct gcaggaccag 1800 cccacccgaa acctggctgc cttcccagcc tcccatgacc ccgaccctgc catccccgca 1860 cccactgcca cgcccagtgc ccgaggagct gtcatccgcc agaattcaga ccccacctct 1920 gaaggacctg gccccagccc gaatccccca gcctgggtcc gcccagataa cgaggcccca 1980 cccaaggtgc ctcagaggac ctcatctatc gccactgccc ttaacaccag tggggccgga 2040 gggtcccggc cagcccaggc agtccgtgcc agacctcgca gcaactccgc ctggcaaatc 2100 tatctgcaaa ggcgggcaga gcggggcacc ccaaagcctc cagggccccc tgctcagccc 2160 cctggcccgc ccaacgcctc tagtaacccc gacctcagga ggagcgaccc tggctgggaa 2220 cgctcggaca gcgtccttcc agcctctcac gggcacctcc cccaggctgg ctcactggag 2280 cggaaccgcg tgggagtctc ctccaaaccg gacagctccc ctgtgctctc ccctgggaat 2340 aaagccaagc ccgacgacca ccgctcacgg ccaggccggc ccgcagactt tgtgttgctg 2400 aaagagcgga ctctggacga ggcccctcgg cctcccaaga aggccatgga ctactcgtcg 2460 tccagcgagg aggtggaaag cagtgaggac gacgaggagg aaggcgaagg cgggccagca 2520 gaggggagca gagatacccc tgggggccgc gatggggata cagacagcgt cagcaccatg 2580 gtggtccacg acgtcgagga gatcaccggg acccagcccc catacggggg cggcaccatg 2640 gtggtccagc gcacccctga agaggagcgg aacctgctgc atgctgacag caatgggtac 2700 acaaacctgc ctgacgtggt ccagcccagc cactcaccca ccgagaacag caaaggccaa 2760 agcccaccct cgaaggatgg gagtggtgac taccagtctc gtgggctggt aaaggcccct 2820 ggcaagagct cgttcacgat gtttgtggat ctagggatct accagcctgg aggcagtggg 2880 gacagcatcc ccatcacagc cctagtgggt ggagagggca ctcggctcga ccagctgcag 2940 tacgacgtga ggaagggttc tgtggtcaac gtgaatccca ccaacacccg ggcccacagt 3000 gagacccctg agatccggaa gtacaagaag cgattcaact ccgagatcct ctgtgcagcc 3060 ctttgggggg tcaacctgct ggtgggcacg gagaacgggc tgatgttgct ggaccgaagt 3120 gggcagggca aggtgtatgg actcattggg cggcgacgct tccagcagat ggatgtgctg 3180 gaggggctca acctgctcat caccatctca gggaaaagga acaaactgcg ggtgtattac 3240 ttgtcctggc tccggaacaa gattctgcac aatgacccag aagtggagaa gaagcagggc 3300 tggaccaccg tgggggacat ggagggctgc gggcactacc gtgttgtgaa atacgagcgg 3360 attaagttcc tggtcatcgc cctcaagagc tccgtggagg tgtatgcctg ggcccccaaa 3420 ccctaccaca aattcatggc cttcaagtcc tttgccgacc tcccccaccg ccctctgctg 3480 gtcgacctga cagtagagga ggggcagcgg ctcaaggtca tctatggctc cagtgctggc 3540 ttccatgctg tggatgtcga ctcggggaac agctatgaca tctacatccc tgtgcacatc 3600 cagagccaga tcacgcccca tgccatcatc ttcctcccca acaccgacgg catggagatg 3660 ctgctgtgct acgaggacga gggtgtctac gtcaacacgt acgggcgcat cattaaggat 3720 gtggtgctgc agtgggggga gatgcctact tctgtggcct acatctgctc caaccagata 3780 atgggctggg gtgagaaagc cattgagatc cgctctgtgg agacgggcca cctcgacggg 3840 gtcttcatgc acaaacgagc tcagaggctc aagttcctgt gtgagcggaa tgacaaggtg 3900 ttttttgcct cagtccgctc tgggggcagc agccaagttt acttcatgac tctgaaccgt 3960 aaccgcatca tgaactggtg acggggccct gggctggggc tgtcccacac tggacccagc 4020 tctccccctg cagccaggct tcccgggccg cccctctttc ccctccctgg gcttttgctt 4080 ttactggttt gatttcactg gagcctgctg ggaacgtgac ctctgacccc tga 4133 12 1459 DNA Homo sapiens 12 caatgttaac ccactctatg tctctcctgc atgtaaaaaa ccactaatcc acatgtatga 60 aaaggagttc acttctgaga tctgctgtgg ttctttgtgg ggagtcaatt tgctgttggg 120 aacccgatct aatctatatc tgatggacag aagtggaaag gctgacatta ctaaacttat 180 aaggcgaaga ccattccgcc agattcaagt cttagagcca ctcaatttgc tgattaccat 240 ctcaggtcat aagaacagac ttcgggtgta tcatctgacc tggttgagga acaagatttt 300 gaataatgat ccagaaagta aaagaaggca agaagaaatg ctgaagacag aggaagcctg 360 caaagctatt gataagttaa caggctgtga acacttcagt gtcctccaac atgaagaaac 420 aacatatatt gcaattgctt tgaaatcatc aattcacctt tatgcatggg caccaaagtc 480 ctttgatgaa agcactgcta ttaaagtatt tccaacactt gatcataagc cagtgacagt 540 tgacctggct attggttctg aaaaaagact aaagattttc ttcagctcag cagatggata 600 tcacctcatc gatgcagaat ctgaggttat gtctgatgtg accctgccaa agaatcccct 660 ggaaatcatt ataccacaga atatcatcat tttacctgat tgcttgggaa ttggcatgat 720 gctcaccttc aatgctgaag ccctctctgt ggaagcaaat gaacaactct tcaagaagat 780 ccttgaaatg tggaaagaca taccatcttc tatagctttt gaatgtacac agcgaaccac 840 aggatggggc caaaaggcca ttgaagtgcg ctctttgcaa tccagggttc tggaaagtga 900 gctgaagcgc aggtcaatta agaagctgag attcctgtgc acccggggtg acaagctgtt 960 ctttacctct accctgcgca atcaccacag ccgggtttac ttcatgacac ttggaaaact 1020 tgaagagctc caaagcaatt atgatgtcta aaagtttcca gtgatttatt accacattat 1080 aaacatcatg tataggcagt ctgcatcttc agatttcaga gattaaatga gtattcagtt 1140 ttatttttag taaagattaa atccaaaact ttacttttaa tgtagcacag aatagtttta 1200 atgagaaatg cagctttatg tataaaatta actatagcaa gctctaggta ctccaatggt 1260 gtacaatgtc ttttgcacaa actttgtaac ttttgttact gtgaattcaa acattactct 1320 ttggacagtt tggacagtat ctgtattcag attttacaac atggagtaaa gaaacctgtt 1380 atgaattaga ttacaagcag ccttcaaaag aattggcact gggataagat ttttcagaaa 1440 agaaaaacat cggcaaact 1459 13 1239 PRT Homo sapiens 13 Met Ala Asn Asp Ser Pro Ala Lys Ser Leu Val Asp Ile Asp Leu Ser 1 5 10 15 Ser Leu Arg Asp Pro Ala Gly Ile Phe Glu Leu Val Glu Val Val Gly 20 25 30 Asn Gly Thr Tyr Gly Gln Val Tyr Lys Gly Arg His Val Lys Thr Gly 35 40 45 Gln Leu Ala Ala Ile Lys Val Met Asp Val Thr Glu Asp Glu Glu Glu 50 55 60 Glu Ile Lys Leu Glu Ile Asn Met Leu Lys Lys Tyr Ser His His Arg 65 70 75 80 Asn Ile Ala Thr Tyr Tyr Gly Ala Phe Ile Lys Lys Ser Pro Pro Gly 85 90 95 His Asp Asp Gln Leu Trp Leu Val Met Glu Phe Cys Gly Ala Gly Ser 100 105 110 Ile Thr Asp Leu Val Lys Asn Thr Lys Gly Asn Thr Leu Lys Glu Asp 115 120 125 Trp Ile Ala Tyr Ile Ser Arg Glu Ile Leu Arg Gly Leu Ala His Leu 130 135 140 His Ile His His Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu 145 150 155 160 Leu Thr Glu Asn Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala 165 170 175 Gln Leu Asp Arg Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro 180 185 190 Tyr Trp Met Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala 195 200 205 Thr Tyr Asp Tyr Arg Ser Asp Leu Trp Ser Cys Gly Ile Thr Ala Ile 210 215 220 Glu Met Ala Glu Gly Ala Pro Pro Leu Cys Asp Met His Pro Met Arg 225 230 235 240 Ala Leu Phe Leu Ile Pro Arg Asn Pro Pro Pro Arg Leu Lys Ser Lys 245 250 255 Lys Trp Ser Lys Lys Phe Phe Ser Phe Ile Glu Gly Cys Leu Val Lys 260 265 270 Asn Tyr Met Gln Arg Pro Ser Thr Glu Gln Leu Leu Lys His Pro Phe 275 280 285 Ile Arg Asp Gln Pro Asn Glu Arg Gln Val Arg Ile Gln Leu Lys Asp 290 295 300 His Ile Asp Arg Thr Arg Lys Lys Arg Gly Glu Lys Asp Glu Thr Glu 305 310 315 320 Tyr Glu Tyr Ser Gly Ser Glu Glu Glu Glu Glu Glu Val Pro Glu Gln 325 330 335 Glu Gly Glu Pro Ser Ser Ile Val Asn Val Pro Gly Glu Ser Thr Leu 340 345 350 Arg Arg Asp Phe Leu Arg Leu Gln Gln Glu Asn Lys Glu Arg Ser Glu 355 360 365 Ala Leu Arg Arg Gln Gln Leu Leu Gln Glu Gln Gln Leu Arg Glu Gln 370 375 380 Glu Glu Tyr Lys Arg Gln Leu Leu Ala Glu Arg Gln Lys Arg Ile Glu 385 390 395 400 Gln Gln Lys Glu Gln Arg Arg Arg Leu Glu Glu Gln Gln Arg Arg Glu 405 410 415 Arg Glu Ala Arg Arg Gln Gln Glu Arg Glu Gln Arg Arg Arg Glu Gln 420 425 430 Glu Glu Lys Arg Arg Leu Glu Glu Leu Glu Arg Arg Arg Lys Glu Glu 435 440 445 Glu Glu Arg Arg Arg Ala Glu Glu Glu Lys Arg Arg Val Glu Arg Glu 450 455 460 Gln Glu Tyr Ile Arg Arg Gln Leu Glu Glu Glu Gln Arg His Leu Glu 465 470 475 480 Val Leu Gln Gln Gln Leu Leu Gln Glu Gln Ala Met Leu Leu Glu Cys 485 490 495 Arg Trp Arg Glu Met Glu Glu His Arg Gln Ala Glu Arg Leu Gln Arg 500 505 510 Gln Leu Gln Gln Glu Gln Ala Tyr Leu Leu Ser Leu Gln His Asp His 515 520 525 Arg Arg Pro His Pro Gln His Ser Gln Gln Pro Pro Pro Pro Gln Gln 530 535 540 Glu Arg Ser Lys Pro Ser Phe His Ala Pro Glu Pro Lys Ala His Tyr 545 550 555 560 Glu Pro Ala Asp Arg Ala Arg Glu Val Glu Asp Arg Phe Arg Lys Thr 565 570 575 Asn His Ser Ser Pro Glu Ala Gln Ser Lys Gln Thr Gly Arg Val Leu 580 585 590 Glu Pro Pro Val Pro Ser Arg Ser Glu Ser Phe Ser Asn Gly Asn Ser 595 600 605 Glu Ser Val His Pro Ala Leu Gln Arg Pro Ala Glu Pro Gln Val Pro 610 615 620 Val Arg Thr Thr Ser Arg Ser Pro Val Leu Ser Arg Arg Asp Ser Pro 625 630 635 640 Leu Gln Gly Ser Gly Gln Gln Asn Ser Gln Ala Gly Gln Arg Asn Ser 645 650 655 Thr Ser Ile Glu Pro Arg Leu Leu Trp Glu Arg Val Glu Lys Leu Val 660 665 670 Pro Arg Pro Gly Ser Gly Ser Ser Ser Gly Ser Ser Asn Ser Gly Ser 675 680 685 Gln Pro Gly Ser His Pro Gly Ser Gln Ser Gly Ser Gly Glu Arg Phe 690 695 700 Arg Val Arg Ser Ser Ser Lys Ser Glu Gly Ser Pro Ser Gln Arg Leu 705 710 715 720 Glu Asn Ala Val Lys Lys Pro Glu Asp Lys Lys Glu Val Phe Arg Pro 725 730 735 Leu Lys Pro Ala Asp Leu Thr Ala Leu Ala Lys Glu Leu Arg Ala Val 740 745 750 Glu Asp Val Arg Pro Pro His Lys Val Thr Asp Tyr Ser Ser Ser Ser 755 760 765 Glu Glu Ser Gly Thr Thr Asp Glu Glu Asp Asp Asp Val Glu Gln Glu 770 775 780 Gly Ala Asp Glu Ser Thr Ser Gly Pro Glu Asp Thr Arg Ala Ala Ser 785 790 795 800 Ser Leu Asn Leu Ser Asn Gly Glu Thr Glu Ser Val Lys Thr Met Ile 805 810 815 Val His Asp Asp Val Glu Ser Glu Pro Ala Met Thr Pro Ser Lys Glu 820 825 830 Gly Thr Leu Ile Val Arg Arg Thr Gln Ser Ala Ser Ser Thr Leu Gln 835 840 845 Lys His Lys Ser Ser Ser Ser Phe Thr Pro Phe Ile Asp Pro Arg Leu 850 855 860 Leu Gln Ile Ser Pro Ser Ser Gly Thr Thr Val Thr Ser Val Val Gly 865 870 875 880 Phe Ser Cys Asp Gly Met Arg Pro Glu Ala Ile Arg Gln Asp Pro Thr 885 890 895 Arg Lys Gly Ser Val Val Asn Val Asn Pro Thr Asn Thr Arg Pro Gln 900 905 910 Ser Asp Thr Pro Glu Ile Arg Lys Tyr Lys Lys Arg Phe Asn Ser Glu 915 920 925 Ile Leu Cys Ala Ala Leu Trp Gly Val Asn Leu Leu Val Gly Thr Glu 930 935 940 Ser Gly Leu Met Leu Leu Asp Arg Ser Gly Gln Gly Lys Val Tyr Pro 945 950 955 960 Leu Ile Asn Arg Arg Arg Phe Gln Gln Met Asp Val Leu Glu Gly Leu 965 970 975 Asn Val Leu Val Thr Ile Ser Gly Lys Lys Asp Lys Leu Arg Val Tyr 980 985 990 Tyr Leu Ser Trp Leu Arg Asn Lys Ile Leu His Asn Asp Pro Glu Val 995 1000 1005 Glu Lys Lys Gln Gly Trp Thr Thr Val Gly Asp Leu Glu Gly Cys Val 1010 1015 1020 His Tyr Lys Val Val Lys Tyr Glu Arg Ile Lys Phe Leu Val Ile Ala 1025 1030 1035 1040 Leu Lys Ser Ser Val Glu Val Tyr Ala Trp Ala Pro Lys Pro Tyr His 1045 1050 1055 Lys Phe Met Ala Phe Lys Ser Phe Gly Glu Leu Val His Lys Pro Leu 1060 1065 1070 Leu Val Asp Leu Thr Val Glu Glu Gly Gln Arg Leu Lys Val Ile Tyr 1075 1080 1085 Gly Ser Cys Ala Gly Phe His Ala Val Asp Val Asp Ser Gly Ser Val 1090 1095 1100 Tyr Asp Ile Tyr Leu Pro Thr His Ile Gln Cys Ser Ile Lys Pro His 1105 1110 1115 1120 Ala Ile Ile Ile Leu Pro Asn Thr Asp Gly Met Glu Leu Leu Val Cys 1125 1130 1135 Tyr Glu Asp Glu Gly Val Tyr Val Asn Thr Tyr Gly Arg Ile Thr Lys 1140 1145 1150 Asp Val Val Leu Gln Trp Gly Glu Met Pro Thr Ser Val Ala Tyr Ile 1155 1160 1165 Arg Ser Asn Gln Thr Met Gly Trp Gly Glu Lys Ala Ile Glu Ile Arg 1170 1175 1180 Ser Val Glu Thr Gly His Leu Asp Gly Val Phe Met His Lys Arg Ala 1185 1190 1195 1200 Gln Arg Leu Lys Phe Leu Cys Glu Arg Asn Asp Lys Val Phe Phe Ala 1205 1210 1215 Ser Val Arg Ser Gly Gly Ser Ser Gln Val Tyr Phe Met Thr Leu Gly 1220 1225 1230 Arg Thr Ser Leu Leu Ser Trp 1235 14 1297 PRT Homo sapiens 14 Ala Phe Gly Glu Val Tyr Glu Gly Arg His Val Lys Thr Gly Gln Leu 1 5 10 15 Ala Ala Ile Lys Val Met Asp Val Thr Gly Asp Glu Glu Glu Glu Ile 20 25 30 Lys Gln Glu Ile Asn Met Leu Lys Lys Tyr Ser His His Arg Asn Ile 35 40 45 Ala Thr Tyr Tyr Gly Ala Phe Ile Lys Lys Asn Pro Pro Gly Met Asp 50 55 60 Asp Gln Leu Trp Leu Val Met Glu Phe Cys Gly Ala Gly Ser Val Thr 65 70 75 80 Asp Leu Ile Lys Asn Thr Lys Gly Asn Thr Leu Lys Glu Glu Trp Ile 85 90 95 Ala Tyr Ile Cys Arg Glu Ile Leu Arg Gly Leu Ser His Leu His Gln 100 105 110 His Lys Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr 115 120 125 Glu Asn Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Leu 130 135 140 Asp Arg Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp 145 150 155 160 Met Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala Thr Tyr 165 170 175 Asp Phe Lys Ser Asp Leu Trp Ser Leu Gly Ile Thr Ala Ile Glu Met 180 185 190 Ala Glu Gly Ala Pro Pro Leu Cys Asp Met His Pro Met Arg Ala Leu 195 200 205 Phe Leu Ile Pro Arg Asn Pro Ala Pro Arg Leu Lys Ser Lys Lys Trp 210 215 220 Ser Lys Lys Phe Gln Ser Phe Ile Glu Ser Cys Leu Val Lys Asn His 225 230 235 240 Ser Gln Arg Pro Ala Thr Glu Gln Leu Met Lys His Pro Phe Ile Arg 245 250 255 Asp Gln Pro Asn Glu Arg Gln Val Arg Ile Gln Leu Lys Asp His Ile 260 265 270 Asp Arg Thr Lys Lys Lys Arg Gly Glu Lys Asp Glu Thr Glu Tyr Glu 275 280 285 Tyr Ser Gly Ser Glu Glu Glu Glu Glu Glu Asn Asp Ser Gly Glu Pro 290 295 300 Ser Ser Ile Leu Asn Leu Pro Arg Glu Ser Thr Leu Arg Arg Asp Phe 305 310 315 320 Leu Arg Leu Gln Leu Ala Asn Lys Glu Arg Ser Glu Ala Leu Arg Arg 325 330 335 Gln Gln Leu Glu Gln Gln Gln Arg Glu Asn Glu Glu His Lys Arg Gln 340 345 350 Leu Leu Ala Glu Arg Gln Lys Arg Ile Glu Glu Gln Lys Glu Gln Arg 355 360 365 Arg Arg Leu Glu Glu Gln Gln Arg Arg Glu Lys Glu Leu Arg Lys Gln 370 375 380 Gln Glu Arg Glu Gln Arg Arg His Tyr Glu Glu Gln Met Arg Arg Glu 385 390 395 400 Glu Glu Arg Arg Arg Ala Glu His Glu Gln Glu Tyr Lys Arg Lys Gln 405 410 415 Leu Glu Glu Gln Arg Gln Ala Glu Arg Leu Gln Arg Gln Leu Lys Gln 420 425 430 Glu Arg Asp Tyr Leu Val Ser Leu Gln His Gln Arg Gln Glu Gln Arg 435 440 445 Pro Val Glu Lys Lys Pro Leu Tyr His Tyr Lys Glu Gly Met Ser Pro 450 455 460 Ser Glu Lys Pro Ala Trp Ala Lys Glu Val Glu Glu Arg Ser Arg Leu 465 470 475 480 Asn Arg Gln Ser Ser Pro Ala Met Pro His Lys Val Ala Asn Arg Ile 485 490 495 Ser Asp Pro Asn Leu Pro Pro Arg Ser Glu Ser Phe Ser Ile Ser Gly 500 505 510 Val Gln Pro Ala Arg Thr Pro Pro Met Leu Arg Pro Val Asp Pro Gln 515 520 525 Ile Pro His Leu Val Ala Val Lys Ser Gln Gly Pro Ala Leu Thr Ala 530 535 540 Ser Gln Ser Val His Glu Gln Pro Thr Lys Gly Leu Ser Gly Phe Gln 545 550 555 560 Glu Ala Leu Asn Val Thr Ser His Arg Val Glu Met Pro Arg Gln Asn 565 570 575 Ser Asp Pro Thr Ser Glu Asn Pro Pro Leu Pro Thr Arg Ile Glu Lys 580 585 590 Phe Asp Arg Ser Ser Trp Leu Arg Gln Glu Glu Asp Ile Pro Pro Lys 595 600 605 Val Pro Gln Arg Thr Thr Ser Ile Ser Pro Ala Leu Ala Arg Lys Asn 610 615 620 Ser Pro Gly Asn Gly Ser Ala Leu Gly Pro Arg Leu Gly Ser Gln Pro 625 630 635 640 Ile Arg Ala Ser Asn Pro Asp Leu Arg Arg Thr Glu Pro Ile Leu Glu 645 650 655 Ser Pro Leu Gln Arg Thr Ser Ser Gly Ser Ser Ser Ser Ser Ser Thr 660 665 670 Pro Ser Ser Gln Pro Ser Ser Gln Gly Gly Ser Gln Pro Gly Ser Gln 675 680 685 Ala Gly Ser Ser Glu Arg Thr Arg Val Arg Ala Asn Ser Lys Ser Glu 690 695 700 Gly Ser Pro Val Leu Pro His Glu Pro Ala Lys Val Lys Pro Glu Glu 705 710 715 720 Ser Arg Asp Ile Thr Arg Pro Ser Arg Pro Ala Ser Tyr Lys Lys Ala 725 730 735 Ile Asp Glu Asp Leu Thr Ala Leu Ala Lys Glu Leu Arg Glu Leu Arg 740 745 750 Ile Glu Glu Thr Asn Arg Pro Met Lys Lys Val Thr Asp Tyr Ser Ser 755 760 765 Ser Ser Glu Glu Ser Glu Ser Ser Glu Glu Glu Glu Glu Asp Gly Glu 770 775 780 Ser Glu Thr His Asp Gly Thr Val Ala Val Ser Asp Ile Pro Arg Leu 785 790 795 800 Ile Pro Thr Gly Ala Pro Gly Ser Asn Glu Gln Tyr Asn Val Gly Met 805 810 815 Val Gly Thr His Gly Leu Glu Thr Ser His Ala Asp Ser Phe Ser Gly 820 825 830 Ser Ile Ser Arg Glu Gly Thr Leu Met Ile Arg Glu Thr Ser Gly Glu 835 840 845 Lys Lys Arg Ser Gly His Ser Asp Ser Asn Gly Phe Ala Gly His Ile 850 855 860 Asn Leu Pro Asp Leu Val Gln Gln Ser His Ser Pro Ala Gly Thr Pro 865 870 875 880 Thr Glu Gly Leu Gly Arg Val Ser Thr His Ser Gln Glu Met Asp Ser 885 890 895 Gly Thr Glu Tyr Gly Met Gly Ser Ser Thr Lys Ala Ser Phe Thr Pro 900 905 910 Phe Val Asp Pro Arg Val Tyr Gln Thr Ser Pro Thr Asp Glu Asp Glu 915 920 925 Glu Asp Glu Glu Ser Ser Ala Ala Ala Leu Phe Thr Gly Glu Leu Leu 930 935 940 Arg Gln Glu Gln Ala Lys Leu Asn Glu Ala Arg Lys Ile Ser Val Val 945 950 955 960 Asn Val Asn Pro Thr Asn Ile Arg Pro His Ser Asp Thr Pro Glu Ile 965 970 975 Arg Lys Tyr Lys Lys Arg Phe Asn Ser Glu Ile Leu Cys Ala Ala Leu 980 985 990 Trp Gly Val Asn Leu Leu Val Gly Thr Glu Asn Gly Leu Met Leu Leu 995 1000 1005 Asp Arg Ser Gly Gln Gly Lys Val Tyr Asn Leu Ile Asn Arg Arg Arg 1010 1015 1020 Phe Gln Gln Met Asp Val Leu Glu Gly Leu Asn Val Leu Val Thr Ile 1025 1030 1035 1040 Ser Gly Lys Lys Asn Lys Leu Arg Val Tyr Tyr Leu Ser Trp Leu Arg 1045 1050 1055 Asn Arg Ile Leu His Asn Asp Pro Glu Val Glu Lys Lys Gln Gly Trp 1060 1065 1070 Ile Thr Val Gly Asp Leu Glu Gly Cys Ile His Tyr Lys Val Val Lys 1075 1080 1085 Tyr Glu Arg Ile Lys Phe Leu Val Ile Ala Leu Lys Asn Ala Val Glu 1090 1095 1100 Ile Tyr Ala Trp Ala Pro Lys Pro Tyr His Lys Phe Met Ala Phe Lys 1105 1110 1115 1120 Ser Phe Ala Asp Leu Gln His Lys Pro Leu Leu Val Asp Leu Thr Val 1125 1130 1135 Glu Glu Gly Gln Arg Leu Lys Val Ile Phe Gly Ser His Thr Gly Phe 1140 1145 1150 His Val Ile Asp Val Asp Ser Gly Asn Ser Tyr Asp Ile Tyr Thr Pro 1155 1160 1165 Ser His Ile Gln Gly Asn Ile Thr Pro His Ala Ile Val Ile Leu Pro 1170 1175 1180 Lys Thr Asp Gly Met Glu Met Leu Val Cys Tyr Glu Asp Glu Gly Val 1185 1190 1195 1200 Tyr Val Asn Thr Tyr Gly Arg Ile Thr Lys Asp Val Val Leu Gln Trp 1205 1210 1215 Gly Glu Met Pro Thr Ser Val Ala Tyr Ile His Ser Asn Gln Ile Met 1220 1225 1230 Gly Trp Gly Glu Lys Ala Ile Glu Ile Arg Ser Val Glu Thr Gly His 1235 1240 1245 Leu Asp Gly Val Phe Met His Lys Arg Ala Gln Arg Leu Lys Phe Leu 1250 1255 1260 Cys Glu Arg Asn Asp Lys Val Phe Phe Ala Ser Val Arg Ser Gly Gly 1265 1270 1275 1280 Ser Ser Gln Val Phe Phe Met Thr Leu Asn Arg Asn Ser Met Met Asn 1285 1290 1295 Trp 15 1326 PRT Homo sapiens 15 Ala Phe Gly Glu Val Tyr Glu Gly Arg His Val Lys Thr Gly Gln Leu 1 5 10 15 Ala Ala Ile Lys Val Met Asp Val Thr Glu Asp Glu Glu Glu Glu Ile 20 25 30 Lys Gln Glu Ile Asn Met Leu Lys Lys Tyr Ser His His Arg Asn Ile 35 40 45 Ala Thr Tyr Tyr Gly Ala Phe Ile Lys Lys Ser Pro Pro Gly Asn Asp 50 55 60 Asp Gln Leu Trp Leu Val Met Glu Phe Cys Gly Ala Gly Ser Val Thr 65 70 75 80 Asp Leu Val Lys Asn Thr Lys Gly Asn Ala Leu Lys Glu Asp Cys Ile 85 90 95 Ala Tyr Ile Cys Arg Glu Ile Leu Arg Gly Leu Ala His Leu His Ala 100 105 110 His Lys Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr 115 120 125 Glu Asn Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Leu 130 135 140 Asp Arg Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp 145 150 155 160 Met Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala Thr Tyr 165 170 175 Asp Tyr Arg Ser Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile Glu Met 180 185 190 Ala Glu Gly Ala Pro Pro Leu Cys Asp Met His Pro Met Arg Ala Leu 195 200 205 Phe Leu Ile Pro Arg Asn Pro Pro Pro Arg Leu Lys Ser Lys Lys Trp 210 215 220 Ser Lys Lys Phe Ile Asp Phe Ile Asp Thr Cys Leu Ile Lys Thr Tyr 225 230 235 240 Leu Ser Arg Pro Pro Thr Glu Gln Leu Leu Lys Phe Pro Phe Ile Arg 245 250 255 Asp Gln Pro Thr Glu Arg Gln Val Arg Ile Gln Leu Lys Asp His Ile 260 265 270 Asp Arg Ser Arg Lys Lys Arg Gly Glu Lys Glu Glu Thr Glu Tyr Glu 275 280 285 Tyr Ser Gly Ser Glu Glu Glu Asp Asp Ser His Gly Glu Glu Gly Glu 290 295 300 Pro Ser Ser Ile Met Asn Val Pro Gly Glu Ser Thr Leu Arg Arg Glu 305 310 315 320 Phe Leu Arg Leu Gln Gln Glu Asn Lys Ser Asn Ser Glu Ala Leu Lys 325 330 335 Gln Gln Gln Gln Leu Gln Gln Gln Gln Gln Arg Asp Pro Glu Ala His 340 345 350 Ile Lys His Leu Leu His Gln Arg Gln Arg Arg Ile Glu Glu Gln Lys 355 360 365 Glu Glu Arg Arg Arg Val Glu Glu Gln Gln Arg Arg Glu Arg Glu Gln 370 375 380 Arg Lys Leu Gln Glu Lys Glu Gln Gln Arg Arg Leu Glu Asp Met Gln 385 390 395 400 Ala Leu Arg Arg Glu Glu Glu Arg Arg Gln Ala Glu Arg Glu Gln Glu 405 410 415 Tyr Ile Arg His Arg Leu Glu Glu Glu Gln Arg Gln Leu Glu Ile Leu 420 425 430 Gln Gln Gln Leu Leu Gln Glu Gln Ala Leu Leu Leu Glu Tyr Lys Arg 435 440 445 Lys Gln Leu Glu Glu Gln Arg Gln Ser Glu Arg Leu Gln Arg Gln Leu 450 455 460 Gln Gln Glu His Ala Tyr Leu Lys Ser Leu Gln Gln Gln Gln Gln Gln 465 470 475 480 Gln Gln Leu Gln Lys Gln Gln Gln Gln Gln Leu Leu Pro Gly Asp Arg 485 490 495 Lys Pro Leu Tyr His Tyr Gly Arg Gly Met Asn Pro Ala Asp Lys Pro 500 505 510 Ala Trp Ala Arg Glu Val Glu Glu Arg Thr Arg Met Asn Lys Gln Gln 515 520 525 Asn Ser Pro Leu Ala Lys Ser Lys Pro Gly Ser Thr Gly Pro Glu Pro 530 535 540 Pro Ile Pro Gln Ala Ser Pro Gly Pro Pro Gly Pro Leu Ser Gln Thr 545 550 555 560 Pro Pro Met Gln Arg Pro Val Glu Pro Gln Glu Gly Pro His Lys Ser 565 570 575 Leu Val Ala His Arg Val Pro Leu Lys Pro Tyr Ala Ala Pro Val Pro 580 585 590 Arg Ser Gln Ser Leu Gln Asp Gln Pro Thr Arg Asn Leu Ala Ala Phe 595 600 605 Pro Ala Ser His Asp Pro Asp Pro Ala Ile Pro Ala Pro Thr Ala Thr 610 615 620 Pro Ser Ala Arg Gly Ala Val Ile Arg Gln Asn Ser Asp Pro Thr Ser 625 630 635 640 Glu Gly Pro Gly Pro Ser Pro Asn Pro Pro Ala Trp Val Arg Pro Asp 645 650 655 Asn Glu Ala Pro Pro Lys Val Pro Gln Arg Thr Ser Ser Ile Ala Thr 660 665 670 Ala Leu Asn Thr Ser Gly Ala Gly Gly Ser Arg Pro Ala Gln Ala Val 675 680 685 Arg Ala Arg Pro Arg Ser Asn Ser Ala Trp Gln Ile Tyr Leu Gln Arg 690 695 700 Arg Ala Glu Arg Gly Thr Pro Lys Pro Pro Gly Pro Pro Ala Gln Pro 705 710 715 720 Pro Gly Pro Pro Asn Ala Ser Ser Asn Pro Asp Leu Arg Arg Ser Asp 725 730 735 Pro Gly Trp Glu Arg Ser Asp Ser Val Leu Pro Ala Ser His Gly His 740 745 750 Leu Pro Gln Ala Gly Ser Leu Glu Arg Asn Arg Val Gly Val Ser Ser 755 760 765 Lys Pro Asp Ser Ser Pro Val Leu Ser Pro Gly Asn Lys Ala Lys Pro 770 775 780 Asp Asp His Arg Ser Arg Pro Gly Arg Pro Ala Asp Phe Val Leu Leu 785 790 795 800 Lys Glu Arg Thr Leu Asp Glu Ala Pro Arg Pro Pro Lys Lys Ala Met 805 810 815 Asp Tyr Ser Ser Ser Ser Glu Glu Val Glu Ser Ser Glu Asp Asp Glu 820 825 830 Glu Glu Gly Glu Gly Gly Pro Ala Glu Gly Ser Arg Asp Thr Pro Gly 835 840 845 Gly Arg Asp Gly Asp Thr Asp Ser Val Ser Thr Met Val Val His Asp 850 855 860 Val Glu Glu Ile Thr Gly Thr Gln Pro Pro Tyr Gly Gly Gly Thr Met 865 870 875 880 Val Val Gln Arg Thr Pro Glu Glu Glu Arg Asn Leu Leu His Ala Asp 885 890 895 Ser Asn Gly Tyr Thr Asn Leu Pro Asp Val Val Gln Pro Ser His Ser 900 905 910 Pro Thr Glu Asn Ser Lys Gly Gln Ser Pro Pro Ser Lys Asp Gly Ser 915 920 925 Gly Asp Tyr Gln Ser Arg Gly Leu Val Lys Ala Pro Gly Lys Ser Ser 930 935 940 Phe Thr Met Phe Val Asp Leu Gly Ile Tyr Gln Pro Gly Gly Ser Gly 945 950 955 960 Asp Ser Ile Pro Ile Thr Ala Leu Val Gly Gly Glu Gly Thr Arg Leu 965 970 975 Asp Gln Leu Gln Tyr Asp Val Arg Lys Gly Ser Val Val Asn Val Asn 980 985 990 Pro Thr Asn Thr Arg Ala His Ser Glu Thr Pro Glu Ile Arg Lys Tyr 995 1000 1005 Lys Lys Arg Phe Asn Ser Glu Ile Leu Cys Ala Ala Leu Trp Gly Val 1010 1015 1020 Asn Leu Leu Val Gly Thr Glu Asn Gly Leu Met Leu Leu Asp Arg Ser 1025 1030 1035 1040 Gly Gln Gly Lys Val Tyr Gly Leu Ile Gly Arg Arg Arg Phe Gln Gln 1045 1050 1055 Met Asp Val Leu Glu Gly Leu Asn Leu Leu Ile Thr Ile Ser Gly Lys 1060 1065 1070 Arg Asn Lys Leu Arg Val Tyr Tyr Leu Ser Trp Leu Arg Asn Lys Ile 1075 1080 1085 Leu His Asn Asp Pro Glu Val Glu Lys Lys Gln Gly Trp Thr Thr Val 1090 1095 1100 Gly Asp Met Glu Gly Cys Gly His Tyr Arg Val Val Lys Tyr Glu Arg 1105 1110 1115 1120 Ile Lys Phe Leu Val Ile Ala Leu Lys Ser Ser Val Glu Val Tyr Ala 1125 1130 1135 Trp Ala Pro Lys Pro Tyr His Lys Phe Met Ala Phe Lys Ser Phe Ala 1140 1145 1150 Asp Leu Pro His Arg Pro Leu Leu Val Asp Leu Thr Val Glu Glu Gly 1155 1160 1165 Gln Arg Leu Lys Val Ile Tyr Gly Ser Ser Ala Gly Phe His Ala Val 1170 1175 1180 Asp Val Asp Ser Gly Asn Ser Tyr Asp Ile Tyr Ile Pro Val His Ile 1185 1190 1195 1200 Gln Ser Gln Ile Thr Pro His Ala Ile Ile Phe Leu Pro Asn Thr Asp 1205 1210 1215 Gly Met Glu Met Leu Leu Cys Tyr Glu Asp Glu Gly Val Tyr Val Asn 1220 1225 1230 Thr Tyr Gly Arg Ile Ile Lys Asp Val Val Leu Gln Trp Gly Glu Met 1235 1240 1245 Pro Thr Ser Val Ala Tyr Ile Cys Ser Asn Gln Ile Met Gly Trp Gly 1250 1255 1260 Glu Lys Ala Ile Glu Ile Arg Ser Val Glu Thr Gly His Leu Asp Gly 1265 1270 1275 1280 Val Phe Met His Lys Arg Ala Gln Arg Leu Lys Phe Leu Cys Glu Arg 1285 1290 1295 Asn Asp Lys Val Phe Phe Ala Ser Val Arg Ser Gly Gly Ser Ser Gln 1300 1305 1310 Val Tyr Phe Met Thr Leu Asn Arg Asn Arg Ile Met Asn Trp 1315 1320 1325 16 349 PRT Homo sapiens 16 Asn Val Asn Pro Leu Tyr Val Ser Pro Ala Cys Lys Lys Pro Leu Ile 1 5 10 15 His Met Tyr Glu Lys Glu Phe Thr Ser Glu Ile Cys Cys Gly Ser Leu 20 25 30 Trp Gly Val Asn Leu Leu Leu Gly Thr Arg Ser Asn Leu Tyr Leu Met 35 40 45 Asp Arg Ser Gly Lys Ala Asp Ile Thr Lys Leu Ile Arg Arg Arg Pro 50 55 60 Phe Arg Gln Ile Gln Val Leu Glu Pro Leu Asn Leu Leu Ile Thr Ile 65 70 75 80 Ser Gly His Lys Asn Arg Leu Arg Val Tyr His Leu Thr Trp Leu Arg 85 90 95 Asn Lys Ile Leu Asn Asn Asp Pro Glu Ser Lys Arg Arg Gln Glu Glu 100 105 110 Met Leu Lys Thr Glu Glu Ala Cys Lys Ala Ile Asp Lys Leu Thr Gly 115 120 125 Cys Glu His Phe Ser Val Leu Gln His Glu Glu Thr Thr Tyr Ile Ala 130 135 140 Ile Ala Leu Lys Ser Ser Ile His Leu Tyr Ala Trp Ala Pro Lys Ser 145 150 155 160 Phe Asp Glu Ser Thr Ala Ile Lys Val Phe Pro Thr Leu Asp His Lys 165 170 175 Pro Val Thr Val Asp Leu Ala Ile Gly Ser Glu Lys Arg Leu Lys Ile 180 185 190 Phe Phe Ser Ser Ala Asp Gly Tyr His Leu Ile Asp Ala Glu Ser Glu 195 200 205 Val Met Ser Asp Val Thr Leu Pro Lys Asn Pro Leu Glu Ile Ile Ile 210 215 220 Pro Gln Asn Ile Ile Ile Leu Pro Asp Cys Leu Gly Ile Gly Met Met 225 230 235 240 Leu Thr Phe Asn Ala Glu Ala Leu Ser Val Glu Ala Asn Glu Gln Leu 245 250 255 Phe Lys Lys Ile Leu Glu Met Trp Lys Asp Ile Pro Ser Ser Ile Ala 260 265 270 Phe Glu Cys Thr Gln Arg Thr Thr Gly Trp Gly Gln Lys Ala Ile Glu 275 280 285 Val Arg Ser Leu Gln Ser Arg Val Leu Glu Ser Glu Leu Lys Arg Arg 290 295 300 Ser Ile Lys Lys Leu Arg Phe Leu Cys Thr Arg Gly Asp Lys Leu Phe 305 310 315 320 Phe Thr Ser Thr Leu Arg Asn His His Ser Arg Val Tyr Phe Met Thr 325 330 335 Leu Gly Lys Leu Glu Glu Leu Gln Ser Asn Tyr Asp Val 340 345 17 4023 DNA Homo sapiens 17 ccgccatgaa ccccggcttc gatttgtccc gccggaaccc gcaggaggac ttcgagctga 60 ttcagcgcat cggcagcggc acctacggcg acgtctacaa ggcacggaat gttaacactg 120 gtgaattagc agcaattaaa gtaataaaat tggaaccagg agaagacttt gcagttgtgc 180 agcaagaaat tattatgatg aaagactgta aacacccaaa tattgttgct tattttggaa 240 gctatctcag gcgagataag ctttggattt gcatggagtt ttgtggaggt ggttctttac 300 aggatattta tcacgtaact ggacctctgt cagaactgca aattgcatat gttagcagag 360 aaacactgca gggattatat tatcttcaca gtaaaggaaa aatgcacaga gatataaagg 420 gagctaacat tctattaacg gataatggtc atgtgaaatt ggctgatttt ggagtatctg 480 cacagataac agctacaatt gccaaacgga agtctttcat tggcacacca tattggatgg 540 ctccagaagt tgcagctgtt gagaggaagg ggggttacaa tcaactctgt gatctctggg 600 cagtgggaat cactgccata gaacttgcag agcttcagcc tcctatgttt gacttacacc 660 caatgagagc attatttcta atgacaaaaa gcaattttca gcctcctaaa ctaaaggata 720 aaatgaaatg gtcaaatagt tttcatcact ttgtgaaaat ggcacttacc aaaaatccga 780 aaaaaagacc tactgctgaa aaattattac agcatccttt tgtaacacaa catttgacac 840 ggtctttggc aatcgagctg ttggataaag taaataatcc agatcattcc acttaccatg 900 atttcgatga tgatgatcct gagcctcttg ttgctgtacc acatagaatt cactcaacaa 960 gtagaaacgt gagagaagaa aaaacacgct cagagataac ctttggccaa gtgaaatttg 1020 atccaccctt aagaaaggag acagaaccac atcatgaact tcccgacagt gatggttttt 1080 tggacagttc agaagaaata tactacactg caagatctaa tctggatctg caactggaat 1140 atggacaagg acaccaaggt ggttactttt taggtgcaaa caagagtctt ctcaagtctg 1200 ttgaagaaga attgcatcag cgaggacacg tcgcacattt agaagatgat gaaggagatg 1260 atgatgaatc taaacactca actctgaaag caaaaattcc acctcctttg ccaccaaagc 1320 ctaagtctat cttcatacca caggaaatgc attctactga ggatgaaaat caaggaacaa 1380 tcaagagatg tcccatgtca gggagcccag caaagccatc ccaagttcca cctagaccac 1440 cacctcccag attaccccca cacaaacctg ttgccttagg aaatggaatg agctccttcc 1500 agttaaatgg tgaacgagat ggctcattat gtcaacaaca gaatgaacat agaggcacaa 1560 acctttcaag aaaagaaaag aaagatgtac caaagcctat tagtaatggt cttcctccaa 1620 cacctaaagt gcatatgggt gcatgttttt caaaagtttt taatgggtgt cccttgaaaa 1680 ttcactgtgc atcatcatgg ataaacccag atacaagaga tcagtacttg atatttggtg 1740 ccgaagaagg gatttatacc ctcaatctta atgaacttca tgaaacatca atggaacagc 1800 tattccctcg aaggtgtaca tggttgtatg taatgaacaa ttgcttgcta tcaatatctg 1860 gtaaagcttc tcagctttat tcccataatt taccagggct ttttgattat gcaagacaaa 1920 tgcaaaagtt acctgttgct attccagcac acaaactccc tgacagaata ctgccaagga 1980 aattttctgt atcagcaaaa atccctgaaa ccaaatggtg ccagaagtgt tgtgttgtaa 2040 gaaatcctta cacgggccat aaatacctat gtggagcact tcagactagc attgttctat 2100 tagaatgggt tgaaccaatg cagaaattta tgttaattaa gcacatagat tttcctatac 2160 catgtccact tagaatgttt gaaatgctgg tagttcctga acaggagtac cctttagttt 2220 gtgttggtgt cagtagaggt agagacttca accaagtggt tcgatttgag acggtcaatc 2280 caaattctac ctcttcatgg tttacagaat cagatacccc acagacaaat gttactcatg 2340 taacccaact ggagagagat accatccttg tatgcttgga ctgttgtata aaaatagtaa 2400 atctccaagg aagattaaaa tctagcagga aattgtcatc agaactcacc tttgatttcc 2460 agattgaatc aatagtgtgc ctacaagaca gtgtgctagc tttctggaaa catggaatgc 2520 aaggtagaag ttttagatct aatgaggtaa cacaagaaat ttcagatagc acaagaattt 2580 tcaggctgct tggatctgac agggtcgtgg ttttggaaag taggccaact gataacccca 2640 cagcaaatag caatttgtac atcctggcgg gtcatgaaaa cagttactga gaattgttgt 2700 gctttgacag ttaactctag aaagaaagaa cactaccact gcaacattaa tggatgcttg 2760 aagctgtaca aaagctgcag taacctgtct tcagttactt tgtaatttat tgtggcatga 2820 gataagatgg ggaaaatttt gttttaagtg gtatggatat atttagcata ttgaaccaca 2880 caagtgctta attcattgtt atgtaatctt tgtacatata ggcagtattt tttctgtgaa 2940 acttcatatt gctgaagaca tacactaaga atttatgtag ataatgtact tttatgagat 3000 gtacaagtaa gtgtcttatc tgtacagatg taaatgttga tgaaaatgca attggggtta 3060 atattttaag aattctttag tatattcttg ggtgtggcta tattacaaaa tgggatgctg 3120 gcaatgaaac aatacattta acactattgt atttttatta tatgtaattt agtaatatga 3180 atataaatct tgtaactttt aaaattgtaa tggaggctgt aatcatttta taatcttttt 3240 aattttaatg caagtacact ggtgtttata tttgcacaaa gtattgatat gtgatgtatt 3300 aagtcacaaa agtaagctgt gacattgtct ataagcattt ggctccacaa atgtatttgg 3360 attgttttct atgtgaagca aaccaattat aattaaccac atgttgtagt aactggtctt 3420 tttatattta agcagaatcc tgtaagattg cttgtctttg cttaaaaaca atacctttga 3480 acatttttga atcacagaat agcggtacca tgatagaata ctgcaattgt ggtcagaatt 3540 acagtatgca caaagaatta attagcatta ttaaagagtc ctcactaaac atttcatatg 3600 atcacactga agaactgtaa cattccatag agtgaagtgg ttcaaatttc tcttggaatt 3660 tttacttttg ttggccttat tttatgatcc ttttcatatt tcttttgact tagagtatta 3720 atacatggcc aaaataattt agttactacc tcatacaaac aatataatgg ttactacaca 3780 tcacaggaac ttagttttgg tttaagtcat ttttgattgc ttttttccaa tggaatatgt 3840 atataccagg ttttagcaaa atgcacactt ttggctcttt ttggtatatg ttctttatat 3900 tttaatgtga gtatatacac taagaacaaa ctaaattgtg atttatgatc ttcatttatt 3960 ttaatgataa tggttttaaa atatgttcct gattgtacat attgtaaaat aaacatgttt 4020 ttt 4023 18 894 PRT Homo sapiens 18 Met Asn Pro Gly Phe Asp Leu Ser Arg Arg Asn Pro Gln Glu Asp Phe 1 5 10 15 Glu Leu Ile Gln Arg Ile Gly Ser Gly Thr Tyr Gly Asp Val Tyr Lys 20 25 30 Ala Arg Asn Val Asn Thr Gly Glu Leu Ala Ala Ile Lys Val Ile Lys 35 40 45 Leu Glu Pro Gly Glu Asp Phe Ala Val Val Gln Gln Glu Ile Ile Met 50 55 60 Met Lys Asp Cys Lys His Pro Asn Ile Val Ala Tyr Phe Gly Ser Tyr 65 70 75 80 Leu Arg Arg Asp Lys Leu Trp Ile Cys Met Glu Phe Cys Gly Gly Gly 85 90 95 Ser Leu Gln Asp Ile Tyr His Val Thr Gly Pro Leu Ser Glu Leu Gln 100 105 110 Ile Ala Tyr Val Ser Arg Glu Thr Leu Gln Gly Leu Tyr Tyr Leu His 115 120 125 Ser Lys Gly Lys Met His Arg Asp Ile Lys Gly Ala Asn Ile Leu Leu 130 135 140 Thr Asp Asn Gly His Val Lys Leu Ala Asp Phe Gly Val Ser Ala Gln 145 150 155 160 Ile Thr Ala Thr Ile Ala Lys Arg Lys Ser Phe Ile Gly Thr Pro Tyr 165 170 175 Trp Met Ala Pro Glu Val Ala Ala Val Glu Arg Lys Gly Gly Tyr Asn 180 185 190 Gln Leu Cys Asp Leu Trp Ala Val Gly Ile Thr Ala Ile Glu Leu Ala 195 200 205 Glu Leu Gln Pro Pro Met Phe Asp Leu His Pro Met Arg Ala Leu Phe 210 215 220 Leu Met Thr Lys Ser Asn Phe Gln Pro Pro Lys Leu Lys Asp Lys Met 225 230 235 240 Lys Trp Ser Asn Ser Phe His His Phe Val Lys Met Ala Leu Thr Lys 245 250 255 Asn Pro Lys Lys Arg Pro Thr Ala Glu Lys Leu Leu Gln His Pro Phe 260 265 270 Val Thr Gln His Leu Thr Arg Ser Leu Ala Ile Glu Leu Leu Asp Lys 275 280 285 Val Asn Asn Pro Asp His Ser Thr Tyr His Asp Phe Asp Asp Asp Asp 290 295 300 Pro Glu Pro Leu Val Ala Val Pro His Arg Ile His Ser Thr Ser Arg 305 310 315 320 Asn Val Arg Glu Glu Lys Thr Arg Ser Glu Ile Thr Phe Gly Gln Val 325 330 335 Lys Phe Asp Pro Pro Leu Arg Lys Glu Thr Glu Pro His His Glu Leu 340 345 350 Pro Asp Ser Asp Gly Phe Leu Asp Ser Ser Glu Glu Ile Tyr Tyr Thr 355 360 365 Ala Arg Ser Asn Leu Asp Leu Gln Leu Glu Tyr Gly Gln Gly His Gln 370 375 380 Gly Gly Tyr Phe Leu Gly Ala Asn Lys Ser Leu Leu Lys Ser Val Glu 385 390 395 400 Glu Glu Leu His Gln Arg Gly His Val Ala His Leu Glu Asp Asp Glu 405 410 415 Gly Asp Asp Asp Glu Ser Lys His Ser Thr Leu Lys Ala Lys Ile Pro 420 425 430 Pro Pro Leu Pro Pro Lys Pro Lys Ser Ile Phe Ile Pro Gln Glu Met 435 440 445 His Ser Thr Glu Asp Glu Asn Gln Gly Thr Ile Lys Arg Cys Pro Met 450 455 460 Ser Gly Ser Pro Ala Lys Pro Ser Gln Val Pro Pro Arg Pro Pro Pro 465 470 475 480 Pro Arg Leu Pro Pro His Lys Pro Val Ala Leu Gly Asn Gly Met Ser 485 490 495 Ser Phe Gln Leu Asn Gly Glu Arg Asp Gly Ser Leu Cys Gln Gln Gln 500 505 510 Asn Glu His Arg Gly Thr Asn Leu Ser Arg Lys Glu Lys Lys Asp Val 515 520 525 Pro Lys Pro Ile Ser Asn Gly Leu Pro Pro Thr Pro Lys Val His Met 530 535 540 Gly Ala Cys Phe Ser Lys Val Phe Asn Gly Cys Pro Leu Lys Ile His 545 550 555 560 Cys Ala Ser Ser Trp Ile Asn Pro Asp Thr Arg Asp Gln Tyr Leu Ile 565 570 575 Phe Gly Ala Glu Glu Gly Ile Tyr Thr Leu Asn Leu Asn Glu Leu His 580 585 590 Glu Thr Ser Met Glu Gln Leu Phe Pro Arg Arg Cys Thr Trp Leu Tyr 595 600 605 Val Met Asn Asn Cys Leu Leu Ser Ile Ser Gly Lys Ala Ser Gln Leu 610 615 620 Tyr Ser His Asn Leu Pro Gly Leu Phe Asp Tyr Ala Arg Gln Met Gln 625 630 635 640 Lys Leu Pro Val Ala Ile Pro Ala His Lys Leu Pro Asp Arg Ile Leu 645 650 655 Pro Arg Lys Phe Ser Val Ser Ala Lys Ile Pro Glu Thr Lys Trp Cys 660 665 670 Gln Lys Cys Cys Val Val Arg Asn Pro Tyr Thr Gly His Lys Tyr Leu 675 680 685 Cys Gly Ala Leu Gln Thr Ser Ile Val Leu Leu Glu Trp Val Glu Pro 690 695 700 Met Gln Lys Phe Met Leu Ile Lys His Ile Asp Phe Pro Ile Pro Cys 705 710 715 720 Pro Leu Arg Met Phe Glu Met Leu Val Val Pro Glu Gln Glu Tyr Pro 725 730 735 Leu Val Cys Val Gly Val Ser Arg Gly Arg Asp Phe Asn Gln Val Val 740 745 750 Arg Phe Glu Thr Val Asn Pro Asn Ser Thr Ser Ser Trp Phe Thr Glu 755 760 765 Ser Asp Thr Pro Gln Thr Asn Val Thr His Val Thr Gln Leu Glu Arg 770 775 780 Asp Thr Ile Leu Val Cys Leu Asp Cys Cys Ile Lys Ile Val Asn Leu 785 790 795 800 Gln Gly Arg Leu Lys Ser Ser Arg Lys Leu Ser Ser Glu Leu Thr Phe 805 810 815 Asp Phe Gln Ile Glu Ser Ile Val Cys Leu Gln Asp Ser Val Leu Ala 820 825 830 Phe Trp Lys His Gly Met Gln Gly Arg Ser Phe Arg Ser Asn Glu Val 835 840 845 Thr Gln Glu Ile Ser Asp Ser Thr Arg Ile Phe Arg Leu Leu Gly Ser 850 855 860 Asp Arg Val Val Val Leu Glu Ser Arg Pro Thr Asp Asn Pro Thr Ala 865 870 875 880 Asn Ser Asn Leu Tyr Ile Leu Ala Gly His Glu Asn Ser Tyr 885 890 19 4196 DNA Homo sapiens 19 gggagggtcc ttgtggcgcc gggcggcggg gtcctgcgtg gagagtggga cgcaacgccg 60 agaccgcgag cagaggctgc gcacagccgg atccggcact cagcgaccgg acccaaggat 120 ccgccgggga acaagccaca ggagagcgac tcaggaacaa gtgtgggaga ggaagcggcg 180 gcggcggcgc cgggcccggg ggtggtgaca gcaggtctga ggttgcatca taaatacaaa 240 ggactgaagt tataaaagag aaaagagaag tttgctgcta aaatgaatct gagcaatatg 300 gaatattttg tgccacacac aaaaaggtac tgaagattta ccccccaaaa aaaattgtca 360 atgagaaata aagctaactg atatcaaaaa gcagagcctg ctctactggc catcatgcgt 420 aaaggggtgc tgaaggaccc agagattgac gatctattct acaaagatga tcctgaggaa 480 ctttttattg gtttgcatga aattggacat ggaagttttg gagcagttta ttttgctaca 540 aatgctcaca ccaatgaggt ggtggcaatt aagaagatgt cctatagtgg gaagcagacc 600 catgagaaat ggcaagatat tcttaaggaa gttaaatttt tacgacaatt gaagcatcct 660 aatactattg agtacaaagg ctgttacttg aaagaacaca ctgcttggtt ggtgatggaa 720 tattgcttag gctcagcctc tgatttatta gaagttcata aaaaaccact tcaggaagtg 780 gagatcgctg ccattactca tggagccttg catggactag cctacctaca ttctcatgca 840 ttgattcata gggatattaa agcaggaaat attcttctaa cagagccagg tcaggtaaaa 900 ctagctgatt ttggatctgc ttcaatggct tctcctgcca actccttcgt gggcacacct 960 tactggatgg ctccagaggt gatcttagct atggatgaag gacagtatga tgggaaagtt 1020 gatatttggt cacttggcat cacttgtatt gaattggcgg aacggaagcc gccccttttc 1080 aacatgaatg caatgagtgc cttatatcac attgcccaga atgactcccc aacgttacag 1140 tctaatgaat ggacagactc ctttaggaga tttgttgatt actgcttgca gaaaatacct 1200 caggaaaggc caacatcagc agaactatta aggcatgact ttgttcgacg agaccggcca 1260 ctacgtgtcc tcattgacct catacagagg acaaaagatg cagttcgtga gctagataac 1320 ctacagtacc gaaaaatgaa aaaaatactt ttccaagaga cacggaatgg acccttgaat 1380 gagtcacagg aggatgagga agacagtgaa catggaacca gcctgaacag ggaaatggac 1440 agcctgggca gcaaccattc cattccaagc atgtccgtga gcacaggcag ccagagcagc 1500 agtgtgaaca gcatgcagga agtcatggac gagagcagtt ccgaacttgt catgatgcac 1560 gatgacgaaa gcacaatcaa ttccagctcc tccgtcgtgc ataagaaaga tcatgtattc 1620 acaagggatg aggcgggcca cggcgatccc aggcctgagc cgcggcctac ccagtcagtt 1680 cagagccagg ccctccacta ccggaacaga gagcgctttg ccacgatcaa atcagcatct 1740 ttggttacac gacagatcca tgagcatgag caggagaacg agttgcggga acagatgtca 1800 ggttataagc ggatgcggcg ccagcaccag aagcagctga tcgccctgga gaacaagctg 1860 aaggctgaga tggacgagca ccgcctcaag ctacagaagg aggtggagac gcatgccaac 1920 aactcgtcca tcgagctgga gaagctggcc aagaagcaag tggctatcat agaaaaggag 1980 gcaaaggtag ctgcagcaga tgagaagaag ttccagcaac agatcttggc ccagcagaag 2040 aaagatttga caactttctt agaaagtcag aagaagcagt ataagatttg taaggaaaaa 2100 ataaaagagg aaatgaatga ggaccatagc acacccaaga aagagaagca agagcggatc 2160 tccaaacata aagagaactt gcagcacaca caggctgaag aggaagccca ccttctcact 2220 caacagagac tgtactacga caaaaattgt cgtttcttca agcggaaaat aatgatcaag 2280 cggcacgagg tggagcagca gaacattcgg gaggaactaa ataaaaagag gacccagaag 2340 gagatggagc atgccatgct aatccggcac gacgagtcca cccgagagct agagtacagg 2400 cagctgcaca cgttacagaa gctacgcatg gatctgatcc gtttacagca ccagacggaa 2460 ctggaaaacc agctggagta caataagagg cgagaaagag aactgcacag aaagcatgtc 2520 atgggacttc ggcaacagcc aaaaaactta aaggccatgg aaatgcaaat taaaaaacag 2580 tttcaggaca cttgcaaagt acagaccaaa cagtataaag cactcaagaa tcaccagttg 2640 gaagttactc caaagaatga gcacaaaaca atcttaaaga cactgaaaga tgagcagaca 2700 agaaaacttg ccattttggc agagcagtat gaacagagta taaatgaaat gatggcctct 2760 caagcgttac ggctagatga ggctcaagaa gcagaatgcc aggccttgag gctacagctc 2820 cagcaggaaa tggagctgct caacgcctac cagagcaaaa tcaagatgca aacagaggca 2880 caacatgaac gtgagctcca gaagctagag cagagagtgt ctctgcgcag agcacacctt 2940 gagcagaaga ttgaagagga gctggctgcc cttcagaagg aacgcagcga gagaataaag 3000 aacctattgg aaaggcaaga gcgagagatt gaaacttttg acatggagag cctcagaatg 3060 ggatttggga atttggttac attagatttt cctaaggagg actacagatg agattaaatt 3120 ttttgccatt tacaaaaaaa aaaaaaaaaa agaaaacaga aaaaaattca gaccctgcaa 3180 aaccacattc cccattttaa cgggcgttgc tctcactctc tctctctctt actcttactg 3240 acatcgtgtc ggactagtgc ctgtttattc ttactccatc aggggccccc ttcctccccc 3300 cgtgtcaact ttcagtgctg gccaaaacct ggccgtctct tctattcaca gtacacgtca 3360 cagtattgat gtgattcaaa atgtttcagt gaaaactttg gagacagttt taacaaaacc 3420 aataaaccaa caacaaaaaa agtggatgta tattgcttta agcaatcact cattaccacc 3480 aatctgtgaa agtaaagcaa aaaataataa taataaatgc caagggggag agagacacaa 3540 tatccgcagc cttacacctt aactagctgc tgcattattt tattttattt tatttttttg 3600 gtatttattc atcaggaata aaaaaaacaa agttttatta aagattgaaa atttgataca 3660 ttttacagaa actaattgtg atgtacatat cagtggtgac atattattac ttttttgggg 3720 acggggggtg ggtggggtga agagatcttg tgatttttaa gaacctgctg gcaagagttt 3780 aacttgtctt cagcatattc tgattgtatc ataatcattt tctgctgttg cagaggatgt 3840 gaatacactt aaggagctca cagaatccca gtagcacaaa ttgggctttg gcaaatcgtg 3900 tattttgtgt atagaaggaa tttaaggaga ggtattactt attttcatat tgtattttaa 3960 ctgtttctct gatcaaattt ttttacttcc tcctcctgtt cctccccacc tccctccttt 4020 tccagttcag tatttggagt tcaacactgt ctctcaatca gatcatcttg atctttttct 4080 ttatctccct tccccttcct aagtcccatt tcttggtcat aaatattgca ttattcacac 4140 tttcaaactg tgtattttct tacaataaaa aatgatgaaa aaaaaaaaaa aaaaaa 4196 20 3824 DNA Homo sapiens 20 tattgaattg gcggaacgga agcctccttt atttaatatg aatgcaatga gtgccttata 60 tcacatagcc caaaatgaat cccctacact acagtctaat gaatggtctg attattttcg 120 caactttgta gattcttgcc tccagaaaat ccctcaagat cgacctacat cagaggaact 180 tttaaagcac atatttgttc ttcgggagcg ccctgaaacc gtgttaatag atctcattca 240 gaggacaaag gatgcagtaa gagagctgga caatctgcag tatcgaaaga tgaagaaact 300 ccttttccag gaggcacata atggaccagc agtagaagca caggaagaag aagaggaaca 360 agatcatggt gttggccgga caggaacagt taatagtgtt ggaagtaatc aatccattcc 420 cagcatgtcc atcagtgcca gcagccaaag cagtagtgtt aacagtcttc cagatgtctc 480 agatgacaag agtgagctag acatgatgga gggagaccac acagtgatgt ctaacagttc 540 tgttatccat ttaaaaccag aggaagaaaa ttacagagaa gagggagatc ctagaacaag 600 agcatcagat ccacaatctc caccccaagt atctcgtcac aaatcacact atcgtaatcg 660 agaacacttt gctactatac ggacagcatc actggttacg aggcaaatgc aagaacatga 720 gcaggactct gagcttagag aacaaatgtc tggctataag cgaatgaggc gacaacatca 780 aaagcaactg atgactctgg aaaacaagct aaaggctgag atggatgaac atcgcctcag 840 attagacaaa gatcttgaaa ctcagcgtaa caattttgct gcagaaatgg agaaacttat 900 caagaaacac caggctgcca tggagaaaga ggctaaagtg atgtccaatg aagagaaaaa 960 atttcagcaa catattcagg cccaacagaa gaaagaactg aatagttttc tcgagtccca 1020 gaaaagagag tataaacttc gaaaagagca gcttaaagag gagctaaatg aaaaccagag 1080 tacccccaaa aaagaaaaac aggagtggct ttcaaagcag aaggagaata tacagcattt 1140 ccaagcagaa gaagaagcta accttcttcg acgtcaaaga caatacctag agctggaatg 1200 ccgtcgcttc aagagaagaa tgttacttgg gcgtcataac ttagagcagg accttgtcag 1260 ggaggagtta aacaaaagac agactcagaa ggacttagag catgccatgc tactccgaca 1320 gcatgaatct atgcaagaac tggagttccg ccacctcaac acaattcaga agatgcgctg 1380 tgagttgatc agattacagc atcaaactga gctcactaac cagctggaat ataataagcg 1440 aagagaacga gaactaagac gaaagcatgt catggaagtt cgacaacagc ctaagagttt 1500 gaagtctaaa gaactccaaa taaaaaagca gtttcaggat acctgcaaaa tccaaaccag 1560 acagtacaaa gcattaagaa atcacctgct ggagactaca ccaaagagtg agcacaaagc 1620 tgttctgaaa cggctcaagg aggaacagac ccggaaatta gctatcttgg ctgagcagta 1680 tgatcacagc attaatgaaa tgctctccac acaagccctg cgtttggatg aagcacagga 1740 agcagagtgc caggttttga agatgcagct gcagcaggaa ctggagctgt tgaatgcgta 1800 tcagagcaaa atcaagatgc aagctgaggc acaacatgat cgagagcttc gcgagcttga 1860 acagagggtc tccctccgga gggcactctt agaacaaaag attgaagaag agatgttggc 1920 tttgcagaat gagcgcacag aacgaatacg aagcctgttg gaacgtcaag ccagagagat 1980 tgaagctttt gactctgaaa gcatgagact aggttttagt aatatggtcc tttctaatct 2040 ctcccctgag gcattcagcc acagctaccc gggagcttct ggttggtcac acaaccctac 2100 tgggggtcca ggacctcact ggggtcatcc catgggtggc ccaccacaag cttggggcca 2160 tccaatgcaa ggtggacccc agccatgggg tcacccttca gggccaatgc aaggggtacc 2220 tcgaggtagc agtatgggag tccgcaatag cccccaggct ctgaggcgga cagcttctgg 2280 gggacggacg gagcagggca tgagcagaag cacgagtgtc acttcacaaa tatccaatgg 2340 gtcacacatg tcttatacat aacttaataa ttgagagtgg caattccgct ggagctgtct 2400 gccaaaagaa actgcctaca gacatcatca cagcagcctc ctcacttggg tactacagtg 2460 tggaagctga gtgcatatgg tatattttat tcatttttgt aaagcgttct gttttgtgtt 2520 tactaattgg gatgtcatag tacttggctg ccgggtttgt ttgtttttgg ggaaattttg 2580 aaaagtggag ttgatattaa aaataaatgt gtatgtgtgt acatatatat acacacacat 2640 acacatatat tatgcatgtg gtgaaaagaa ttggctagat aggggatttt tctgaacact 2700 gcaaaaatag aacgtagcaa aatggcttca gttatcactt ttgggtgtct gtatcctaag 2760 aagtttctga aaagatctaa agccttttta tcccatatcc caaattctta tgagccactc 2820 acagcaggca gcatatgttg aaataagtta ttactggtac acacctgcat tgcctcacca 2880 gtgtatttat ttgttattaa attgatctga cttctcagcc tcatttggac taaaaaaaga 2940 aagcagaaat ccatgaacac attgcttctc ggccttttgg ctaagatcaa gtgtagaaat 3000 ccatgaacac taaaggactt cattgatttt ttcagagagt agaaaacaac ttagtttttc 3060 ttttttcctg aatgcgtcat aggcttgtga gtgatttttg tccattcaat tgtgccttct 3120 ttgtattatg ataagatggg ggtacttaag gagatcacaa gttgtgtgag gattgcatta 3180 acaaacctat gagccttcaa tggggaagac cagaagggtg agaggggccc tgaaagttca 3240 tatggtgggt atgtcccgca gcagagtgag gagatgaagc ttacgtgtcc tgacgttttg 3300 ttgcttatac tgtgatatct catcctagct aagctctata atgcccaaga ccccaaacag 3360 tacttttact ttgtttgtac aaaaacaaag acatatagcc aatacaaatc aaatgccgga 3420 ggtgtttgat gccatatttg caaattgcca tctattgaaa ttctcgtcac actacataga 3480 cataattgtt atctcctttt ggcttatgtg attttctgtt tacaagtaga atagccaatt 3540 atttaaatgt ttagttgcca cagtgaacca ggagtcactg agccaatgac tttaccagct 3600 gctgactaat cttcatcacc actgtagatt ttgctgcatg tgcaggtcct ctatttttaa 3660 ttgctgtttt cgttgctgca gtactttaca aacttctagt tcgttgagac ttagtgacca 3720 tttggcatca agttaacatc acacaatagg aaacaccact tccacaagtc tcaagcctca 3780 gtgctaaagt actactgaaa aggaactagg aagtttggcc aatt 3824 21 2249 DNA Murine sp. 21 gcaggatgcc atcaactaac agagcaggca gtctaaagga ccctgaaatt gcagagctct 60 tcttcaaaga agatccggaa aagctcttca cagatctcag agaaatcggc catgggagct 120 ttggagcagt atattttgca cgagatgtgc gtactaatga agtggtggcc atcaagaaaa 180 tgtcttatag tggaaagcag tctactgaga aatggcagga tattattaag gaagtcaagt 240 ttctacaaag aataaaacat cccaacagta tagaatacaa aggctgctat ttacgtgaac 300 acacagcatg gcttgtaatg gaatattgtt taggatctgc ttcagattta ttagaagttc 360 ataaaaagcc attacaagaa gtggaaatag cagcaattac acatggtgct ctccagggac 420 tagcttattt acattctcat accatgatcc atagagatat caaagcagga aatatccttc 480 tgacagaacc aggccaagtg aaacttgctg actttggatc tgcttccatg gcttcccctg 540 ccaattcttt tgtgggaaca ccatattgga tggccccaga agtaatttta gccatggatg 600 aaggacagta tgatggcaaa gttgatgtat ggtctcttgg aataacgtgt attgaattag 660 ccgagaggaa gcctccttta tttaatatga atgcaatgag tgccttatat cacatagccc 720 aaaatgaatc ccctacacta caatctaata tgaatgattc ttgcctccag aaaatccctc 780 aagatcgccc tacatcagag gaacttttaa agcacatgtt tgttcttcga gagcgccctg 840 aaacagtgtt aatagatctt attcaaagga caaaggatgc agtaagagag ctggacaatc 900 tgcagtatcg aaagatgaag aaactccttt tccaggaggc acataatggg ccagcggtag 960 aagcacagga agaagaggag gagcaagatc atggtgttgg ccgaacagga acagtgaata 1020 gtgttggaag caatcagtct atccctagta tgtctatcag tgccagcagt caaagcagca 1080 gtgttaatag tcttccagat gcatcagatg acaagagtga gctagacatg atggagggag 1140 accatacagt gatgtctaac agttctgtca tccacttaaa acctgaggag gaaaattacc 1200 aggaagaagg agatcctaga acaagagcat cagacccaca gtctccccct caggtgtctc 1260 gtcacaagtc acattatcgt aatagagaac actttgcaac catacgaaca gcatcactgg 1320 ttacaagaca gatgcaagaa catgagcagg actctgaact tagagaacag atgtctggtt 1380 ataagcggat gaggcgacag catcaaaagc agctgatgac gctggaaaat aaactgaagg 1440 cagagatgga cgaacatcgg ctcagattag acaaagatct tgaaactcag cgtaacaatt 1500 tcgctgcaga aatggagaaa cttattaaga aacaccaagc tgctatggaa aaagaggcta 1560 aagtgatggc caatgaggag aaaaaattcc agcaacacat tcaggctcaa cagaaaaaag 1620 aactgaatag ctttttggag tctcaaaaaa gagaatataa acttcgcaaa gagcagctta 1680 aggaggagct gaatgaaaac cagagcacac ctaaaaaaga aaagcaggaa tggctttcaa 1740 agcagaagga gaatatacag cattttcagg cagaagaaga agctaatctt cttcgacgtc 1800 aaaggcagta tctagagcta gaatgtcgtc gcttcaaaag aagaatgtta cttgggcgac 1860 ataacttgga acaggacctt gtcagggagg agttaaacaa aaggcagact caaaaggact 1920 tggaacatgc aatgctattg cgacagcatg aatcaatgca agaactggag tttcgccatc 1980 tcaacactat tcagaagatg cgctgtgagt tgatcagact gcagcatcaa actgagctca 2040 ctaaccagct agagtacaat aagagaaggg aacgggaact gaggcgaaaa catgtcatgg 2100 aagttcgaca acaacctaag agtctgaagt ctaaagaact ccaaataaaa aagcagtttc 2160 aggatacctg caaaattcaa accagacagt acaaagcatt aaggaatcac ctactggaga 2220 ctacaccaaa gaatgagcac aaagcaatc 2249 22 898 PRT Homo sapiens 22 Met Arg Lys Gly Val Leu Lys Asp Pro Glu Ile Asp Asp Leu Phe Tyr 1 5 10 15 Lys Asp Asp Pro Glu Glu Leu Phe Ile Gly Leu His Glu Ile Gly His 20 25 30 Gly Ser Phe Gly Ala Val Tyr Phe Ala Thr Asn Ala His Thr Asn Glu 35 40 45 Val Val Ala Ile Lys Lys Met Ser Tyr Ser Gly Lys Gln Thr His Glu 50 55 60 Lys Trp Gln Asp Ile Leu Lys Glu Val Lys Phe Leu Arg Gln Leu Lys 65 70 75 80 His Pro Asn Thr Ile Glu Tyr Lys Gly Cys Tyr Leu Lys Glu His Thr 85 90 95 Ala Trp Leu Val Met Glu Tyr Cys Leu Gly Ser Ala Ser Asp Leu Leu 100 105 110 Glu Val His Lys Lys Pro Leu Gln Glu Val Glu Ile Ala Ala Ile Thr 115 120 125 His Gly Ala Leu His Gly Leu Ala Tyr Leu His Ser His Ala Leu Ile 130 135 140 His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Thr Glu Pro Gly Gln 145 150 155 160 Val Lys Leu Ala Asp Phe Gly Ser Ala Ser Met Ala Ser Pro Ala Asn 165 170 175 Ser Phe Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Ile Leu Ala 180 185 190 Met Asp Glu Gly Gln Tyr Asp Gly Lys Val Asp Ile Trp Ser Leu Gly 195 200 205 Ile Thr Cys Ile Glu Leu Ala Glu Arg Lys Pro Pro Leu Phe Asn Met 210 215 220 Asn Ala Met Ser Ala Leu Tyr His Ile Ala Gln Asn Asp Ser Pro Thr 225 230 235 240 Leu Gln Ser Asn Glu Trp Thr Asp Ser Phe Arg Arg Phe Val Asp Tyr 245 250 255 Cys Leu Gln Lys Ile Pro Gln Glu Arg Pro Thr Ser Ala Glu Leu Leu 260 265 270 Arg His Asp Phe Val Arg Arg Asp Arg Pro Leu Arg Val Leu Ile Asp 275 280 285 Leu Ile Gln Arg Thr Lys Asp Ala Val Arg Glu Leu Asp Asn Leu Gln 290 295 300 Tyr Arg Lys Met Lys Lys Ile Leu Phe Gln Glu Thr Arg Asn Gly Pro 305 310 315 320 Leu Asn Glu Ser Gln Glu Asp Glu Glu Asp Ser Glu His Gly Thr Ser 325 330 335 Leu Asn Arg Glu Met Asp Ser Leu Gly Ser Asn His Ser Ile Pro Ser 340 345 350 Met Ser Val Ser Thr Gly Ser Gln Ser Ser Ser Val Asn Ser Met Gln 355 360 365 Glu Val Met Asp Glu Ser Ser Ser Glu Leu Val Met Met His Asp Asp 370 375 380 Glu Ser Thr Ile Asn Ser Ser Ser Ser Val Val His Lys Lys Asp His 385 390 395 400 Val Phe Thr Arg Asp Glu Ala Gly His Gly Asp Pro Arg Pro Glu Pro 405 410 415 Arg Pro Thr Gln Ser Val Gln Ser Gln Ala Leu His Tyr Arg Asn Arg 420 425 430 Glu Arg Phe Ala Thr Ile Lys Ser Ala Ser Leu Val Thr Arg Gln Ile 435 440 445 His Glu His Glu Gln Glu Asn Glu Leu Arg Glu Gln Met Ser Gly Tyr 450 455 460 Lys Arg Met Arg Arg Gln His Gln Lys Gln Leu Ile Ala Leu Glu Asn 465 470 475 480 Lys Leu Lys Ala Glu Met Asp Glu His Arg Leu Lys Leu Gln Lys Glu 485 490 495 Val Glu Thr His Ala Asn Asn Ser Ser Ile Glu Leu Glu Lys Leu Ala 500 505 510 Lys Lys Gln Val Ala Ile Ile Glu Lys Glu Ala Lys Val Ala Ala Ala 515 520 525 Asp Glu Lys Lys Phe Gln Gln Gln Ile Leu Ala Gln Gln Lys Lys Asp 530 535 540 Leu Thr Thr Phe Leu Glu Ser Gln Lys Lys Gln Tyr Lys Ile Cys Lys 545 550 555 560 Glu Lys Ile Lys Glu Glu Met Asn Glu Asp His Ser Thr Pro Lys Lys 565 570 575 Glu Lys Gln Glu Arg Ile Ser Lys His Lys Glu Asn Leu Gln His Thr 580 585 590 Gln Ala Glu Glu Glu Ala His Leu Leu Thr Gln Gln Arg Leu Tyr Tyr 595 600 605 Asp Lys Asn Cys Arg Phe Phe Lys Arg Lys Ile Met Ile Lys Arg His 610 615 620 Glu Val Glu Gln Gln Asn Ile Arg Glu Glu Leu Asn Lys Lys Arg Thr 625 630 635 640 Gln Lys Glu Met Glu His Ala Met Leu Ile Arg His Asp Glu Ser Thr 645 650 655 Arg Glu Leu Glu Tyr Arg Gln Leu His Thr Leu Gln Lys Leu Arg Met 660 665 670 Asp Leu Ile Arg Leu Gln His Gln Thr Glu Leu Glu Asn Gln Leu Glu 675 680 685 Tyr Asn Lys Arg Arg Glu Arg Glu Leu His Arg Lys His Val Met Gly 690 695 700 Leu Arg Gln Gln Pro Lys Asn Leu Lys Ala Met Glu Met Gln Ile Lys 705 710 715 720 Lys Gln Phe Gln Asp Thr Cys Lys Val Gln Thr Lys Gln Tyr Lys Ala 725 730 735 Leu Lys Asn His Gln Leu Glu Val Thr Pro Lys Asn Glu His Lys Thr 740 745 750 Ile Leu Lys Thr Leu Lys Asp Glu Gln Thr Arg Lys Leu Ala Ile Leu 755 760 765 Ala Glu Gln Tyr Glu Gln Ser Ile Asn Glu Met Met Ala Ser Gln Ala 770 775 780 Leu Arg Leu Asp Glu Ala Gln Glu Ala Glu Cys Gln Ala Leu Arg Leu 785 790 795 800 Gln Leu Gln Gln Glu Met Glu Leu Leu Asn Ala Tyr Gln Ser Lys Ile 805 810 815 Lys Met Gln Thr Glu Ala Gln His Glu Arg Glu Leu Gln Lys Leu Glu 820 825 830 Gln Arg Val Ser Leu Arg Arg Ala His Leu Glu Gln Lys Ile Glu Glu 835 840 845 Glu Leu Ala Ala Leu Gln Lys Glu Arg Ser Glu Arg Ile Lys Asn Leu 850 855 860 Leu Glu Arg Gln Glu Arg Glu Ile Glu Thr Phe Asp Met Glu Ser Leu 865 870 875 880 Arg Met Gly Phe Gly Asn Leu Val Thr Leu Asp Phe Pro Lys Glu Asp 885 890 895 Tyr Arg 23 786 PRT Homo sapiens 23 Ile Glu Leu Ala Glu Arg Lys Pro Pro Leu Phe Asn Met Asn Ala Met 1 5 10 15 Ser Ala Leu Tyr His Ile Ala Gln Asn Glu Ser Pro Thr Leu Gln Ser 20 25 30 Asn Glu Trp Ser Asp Tyr Phe Arg Asn Phe Val Asp Ser Cys Leu Gln 35 40 45 Lys Ile Pro Gln Asp Arg Pro Thr Ser Glu Glu Leu Leu Lys His Ile 50 55 60 Phe Val Leu Arg Glu Arg Pro Glu Thr Val Leu Ile Asp Leu Ile Gln 65 70 75 80 Arg Thr Lys Asp Ala Val Arg Glu Leu Asp Asn Leu Gln Tyr Arg Lys 85 90 95 Met Lys Lys Leu Leu Phe Gln Glu Ala His Asn Gly Pro Ala Val Glu 100 105 110 Ala Gln Glu Glu Glu Glu Glu Gln Asp His Gly Val Gly Arg Thr Gly 115 120 125 Thr Val Asn Ser Val Gly Ser Asn Gln Ser Ile Pro Ser Met Ser Ile 130 135 140 Ser Ala Ser Ser Gln Ser Ser Ser Val Asn Ser Leu Pro Asp Val Ser 145 150 155 160 Asp Asp Lys Ser Glu Leu Asp Met Met Glu Gly Asp His Thr Val Met 165 170 175 Ser Asn Ser Ser Val Ile His Leu Lys Pro Glu Glu Glu Asn Tyr Arg 180 185 190 Glu Glu Gly Asp Pro Arg Thr Arg Ala Ser Asp Pro Gln Ser Pro Pro 195 200 205 Gln Val Ser Arg His Lys Ser His Tyr Arg Asn Arg Glu His Phe Ala 210 215 220 Thr Ile Arg Thr Ala Ser Leu Val Thr Arg Gln Met Gln Glu His Glu 225 230 235 240 Gln Asp Ser Glu Leu Arg Glu Gln Met Ser Gly Tyr Lys Arg Met Arg 245 250 255 Arg Gln His Gln Lys Gln Leu Met Thr Leu Glu Asn Lys Leu Lys Ala 260 265 270 Glu Met Asp Glu His Arg Leu Arg Leu Asp Lys Asp Leu Glu Thr Gln 275 280 285 Arg Asn Asn Phe Ala Ala Glu Met Glu Lys Leu Ile Lys Lys His Gln 290 295 300 Ala Ala Met Glu Lys Glu Ala Lys Val Met Ser Asn Glu Glu Lys Lys 305 310 315 320 Phe Gln Gln His Ile Gln Ala Gln Gln Lys Lys Glu Leu Asn Ser Phe 325 330 335 Leu Glu Ser Gln Lys Arg Glu Tyr Lys Leu Arg Lys Glu Gln Leu Lys 340 345 350 Glu Glu Leu Asn Glu Asn Gln Ser Thr Pro Lys Lys Glu Lys Gln Glu 355 360 365 Trp Leu Ser Lys Gln Lys Glu Asn Ile Gln His Phe Gln Ala Glu Glu 370 375 380 Glu Ala Asn Leu Leu Arg Arg Gln Arg Gln Tyr Leu Glu Leu Glu Cys 385 390 395 400 Arg Arg Phe Lys Arg Arg Met Leu Leu Gly Arg His Asn Leu Glu Gln 405 410 415 Asp Leu Val Arg Glu Glu Leu Asn Lys Arg Gln Thr Gln Lys Asp Leu 420 425 430 Glu His Ala Met Leu Leu Arg Gln His Glu Ser Met Gln Glu Leu Glu 435 440 445 Phe Arg His Leu Asn Thr Ile Gln Lys Met Arg Cys Glu Leu Ile Arg 450 455 460 Leu Gln His Gln Thr Glu Leu Thr Asn Gln Leu Glu Tyr Asn Lys Arg 465 470 475 480 Arg Glu Arg Glu Leu Arg Arg Lys His Val Met Glu Val Arg Gln Gln 485 490 495 Pro Lys Ser Leu Lys Ser Lys Glu Leu Gln Ile Lys Lys Gln Phe Gln 500 505 510 Asp Thr Cys Lys Ile Gln Thr Arg Gln Tyr Lys Ala Leu Arg Asn His 515 520 525 Leu Leu Glu Thr Thr Pro Lys Ser Glu His Lys Ala Val Leu Lys Arg 530 535 540 Leu Lys Glu Glu Gln Thr Arg Lys Leu Ala Ile Leu Ala Glu Gln Tyr 545 550 555 560 Asp His Ser Ile Asn Glu Met Leu Ser Thr Gln Ala Leu Arg Leu Asp 565 570 575 Glu Ala Gln Glu Ala Glu Cys Gln Val Leu Lys Met Gln Leu Gln Gln 580 585 590 Glu Leu Glu Leu Leu Asn Ala Tyr Gln Ser Lys Ile Lys Met Gln Ala 595 600 605 Glu Ala Gln His Asp Arg Glu Leu Arg Glu Leu Glu Gln Arg Val Ser 610 615 620 Leu Arg Arg Ala Leu Leu Glu Gln Lys Ile Glu Glu Glu Met Leu Ala 625 630 635 640 Leu Gln Asn Glu Arg Thr Glu Arg Ile Arg Ser Leu Leu Glu Arg Gln 645 650 655 Ala Arg Glu Ile Glu Ala Phe Asp Ser Glu Ser Met Arg Leu Gly Phe 660 665 670 Ser Asn Met Val Leu Ser Asn Leu Ser Pro Glu Ala Phe Ser His Ser 675 680 685 Tyr Pro Gly Ala Ser Gly Trp Ser His Asn Pro Thr Gly Gly Pro Gly 690 695 700 Pro His Trp Gly His Pro Met Gly Gly Pro Pro Gln Ala Trp Gly His 705 710 715 720 Pro Met Gln Gly Gly Pro Gln Pro Trp Gly His Pro Ser Gly Pro Met 725 730 735 Gln Gly Val Pro Arg Gly Ser Ser Met Gly Val Arg Asn Ser Pro Gln 740 745 750 Ala Leu Arg Arg Thr Ala Ser Gly Gly Arg Thr Glu Gln Gly Met Ser 755 760 765 Arg Ser Thr Ser Val Thr Ser Gln Ile Ser Asn Gly Ser His Met Ser 770 775 780 Tyr Thr 785 24 748 PRT Murine sp. 24 Met Pro Ser Thr Asn Arg Ala Gly Ser Leu Lys Asp Pro Glu Ile Ala 1 5 10 15 Glu Leu Phe Phe Lys Glu Asp Pro Glu Lys Leu Phe Thr Asp Leu Arg 20 25 30 Glu Ile Gly His Gly Ser Phe Gly Ala Val Tyr Phe Ala Arg Asp Val 35 40 45 Arg Thr Asn Glu Val Val Ala Ile Lys Lys Met Ser Tyr Ser Gly Lys 50 55 60 Gln Ser Thr Glu Lys Trp Gln Asp Ile Ile Lys Glu Val Lys Phe Leu 65 70 75 80 Gln Arg Ile Lys His Pro Asn Ser Ile Glu Tyr Lys Gly Cys Tyr Leu 85 90 95 Arg Glu His Thr Ala Trp Leu Val Met Glu Tyr Cys Leu Gly Ser Ala 100 105 110 Ser Asp Leu Leu Glu Val His Lys Lys Pro Leu Gln Glu Val Glu Ile 115 120 125 Ala Ala Ile Thr His Gly Ala Leu Gln Gly Leu Ala Tyr Leu His Ser 130 135 140 His Thr Met Ile His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Thr 145 150 155 160 Glu Pro Gly Gln Val Lys Leu Ala Asp Phe Gly Ser Ala Ser Met Ala 165 170 175 Ser Pro Ala Asn Ser Phe Val Gly Thr Pro Tyr Trp Met Ala Pro Glu 180 185 190 Val Ile Leu Ala Met Asp Glu Gly Gln Tyr Asp Gly Lys Val Asp Val 195 200 205 Trp Ser Leu Gly Ile Thr Cys Ile Glu Leu Ala Glu Arg Lys Pro Pro 210 215 220 Leu Phe Asn Met Asn Ala Met Ser Ala Leu Tyr His Ile Ala Gln Asn 225 230 235 240 Glu Ser Pro Thr Leu Gln Ser Asn Met Asn Asp Ser Cys Leu Gln Lys 245 250 255 Ile Pro Gln Asp Arg Pro Thr Ser Glu Glu Leu Leu Lys His Met Phe 260 265 270 Val Leu Arg Glu Arg Pro Glu Thr Val Leu Ile Asp Leu Ile Gln Arg 275 280 285 Thr Lys Asp Ala Val Arg Glu Leu Asp Asn Leu Gln Tyr Arg Lys Met 290 295 300 Lys Lys Leu Leu Phe Gln Glu Ala His Asn Gly Pro Ala Val Glu Ala 305 310 315 320 Gln Glu Glu Glu Glu Glu Gln Asp His Gly Val Gly Arg Thr Gly Thr 325 330 335 Val Asn Ser Val Gly Ser Asn Gln Ser Ile Pro Ser Met Ser Ile Ser 340 345 350 Ala Ser Ser Gln Ser Ser Ser Val Asn Ser Leu Pro Asp Ala Ser Asp 355 360 365 Asp Lys Ser Glu Leu Asp Met Met Glu Gly Asp His Thr Val Met Ser 370 375 380 Asn Ser Ser Val Ile His Leu Lys Pro Glu Glu Glu Asn Tyr Gln Glu 385 390 395 400 Glu Gly Asp Pro Arg Thr Arg Ala Ser Asp Pro Gln Ser Pro Pro Gln 405 410 415 Val Ser Arg His Lys Ser His Tyr Arg Asn Arg Glu His Phe Ala Thr 420 425 430 Ile Arg Thr Ala Ser Leu Val Thr Arg Gln Met Gln Glu His Glu Gln 435 440 445 Asp Ser Glu Leu Arg Glu Gln Met Ser Gly Tyr Lys Arg Met Arg Arg 450 455 460 Gln His Gln Lys Gln Leu Met Thr Leu Glu Asn Lys Leu Lys Ala Glu 465 470 475 480 Met Asp Glu His Arg Leu Arg Leu Asp Lys Asp Leu Glu Thr Gln Arg 485 490 495 Asn Asn Phe Ala Ala Glu Met Glu Lys Leu Ile Lys Lys His Gln Ala 500 505 510 Ala Met Glu Lys Glu Ala Lys Val Met Ala Asn Glu Glu Lys Lys Phe 515 520 525 Gln Gln His Ile Gln Ala Gln Gln Lys Lys Glu Leu Asn Ser Phe Leu 530 535 540 Glu Ser Gln Lys Arg Glu Tyr Lys Leu Arg Lys Glu Gln Leu Lys Glu 545 550 555 560 Glu Leu Asn Glu Asn Gln Ser Thr Pro Lys Lys Glu Lys Gln Glu Trp 565 570 575 Leu Ser Lys Gln Lys Glu Asn Ile Gln His Phe Gln Ala Glu Glu Glu 580 585 590 Ala Asn Leu Leu Arg Arg Gln Arg Gln Tyr Leu Glu Leu Glu Cys Arg 595 600 605 Arg Phe Lys Arg Arg Met Leu Leu Gly Arg His Asn Leu Glu Gln Asp 610 615 620 Leu Val Arg Glu Glu Leu Asn Lys Arg Gln Thr Gln Lys Asp Leu Glu 625 630 635 640 His Ala Met Leu Leu Arg Gln His Glu Ser Met Gln Glu Leu Glu Phe 645 650 655 Arg His Leu Asn Thr Ile Gln Lys Met Arg Cys Glu Leu Ile Arg Leu 660 665 670 Gln His Gln Thr Glu Leu Thr Asn Gln Leu Glu Tyr Asn Lys Arg Arg 675 680 685 Glu Arg Glu Leu Arg Arg Lys His Val Met Glu Val Arg Gln Gln Pro 690 695 700 Lys Ser Leu Lys Ser Lys Glu Leu Gln Ile Lys Lys Gln Phe Gln Asp 705 710 715 720 Thr Cys Lys Ile Gln Thr Arg Gln Tyr Lys Ala Leu Arg Asn His Leu 725 730 735 Leu Glu Thr Thr Pro Lys Asn Glu His Lys Ala Ile 740 745 25 2795 DNA Homo sapiens 25 cgaagccaca gcccgagccc gagcccgagc ccgagccggc gccaccgcgc ccccggccat 60 ggcttttgcc aatttccgcc gcatcctgcg cctgtctacc ttcgagaaga gaaagtcccg 120 cgaatatgag cacgtccgcc gcgacctgga ccccaacgag gtgtgggaga tcgtgggcga 180 gctgggcgac ggcgccttcg gcaaggttta caaggccaag aataaggaga cgggtgcttt 240 ggctgcggcc aaagtcattg aaaccaagag tgaggaggag ctggaggact acatcgtgga 300 gattgagatc ctggccacct gcgaccaccc ctacattgtg aagctcctgg gagcctacta 360 tcacgacggg aagctgtgga tcatgattga gttctgtcca gggggagccg tggacgccat 420 catgctggag ctggacagag gcctcacgga gccccagata caggtggttt gccgccagat 480 gctagaagcc ctcaacttcc tgcacagcaa gaggatcatc caccgagatc tgaaagctgg 540 caacgtgctg atgaccctcg agggagacat caggctggct gactttggtg tgtctgccaa 600 gaatctgaag actctacaga aacgagattc cttcatcggc acgccttact ggatggcccc 660 cgaggtggtc atgtgtgaga ccatgaaaga cacgccctac gactacaaag ccgacatctg 720 gtccctgggc atcacgctga ttgagatggc ccagatcgag ccgccacacc acgagctcaa 780 ccccatgcgg gtcctgctaa agatcgccaa gtcggaccct cccacgctgc tcacgccctc 840 caagtggtct gtagagttcc gtgacttcct gaagatagcc ctggataaga acccagaaac 900 ccgacccagt gccgcgcagc tgctggagca tcccttcgtc agcagcatca ccagtaacaa 960 ggctctgcgg gagctggtgg ctgaggccaa ggccgaggtg atggaagaga tcgaagacgg 1020 ccgggatgag ggggaagagg aggacgccgt ggatgccgcc tccaccctgg agaaccatac 1080 tcagaactcc tctgaggtga gtccgccaag cctcaatgct gacaagcctc tcgaggagtc 1140 accttccacc ccgctggcac ccagccagtc tcaggacagt gtgaatgagc cctgcagcca 1200 gccctctggg gacagatccc tccaaaccac cagtccccca gtcgtggccc ctggaaatga 1260 gaacggcctg gcagtgcctg tgcccctgcg gaagtcccga cccgtgtcaa tggatgccag 1320 aattcaggta gcccaggaga agcaagttgc tgagcagggt ggggacctca gcccagcagc 1380 caacagatct caaaaggcca gccagagccg gcccaacagc agcgccctgg agaccttggg 1440 tggggagaag ctggccaatg gcagcctgga gccacctgcc caggcagctc cagggccttc 1500 caagagggac tcggactgca gcagcctctg cacctctgag agcatggact atggtaccaa 1560 tctctccact gacctgtcgc tgaacaaaga gatgggctct ctgtccatca aggacccgaa 1620 actgtacaaa aaaaccctca agcggacacg caaatttgtg gtggatggtg tggaggtgag 1680 catcaccacc tccaagatca tcagcgaaga tgagaagaag gatgaggaga tgagatttct 1740 caggcgccag gaactccgag agcttcggct gctccagaaa gaagagcatc ggaaccagac 1800 ccagctgagt aacaagcatg agctgcagct ggagcaaatg cataaacgtt ttgaacagga 1860 aatcaacgcc aagaagaagt tctttgacac ggaattagag aacctggagc gtcagcaaaa 1920 gcagcaagtg gagaagatgg agcaagacca tgccgtgcgc cgccgggagg aggccaggcg 1980 gatccgcctg gagcaggatc gggactacac caggttccaa gagcagctca aactgatgaa 2040 gaaagaggtg aagaacgagg tggagaagct cccccgacag cagcggaagg aaagcatgaa 2100 gcagaagatg gaggagcaca cgcagaaaaa gcagcttctt gaccgggact ttgtagccaa 2160 gcagaaggag gacctggagc tggccatgaa gaggctcacc accgacaaca ggcgggagat 2220 ctgtgacaag gagcgcgagt gcctcatgaa gaagcaggag ctccttcgag accgggaagc 2280 agccctgtgg gagatggaag agcaccagct gcaggagagg caccagctgg tgaagcagca 2340 gctcaaagac cagtacttcc tccagcggca cgagctgctg cgcaagcatg agaaggagcg 2400 ggagcagatg cagcgctaca accagcgcat gatagagcag ctgaaggtgc ggcagcaaca 2460 ggaaaaggcg cggctgccca agatccagag gagtgagggc aagacgcgca tggccatgta 2520 caagaagagc ctccacatca acggcggggg cagcgcagct gagcagcgtg agaagatcaa 2580 gcagttctcc cagcaggagg agaagaggca gaagtcggag cggctgcagc aacagcagaa 2640 acacgagaac cagatgcggg acatgctggc gcagtgcgag agcaacatga gcgagctgca 2700 gcagctgcag aatgaaaagt gccacctcct ggtagagcac gaaacccaga aactgaaggc 2760 cctggatgag agccataacc agaacctgaa ggaat 2795 26 912 PRT Homo sapiens 26 Met Ala Phe Ala Asn Phe Arg Arg Ile Leu Arg Leu Ser Thr Phe Glu 1 5 10 15 Lys Arg Lys Ser Arg Glu Tyr Glu His Val Arg Arg Asp Leu Asp Pro 20 25 30 Asn Glu Val Trp Glu Ile Val Gly Glu Leu Gly Asp Gly Ala Phe Gly 35 40 45 Lys Val Tyr Lys Ala Lys Asn Lys Glu Thr Gly Ala Leu Ala Ala Ala 50 55 60 Lys Val Ile Glu Thr Lys Ser Glu Glu Glu Leu Glu Asp Tyr Ile Val 65 70 75 80 Glu Ile Glu Ile Leu Ala Thr Cys Asp His Pro Tyr Ile Val Lys Leu 85 90 95 Leu Gly Ala Tyr Tyr His Asp Gly Lys Leu Trp Ile Met Ile Glu Phe 100 105 110 Cys Pro Gly Gly Ala Val Asp Ala Ile Met Leu Glu Leu Asp Arg Gly 115 120 125 Leu Thr Glu Pro Gln Ile Gln Val Val Cys Arg Gln Met Leu Glu Ala 130 135 140 Leu Asn Phe Leu His Ser Lys Arg Ile Ile His Arg Asp Leu Lys Ala 145 150 155 160 Gly Asn Val Leu Met Thr Leu Glu Gly Asp Ile Arg Leu Ala Asp Phe 165 170 175 Gly Val Ser Ala Lys Asn Leu Lys Thr Leu Gln Lys Arg Asp Ser Phe 180 185 190 Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Met Cys Glu Thr 195 200 205 Met Lys Asp Thr Pro Tyr Asp Tyr Lys Ala Asp Ile Trp Ser Leu Gly 210 215 220 Ile Thr Leu Ile Glu Met Ala Gln Ile Glu Pro Pro His His Glu Leu 225 230 235 240 Asn Pro Met Arg Val Leu Leu Lys Ile Ala Lys Ser Asp Pro Pro Thr 245 250 255 Leu Leu Thr Pro Ser Lys Trp Ser Val Glu Phe Arg Asp Phe Leu Lys 260 265 270 Ile Ala Leu Asp Lys Asn Pro Glu Thr Arg Pro Ser Ala Ala Gln Leu 275 280 285 Leu Glu His Pro Phe Val Ser Ser Ile Thr Ser Asn Lys Ala Leu Arg 290 295 300 Glu Leu Val Ala Glu Ala Lys Ala Glu Val Met Glu Glu Ile Glu Asp 305 310 315 320 Gly Arg Asp Glu Gly Glu Glu Glu Asp Ala Val Asp Ala Ala Ser Thr 325 330 335 Leu Glu Asn His Thr Gln Asn Ser Ser Glu Val Ser Pro Pro Ser Leu 340 345 350 Asn Ala Asp Lys Pro Leu Glu Glu Ser Pro Ser Thr Pro Leu Ala Pro 355 360 365 Ser Gln Ser Gln Asp Ser Val Asn Glu Pro Cys Ser Gln Pro Ser Gly 370 375 380 Asp Arg Ser Leu Gln Thr Thr Ser Pro Pro Val Val Ala Pro Gly Asn 385 390 395 400 Glu Asn Gly Leu Ala Val Pro Val Pro Leu Arg Lys Ser Arg Pro Val 405 410 415 Ser Met Asp Ala Arg Ile Gln Val Ala Gln Glu Lys Gln Val Ala Glu 420 425 430 Gln Gly Gly Asp Leu Ser Pro Ala Ala Asn Arg Ser Gln Lys Ala Ser 435 440 445 Gln Ser Arg Pro Asn Ser Ser Ala Leu Glu Thr Leu Gly Gly Glu Lys 450 455 460 Leu Ala Asn Gly Ser Leu Glu Pro Pro Ala Gln Ala Ala Pro Gly Pro 465 470 475 480 Ser Lys Arg Asp Ser Asp Cys Ser Ser Leu Cys Thr Ser Glu Ser Met 485 490 495 Asp Tyr Gly Thr Asn Leu Ser Thr Asp Leu Ser Leu Asn Lys Glu Met 500 505 510 Gly Ser Leu Ser Ile Lys Asp Pro Lys Leu Tyr Lys Lys Thr Leu Lys 515 520 525 Arg Thr Arg Lys Phe Val Val Asp Gly Val Glu Val Ser Ile Thr Thr 530 535 540 Ser Lys Ile Ile Ser Glu Asp Glu Lys Lys Asp Glu Glu Met Arg Phe 545 550 555 560 Leu Arg Arg Gln Glu Leu Arg Glu Leu Arg Leu Leu Gln Lys Glu Glu 565 570 575 His Arg Asn Gln Thr Gln Leu Ser Asn Lys His Glu Leu Gln Leu Glu 580 585 590 Gln Met His Lys Arg Phe Glu Gln Glu Ile Asn Ala Lys Lys Lys Phe 595 600 605 Phe Asp Thr Glu Leu Glu Asn Leu Glu Arg Gln Gln Lys Gln Gln Val 610 615 620 Glu Lys Met Glu Gln Asp His Ala Val Arg Arg Arg Glu Glu Ala Arg 625 630 635 640 Arg Ile Arg Leu Glu Gln Asp Arg Asp Tyr Thr Arg Phe Gln Glu Gln 645 650 655 Leu Lys Leu Met Lys Lys Glu Val Lys Asn Glu Val Glu Lys Leu Pro 660 665 670 Arg Gln Gln Arg Lys Glu Ser Met Lys Gln Lys Met Glu Glu His Thr 675 680 685 Gln Lys Lys Gln Leu Leu Asp Arg Asp Phe Val Ala Lys Gln Lys Glu 690 695 700 Asp Leu Glu Leu Ala Met Lys Arg Leu Thr Thr Asp Asn Arg Arg Glu 705 710 715 720 Ile Cys Asp Lys Glu Arg Glu Cys Leu Met Lys Lys Gln Glu Leu Leu 725 730 735 Arg Asp Arg Glu Ala Ala Leu Trp Glu Met Glu Glu His Gln Leu Gln 740 745 750 Glu Arg His Gln Leu Val Lys Gln Gln Leu Lys Asp Gln Tyr Phe Leu 755 760 765 Gln Arg His Glu Leu Leu Arg Lys His Glu Lys Glu Arg Glu Gln Met 770 775 780 Gln Arg Tyr Asn Gln Arg Met Ile Glu Gln Leu Lys Val Arg Gln Gln 785 790 795 800 Gln Glu Lys Ala Arg Leu Pro Lys Ile Gln Arg Ser Glu Gly Lys Thr 805 810 815 Arg Met Ala Met Tyr Lys Lys Ser Leu His Ile Asn Gly Gly Gly Ser 820 825 830 Ala Ala Glu Gln Arg Glu Lys Ile Lys Gln Phe Ser Gln Gln Glu Glu 835 840 845 Lys Arg Gln Lys Ser Glu Arg Leu Gln Gln Gln Gln Lys His Glu Asn 850 855 860 Gln Met Arg Asp Met Leu Ala Gln Cys Glu Ser Asn Met Ser Glu Leu 865 870 875 880 Gln Gln Leu Gln Asn Glu Lys Cys His Leu Leu Val Glu His Glu Thr 885 890 895 Gln Lys Leu Lys Ala Leu Asp Glu Ser His Asn Gln Asn Leu Lys Glu 900 905 910 27 3604 DNA Homo sapiens 27 cgttcctggg cttcccgctc cgcaggcctg cggaggactg gcccagcaag gtcccaggtc 60 ttccctctcc ttagcgccta agagagaggc ccagtgcggg tgaggagtcg cgaggaagag 120 gcggaaggcg ccggaaggca ccatgttccg caagaaaaag aagaaacgcc ctgagatctc 180 agcgccacag aacttccagc accgtgtcca cacctccttc gaccccaaag aaggcaagtt 240 tgtgggcctc cccccacaat ggcagaacat cctggacaca ctgcggcgcc ccaagcccgt 300 ggtggaccct tcgcgaatca cacgggtgca gctccagccc atgaagacag tggtgcgggg 360 cagcgcgatg cctgtggatg gctacatctc ggggctgctc aacgacatcc agaagttgtc 420 agtcatcagc tccaacaccc tgcgtggccg cagccccacc agccggcggc gggcacagtc 480 cctggggctg ctgggggatg agcactgggc caccgaccca gacatgtacc tccagagccc 540 ccagtctgag cgcactgacc cccacggcct ctacctcagc tgcaacgggg gcacaccagc 600 aggccacaag cagatgccgt ggcccgagcc acagagccca cgggtcctgc ccaatgggct 660 ggctgcaaag gcacagtccc tgggccccgc cgagtttcag ggtgcctcgc agcgctgtct 720 gcagctgggt gcctgcctgc agagctcccc accaggagcc tcgcccccca cgggcaccaa 780 taggcatgga atgaaggctg ccaagcatgg ctctgaggag gcccggccac agtcctgcct 840 ggtgggctca gccacaggca ggccaggtgg ggaaggcagc cctagcccta agacccggga 900 gagcagcctg aagcgcaggc tattccgaag catgttcctg tccactgctg ccacagcccc 960 tccaagcagc agcaagccag gccctccacc acagagcaag cccaactcct ctttccgacc 1020 gccgcagaaa gacaaccccc caagcctggt ggccaaggcc cagtccttgc cctcggacca 1080 gccggtgggg accttcagcc ctctgaccac ttcggatacc agcagccccc agaagtccct 1140 ccgcacagcc ccggccacag gccagcttcc aggccggtct tccccagcgg gatccccccg 1200 cacctggcac gcccagatca gcaccagcaa cctgtacctg ccccaggacc ccacggttgc 1260 caagggtgcc ctggctggtg aggacacagg tgttgtgaca catgagcagt tcaaggctgc 1320 gctcaggatg gtggtggacc agggtgaccc ccggctgctg ctggacagct acgtgaagat 1380 tggcgagggc tccaccggca tcgtctgctt ggcccgggag aagcactcgg gccgccaggt 1440 ggccgtcaag atgatggacc tcaggaagca gcagcgcagg gagctgctct tcaacgaggt 1500 ggtgatcatg cgggactacc agcacttcaa cgtggtggag atgtacaaga gctacctggt 1560 gggcgaggag ctgtgggtgc tcatggagtt cctgcaggga ggagccctca cagacatcgt 1620 ctcccaagtc aggctgaatg aggagcagat tgccactgtg tgtgaggctg tgctgcaggc 1680 cctggcctac ctgcatgctc agggtgtcat ccaccgggac atcaagagtg actccatcct 1740 gctgaccctc gatggcaggg tgaagctctc ggacttcgga ttctgtgctc agatcagcaa 1800 agacgtccct aagaggaagt ccctggtggg aaccccctac tggatggctc ctgaagtgat 1860 ctccaggtct ttgtatgcca ctgaggtgga tatctggtct ctgggcatca tggtgattga 1920 gatggtagat ggggagccac cgtacttcag tgactcccca gtgcaagcca tgaagaggct 1980 ccgggacagc cccccaccca agctgaaaaa ctctcacaag gtctccccag tgctgcgaga 2040 cttcctggag cggatgctgg tgcgggaccc ccaagagaga gccacagccc aggagctcct 2100 agaccacccc ttcctgctgc agacagggct acctgagtgc ctggtgcccc tgatccagct 2160 ctaccgaaag cagacctcca cctgctgagc ccaccccaag tatgcctgcc acctacgccc 2220 acaggcaggg cacactgggc agccagcctg ccggcaggac ttgcctgcct cctcctctca 2280 gtattctctc caaagattga aatgtgaagc cccagcccca ccctctgccc ttcagcctac 2340 tgggccaggc cggacctgcc ccctcagtgt ctctccctcc cgagtcccca gatggagacc 2400 cctttctaca ggatgacccc ttgatatttg cacagggata tttctaagaa acgcagaggc 2460 cagcgttcct ggcctctgca gccaacacag tagaaaaggc tgctgtggtt ttttaaaggc 2520 agttgtccac tagtgtccta ggccactgca gagggcagac tgctggtctc cacagatacc 2580 tgctgttctc agctccagct tcaaacctcg agtctcgaga gggccacggg gtggttttta 2640 tgaccggaat cccgcttcct ccctcacgtc tgatgtcctg aaggtgcagt cccacctgta 2700 cagcccctcc ccgccaagaa ctgtgaatgg cctgctccag gccatggctg ggggcaggga 2760 gtgaggggac aatttctgag tgaaagagaa agaatggggt cggtggtgaa ggtgctctca 2820 ctttacagaa tggagagaac atcgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 2880 tgtgtgtgtg tgtgtgtgtg tgtgtgtaag gggaggaaag ccaccttgac agcccaggtc 2940 cctccaggtc acccacagcc agtttcagga aggctgcccc tctctcccac taagttctgg 3000 cctgaaggga cctgctttct tggcctggct tccacctctc cactcctgtg tctacctggc 3060 cagtggagtg gtccatgcta agtctaacac tcctgggagc tcaggaggct tctgagcttc 3120 tcctgtactg tgcatcgtga gggccagaga caggaatgta aggattggca actgtgttac 3180 ctttcaagtt tatctcaata accaggtcat cagggaccca ttgttctctt cagaacccta 3240 tctgggagag aaggcgaacc acctccgggt ttccatcatg tcaaggtcac aggcatccat 3300 gtgtgcaaac catctgcccc agctgcctcc acagactgct gtctccttgt cctcctcggc 3360 cctgccccac ttcagggctg ctgtgagatg gaattccagg aaagaacttc aggtgtctgg 3420 accctttcta tctagataat atttttagat tcttctgctc cctagtgacc tacctggggg 3480 caaagaaatt gcaaggactt ttttttaagg gtcagagttt tcaaaacaaa agcatcttcc 3540 ctagaaattt ttgtgaattg tttgcacttg tgcctgtttt aaattaaatt gagtgttcaa 3600 agcc 3604 28 2050 DNA Homo sapiens 28 ggccagtggg gcgaaactgg cagctggccg gccctttaac acctacccga gggctgacac 60 ggaccaccca tcccggggtg cccaggggga gcctcatgac gtggccccta acgggccatc 120 agcggggggc ctggccatcc cccagtcctc ctcctcctcc tcccggcctc ccacccgagc 180 ccgaggtgcc cccagccctg gagtgctggg accccacgcc tcagagcccc agctggcccc 240 tccagcctgc acccccgccg cccctgctgt tcctgggccc cctggccccc gctcaccaca 300 gcgggagcca cagcgagtat cccatgagca gttccgggct gccctgcagc tggtggtgga 360 cccaggcgac ccccgctcct acctggacaa cttcatcaag attggcgagg gctccacggg 420 catcgtgtgc atcgccaccg tgcgcagctc gggcaagctg gtggccgtca agaagatgga 480 cctgcgcaag cagcagaggc gcgagctgct cttcaacgag gtggtaatca tgagggacta 540 ccagcacgag aatgtggtgg agatgtacaa cagctacctg gtgggggacg agctctgggt 600 ggtcatggag ttcctggaag gaggcgccct caccgacatc gtcacccaca ccaggatgaa 660 cgaggagcag atcgcggccg tgtgccttgc agtgctgcag gccctgtcgg tgctccacgc 720 ccagggcgtc atccaccggg acatcaagag cgactcgatc ctgctgaccc atgatggcag 780 ggtgaagctg tcagactttg ggttctgcgc ccaggtgagc aaggaagtgc cccgaaggaa 840 gtcgctggtc ggcacgccct actggatggc cccagagctc atctcccgcc ttccctacgg 900 gccagaggta gacatctggt cgctggggat aatggtgatt gagatggtgg acggagagcc 960 cccctacttc aacgagccac ccctcaaagc catgaagatg attcgggaca acctgccacc 1020 ccgactgaag aacctgcaca aggtgtcgcc atccctgaag ggcttcctgg accgcctgct 1080 ggtgcgagac cctgcccagc gggccacggc agccgagctg ctgaagcacc cattcctggc 1140 caaggcaggg ccgcctgcca gcatcgtgcc cctcatgcgc cagaaccgca ccagatgagg 1200 cccagcgccc ttcccctcaa ccaaagagcc cccccgggtc acccccgccc cactgaggcc 1260 agtagggggc caggcctccc actcctccca gcccgggaga tgctccgcgt ggcaccaccc 1320 tccttgctgg gggtagatga gaccctacta ctgaactcca gttttgatct cgtgactttt 1380 agaaaaacac agggactcgt gggagcaagc gaggctccca ggacccccac cctctgggac 1440 aggccctccc ccatgttctt ctgtctccag gaagggcagc ggccctccca tcactggaag 1500 tctgcagtgg gggtcgctgg gggtggagag aacactaaga ggtgaacatg tatgagtgtg 1560 tgcacgcgtg tgagtgtgca tgtgtgtgtg tgtgcaaagg tccagccacc ccgtcctcca 1620 gcccgcaagg ggtgtctggc gccttgcctg acacccagcc ccctctcccc ctgagccatt 1680 gtgggggtcg atcatgaatg tccgaagagt ggccttttcc cgtagccctg cgcccccttt 1740 ctgtggctgg atggggagac aggtcagggc cccccaccct ctccagcccc tgcagcaaat 1800 gactactgca cctggacagc ctcctctttt ctagaagtct atttatattg tcattttata 1860 acactctagc ccctgccctt attgggggac agatggtccc tgtcctgcgg ggtggccctg 1920 gcagaaccac tgcctgaaga accaggttcc tgcccggtca gcgcagcccc agcccgccca 1980 cccctgcctc gagttagttt tacaattaaa acattgtctt gttttgtgaa aaaaaaaaaa 2040 aaaaaaaaaa 2050 29 681 PRT Homo sapiens 29 Met Phe Arg Lys Lys Lys Lys Lys Arg Pro Glu Ile Ser Ala Pro Gln 1 5 10 15 Asn Phe Gln His Arg Val His Thr Ser Phe Asp Pro Lys Glu Gly Lys 20 25 30 Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile Leu Asp Thr Leu Arg 35 40 45 Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile Thr Arg Val Gln Leu 50 55 60 Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala Met Pro Val Asp Gly 65 70 75 80 Tyr Ile Ser Gly Leu Leu Asn Asp Ile Gln Lys Leu Ser Val Ile Ser 85 90 95 Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser Arg Arg Arg Ala Gln 100 105 110 Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala Thr Asp Pro Asp Met 115 120 125 Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp Pro His Gly Leu Tyr 130 135 140 Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His Lys Gln Met Pro Trp 145 150 155 160 Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn Gly Leu Ala Ala Lys 165 170 175 Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly Ala Ser Gln Arg Cys 180 185 190 Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro Pro Gly Ala Ser Pro 195 200 205 Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala Ala Lys His Gly Ser 210 215 220 Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly Ser Ala Thr Gly Arg 225 230 235 240 Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr Arg Glu Ser Ser Leu 245 250 255 Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser Thr Ala Ala Thr Ala 260 265 270 Pro Pro Ser Ser Ser Lys Pro Gly Pro Pro Pro Gln Ser Lys Pro Asn 275 280 285 Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro Pro Ser Leu Val Ala 290 295 300 Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val Gly Thr Phe Ser Pro 305 310 315 320 Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala 325 330 335 Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro 340 345 350 Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln 355 360 365 Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val 370 375 380 Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln 385 390 395 400 Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly 405 410 415 Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys His Ser Gly Arg Gln 420 425 430 Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu 435 440 445 Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln His Phe Asn Val 450 455 460 Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu Trp Val Leu 465 470 475 480 Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val Ser Gln Val 485 490 495 Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu Gln 500 505 510 Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile Lys 515 520 525 Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg Val Lys Leu Ser Asp 530 535 540 Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val Pro Lys Arg Lys Ser 545 550 555 560 Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Ile Ser Arg Ser 565 570 575 Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu Gly Ile Met Val Ile 580 585 590 Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser Asp Ser Pro Val Gln 595 600 605 Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro Lys Leu Lys Asn Ser 610 615 620 His Lys Val Ser Pro Val Leu Arg Asp Phe Leu Glu Arg Met Leu Val 625 630 635 640 Arg Asp Pro Gln Glu Arg Ala Thr Ala Gln Glu Leu Leu Asp His Pro 645 650 655 Phe Leu Leu Gln Thr Gly Leu Pro Glu Cys Leu Val Pro Leu Ile Gln 660 665 670 Leu Tyr Arg Lys Gln Thr Ser Thr Cys 675 680 30 398 PRT Homo sapiens 30 Ala Ser Gly Ala Lys Leu Ala Ala Gly Arg Pro Phe Asn Thr Tyr Pro 1 5 10 15 Arg Ala Asp Thr Asp His Pro Ser Arg Gly Ala Gln Gly Glu Pro His 20 25 30 Asp Val Ala Pro Asn Gly Pro Ser Ala Gly Gly Leu Ala Ile Pro Gln 35 40 45 Ser Ser Ser Ser Ser Ser Arg Pro Pro Thr Arg Ala Arg Gly Ala Pro 50 55 60 Ser Pro Gly Val Leu Gly Pro His Ala Ser Glu Pro Gln Leu Ala Pro 65 70 75 80 Pro Ala Cys Thr Pro Ala Ala Pro Ala Val Pro Gly Pro Pro Gly Pro 85 90 95 Arg Ser Pro Gln Arg Glu Pro Gln Arg Val Ser His Glu Gln Phe Arg 100 105 110 Ala Ala Leu Gln Leu Val Val Asp Pro Gly Asp Pro Arg Ser Tyr Leu 115 120 125 Asp Asn Phe Ile Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Ile 130 135 140 Ala Thr Val Arg Ser Ser Gly Lys Leu Val Ala Val Lys Lys Met Asp 145 150 155 160 Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile 165 170 175 Met Arg Asp Tyr Gln His Glu Asn Val Val Glu Met Tyr Asn Ser Tyr 180 185 190 Leu Val Gly Asp Glu Leu Trp Val Val Met Glu Phe Leu Glu Gly Gly 195 200 205 Ala Leu Thr Asp Ile Val Thr His Thr Arg Met Asn Glu Glu Gln Ile 210 215 220 Ala Ala Val Cys Leu Ala Val Leu Gln Ala Leu Ser Val Leu His Ala 225 230 235 240 Gln Gly Val Ile His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr 245 250 255 His Asp Gly Arg Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val 260 265 270 Ser Lys Glu Val Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp 275 280 285 Met Ala Pro Glu Leu Ile Ser Arg Leu Pro Tyr Gly Pro Glu Val Asp 290 295 300 Ile Trp Ser Leu Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro 305 310 315 320 Pro Tyr Phe Asn Glu Pro Pro Leu Lys Ala Met Lys Met Ile Arg Asp 325 330 335 Asn Leu Pro Pro Arg Leu Lys Asn Leu His Lys Val Ser Pro Ser Leu 340 345 350 Lys Gly Phe Leu Asp Arg Leu Leu Val Arg Asp Pro Ala Gln Arg Ala 355 360 365 Thr Ala Ala Glu Leu Leu Lys His Pro Phe Leu Ala Lys Ala Gly Pro 370 375 380 Pro Ala Ser Ile Val Pro Leu Met Arg Gln Asn Arg Thr Arg 385 390 395 31 1001 PRT Artificial Sequence Description of Artificial Sequence Synthetic murine/human SULU3 31 Met Pro Ser Thr Asn Arg Ala Gly Ser Leu Lys Asp Pro Glu Ile Ala 1 5 10 15 Glu Leu Phe Phe Lys Glu Asp Pro Glu Lys Leu Phe Thr Asp Leu Arg 20 25 30 Glu Ile Gly His Gly Ser Phe Gly Ala Val Tyr Phe Ala Arg Asp Val 35 40 45 Arg Thr Asn Glu Val Val Ala Ile Lys Lys Met Ser Tyr Ser Gly Lys 50 55 60 Gln Ser Thr Glu Lys Trp Gln Asp Ile Ile Lys Glu Val Lys Phe Leu 65 70 75 80 Gln Arg Ile Lys His Pro Asn Ser Ile Glu Tyr Lys Gly Cys Tyr Leu 85 90 95 Arg Glu His Thr Ala Trp Leu Val Met Glu Tyr Cys Leu Gly Ser Ala 100 105 110 Ser Asp Leu Leu Glu Val His Lys Lys Pro Leu Gln Glu Val Glu Ile 115 120 125 Ala Ala Ile Thr His Gly Ala Leu Gln Gly Leu Ala Tyr Leu His Ser 130 135 140 His Thr Met Ile His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Thr 145 150 155 160 Glu Pro Gly Gln Val Lys Leu Ala Asp Phe Gly Ser Ala Ser Met Ala 165 170 175 Ser Pro Ala Asn Ser Phe Val Gly Thr Pro Tyr Trp Met Ala Pro Glu 180 185 190 Val Ile Leu Ala Met Asp Glu Gly Gln Tyr Asp Gly Lys Val Asp Val 195 200 205 Trp Ser Leu Gly Ile Thr Cys Ile Glu Leu Ala Glu Arg Lys Pro Pro 210 215 220 Leu Phe Asn Met Asn Ala Met Ser Ala Leu Tyr His Ile Ala Gln Asn 225 230 235 240 Glu Ser Pro Thr Leu Gln Ser Asn Glu Trp Ser Asp Tyr Phe Arg Asn 245 250 255 Phe Val Asp Ser Cys Leu Gln Lys Ile Pro Gln Asp Arg Pro Thr Ser 260 265 270 Glu Glu Leu Leu Lys His Ile Phe Val Leu Arg Glu Arg Pro Glu Thr 275 280 285 Val Leu Ile Asp Leu Ile Gln Arg Thr Lys Asp Ala Val Arg Glu Leu 290 295 300 Asp Asn Leu Gln Tyr Arg Lys Met Lys Lys Leu Leu Phe Gln Glu Ala 305 310 315 320 His Asn Gly Pro Ala Val Glu Ala Gln Glu Glu Glu Glu Glu Gln Asp 325 330 335 His Gly Val Gly Arg Thr Gly Thr Val Asn Ser Val Gly Ser Asn Gln 340 345 350 Ser Ile Pro Ser Met Ser Ile Ser Ala Ser Ser Gln Ser Ser Ser Val 355 360 365 Asn Ser Leu Pro Asp Val Ser Asp Asp Lys Ser Glu Leu Asp Met Met 370 375 380 Glu Gly Asp His Thr Val Met Ser Asn Ser Ser Val Ile His Leu Lys 385 390 395 400 Pro Glu Glu Glu Asn Tyr Arg Glu Glu Gly Asp Pro Arg Thr Arg Ala 405 410 415 Ser Asp Pro Gln Ser Pro Pro Gln Val Ser Arg His Lys Ser His Tyr 420 425 430 Arg Asn Arg Glu His Phe Ala Thr Ile Arg Thr Ala Ser Leu Val Thr 435 440 445 Arg Gln Met Gln Glu His Glu Gln Asp Ser Glu Leu Arg Glu Gln Met 450 455 460 Ser Gly Tyr Lys Arg Met Arg Arg Gln His Gln Lys Gln Leu Met Thr 465 470 475 480 Leu Glu Asn Lys Leu Lys Ala Glu Met Asp Glu His Arg Leu Arg Leu 485 490 495 Asp Lys Asp Leu Glu Thr Gln Arg Asn Asn Phe Ala Ala Glu Met Glu 500 505 510 Lys Leu Ile Lys Lys His Gln Ala Ala Met Glu Lys Glu Ala Lys Val 515 520 525 Met Ser Asn Glu Glu Lys Lys Phe Gln Gln His Ile Gln Ala Gln Gln 530 535 540 Lys Lys Glu Leu Asn Ser Phe Leu Glu Ser Gln Lys Arg Glu Tyr Lys 545 550 555 560 Leu Arg Lys Glu Gln Leu Lys Glu Glu Leu Asn Glu Asn Gln Ser Thr 565 570 575 Pro Lys Lys Glu Lys Gln Glu Trp Leu Ser Lys Gln Lys Glu Asn Ile 580 585 590 Gln His Phe Gln Ala Glu Glu Glu Ala Asn Leu Leu Arg Arg Gln Arg 595 600 605 Gln Tyr Leu Glu Leu Glu Cys Arg Arg Phe Lys Arg Arg Met Leu Leu 610 615 620 Gly Arg His Asn Leu Glu Gln Asp Leu Val Arg Glu Glu Leu Asn Lys 625 630 635 640 Arg Gln Thr Gln Lys Asp Leu Glu His Ala Met Leu Leu Arg Gln His 645 650 655 Glu Ser Met Gln Glu Leu Glu Phe Arg His Leu Asn Thr Ile Gln Lys 660 665 670 Met Arg Cys Glu Leu Ile Arg Leu Gln His Gln Thr Glu Leu Thr Asn 675 680 685 Gln Leu Glu Tyr Asn Lys Arg Arg Glu Arg Glu Leu Arg Arg Lys His 690 695 700 Val Met Glu Val Arg Gln Gln Pro Lys Ser Leu Lys Ser Lys Glu Leu 705 710 715 720 Gln Ile Lys Lys Gln Phe Gln Asp Thr Cys Lys Ile Gln Thr Arg Gln 725 730 735 Tyr Lys Ala Leu Arg Asn His Leu Leu Glu Thr Thr Pro Lys Ser Glu 740 745 750 His Lys Ala Val Leu Lys Arg Leu Lys Glu Glu Gln Thr Arg Lys Leu 755 760 765 Ala Ile Leu Ala Glu Gln Tyr Asp His Ser Ile Asn Glu Met Leu Ser 770 775 780 Thr Gln Ala Leu Arg Leu Asp Glu Ala Gln Glu Ala Glu Cys Gln Val 785 790 795 800 Leu Lys Met Gln Leu Gln Gln Glu Leu Glu Leu Leu Asn Ala Tyr Gln 805 810 815 Ser Lys Ile Lys Met Gln Ala Glu Ala Gln His Asp Arg Glu Leu Arg 820 825 830 Glu Leu Glu Gln Arg Val Ser Leu Arg Arg Ala Leu Leu Glu Gln Lys 835 840 845 Ile Glu Glu Glu Met Leu Ala Leu Gln Asn Glu Arg Thr Glu Arg Ile 850 855 860 Arg Ser Leu Leu Glu Arg Gln Ala Arg Glu Ile Glu Ala Phe Asp Ser 865 870 875 880 Glu Ser Met Arg Leu Gly Phe Ser Asn Met Val Leu Ser Asn Leu Ser 885 890 895 Pro Glu Ala Phe Ser His Ser Tyr Pro Gly Ala Ser Gly Trp Ser His 900 905 910 Asn Pro Thr Gly Gly Pro Gly Pro His Trp Gly His Pro Met Gly Gly 915 920 925 Pro Pro Gln Ala Trp Gly His Pro Met Gln Gly Gly Pro Gln Pro Trp 930 935 940 Gly His Pro Ser Gly Pro Met Gln Gly Val Pro Arg Gly Ser Ser Met 945 950 955 960 Gly Val Arg Asn Ser Pro Gln Ala Leu Arg Arg Thr Ala Ser Gly Gly 965 970 975 Arg Thr Glu Gln Gly Met Ser Arg Ser Thr Ser Val Thr Ser Gln Ile 980 985 990 Ser Asn Gly Ser His Met Ser Tyr Thr 995 1000 32 25 DNA Artificial Sequence Description of Artificial Sequence Primer 32 ctgaattcgg ngcnttyggn aargt 25 33 24 DNA Artificial Sequence Description of Artificial Sequence Primer 33 gctggatccy tcnggnggca tcca 24 34 23 DNA Artificial Sequence Description of Artificial Sequence Primer 34 gcnttyggng argtntayga rgg 23 35 24 DNA Artificial Sequence Description of Artificial Sequence Primer 35 gctggatccy tcnggnswca tcca 24 36 23 DNA Artificial Sequence Description of Artificial Sequence Primer 36 gagttyggng argtnttyyt ngc 23 37 6 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 37 Gly Ala Phe Gly Lys Val 1 5 38 5 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 38 Trp Met Pro Pro Glu 1 5 39 8 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 39 Ala Phe Gly Glu Val Tyr Glu Gly 1 5 40 5 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 40 Trp Met Ser Pro Glu 1 5 41 8 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 41 Glu Phe Gly Glu Val Tyr Glu Gly 1 5 42 21 DNA Artificial Sequence Description of Artificial Sequence Primer 42 cacagaaacg gtcagattca c 21 43 22 DNA Artificial Sequence Description of Artificial Sequence Primer 43 gatcagggtg acatcaaggg ac 22 44 22 DNA Artificial Sequence Description of Artificial Sequence Primer 44 ctcatctgta cacacttcat gg 22 45 21 DNA Artificial Sequence Description of Artificial Sequence Primer 45 gattcccaca ctgtagatgt c 21 46 24 DNA Artificial Sequence Description of Artificial Sequence Primer 46 ggccctcgac tacatccacc acat 24 47 24 DNA Artificial Sequence Description of Artificial Sequence Primer 47 caacgaaact aacacagcat aagg 24 48 23 DNA Artificial Sequence Description of Artificial Sequence Primer 48 atggcgaacg actctcccgc gaa 23 49 26 DNA Artificial Sequence Description of Artificial Sequence Primer 49 acaccaaaat caacaagttt cacctc 26 50 23 DNA Artificial Sequence Description of Artificial Sequence Primer 50 agttacaagg aattccaagt tct 23 51 23 DNA Artificial Sequence Description of Artificial Sequence Primer 51 atgaagagga agaaatcaaa ctg 23 52 20 DNA Artificial Sequence Description of Artificial Sequence Primer 52 agatggactg tactgggagg 20 53 20 DNA Artificial Sequence Description of Artificial Sequence Primer 53 actttgtgca gctctgtggg 20 54 21 DNA Artificial Sequence Description of Artificial Sequence Primer 54 aaggttatgg atgtcacagg g 21 55 20 DNA Artificial Sequence Description of Artificial Sequence Primer 55 ctcacaaggt tgccaacagg 20 56 21 DNA Artificial Sequence Description of Artificial Sequence Primer 56 agtccccacc agaaggttta c 21 57 19 DNA Artificial Sequence Description of Artificial Sequence Primer 57 tcaggggtca gaggtcacg 19 58 21 DNA Artificial Sequence Description of Artificial Sequence Primer 58 cccaaaccct accacaaatt c 21 59 20 DNA Artificial Sequence Description of Artificial Sequence Primer 59 cccccgggaa acgatgacca 20 60 23 DNA Artificial Sequence Description of Artificial Sequence Primer 60 agccgctgcc cctcctctac tgt 23 61 23 DNA Artificial Sequence Description of Artificial Sequence Primer 61 accgcaacat cgccacctac tac 23 62 19 DNA Artificial Sequence Description of Artificial Sequence Primer 62 ctcgacgtcg tggaccacc 19 63 24 DNA Artificial Sequence Description of Artificial Sequence Primer 63 caatgttaac ccactctatg tctc 24 64 23 DNA Artificial Sequence Description of Artificial Sequence Primer 64 agtttgccga tgtttttctt ttc 23 65 19 DNA Artificial Sequence Description of Artificial Sequence Primer 65 ccgccatgaa ccccggctt 19 66 21 DNA Artificial Sequence Description of Artificial Sequence Primer 66 cgattgccaa agaccgtgtc a 21 67 23 DNA Artificial Sequence Description of Artificial Sequence Primer 67 agaagttgca gctgttgaga gga 23 68 21 DNA Artificial Sequence Description of Artificial Sequence Primer 68 tatggcccgt gtaaggattt c 21 69 23 DNA Artificial Sequence Description of Artificial Sequence Primer 69 gtgccagaag tgttgtgttg taa 23 70 22 DNA Artificial Sequence Description of Artificial Sequence Primer 70 tattgaattg gcggaacgga ag 22 71 24 DNA Artificial Sequence Description of Artificial Sequence Primer 71 ttgttttgtg ctcattcttt ggag 24 72 24 DNA Artificial Sequence Description of Artificial Sequence Primer 72 gattgctttg tgctcattct ttgg 24 73 21 DNA Artificial Sequence Description of Artificial Sequence Primer 73 ttgttctaag agtgccctcc g 21 74 19 DNA Artificial Sequence Description of Artificial Sequence Primer 74 aagaccatgc cgtgcgccg 19 75 23 DNA Artificial Sequence Description of Artificial Sequence Primer 75 attccttcag gttctggtta tgg 23 76 19 DNA Artificial Sequence Description of Artificial Sequence Primer 76 agtccgccaa gcctcaatg 19 77 21 DNA Artificial Sequence Description of Artificial Sequence Primer 77 caccttcagc tgctctatca t 21 78 12 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 540A 78 His Gly Asp Pro Arg Pro Glu Pro Arg Pro Thr Gln 1 5 10 79 10 PRT Artificial Sequence Description of Artificial Sequence Syntbetic peptide 539A 79 Cys Leu Asp Phe Pro Lys Glu Asp Tyr Arg 1 5 10 80 19 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 541A 80 Asp Pro Arg Thr Arg Ala Ser Asp Pro Gln Ser Pro Pro Gln Val Ser 1 5 10 15 Arg His Lys 81 14 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 542A 81 Pro Ser Thr Asn Arg Ala Gly Ser Leu Lys Asp Pro Glu Cys 1 5 10 82 15 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 554A 82 Cys Leu Val Pro Leu Ile Gln Leu Tyr Arg Lys Gln Thr Ser Thr 1 5 10 15 83 10 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 579A 83 Cys Pro Leu Met Arg Gln Asn Arg Thr Arg 1 5 10 84 426 PRT Homo sapiens 84 Met Ala His Leu Arg Gly Phe Ala Asn Gln His Ser Arg Val Asp Pro 1 5 10 15 Glu Glu Leu Phe Thr Lys Leu Asp Arg Ile Gly Lys Gly Ser Phe Gly 20 25 30 Glu Val Tyr Lys Gly Ile Asp Asn His Thr Lys Glu Val Val Ala Ile 35 40 45 Lys Ile Ile Asp Leu Glu Glu Ala Glu Asp Glu Ile Glu Asp Ile Gln 50 55 60 Gln Glu Ile Thr Val Leu Ser Gln Cys Asp Ser Pro Tyr Ile Thr Arg 65 70 75 80 Tyr Phe Gly Ser Tyr Leu Lys Ser Thr Lys Leu Trp Ile Ile Met Glu 85 90 95 Tyr Leu Gly Gly Gly Ser Ala Leu Asp Leu Leu Lys Pro Gly Pro Leu 100 105 110 Glu Glu Thr Tyr Ile Ala Thr Ile Leu Arg Glu Ile Leu Lys Gly Leu 115 120 125 Asp Tyr Leu His Ser Glu Arg Lys Ile His Arg Asp Ile Lys Ala Ala 130 135 140 Asn Val Leu Leu Ser Glu Gln Gly Asp Val Lys Leu Ala Asp Phe Gly 145 150 155 160 Val Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg Asn Thr Phe Val 165 170 175 Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Lys Gln Ser Ala Tyr 180 185 190 Asp Phe Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile Glu Leu 195 200 205 Ala Lys Gly Glu Pro Pro Asn Ser Asp Leu His Pro Met Arg Val Leu 210 215 220 Phe Leu Ile Pro Lys Asn Ser Pro Pro Thr Leu Glu Gly Gln His Ser 225 230 235 240 Lys Pro Phe Lys Glu Phe Val Glu Ala Cys Leu Asn Lys Asp Pro Arg 245 250 255 Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys His Lys Phe Ile Thr Arg 260 265 270 Tyr Thr Lys Lys Thr Ser Phe Leu Thr Glu Leu Ile Asp Arg Tyr Lys 275 280 285 Arg Trp Lys Ser Glu Gly His Gly Glu Glu Ser Ser Ser Glu Asp Ser 290 295 300 Asp Ile Asp Gly Glu Ala Glu Asp Gly Glu Gln Gly Pro Ile Trp Thr 305 310 315 320 Phe Pro Pro Thr Ile Arg Pro Ser Pro His Ser Lys Leu His Lys Gly 325 330 335 Thr Ala Leu His Ser Ser Gln Lys Pro Ala Glu Pro Val Lys Arg Gln 340 345 350 Pro Arg Ser Gln Cys Leu Ser Thr Leu Val Arg Pro Val Phe Gly Glu 355 360 365 Leu Lys Glu Lys His Lys Gln Ser Gly Gly Ser Val Gly Ala Leu Glu 370 375 380 Glu Leu Glu Asn Ala Phe Ser Leu Ala Glu Glu Ser Cys Pro Gly Ile 385 390 395 400 Ser Asp Lys Leu Met Val His Leu Val Glu Arg Val Gln Arg Phe Ser 405 410 415 His Asn Arg Asn His Leu Thr Ser Thr Arg 420 425 85 431 PRT Homo sapiens 85 Met Ala His Ser Pro Val Gln Ser Gly Leu Pro Gly Met Gln Asn Leu 1 5 10 15 Lys Ala Asp Pro Glu Glu Leu Phe Thr Lys Leu Glu Lys Ile Gly Lys 20 25 30 Gly Ser Phe Gly Glu Val Phe Lys Gly Ile Asp Asn Arg Thr Gln Lys 35 40 45 Val Val Ala Ile Lys Ile Ile Asp Leu Glu Glu Ala Glu Asp Glu Ile 50 55 60 Glu Asp Ile Gln Gln Glu Ile Thr Val Leu Ser Gln Cys Asp Ser Pro 65 70 75 80 Tyr Val Thr Lys Tyr Tyr Gly Ser Tyr Leu Lys Asp Thr Lys Leu Trp 85 90 95 Ile Ile Met Glu Tyr Leu Gly Gly Gly Ser Ala Leu Asp Leu Leu Glu 100 105 110 Pro Gly Pro Leu Asp Glu Thr Gln Ile Ala Thr Ile Leu Arg Glu Ile 115 120 125 Leu Lys Gly Leu Asp Tyr Leu His Ser Glu Lys Lys Ile His Arg Asp 130 135 140 Ile Lys Ala Ala Asn Val Leu Leu Ser Glu His Gly Glu Val Lys Leu 145 150 155 160 Ala Asp Phe Gly Val Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg 165 170 175 Asn Thr Phe Val Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Lys 180 185 190 Gln Ser Ala Tyr Asp Ser Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr 195 200 205 Ala Ile Glu Leu Ala Arg Gly Glu Pro Pro His Ser Glu Leu His Pro 210 215 220 Met Lys Val Leu Phe Leu Ile Pro Lys Asn Asn Pro Pro Thr Leu Glu 225 230 235 240 Gly Asn Tyr Ser Lys Pro Leu Lys Glu Phe Val Glu Ala Cys Leu Asn 245 250 255 Lys Glu Pro Ser Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys His Lys 260 265 270 Phe Ile Leu Arg Asn Ala Lys Lys Thr Ser Tyr Leu Thr Glu Leu Ile 275 280 285 Asp Arg Tyr Lys Arg Trp Lys Ala Glu Gln Ser His Asp Asp Ser Ser 290 295 300 Ser Glu Asp Ser Asp Ala Glu Thr Asp Gly Gln Ala Ser Gly Gly Ser 305 310 315 320 Asp Ser Gly Asp Trp Ile Phe Thr Ile Arg Glu Lys Asp Pro Lys Asn 325 330 335 Leu Glu Asn Gly Ala Leu Gln Pro Ser Asp Leu Asp Arg Asn Lys Met 340 345 350 Lys Asp Ile Pro Lys Arg Pro Phe Ser Gln Cys Leu Ser Thr Ile Ile 355 360 365 Ser Pro Leu Phe Ala Glu Leu Lys Glu Lys Ser Gln Ala Cys Gly Gly 370 375 380 Asn Leu Gly Ser Ile Glu Glu Leu Arg Gly Ala Ile Tyr Leu Ala Glu 385 390 395 400 Glu Ala Cys Pro Gly Ile Ser Asp Thr Met Val Ala Gln Leu Val Gln 405 410 415 Arg Leu Gln Arg Tyr Ser Leu Ser Gly Gly Gly Thr Ser Ser His 420 425 430 86 443 PRT Caenorhabditis elegans MOD_RES (389)..(390) Any amino acid 86 Met Thr Thr Thr Ser Ser Asp Glu Leu Pro Arg Gln Ala Asp Asp Asp 1 5 10 15 Ser Met Lys Trp Asp Arg Ile Tyr Ile Gln Lys Leu Asp Pro Glu Val 20 25 30 Ile Phe Thr Lys Gln Glu Arg Ile Gly Arg Gly Ser Phe Gly Glu Val 35 40 45 Tyr Lys Gly Ile Asp Asn Arg Thr Gly Arg Val Val Ala Ile Lys Ile 50 55 60 Ile Asp Leu Glu Gln Ala Glu Asp Glu Ile Glu Asp Ile Gln Gln Glu 65 70 75 80 Ile Gln Val Leu Ser Gln Cys Asp Ser Gln Tyr Val Thr Lys Tyr Phe 85 90 95 Gly Ser Phe Leu Lys Gly Ser Lys Leu Trp Ile Ile Met Glu Tyr Leu 100 105 110 Gly Gly Gly Ser Ala Leu Asp Leu Thr Lys Ser Gly Lys Leu Asp Glu 115 120 125 Ser His Ile Ala Val Ile Leu Arg Glu Ile Leu Lys Gly Leu Glu Tyr 130 135 140 Leu His Ser Glu Arg Lys Ile His Arg Asp Ile Lys Ala Ala Asn Val 145 150 155 160 Leu Val Ser Glu His Gly Asp Val Lys Val Ala Asp Phe Gly Val Ala 165 170 175 Gly Gln Leu Thr Glu Thr Val Lys Lys Arg Ile Thr Phe Val Gly Ser 180 185 190 Pro Phe Trp Met Ala Pro Glu Leu Ile Lys Gln Ser Ser Tyr Asp Tyr 195 200 205 Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile Glu Leu Ala Asn 210 215 220 Gly Glu Pro Pro His Ser Asp Leu His Pro Met Arg Val Leu Phe Leu 225 230 235 240 Ile Pro Lys Asn Pro Pro Pro Val Leu Gln Gly Ser Gln Trp Ser Lys 245 250 255 Pro Phe Lys Glu Phe Val Glu Met Cys Leu Asn Lys Asp Pro Glu Asn 260 265 270 Arg Pro Ser Ala Ser Thr Leu Leu Lys His Gln Phe Ile Lys Arg Ala 275 280 285 Lys Lys Asn Ser Ile Leu Val Asp Leu Ile Glu Arg Ala Ala Glu Tyr 290 295 300 Arg Leu Arg Thr Gly Val Ser Ser Asp Ser Asp Leu Asp Glu Asp Ser 305 310 315 320 Asp Gly Gly Gly Gly Thr Ser Lys Trp Asp Tyr Pro Thr Val Arg Gly 325 330 335 Pro Arg Val Ser Ala Asp Asp Asp Gly Thr Val Arg Gln Arg Thr Asp 340 345 350 Arg Pro Arg Ala Gln Val Asp Arg Arg Ser Pro Ser Gly Ser Pro Gly 355 360 365 Gly Thr Ile Val Arg Gly Ser Pro Gln Val Ala Ala Val Ala Glu Gln 370 375 380 Leu Arg Asn Ser Xaa Xaa Ala Leu Asp Gln Leu Arg His Val Phe Arg 385 390 395 400 Asp Val Glu Asp Ser Cys Pro Gly Ile Cys Asn Glu Leu Ile Glu Glu 405 410 415 Leu Met Gln Arg Ile Ala Val Pro Gln Val Ser Gln Ser Asp Leu Asp 420 425 430 Ala Ala Ile Arg Arg Leu Thr Thr Pro Pro Ser 435 440 87 275 PRT Saccharomyces pombe 87 Leu Leu Tyr Arg Asn Phe Val Lys Ile Gly Gln Gly Ala Ser Gly Asp 1 5 10 15 Val Tyr Ser Ala Arg Gln Val Gly Thr Asn Leu Ser Val Ala Ile Lys 20 25 30 Lys Met Asn Ile Asn Gln Gln Pro Lys Lys Glu Phe Ile Val Asn Glu 35 40 45 Ile Leu Val Met Lys Ser His His His Lys Asn Ile Val Asn Phe Ile 50 55 60 Asp Thr Phe Phe Tyr Lys Ser Glu Leu Trp Met Val Met Glu Tyr Met 65 70 75 80 Arg Gly Gly Ser Leu Thr Glu Val Val Thr Asn Asn Thr Leu Ser Glu 85 90 95 Gly Gln Ile Ala Ala Ile Cys Lys Glu Thr Leu Glu Gly Leu Gln His 100 105 110 Leu His Glu Asn Gly Ile Val His Arg Asp Ile Lys Ser Asp Asn Ile 115 120 125 Leu Leu Ser Leu Gln Gly Asp Ile Lys Leu Thr Asp Phe Gly Phe Cys 130 135 140 Ala Gln Ile Asp Ser Asn Met Thr Lys Arg Thr Thr Met Val Gly Thr 145 150 155 160 Pro Tyr Trp Met Ala Pro Glu Val Val Thr Arg Lys Glu Tyr Gly Phe 165 170 175 Lys Val Asp Val Trp Ser Leu Gly Ile Met Ala Ile Glu Met Val Glu 180 185 190 Gly Glu Pro Pro Tyr Leu Asn Glu Asn Pro Leu Arg Ala Leu Tyr Leu 195 200 205 Ile Ala Thr Ile Gly Thr Pro Lys Ile Ser Arg Pro Glu Leu Leu Ser 210 215 220 Ser Val Phe His Asp Phe Leu Ser Lys Ser Leu Thr Val Asn Pro Lys 225 230 235 240 Gln Arg Pro Ser Ser Gly Glu Leu Leu Arg His Pro Phe Leu Lys Gln 245 250 255 Ala Val Pro Val Ser Ser Leu Ile Pro Leu Ile Lys Ser Ile His His 260 265 270 Ser Gly Lys 275 88 1109 PRT Caenorhabditis elegans 88 Met Ser Ser Ser Gly Leu Asp Glu Ile Asp Leu Asn Ser Leu Arg Asp 1 5 10 15 Pro Ala Gly Ile Phe Glu Leu Ile Glu Val Val Gly Asn Gly Thr Tyr 20 25 30 Gly Gln Val Tyr Lys Gly Arg His Val Lys Thr Ala Gln Leu Ala Ala 35 40 45 Ile Lys Ile Met Asn Ile Asn Glu Asp Glu Glu Asp Glu Ile Lys Leu 50 55 60 Glu Ile Asn Met Leu Lys Lys His Ser His His Arg Asn Val Ala Thr 65 70 75 80 Tyr Tyr Gly Ala Phe Ile Lys Lys Leu Pro Ser Ser Thr Gly Lys His 85 90 95 Asp Gln Leu Trp Leu Val Met Glu Phe Cys Gly Ser Gly Ser Ile Thr 100 105 110 Asp Leu Val Lys Asn Thr Lys Gly Gly Ser Leu Lys Glu Glu Trp Ile 115 120 125 Ala Tyr Ile Cys Arg Glu Ile Leu Arg Gly Leu Tyr His Leu His Gln 130 135 140 Ser Lys Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr 145 150 155 160 Asp Ser Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Leu 165 170 175 Asp Lys Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp 180 185 190 Met Ala Pro Glu Val Ile Ala Cys Asp Glu Ser Pro Glu Ala Thr Tyr 195 200 205 Asp Ser Arg Ser Asp Leu Trp Ser Leu Gly Ile Thr Ala Leu Glu Met 210 215 220 Ala Glu Gly His Pro Pro Leu Cys Asp Met His Pro Met Arg Ala Leu 225 230 235 240 Phe Leu Ile Pro Arg Asn Pro Pro Pro Lys Leu Lys Arg Asn Lys Lys 245 250 255 Trp Thr Lys Lys Phe Glu Thr Phe Ile Glu Thr Val Leu Val Lys Asp 260 265 270 Tyr His Gln Arg Pro Tyr Thr Gly Ala Leu Leu Arg His Pro Phe Ile 275 280 285 Lys Glu Gln Pro His Glu Gln Thr Ile Arg His Ser Ile Lys Glu His 290 295 300 Ile Asp Arg Asn Arg Arg Val Lys Lys Asp Asp Ala Asp Tyr Glu Tyr 305 310 315 320 Ser Gly Ser Glu Asp Asp Glu Pro Ser Pro Asn Asn Arg Asp Asp Ser 325 330 335 Glu Ser Ser Ser Met Ile Pro Met Asp Asn Thr Leu Arg Lys Gly Phe 340 345 350 Gln Lys Leu Gln Glu Ser Ser Arg Gly Phe Ala Glu Pro Gly Ala Gln 355 360 365 Gln Leu Arg Arg Leu Pro Gln Gln Pro Ala Pro Ala Pro Phe Gln Tyr 370 375 380 Gln Gln Ser Arg Tyr Val Glu Pro Arg Arg Glu Ser Ser Glu Val Lys 385 390 395 400 Leu Arg Ala Val Ser Ser Arg Gly Ala Ala Asp Gly Pro Arg His Ser 405 410 415 Pro Ala Ser Arg Pro Arg Pro Arg Ser Pro Gln Gln Ser His Pro Ala 420 425 430 Ala Pro His Leu Ala Asp Leu Ala Asn Tyr Glu Lys Arg Arg Arg Ser 435 440 445 Glu Arg Glu Glu Arg Arg Glu Arg Glu Arg Gln Ala His His Ala Met 450 455 460 Pro Ile Ala Arg Val Ser Ala Ser Val Pro Ala Pro Gln Gln Ser Arg 465 470 475 480 Lys Met Ser Glu Pro Leu Leu Ile Thr His Val Lys Pro Glu Asp Leu 485 490 495 Asp Val Leu Ala Ser Glu Leu Ser Lys Met Gly Gly His His Asn Gly 500 505 510 Arg Ser Arg Glu Glu Ser Met Ser Pro Pro Pro Pro Ala Pro Pro Pro 515 520 525 Arg Glu Ala Ser Ile Ser Ser Ile Thr Asp Thr Ile Asp Val Gly Glu 530 535 540 Leu Asp Asn Gly Ala Asp Ala Glu Trp Asp Asp Leu Lys Asp Ile Met 545 550 555 560 Met Asn Gly Glu Gly Thr Leu Arg Gly Pro Asn Lys Pro Leu Pro Pro 565 570 575 Thr Pro Thr Asp Gly Glu Asn Thr Leu Val Ser Asp Val Arg Arg Asn 580 585 590 Gly Asn Gly Asn Ser Gly His Gly Ala Tyr Lys Gly Lys Lys Ile Pro 595 600 605 Glu Ile Arg Pro Gly Ile Ile Ser Leu Asp Asp Asp Asp Ser Asp Ser 610 615 620 Asp Asn Glu Glu Gly Asn Glu Pro Leu Met Phe Lys Pro Ile Val Arg 625 630 635 640 Cys Pro Phe Ser Ile Phe Phe Trp Phe Leu Ser Ala Asn Val Ile His 645 650 655 Ser Val Asp Gly Ser Ile Pro Leu Val Lys His Leu Ile Trp Phe Gln 660 665 670 Asn Ala Ser Ser Ser Arg Gly Ala Leu Pro Asp Leu Leu Pro Lys Ser 675 680 685 Pro Asp Leu Arg Arg Gln Ile Asn Asp Gln Thr Arg Gln Met Ser Asp 690 695 700 Asp Arg Ala Asp Glu Gln Pro Asn Gly Phe Gln Asn Ser Asp Ser Arg 705 710 715 720 Ser Ser Ile Gln His Ser Phe Ser Asn Arg Asp Arg Glu Lys Ser Phe 725 730 735 Val Gly Tyr Phe Gly Gly Gly Ala Gly Ala Gly Gly Gly Thr Val Asn 740 745 750 Arg Pro Gly Arg Pro Gln Asp Ile Asn Gln Val Gln Val Asn Val Thr 755 760 765 Pro Asn Ser Asn Gly Thr Pro Ala Glu Asn Asp Ala Pro Glu Ile Arg 770 775 780 Lys Tyr Lys Lys Lys Phe Ser Gly Glu Ile Leu Cys Ala Ala Leu Trp 785 790 795 800 Gly Val Asn Leu Leu Ile Gly Thr Asp Ser Gly Leu Met Leu Leu Asp 805 810 815 Arg Ser Gly Gln Gly Lys Val Tyr Pro Leu Ile Ser Arg Arg Arg Phe 820 825 830 Asp Gln Met Thr Val Leu Glu Gly Gln Asn Ile Leu Ala Thr Ile Ser 835 840 845 Gly Arg Lys Arg Arg Ile Arg Val Tyr Tyr Leu Ser Trp Leu Arg Gln 850 855 860 Lys Ile Leu Arg Thr Glu Gly Ala Gly Ser Ala Asn Thr Thr Glu Lys 865 870 875 880 Arg Asn Gly Trp Val Asn Val Gly Asp Leu Gln Gly Ala Ile His Phe 885 890 895 Lys Ile Val Arg Tyr Glu Arg Ile Lys Phe Leu Val Val Gly Leu Glu 900 905 910 Ser Ser Ile Glu Ile Tyr Ala Trp Ala Pro Lys Pro Tyr His Lys Phe 915 920 925 Met Ser Phe Lys Ser Phe Gly Ser Leu Ser His Val Pro Leu Ile Val 930 935 940 Asp Leu Thr Val Glu Asp Asn Ala Arg Leu Lys Val Leu Tyr Gly Ser 945 950 955 960 Thr Gly Gly Phe His Ala Ile Asp Leu Asp Ser Ala Ala Val Tyr Asp 965 970 975 Ile Tyr Thr Pro Ala Gln Ser Gly Gln Thr Thr Thr Pro His Cys Ile 980 985 990 Val Val Leu Pro Asn Ser Asn Gly Met Gln Leu Leu Leu Cys Tyr Asp 995 1000 1005 Asn Glu Gly Val Tyr Val Asn Thr Tyr Gly Arg Met Thr Lys Asn Val 1010 1015 1020 Val Leu Gln Trp Gly Glu Met Pro Ser Ser Val Ala Tyr Ile Ser Thr 1025 1030 1035 1040 Gly Gln Ile Met Gly Trp Gly Asn Lys Ala Ile Glu Ile Arg Ser Val 1045 1050 1055 Asp Thr Gly His Leu Asp Gly Val Phe Met His Lys Lys Ala Gln Lys 1060 1065 1070 Leu Lys Phe Leu Cys Glu Arg Asn Asp Lys Val Phe Phe Ser Ser Ala 1075 1080 1085 Lys Gly Gly Gly Ser Cys Gln Ile Tyr Phe Met Thr Leu Asn Lys Pro 1090 1095 1100 Gly Leu Thr Asn Trp 1105 89 1233 PRT Murine sp. 89 Met Ala Asn Asp Ser Pro Ala Lys Ser Leu Val Asp Ile Asp Leu Ser 1 5 10 15 Ser Leu Arg Asp Pro Ala Gly Ile Phe Glu Leu Val Glu Val Val Gly 20 25 30 Asn Gly Thr Tyr Gly Gln Val Tyr Lys Gly Arg His Val Lys Thr Val 35 40 45 Thr Ala Ala Ile Lys Val Met Asp Val Thr Glu Asp Glu Glu Glu Glu 50 55 60 Ile Thr Leu Glu Ile Asn Met Leu Lys Lys Tyr Ser His His Arg Asn 65 70 75 80 Ile Ala Thr Tyr Tyr Gly Ala Phe Ile Lys Lys Ser Pro Pro Gly His 85 90 95 Asp Asp Gln Leu Trp Leu Val Met Glu Phe Cys Gly Ala Gly Ser Ile 100 105 110 Thr Asp Leu Val Lys Asn Thr Lys Gly Asn Thr Leu Lys Glu Asp Trp 115 120 125 Ile Ala Tyr Ile Ser Arg Glu Ile Leu Arg Gly Leu Ala His Leu His 130 135 140 Ile His His Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu 145 150 155 160 Thr Glu Asn Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln 165 170 175 Leu Asp Arg Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr 180 185 190 Trp Met Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala Thr 195 200 205 Tyr Asp Tyr Arg Ser Asp Leu Trp Ser Cys Gly Ile Thr Ala Ile Glu 210 215 220 Met Ala Glu Gly Gly Pro Pro Leu Cys Asp Met His Pro Met Arg Ala 225 230 235 240 Leu Phe Leu Ile Pro Arg Asn Pro Pro Pro Arg Leu Lys Ser Lys Lys 245 250 255 Trp Ser Lys Lys Phe Phe Ser Phe Ile Glu Gly Cys Leu Val Lys Asn 260 265 270 Tyr Met Gln Arg Pro Ser Thr Glu Gln Leu Leu Lys His Pro Phe Ile 275 280 285 Arg Asp Gln Pro Asn Glu Arg Gln Val Arg Ile Gln Leu Lys Asp His 290 295 300 Ile Asp Arg Thr Arg Lys Lys Arg Gly Glu Lys Asp Glu Thr Glu Tyr 305 310 315 320 Glu Tyr Ser Gly Ser Glu Glu Glu Glu Glu Glu Val Pro Glu Gln Glu 325 330 335 Gly Glu Pro Ser Ser Ile Val Asn Val Pro Gly Glu Ser Thr Leu Arg 340 345 350 Arg Asp Phe Leu Arg Leu Gln Gln Glu Asn Lys Glu Arg Ser Glu Ala 355 360 365 Leu Arg Arg Gln Gln Leu Leu Gln Glu Gln Gln Leu Arg Glu Gln Glu 370 375 380 Glu Tyr Lys Arg Gln Leu Leu Ala Glu Arg Gln Lys Arg Ile Glu Gln 385 390 395 400 Gln Lys Glu Gln Arg Arg Arg Leu Glu Glu Gln Gln Arg Arg Glu Arg 405 410 415 Glu Ala Arg Arg Gln Gln Glu Arg Glu Gln Arg Arg Arg Glu Gln Glu 420 425 430 Glu Lys Arg Arg Leu Glu Glu Leu Glu Arg Arg Arg Lys Glu Glu Glu 435 440 445 Glu Arg Arg Arg Ala Glu Glu Glu Lys Arg Arg Val Glu Arg Glu Gln 450 455 460 Glu Tyr Ile Arg Arg Gln Leu Glu Glu Glu Gln Arg His Leu Glu Ile 465 470 475 480 Leu Gln Gln Gln Leu Leu Gln Glu Gln Ala Met Leu Leu His Asp His 485 490 495 Arg Arg Pro His Ala Gln Gln Gln Pro Pro Pro Pro Gln Gln Gln Asp 500 505 510 Arg Ser Lys Pro Ser Phe His Ala Pro Glu Pro Lys Pro His Tyr Asp 515 520 525 Pro Ala Asp Arg Ala Arg Glu Val Gln Trp Ser His Leu Ala Ser Leu 530 535 540 Lys Asn Asn Val Ser Pro Val Ser Arg Ser His Ser Phe Ser Asp Pro 545 550 555 560 Ser Pro Lys Phe Ala His His His Leu Arg Ser Gln Asp Pro Cys Pro 565 570 575 Pro Ser Arg Ser Glu Gly Leu Ser Gln Ser Ser Asp Ser Lys Ser Glu 580 585 590 Val Pro Glu Pro Thr Gln Lys Ala Trp Ser Arg Ser Asp Ser Asp Glu 595 600 605 Val Pro Pro Arg Val Pro Val Arg Thr Thr Ser Arg Ser Pro Val Leu 610 615 620 Ser Arg Arg Asp Ser Pro Leu Gln Gly Gly Gly Gln Gln Asn Ser Gln 625 630 635 640 Ala Gly Gln Arg Asn Ser Thr Ser Ser Ile Glu Pro Arg Leu Leu Trp 645 650 655 Glu Arg Val Glu Lys Leu Val Pro Arg Pro Gly Ser Gly Ser Ser Ser 660 665 670 Gly Ser Ser Asn Ser Gly Ser Gln Pro Gly Ser His Pro Gly Ser Gln 675 680 685 Ser Gly Ser Gly Glu Arg Phe Arg Val Arg Ser Ser Ser Lys Ser Glu 690 695 700 Gly Ser Pro Ser Pro Arg Gln Glu Ser Ala Ala Lys Lys Pro Asp Asp 705 710 715 720 Lys Lys Glu Val Phe Arg Ser Leu Lys Pro Ala Gly Glu Val Asp Leu 725 730 735 Thr Ala Leu Ala Lys Glu Leu Arg Ala Val Glu Asp Val Arg Pro Pro 740 745 750 His Lys Val Thr Asp Tyr Ser Ser Ser Ser Glu Glu Ser Gly Thr Thr 755 760 765 Asp Glu Glu Glu Glu Asp Val Glu Gln Glu Gly Ala Asp Asp Ser Thr 770 775 780 Ser Gly Pro Glu Asp Thr Arg Ala Ala Ser Ser Pro Asn Leu Ser Asn 785 790 795 800 Gly Glu Thr Glu Ser Val Lys Thr Met Ile Val His Asp Asp Val Glu 805 810 815 Ser Glu Pro Ala Met Thr Pro Ser Lys Glu Gly Thr Leu Ile Val Arg 820 825 830 Gln Thr Gln Ser Ala Ser Ser Thr Leu Gln Lys His Lys Ser Ser Ser 835 840 845 Ser Phe Thr Pro Phe Ile Asp Pro Arg Leu Leu Gln Ile Ser Pro Ser 850 855 860 Ser Gly Thr Thr Val Thr Ser Val Val Gly Phe Ser Cys Asp Gly Leu 865 870 875 880 Arg Pro Glu Ala Ile Arg Gln Asp Pro Thr Arg Lys Gly Ser Val Val 885 890 895 Asn Val Asn Pro Thr Asn Thr Arg Pro Gln Ser Asp Thr Pro Glu Ile 900 905 910 Arg Lys Tyr Lys Lys Arg Phe Asn Ser Glu Ile Leu Cys Ala Ala Leu 915 920 925 Trp Gly Val Asn Leu Leu Val Gly Thr Glu Ser Gly Leu Met Leu Leu 930 935 940 Asp Arg Ser Gly Gln Gly Lys Val Tyr Pro Leu Ile Ser Arg Arg Arg 945 950 955 960 Phe Gln Gln Met Asp Val Leu Glu Gly Leu Asn Val Leu Val Thr Ile 965 970 975 Ser Gly Lys Lys Asp Lys Leu Arg Val Tyr Tyr Leu Ser Trp Leu Arg 980 985 990 Asn Lys Ile Leu His Asn Asp Pro Glu Val Glu Lys Lys Gln Gly Trp 995 1000 1005 Thr Thr Val Gly Asp Leu Glu Gly Cys Val His Tyr Lys Val Val Lys 1010 1015 1020 Tyr Glu Arg Ile Lys Phe Leu Val Ile Ala Leu Lys Ser Ser Val Glu 1025 1030 1035 1040 Val Tyr Ala Trp Ala Pro Lys Pro Tyr His Lys Phe Met Ala Phe Lys 1045 1050 1055 Ser Phe Gly Glu Leu Leu His Lys Pro Leu Leu Val Asp Leu Thr Val 1060 1065 1070 Glu Glu Gly Gln Arg Leu Lys Val Ile Tyr Gly Ser Cys Ala Gly Phe 1075 1080 1085 His Ala Val Asp Val Asp Ser Gly Ser Val Tyr Asp Ile Tyr Leu Pro 1090 1095 1100 Thr His Ile Gln Cys Ser Ile Lys Pro His Ala Ile Ile Ile Leu Pro 1105 1110 1115 1120 Asn Thr Asp Gly Met Glu Leu Leu Val Cys Tyr Glu Asp Glu Gly Val 1125 1130 1135 Tyr Val Asn Thr Tyr Gly Arg Ile Thr Lys Asp Val Val Leu Gln Trp 1140 1145 1150 Gly Glu Met Pro Thr Ser Val Ala Tyr Ile Arg Ser Asn Gln Thr Met 1155 1160 1165 Gly Trp Gly Glu Lys Ala Ile Glu Ile Arg Ser Val Glu Thr Gly His 1170 1175 1180 Leu Asp Gly Val Phe Met His Lys Arg Ala Gln Arg Leu Lys Phe Leu 1185 1190 1195 1200 Cys Gly Arg Asn Asp Lys Val Phe Phe Ser Ser Val Arg Ser Gly Gly 1205 1210 1215 Ser Ser Gln Val Tyr Phe Met Thr Leu Gly Arg Thr Ser Leu Leu Ser 1220 1225 1230 Trp 90 982 PRT Caenorhabditis elegans 90 Met Ala Pro Ala Val Leu Asp Lys Pro Gly Val Ile Lys Asp Pro Ser 1 5 10 15 Ile Ala Ala Leu Phe Ser Asn Lys Asp Pro Glu Gln Arg Tyr Gln Asp 20 25 30 Leu Arg Glu Ile Gly His Gly Ser Phe Gly Ala Val Tyr Phe Ala Tyr 35 40 45 Asp Lys Lys Asn Glu Gln Thr Val Ala Ile Lys Lys Met Asn Phe Ser 50 55 60 Gly Lys Gln Ala Val Glu Lys Trp Asn Asp Ile Leu Lys Glu Val Ser 65 70 75 80 Phe Leu Asn Thr Val Val His Pro His Ile Val Asp Tyr Lys Ala Cys 85 90 95 Phe Leu Lys Asp Thr Thr Cys Trp Leu Val Met Glu Tyr Cys Ile Gly 100 105 110 Ser Ala Ala Asp Ile Val Asp Val Leu Arg Lys Gly Met Arg Glu Val 115 120 125 Glu Ile Ala Ala Ile Cys Ser Gln Thr Leu Asp Ala Leu Arg Tyr Leu 130 135 140 His Ser Leu Lys Arg Ile His Arg Asp Ile Lys Ala Gly Asn Ile Leu 145 150 155 160 Leu Ser Asp His Ala Ile Val Lys Leu Ala Asp Phe Gly Ser Ala Ser 165 170 175 Leu Val Asp Pro Ala Gln Thr Phe Ile Gly Thr Pro Phe Phe Met Ala 180 185 190 Pro Glu Val Ile Leu Ala Met Asp Glu Gly His Tyr Thr Asp Arg Ala 195 200 205 Asp Ile Trp Ser Leu Gly Ile Thr Cys Ile Glu Leu Ala Glu Arg Arg 210 215 220 Pro Pro Leu Phe Ser Met Asn Ala Met Ser Ala Leu Tyr His Ile Ala 225 230 235 240 Gln Asn Asp Pro Pro Thr Leu Ser Pro Ile Asp Thr Ser Glu Gln Pro 245 250 255 Glu Trp Ser Leu Glu Phe Val Gln Phe Ile Asp Lys Cys Leu Arg Lys 260 265 270 Pro Ala Glu Glu Arg Met Ser Ala Glu Glu Cys Phe Arg His Pro Phe 275 280 285 Ile Gln Arg Ser Arg Pro Ser Asp Thr Ile Gln Glu Leu Ile Gln Arg 290 295 300 Thr Lys Asn Met Val Leu Glu Leu Asp Asn Phe Gln Tyr Lys Lys Met 305 310 315 320 Arg Lys Leu Met Tyr Leu Asp Glu Thr Glu Gly Lys Glu Gly Ser Glu 325 330 335 Gly Asn Gly Ala Ser Asp Asp Leu Asp Phe His Gly Asn Glu Ala Asn 340 345 350 Ser Ile Gly Arg Ala Gly Asp Ser Ala Ser Ser Arg Ser Ala Ser Leu 355 360 365 Thr Ser Phe Arg Ser Met Gln Ser Ser Gly Gly Ala Gly Leu Leu Val 370 375 380 Ser Thr Asn Thr Thr Gly Ala Met Asp Asn Val His Gly Ser Ser Gly 385 390 395 400 Tyr Gly Asn Gly Ser Ser Ser Thr Thr Ser Ser Ala Arg Arg Arg Pro 405 410 415 Pro Ile Pro Ser Gln Met Leu Ser Ser Thr Ser Thr Ser Gly Val Gly 420 425 430 Thr Met Pro Ser His Gly Ser Val Gly Ala Ser Ile Thr Ala Ile Ala 435 440 445 Val Asn Pro Thr Pro Ser Pro Ser Glu Pro Ile Pro Thr Ser Gln Pro 450 455 460 Thr Ser Lys Ser Glu Ser Ser Ser Ile Leu Glu Thr Ala His Asp Asp 465 470 475 480 Pro Leu Asp Thr Ser Ile Arg Ala Pro Val Lys Asp Leu His Met Pro 485 490 495 His Arg Ala Val Lys Glu Arg Ile Ala Thr Leu Gln Asn His Lys Phe 500 505 510 Ala Thr Leu Arg Ser Gln Arg Ile Ile Asn Gln Glu Gln Glu Glu Tyr 515 520 525 Thr Lys Glu Asn Asn Met Tyr Glu Gln Met Ser Lys Tyr Lys His Leu 530 535 540 Arg Gln Ala His His Lys Glu Leu Gln Gln Phe Glu Glu Arg Cys Ala 545 550 555 560 Leu Asp Arg Glu Gln Leu Arg Val Lys Met Asp Arg Glu Leu Glu Gln 565 570 575 Leu Thr Thr Thr Tyr Ser Lys Glu Lys Met Arg Val Arg Cys Ser Gln 580 585 590 Asn Asn Glu Leu Asp Lys Arg Lys Lys Asp Ile Glu Asp Gly Glu Lys 595 600 605 Lys Met Lys Lys Thr Lys Asn Ser Gln Asn Gln Gln Gln Met Lys Leu 610 615 620 Tyr Ser Ala Gln Gln Leu Lys Glu Tyr Lys Tyr Asn Lys Glu Ala Gln 625 630 635 640 Lys Thr Arg Leu Arg Ser Leu Asn Met Pro Arg Ser Thr Tyr Glu Asn 645 650 655 Ala Met Lys Glu Val Lys Ala Asp Leu Asn Arg Val Lys Asp Ala Arg 660 665 670 Glu Asn Asp Phe Asp Glu Lys Leu Arg Ala Glu Leu Glu Asp Glu Ile 675 680 685 Val Arg Tyr Arg Arg Gln Gln Leu Ser Asn Leu His Gln Leu Glu Glu 690 695 700 Gln Leu Asp Asp Glu Asp Val Asn Val Gln Glu Arg Gln Met Asp Thr 705 710 715 720 Arg His Gly Leu Leu Ser Lys Gln His Glu Met Thr Arg Asp Leu Glu 725 730 735 Ile Gln His Leu Asn Glu Leu His Ala Met Lys Lys Arg His Leu Glu 740 745 750 Thr Gln His Glu Ala Glu Ser Ala Ser Gln Asn Glu Tyr Thr Gln Arg 755 760 765 Gln Gln Asp Glu Leu Arg Lys Lys His Ala Met Gln Ser Arg Gln Gln 770 775 780 Pro Arg Asp Leu Lys Ile Gln Glu Ala Gln Ile Arg Lys Gln Tyr Arg 785 790 795 800 Gln Val Val Lys Thr Gln Thr Arg Gln Phe Lys Leu Tyr Leu Thr Gln 805 810 815 Met Val Gln Val Val Pro Lys Asp Glu Gln Lys Glu Leu Thr Ser Arg 820 825 830 Leu Lys Gln Asp Gln Met Gln Lys Val Ala Leu Leu Ala Ser Gln Tyr 835 840 845 Glu Ser Gln Ile Lys Lys Met Val Gln Asp Lys Thr Val Lys Leu Glu 850 855 860 Ser Trp Gln Glu Asp Glu Gln Arg Val Leu Ser Glu Lys Leu Glu Lys 865 870 875 880 Glu Leu Glu Glu Leu Ile Ala Tyr Gln Lys Lys Thr Arg Ala Thr Leu 885 890 895 Glu Glu Gln Ile Lys Lys Glu Arg Thr Ala Leu Glu Glu Arg Ile Gly 900 905 910 Thr Arg Arg Ala Met Leu Glu Gln Lys Ile Ile Glu Glu Arg Glu Gln 915 920 925 Met Gly Glu Met Arg Arg Leu Lys Lys Glu Gln Ile Arg Asp Arg His 930 935 940 Ser Gln Glu Arg His Arg Leu Glu Asn His Phe Val Arg Thr Gly Ser 945 950 955 960 Thr Ser Arg Ser Ser Gly Gly Ile Ala Pro Gly Val Gly Asn Ser Ser 965 970 975 Ser Ile Gln Met Ala Met 980 91 842 PRT Homo sapiens 91 Leu Arg Pro Ala Ala Asp Ile Leu Arg Arg Asn Pro Gln Gln Asp Tyr 1 5 10 15 Glu Leu Val Gln Arg Val Gly Ser Gly Thr Tyr Gly Asp Val Tyr Lys 20 25 30 Ala Arg Asn Val His Thr Gly Glu Leu Ala Ala Val Lys Ile Ile Lys 35 40 45 Leu Glu Pro Gly Asp Asp Phe Ser Leu Ile Gln Gln Glu Ile Phe Met 50 55 60 Val Lys Glu Cys Lys His Cys Asn Ile Val Ala Tyr Phe Gly Ser Tyr 65 70 75 80 Leu Ser Arg Glu Lys Leu Trp Ile Cys Met Glu Tyr Cys Gly Gly Gly 85 90 95 Ser Leu Gln Asp Ile Tyr His Val Thr Gly Pro Leu Ser Glu Leu Gln 100 105 110 Ile Ala Tyr Val Cys Arg Glu Thr Leu Gln Gly Leu Ala Tyr Leu His 115 120 125 Thr Lys Gly Lys Met His Arg Asp Ile Lys Gly Ala Asn Ile Leu Leu 130 135 140 Thr Asp His Gly Asp Val Lys Leu Ala Asp Phe Gly Val Ala Ala Lys 145 150 155 160 Ile Thr Ala Thr Ile Ala Lys Arg Lys Ser Phe Ile Gly Thr Pro Tyr 165 170 175 Trp Met Ala Pro Glu Val Ala Ala Val Glu Lys Asn Gly Gly Tyr Asn 180 185 190 Gln Leu Cys Asp Ile Trp Ala Val Gly Ile Thr Ala Ile Glu Leu Gly 195 200 205 Glu Leu Gln Pro Pro Met Phe Asp Leu His Pro Met Arg Ala Leu Phe 210 215 220 Leu Met Ser Lys Ser Asn Phe Gln Pro Pro Lys Leu Lys Asp Lys Thr 225 230 235 240 Lys Trp Ser Ser Thr Phe His Asn Phe Val Lys Ile Ala Leu Thr Lys 245 250 255 Asn Pro Lys Lys Arg Pro Thr Ala Glu Arg Leu Leu Thr His Thr Phe 260 265 270 Val Ala Gln Pro Gly Leu Ser Arg Ala Leu Ala Val Glu Leu Leu Asp 275 280 285 Lys Val Asn Asn Pro Asp Asn His Ala His Tyr Thr Glu Ala Asp Asp 290 295 300 Asp Asp Phe Glu Pro His Ala Ile Ile Arg His Thr Ile Arg Ser Thr 305 310 315 320 Asn Arg Asn Ala Arg Ala Glu Arg Thr Ala Ser Glu Ile Asn Phe Asp 325 330 335 Lys Leu Gln Phe Glu Pro Pro Leu Arg Lys Glu Thr Glu Ala Arg Asp 340 345 350 Glu Met Gly Leu Ser Ser Asp Pro Asn Phe Met Leu Gln Trp Asn Pro 355 360 365 Phe Val Asp Gly Ala Asn Thr Gly Lys Ser Thr Ser Lys Arg Ala Ile 370 375 380 Pro Pro Pro Leu Pro Pro Lys Pro Arg Ile Ser Ser Tyr Pro Glu Asp 385 390 395 400 Asn Phe Pro Asp Glu Glu Lys Ala Ser Thr Ile Lys His Cys Pro Asp 405 410 415 Ser Glu Ser Arg Ala Pro Gln Ile Leu Arg Arg Gln Ser Ser Pro Ser 420 425 430 Cys Gly Pro Val Ala Glu Thr Ser Ser Ile Gly Asn Gly Asp Gly Ile 435 440 445 Ser Lys Leu Met Ser Glu Asn Thr Glu Gly Ser Ala Gln Ala Pro Gln 450 455 460 Leu Pro Arg Lys Asn Asp Lys Arg Asp Phe Pro Lys Pro Ala Ile Asn 465 470 475 480 Gly Leu Pro Pro Thr Pro Lys Val Leu Met Gly Ala Cys Phe Ser Lys 485 490 495 Val Phe Asp Gly Cys Pro Leu Lys Ile Asn Cys Ala Thr Ser Trp Ile 500 505 510 His Pro Asp Thr Lys Asp Gln Tyr Ile Ile Phe Gly Thr Glu Asp Gly 515 520 525 Ile Tyr Thr Leu Asn Leu Asn Glu Leu His Glu Ala Thr Met Glu Gln 530 535 540 Leu Phe Pro Arg Lys Cys Thr Trp Leu Tyr Val Ile Asn Asn Thr Leu 545 550 555 560 Met Ser Leu Ser Glu Gly Lys Thr Phe Gln Leu Tyr Ser His Asn Leu 565 570 575 Ile Ala Leu Phe Glu His Ala Lys Lys Pro Gly Leu Ala Ala His Ile 580 585 590 Gln Thr His Arg Phe Pro Asp Arg Ile Leu Pro Arg Lys Phe Ala Leu 595 600 605 Thr Thr Lys Ile Pro Asp Thr Lys Gly Cys His Lys Cys Cys Ile Val 610 615 620 Arg Asn Pro Tyr Thr Gly His Lys Tyr Leu Cys Gly Ala Leu Gln Ser 625 630 635 640 Gly Ile Val Leu Leu Gln Trp Tyr Glu Pro Met Gln Lys Phe Met Leu 645 650 655 Ile Lys His Phe Asp Phe Pro Leu Pro Ser Pro Leu Asn Val Phe Glu 660 665 670 Met Leu Val Ile Pro Glu Gln Glu Tyr Pro Met Val Cys Val Ala Ile 675 680 685 Ser Lys Gly Thr Glu Ser Asn Gln Val Val Gln Phe Glu Thr Ile Asn 690 695 700 Leu Asn Ser Ala Ser Ser Trp Phe Thr Glu Ile Gly Ala Gly Ser Gln 705 710 715 720 Gln Leu Asp Ser Ile His Val Thr Gln Leu Glu Arg Asp Thr Val Leu 725 730 735 Val Cys Leu Asp Lys Phe Val Lys Ile Val Asn Leu Gln Gly Lys Leu 740 745 750 Lys Ser Ser Lys Lys Leu Ala Ser Glu Leu Ser Phe Asp Phe Arg Ile 755 760 765 Glu Ser Val Val Cys Leu Gln Asp Ser Val Leu Ala Phe Trp Lys His 770 775 780 Gly Met Gln Gly Lys Ser Phe Lys Ser Asp Glu Val Thr Gln Glu Ile 785 790 795 800 Ser Asp Glu Thr Arg Val Phe Arg Leu Leu Gly Ser Asp Arg Val Val 805 810 815 Val Leu Glu Ser Arg Pro Thr Glu Asn Pro Thr Ala His Ser Asn Leu 820 825 830 Tyr Ile Leu Ala Gly His Glu Asn Ser Tyr 835 840 92 911 PRT Murine sp. 92 Met Ala Phe Ala Asn Phe Arg Arg Ile Leu Arg Leu Ser Thr Phe Glu 1 5 10 15 Lys Arg Lys Ser Arg Glu Tyr Glu His Val Arg Arg Asp Leu Asp Pro 20 25 30 Asn Asp Val Trp Glu Ile Val Gly Glu Leu Gly Asp Gly Ala Phe Gly 35 40 45 Lys Val Tyr Lys Ala Lys Asn Lys Glu Thr Gly Ala Leu Ala Ala Ala 50 55 60 Lys Val Ile Glu Thr Lys Ser Glu Glu Glu Leu Glu Asp Tyr Ile Val 65 70 75 80 Glu Ile Glu Ile Leu Ala Thr Cys Asp His Pro Tyr Ile Val Lys Leu 85 90 95 Leu Gly Ala Tyr Tyr Tyr Asp Gly Lys Leu Trp Ile Met Ile Glu Phe 100 105 110 Cys Pro Gly Gly Ala Val Asp Ala Ile Met Leu Glu Leu Asp Arg Gly 115 120 125 Leu Thr Glu Pro Gln Ile Gln Val Val Cys Arg Gln Met Leu Glu Ala 130 135 140 Leu Asn Phe Leu His Gly Lys Arg Ile Ile His Arg Asp Leu Lys Ala 145 150 155 160 Gly Asn Val Leu Met Thr Leu Glu Gly Asp Ile Arg Leu Ala Asp Phe 165 170 175 Gly Val Ser Ala Lys Asn Leu Lys Thr Leu Gln Lys Arg Asp Ser Phe 180 185 190 Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Leu Cys Glu Thr 195 200 205 Met Lys Asp Ala Pro Tyr Asp Tyr Lys Ala Asp Ile Trp Ser Leu Gly 210 215 220 Ile Thr Leu Ile Glu Met Ala Gln Ile Glu Pro Pro His His Glu Leu 225 230 235 240 Asn Pro Met Arg Val Leu Leu Lys Ile Ala Lys Ser Asp Pro Pro Thr 245 250 255 Leu Leu Thr Pro Ser Lys Trp Ser Val Glu Phe Arg Asp Phe Leu Lys 260 265 270 Ile Ala Leu Asp Lys Asn Pro Glu Thr Arg Pro Ser Ala Ala Gln Leu 275 280 285 Leu Gln His Pro Phe Val Ser Arg Val Thr Ser Asn Lys Ala Leu Arg 290 295 300 Glu Leu Val Ala Glu Ala Lys Ala Glu Val Met Glu Glu Ile Glu Asp 305 310 315 320 Gly Arg Glu Asp Gly Glu Glu Glu Asp Ala Val Asp Ala Val Pro Pro 325 330 335 Leu Val Asn His Thr Gln Asp Ser Ala Asn Val Thr Gln Pro Ser Leu 340 345 350 Asp Ser Asn Lys Leu Leu Gln Asp Ser Ser Thr Pro Leu Pro Pro Ser 355 360 365 Gln Pro Gln Glu Pro Val Asn Gly Pro Cys Ser Gln Pro Ser Gly Asp 370 375 380 Gly Pro Leu Gln Thr Thr Ser Pro Ala Asp Gly Leu Ser Lys Asn Asp 385 390 395 400 Asn Asp Leu Lys Val Pro Val Pro Leu Arg Lys Ser Arg Pro Leu Ser 405 410 415 Met Asp Ala Arg Ile Gln Met Asp Glu Glu Lys Gln Ile Pro Asp Gln 420 425 430 Asp Glu Asn Pro Ser Pro Ala Ala Ser Lys Ser Gln Lys Ala Asn Gln 435 440 445 Ser Arg Pro Asn Ser Ser Ala Leu Glu Thr Leu Gly Gly Glu Ala Leu 450 455 460 Thr Asn Gly Gly Leu Glu Leu Pro Ser Ser Val Thr Pro Ser His Ser 465 470 475 480 Lys Arg Ala Ser Asp Cys Ser Asn Leu Ser Thr Ser Glu Ser Met Asp 485 490 495 Tyr Gly Thr Ser Leu Ser Ala Asp Leu Ser Leu Asn Lys Glu Thr Gly 500 505 510 Ser Leu Ser Leu Lys Gly Ser Lys Leu His Asn Lys Thr Leu Lys Arg 515 520 525 Thr Arg Arg Phe Val Val Asp Gly Val Glu Val Ser Ile Thr Thr Ser 530 535 540 Lys Ile Ile Ser Glu Asp Glu Lys Lys Asp Glu Glu Met Arg Phe Leu 545 550 555 560 Arg Arg Gln Glu Leu Arg Glu Leu Arg Leu Leu Gln Lys Glu Glu His 565 570 575 Arg Asn Gln Thr Gln Leu Ser Ser Lys His Glu Leu Gln Leu Glu Gln 580 585 590 Met His Lys Arg Phe Glu Gln Glu Ile Asn Ala Lys Lys Lys Phe Tyr 595 600 605 Asp Val Glu Leu Glu Asn Leu Glu Arg Gln Gln Lys Gln Gln Val Glu 610 615 620 Lys Met Glu Gln Asp His Ser Val Arg Arg Lys Glu Glu Ala Lys Arg 625 630 635 640 Ile Arg Leu Glu Gln Asp Arg Asp Tyr Ala Lys Phe Gln Glu Gln Leu 645 650 655 Lys Gln Met Lys Lys Glu Val Lys Ser Glu Val Glu Lys Leu Pro Arg 660 665 670 Gln Gln Arg Lys Glu Ser Met Lys Gln Lys Met Glu Glu His Ser Gln 675 680 685 Lys Lys Gln Arg Leu Asp Arg Asp Phe Val Ala Lys Gln Lys Glu Asp 690 695 700 Leu Glu Leu Ala Met Arg Lys Leu Thr Thr Glu Asn Arg Arg Glu Ile 705 710 715 720 Cys Asp Lys Glu Arg Asp Cys Leu Ser Lys Lys Gln Glu Leu Leu Arg 725 730 735 Asp Arg Glu Ala Ala Leu Trp Glu Met Glu Glu His Gln Leu Gln Glu 740 745 750 Arg His Gln Leu Val Lys Gln Gln Leu Lys Asp Gln Tyr Phe Leu Gln 755 760 765 Arg His Asp Leu Leu Arg Lys His Glu Lys Glu Arg Glu Gln Met Gln 770 775 780 Arg Tyr Asn Gln Arg Met Met Glu Gln Leu Lys Val Arg Gln Gln Gln 785 790 795 800 Glu Lys Ala Arg Leu Pro Lys Ile Gln Arg Ser Asp Gly Glu Thr Arg 805 810 815 Met Ala Met Tyr Lys Lys Ser Leu His Ile Asn Gly Ala Gly Ser Ala 820 825 830 Ser Glu Gln Arg Glu Lys Ile Lys Gln Phe Ser Gln Gln Glu Glu Lys 835 840 845 Arg Gln Lys Ala Glu Arg Leu Gln Gln Gln Gln Lys His Glu His Gln 850 855 860 Met Arg Asp Met Val Ala Gln Cys Glu Ser Asn Met Ser Glu Leu Gln 865 870 875 880 Gln Leu Gln Asn Glu Lys Cys Tyr Leu Leu Val Glu His Glu Thr Gln 885 890 895 Lys Leu Lys Ala Leu Asp Glu Ser His Asn Gln Ser Leu Lys Glu 900 905 910 93 545 PRT Homo sapiens 93 Met Ser Asn Asn Gly Leu Asp Ile Gln Asp Lys Pro Pro Ala Pro Pro 1 5 10 15 Met Arg Asn Thr Ser Thr Met Ile Gly Ala Gly Ser Lys Asp Ala Gly 20 25 30 Thr Leu Asn His Gly Ser Lys Pro Leu Pro Pro Asn Pro Glu Glu Lys 35 40 45 Lys Lys Lys Asp Arg Phe Tyr Arg Ser Ile Leu Pro Gly Asp Lys Thr 50 55 60 Asn Lys Lys Lys Glu Lys Glu Arg Pro Glu Ile Ser Leu Pro Ser Asp 65 70 75 80 Phe Glu His Thr Ile His Val Gly Phe Asp Ala Val Thr Gly Glu Phe 85 90 95 Thr Gly Met Pro Glu Gln Trp Ala Arg Leu Leu Gln Thr Ser Asn Ile 100 105 110 Thr Lys Ser Glu Gln Lys Lys Asn Pro Gln Ala Val Leu Asp Val Leu 115 120 125 Glu Phe Tyr Asn Ser Lys Lys Thr Ser Asn Ser Gln Lys Tyr Met Ser 130 135 140 Phe Thr Asp Lys Ser Ala Glu Asp Tyr Asn Ser Ser Asn Ala Leu Asn 145 150 155 160 Val Lys Ala Val Ser Glu Thr Pro Ala Val Pro Pro Val Ser Glu Asp 165 170 175 Glu Asp Asp Asp Asp Asp Asp Ala Thr Pro Pro Pro Val Ile Ala Pro 180 185 190 Arg Pro Glu His Thr Lys Ser Val Tyr Thr Arg Ser Val Ile Glu Pro 195 200 205 Leu Pro Val Thr Pro Thr Arg Asp Val Ala Thr Ser Pro Ile Ser Pro 210 215 220 Thr Glu Asn Asn Thr Thr Pro Pro Asp Ala Leu Thr Leu Asn Thr Glu 225 230 235 240 Lys Gln Lys Lys Lys Pro Lys Met Ser Asp Glu Glu Ile Leu Glu Lys 245 250 255 Leu Arg Ser Ile Val Ser Val Gly Asp Pro Lys Lys Lys Tyr Thr Arg 260 265 270 Phe Glu Lys Ile Gly Gln Gly Ala Ser Gly Thr Val Tyr Thr Ala Met 275 280 285 Asp Val Ala Thr Gly Gln Glu Val Ala Ile Lys Gln Met Asn Leu Gln 290 295 300 Gln Gln Pro Lys Lys Glu Leu Ile Ile Asn Glu Ile Leu Val Met Arg 305 310 315 320 Glu Asn Lys Asn Pro Asn Ile Val Asn Tyr Leu Asp Ser Tyr Leu Val 325 330 335 Gly Asp Glu Leu Trp Val Val Met Glu Tyr Leu Ala Gly Gly Ser Leu 340 345 350 Thr Asp Val Val Thr Glu Thr Cys Met Asp Glu Gly Gln Ile Ala Ala 355 360 365 Val Cys Arg Glu Cys Leu Gln Ala Leu Glu Ser Leu His Ser Asn Gln 370 375 380 Val Ile His Arg Asp Ile Lys Ser Asp Asn Ile Leu Leu Gly Met Asp 385 390 395 400 Gly Ser Val Lys Leu Thr Asp Phe Gly Phe Cys Ala Gln Ile Thr Pro 405 410 415 Glu Gln Ser Lys Arg Ser Thr Met Val Gly Thr Pro Tyr Trp Met Ala 420 425 430 Pro Glu Val Val Thr Arg Lys Ala Tyr Gly Pro Lys Val Asp Ile Trp 435 440 445 Ser Leu Gly Ile Met Ala Ile Glu Met Ile Glu Gly Glu Pro Pro Tyr 450 455 460 Leu Asn Glu Asn Pro Leu Arg Ala Leu Tyr Leu Ile Ala Thr Asn Gly 465 470 475 480 Thr Pro Glu Leu Gln Asn Pro Glu Lys Leu Ser Ala Ile Phe Arg Asp 485 490 495 Phe Leu Asn Arg Cys Leu Glu Met Asp Val Glu Lys Arg Gly Ser Ala 500 505 510 Lys Glu Leu Leu Gln His Gln Phe Leu Lys Ile Ala Lys Pro Leu Ser 515 520 525 Ser Leu Thr Pro Leu Ile Ala Ala Ala Lys Glu Ala Thr Lys Asn Asn 530 535 540 His 545 94 506 PRT Homo sapiens 94 Met Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Ser Ala Asn 1 5 10 15 His Ser Leu Lys Pro Leu Pro Ser Val Pro Glu Glu Lys Lys Pro Arg 20 25 30 His Lys Ile Ile Ser Ile Phe Ser Gly Thr Glu Lys Gly Ser Lys Lys 35 40 45 Lys Glu Lys Glu Arg Pro Glu Ile Ser Pro Pro Ser Asp Phe Glu His 50 55 60 Thr Ile His Val Gly Phe Asp Thr Val Thr Gly Glu Phe Thr Gly Met 65 70 75 80 Pro Glu Gln Trp Ala Arg Leu Leu Gln Thr Ser Asn Ile Thr Lys Leu 85 90 95 Glu Gln Lys Lys Asn Pro Gln Ala Val Leu Asp Val Leu Lys Phe Tyr 100 105 110 Asp Ser Asn Thr Val Lys Gln Lys Tyr Leu Ser Phe Thr Pro Pro Glu 115 120 125 Lys Asp Gly Phe Pro Ser Gly Thr Pro Ala Leu Asn Ala Lys Gly Thr 130 135 140 Glu Ala Pro Ala Val Val Thr Glu Glu Glu Asp Asp Asp Glu Glu Thr 145 150 155 160 Ala Pro Pro Val Ile Ala Pro Arg Pro Asp His Thr Lys Ser Ile Tyr 165 170 175 Thr Arg Ser Val Ile Asp Pro Val Pro Ala Pro Val Gly Asp Ser His 180 185 190 Val Asp Gly Ala Ala Lys Ser Leu Asp Lys Gln Lys Lys Lys Thr Lys 195 200 205 Met Thr Asp Glu Glu Ile Met Glu Lys Leu Arg Thr Ile Val Ser Ile 210 215 220 Gly Asp Pro Lys Lys Lys Tyr Thr Arg Tyr Glu Lys Ile Gly Gln Gly 225 230 235 240 Ala Ser Gly Thr Val Phe Thr Ala Thr Asp Val Ala Leu Gly Gln Glu 245 250 255 Val Ala Ile Lys Gln Ile Asn Leu Gln Lys Gln Pro Lys Lys Glu Leu 260 265 270 Ile Ile Asn Glu Ile Leu Val Met Lys Glu Leu Lys Asn Pro Asn Ile 275 280 285 Val Asn Phe Leu Asp Ser Tyr Leu Val Gly Asp Glu Leu Phe Val Val 290 295 300 Met Glu Tyr Leu Ala Gly Arg Ser Leu Thr Asp Val Val Thr Glu Thr 305 310 315 320 Cys Met Asp Glu Ala Gln Ile Ala Ala Val Cys Arg Glu Cys Leu Gln 325 330 335 Ala Leu Glu Phe Leu His Ala Asn Gln Val Ile His Arg Asp Ile Lys 340 345 350 Ser Asp Asn Val Leu Leu Gly Met Glu Gly Ser Val Lys Leu Thr Asp 355 360 365 Phe Gly Phe Cys Ala Gln Ile Thr Pro Glu Gln Ser Lys Arg Ser Thr 370 375 380 Met Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Thr Arg Lys 385 390 395 400 Ala Tyr Gly Pro Lys Val Asp Ile Trp Ser Leu Gly Ile Met Ala Ile 405 410 415 Glu Met Val Glu Gly Glu Pro Pro Tyr Leu Asn Glu Asn Pro Leu Arg 420 425 430 Ala Leu Tyr Leu Ile Ala Thr Asn Gly Thr Pro Glu Leu Gln Asn Pro 435 440 445 Glu Lys Leu Ser Pro Ile Phe Arg Asp Phe Leu Asn Arg Cys Leu Glu 450 455 460 Met Asp Val Glu Lys Arg Gly Ser Ala Lys Glu Leu Leu Gln His Pro 465 470 475 480 Phe Leu Lys Leu Ala Lys Pro Leu Ser Ser Leu Thr Pro Leu Ile Met 485 490 495 Ala Ala Lys Glu Ala Met Lys Ser Asn Arg 500 505 95 544 PRT Murine sp. 95 Met Ser Asp Ser Leu Asp Asn Glu Glu Lys Pro Pro Ala Pro Pro Leu 1 5 10 15 Arg Met Asn Ser Asn Asn Arg Asp Ser Ser Ala Leu Asn His Ser Ser 20 25 30 Lys Pro Leu Pro Met Ala Pro Glu Glu Lys Asn Lys Lys Ala Arg Leu 35 40 45 Arg Ser Ile Phe Pro Gly Gly Gly Asp Lys Thr Asn Lys Lys Lys Glu 50 55 60 Lys Glu Arg Pro Glu Ile Ser Leu Pro Ser Asp Phe Glu His Thr Ile 65 70 75 80 His Val Gly Phe Asp Ala Val Thr Gly Glu Phe Thr Gly Ile Pro Glu 85 90 95 Gln Trp Ala Arg Leu Leu Gln Thr Ser Asn Ile Thr Lys Leu Glu Gln 100 105 110 Lys Lys Asn Pro Gln Ala Val Leu Asp Val Leu Lys Phe Tyr Asp Ser 115 120 125 Lys Glu Thr Val Asn Asn Gln Lys Tyr Met Ser Phe Thr Ser Gly Asp 130 135 140 Lys Ser Ala His Gly Tyr Ile Ala Ala His Gln Ser Asn Thr Lys Thr 145 150 155 160 Gly Ser Glu Pro Pro Leu Ala Pro Pro Val Ser Glu Glu Glu Asp Glu 165 170 175 Glu Glu Glu Glu Glu Glu Asp Asp Asn Glu Pro Pro Pro Val Ile Ala 180 185 190 Pro Arg Pro Glu His Thr Lys Ser Ile Tyr Thr Arg Ser Val Val Glu 195 200 205 Ser Ile Ala Ser Pro Ala Ala Pro Asn Lys Glu Asp Ile Pro Pro Ser 210 215 220 Ala Glu Asn Ala Asn Ser Thr Thr Leu Tyr Arg Asn Thr Asp Arg Gln 225 230 235 240 Arg Lys Lys Ser Lys Met Thr Asp Glu Glu Ile Leu Glu Lys Leu Arg 245 250 255 Ser Ile Val Ser Val Gly Asp Pro Lys Lys Lys Tyr Thr Arg Leu Glu 260 265 270 Lys Ile Gly Gln Gly Ala Ser Gly Thr Val Tyr Thr Ala Leu Asp Ile 275 280 285 Ala Thr Gly Gln Glu Val Ala Ile Lys Gln Met Asn Leu Gln Gln Gln 290 295 300 Pro Lys Lys Glu Leu Ile Ile Asn Glu Ile Leu Val Met Arg Glu Asn 305 310 315 320 Lys Asn Pro Asn Ile Val Asn Tyr Leu Asp Ser Tyr Leu Val Gly Asp 325 330 335 Glu Leu Trp Val Val Met Glu Tyr Leu Ala Gly Gly Ser Leu Thr Asp 340 345 350 Val Val Thr Glu Thr Cys Met Asp Val Gly Gln Ile Ala Ala Val Cys 355 360 365 Arg Glu Cys Leu Gln Ala Leu Asp Phe Leu His Ser Asn Gln Val Ile 370 375 380 His Arg Asp Ile Lys Ser Asp Asn Ile Leu Leu Gly Met Asp Gly Ser 385 390 395 400 Val Lys Leu Thr Asp Phe Gly Phe Cys Ala Gln Ile Thr Pro Glu Gln 405 410 415 Ser Lys Arg Ser Thr Met Val Gly Thr Pro Tyr Trp Met Ala Pro Glu 420 425 430 Val Val Thr Arg Lys Ala Tyr Gly Pro Lys Val Asp Ile Trp Ser Leu 435 440 445 Gly Ile Met Ala Ile Glu Met Val Glu Gly Glu Pro Pro Tyr Leu Asn 450 455 460 Glu Asn Pro Leu Arg Ala Leu Tyr Leu Ile Ala Thr Asn Gly Thr Pro 465 470 475 480 Glu Leu Gln Asn Pro Glu Arg Leu Ser Ala Val Phe His Asp Phe Leu 485 490 495 Asn Arg Cys Leu Glu Met Asp Val Asp Arg Arg Gly Ser Ala Lys Glu 500 505 510 Leu Leu Gln His Pro Phe Leu Lys Leu Ala Lys Pro Leu Ser Ser Leu 515 520 525 Thr Pro Leu Ile Ile Ala Ala Lys Glu Ala Ile Lys Asn Ser Ser Arg 530 535 540 96 2110 DNA Homo sapiens 96 ggccaagacg gtcggggctg cttgctaact ccaggaacag gtttaagttt ttgaaactga 60 agtaggtcta cacagtagga actcatgtca tttcttgtaa gtaaaccaga gcgaatcagg 120 cggtgggtct cggaaaagtt cattgttgag ggcttaagag atttggaact atttggagac 180 caatgatgcg agctcagagt caatagcatc cttctctaaa caggaggtca tgagtagctt 240 tctgccagag ggagggtgtt acgagctgct cactgtgata ggcaaaggat ttgaggacct 300 gatgactgtg aatctagcaa ggtacaaacc aacaggagag tacgtgactg tacggaggat 360 taacctagaa gcttgttcca atgagatggt aacattcttg cagggcgagc tgcatgtctc 420 caaactcttc aaccatccca atatcgtgcc atatcgagcc acttttattg cagacaatga 480 gctgtgggtt gtcacatcat tcatggcata cggttctgca aaagatctca tctgtacaca 540 cttcatggat ggcatgaatg agctggcgat tgcttacatc ctgcaggggg tgctgaaggc 600 cctcgactac atccaccaca tgggatatgt acacaggagt gtcaaagcca gccacatcct 660 gatctctgtg gatgggaagg tctacctgtc tggtttgcgc agcaacctca gcatgataag 720 ccatgggcag cggcagcgag tggtccacga ttttcccaag tacagtgtca aggttctgcc 780 gtggctcagc cccgaggtcc tccagcagaa tctccagggt tatgatgcca agtctgacat 840 ctacagtgtg ggaatcacag cctgtgaact ggccaacggc catgtcccct ttaaggatat 900 gcctgccacc cagatgctgc tagagaaact gaacggcaca gtgccctgcc tgttggatac 960 cagcaccatc cccgctgagg agctgaccat gagcccttcg cgctcagtgg ccaactctgg 1020 cctgagtgac agcctgacca ccagcacccc ccggccctcc aacggtgact cgccctccca 1080 cccctaccac cgaaccttct ccccccactt ccaccacttt gtggagcagt gccttcagcg 1140 caacccggat gccaggccca gtgccagcac cctcctgaac cactctttct tcaagcagat 1200 caagcgacgt gcctcagagg ctttgcccga attgcttcgt cctgtcaccc ccatcaccaa 1260 ttttgagggc agccagtctc aggaccacag tggaatcttt ggcctggtaa caaacctgga 1320 agagctggag gtggacgatt gggagttctg agcctctgca aactgtgcgc attctccagc 1380 cagggatgca gaggccaccc agaggccctt cctgagggcc ggccacattc ccgccctcct 1440 gggcagattg ggtagaaagg acattcttcc aggaaagttg actgctgact gattgggaaa 1500 gaaaatcctg gagagatact tcactgctcc aaggcttttg agacacaagg gaatctcaac 1560 aaccagggat caggagggtc caaagccgac attcccagtc ctgtgagctc aggtgacctc 1620 ctccgcagaa gagagatgct gctctggccc tgggagctga attccaagcc cagggtttgg 1680 ctccttaaac ccgaggaccg ccacctcttc ccagtgcttg cgaccagcct cattctattt 1740 aactttgctc tcagatgcct cagatgctat aggtcagtga aagggcaagt agtaagctgc 1800 ctgcctccct tccctcagac ctctccctca taattccaga gaagggcatt tctgtctttt 1860 taagcacaga ctaaggctgg aacagtccat ccttatccct cttctggctt gggccctgac 1920 acctaagtct ttcccacggt ttatgtgtgt gcctcattcc tttcccacca agaatccatc 1980 ttagcgcctc ctgccagctg ccctggtgct ttctccaagg gccatcagtg tcttgcctag 2040 cttgagggct taagtcctta tgctgtgtta gtttcgttgt cagaacaaat taaaattttc 2100 agagacgctg 2110 97 373 PRT Homo sapiens 97 Met Ser Ser Phe Leu Pro Glu Gly Gly Cys Tyr Glu Leu Leu Thr Val 1 5 10 15 Ile Gly Lys Gly Phe Glu Asp Leu Met Thr Val Asn Leu Ala Arg Tyr 20 25 30 Lys Pro Thr Gly Glu Tyr Val Thr Val Arg Arg Ile Asn Leu Glu Ala 35 40 45 Cys Ser Asn Glu Met Val Thr Phe Leu Gln Gly Glu Leu His Val Ser 50 55 60 Lys Leu Phe Asn His Pro Asn Ile Val Pro Tyr Arg Ala Thr Phe Ile 65 70 75 80 Ala Asp Asn Glu Leu Trp Val Val Thr Ser Phe Met Ala Tyr Gly Ser 85 90 95 Ala Lys Asp Leu Ile Cys Thr His Phe Met Asp Gly Met Asn Glu Leu 100 105 110 Ala Ile Ala Tyr Ile Leu Gln Gly Val Leu Lys Ala Leu Asp Tyr Ile 115 120 125 His His Met Gly Tyr Val His Arg Ser Val Lys Ala Ser His Ile Leu 130 135 140 Ile Ser Val Asp Gly Lys Val Tyr Leu Ser Gly Leu Arg Ser Asn Leu 145 150 155 160 Ser Met Ile Ser His Gly Gln Arg Gln Arg Val Val His Asp Phe Pro 165 170 175 Lys Tyr Ser Val Lys Val Leu Pro Trp Leu Ser Pro Glu Val Leu Gln 180 185 190 Gln Asn Leu Gln Gly Tyr Asp Ala Lys Ser Asp Ile Tyr Ser Val Gly 195 200 205 Ile Thr Ala Cys Glu Leu Ala Asn Gly His Val Pro Phe Lys Asp Met 210 215 220 Pro Ala Thr Gln Met Leu Leu Glu Lys Leu Asn Gly Thr Val Pro Cys 225 230 235 240 Leu Leu Asp Thr Ser Thr Ile Pro Ala Glu Glu Leu Thr Met Ser Pro 245 250 255 Ser Arg Ser Val Ala Asn Ser Gly Leu Ser Asp Ser Leu Thr Thr Ser 260 265 270 Thr Pro Arg Pro Ser Asn Gly Asp Ser Pro Ser His Pro Tyr His Arg 275 280 285 Thr Phe Ser Pro His Phe His His Phe Val Glu Gln Cys Leu Gln Arg 290 295 300 Asn Pro Asp Ala Arg Pro Ser Ala Ser Thr Leu Leu Asn His Ser Phe 305 310 315 320 Phe Lys Gln Ile Lys Arg Arg Ala Ser Glu Ala Leu Pro Glu Leu Leu 325 330 335 Arg Pro Val Thr Pro Ile Thr Asn Phe Glu Gly Ser Gln Ser Gln Asp 340 345 350 His Ser Gly Ile Phe Gly Leu Val Thr Asn Leu Glu Glu Leu Glu Val 355 360 365 Asp Asp Trp Glu Phe 370 98 2001 DNA Homo sapiens 98 aaggaagata aaacaaaagc cttctttgga atagatggat ttttgtcact ttctgtgtga 60 actaaagtga ttcaatgtct cttttggatt gcttctgcac ttcaagaaca caagttgaat 120 cactcagacc tgaaaaacag tctgaaacca gtatccatca atacttggtt gatgagccaa 180 ccctttcctg gtcacgtcca tccactagag ccagtgaagt actatgttcc accaacgttt 240 ctcactatga gctccaagta gaaataggaa gaggatttga caacttgact tctgtccatc 300 ttgcacggca tactcccacg ggaacactgg taactataaa aattacaaat ctggaaaact 360 gcaatgaaga acgcctgaaa gctttacaga aagccgtgat tctatcccac tttttccggc 420 atcccaatat tacaacttat tggacagttt tcactgttgg cagctggctt tgggttattt 480 ctccatttat ggcctatggt tcagcaagtc aactcttgag gacctatttt cctgaaggaa 540 tgagtgaaac tttaataaga aacattctct ttggagccgt gagagggttg aactatctgc 600 accaaaatgg ctgtattcac aggagtatta aagccagcca tatcctcatt tctggtgatg 660 gcctagtgac cctctctggc ctttcccatc tgcatagttt ggttaagcat ggacagaggc 720 atagggctgt gtatgatttc ccacagttca gcacatcagt gcagccgtgg ctgagtccag 780 aactactgag acaggattta catgggtata atgtgaagtc agatatttac agtgttggga 840 ttacagcatg tgaattagcc agtgggcagg tgcctttcca ggacatgcat agaactcaga 900 tgctgttaca gaaactgaaa ggtcctcctt atagcccatt ggatatcagt attttccctc 960 aatcagaatc cagaatgaaa aattcccagt caggtgtaga ctctgggatt ggagaaagtg 1020 tgcttgtctc cagtggaact cacacagtaa atagtgaccg attacacaca ccatcctcaa 1080 aaactttctc tcctgccttc tttagcttgg tacagctctg tttgcaacaa gatcctgaga 1140 aaaggccatc agcaagcagt ttattgtccc atgttttctt caaacagatg aaagaagaaa 1200 gccaggattc aatactttca ctgttgcctc ctgcttataa caagccatca atatcattgc 1260 ctccagtgtt accttggact gagccagaat gtgattttcc tgatgaaaaa gactcatact 1320 gggaattcta gggctgccaa atcattttat gtcctatata cttgacactt tctccttgct 1380 gctttttctt ctgtatttct aggtacaaat accagaatta tacttgaaaa tacagttggt 1440 gcactggaga atctattatt taaaaccact ctgttcaaag gggcaccagt ttgtagtccc 1500 tctgtttcgc acagagtact atgacaagga aacatcagaa ttactaatct agctagtgtc 1560 atttattctg gaattttttt ctaagctgtg actaactctt tttatctctc aatataattt 1620 ttgagccagt taattttttt cagtattttg ctgtcccttg ggaatgggcc ctcagaggac 1680 agtgcttcca agtacatctt ctcccagatt ctctggcctt tttaatgagc tattgttaaa 1740 ccaacaggct agtttatctt acatcagacc cttttctggt agagggaaaa tgtttgtgct 1800 ttcccttttt cttctgttaa tacttatggt aacacctaac tgagcctcac tcacattaaa 1860 tgattcactt gaaatatata cagaaattgt aatttgcttt tttttaaaaa agggggctaa 1920 agtaacactt tcctacttat gtaaattata gatcctaaat tcacgcaccc cgtgggagct 1980 caataaagat ttactgaatt g 2001 99 418 PRT Homo sapiens 99 Met Ser Leu Leu Asp Cys Phe Cys Thr Ser Arg Thr Gln Val Glu Ser 1 5 10 15 Leu Arg Pro Glu Lys Gln Ser Glu Thr Ser Ile His Gln Tyr Leu Val 20 25 30 Asp Glu Pro Thr Leu Ser Trp Ser Arg Pro Ser Thr Arg Ala Ser Glu 35 40 45 Val Leu Cys Ser Thr Asn Val Ser His Tyr Glu Leu Gln Val Glu Ile 50 55 60 Gly Arg Gly Phe Asp Asn Leu Thr Ser Val His Leu Ala Arg His Thr 65 70 75 80 Pro Thr Gly Thr Leu Val Thr Ile Lys Ile Thr Asn Leu Glu Asn Cys 85 90 95 Asn Glu Glu Arg Leu Lys Ala Leu Gln Lys Ala Val Ile Leu Ser His 100 105 110 Phe Phe Arg His Pro Asn Ile Thr Thr Tyr Trp Thr Val Phe Thr Val 115 120 125 Gly Ser Trp Leu Trp Val Ile Ser Pro Phe Met Ala Tyr Gly Ser Ala 130 135 140 Ser Gln Leu Leu Arg Thr Tyr Phe Pro Glu Gly Met Ser Glu Thr Leu 145 150 155 160 Ile Arg Asn Ile Leu Phe Gly Ala Val Arg Gly Leu Asn Tyr Leu His 165 170 175 Gln Asn Gly Cys Ile His Arg Ser Ile Lys Ala Ser His Ile Leu Ile 180 185 190 Ser Gly Asp Gly Leu Val Thr Leu Ser Gly Leu Ser His Leu His Ser 195 200 205 Leu Val Lys His Gly Gln Arg His Arg Ala Val Tyr Asp Phe Pro Gln 210 215 220 Phe Ser Thr Ser Val Gln Pro Trp Leu Ser Pro Glu Leu Leu Arg Gln 225 230 235 240 Asp Leu His Gly Tyr Asn Val Lys Ser Asp Ile Tyr Ser Val Gly Ile 245 250 255 Thr Ala Cys Glu Leu Ala Ser Gly Gln Val Pro Phe Gln Asp Met His 260 265 270 Arg Thr Gln Met Leu Leu Gln Lys Leu Lys Gly Pro Pro Tyr Ser Pro 275 280 285 Leu Asp Ile Ser Ile Phe Pro Gln Ser Glu Ser Arg Met Lys Asn Ser 290 295 300 Gln Ser Gly Val Asp Ser Gly Ile Gly Glu Ser Val Leu Val Ser Ser 305 310 315 320 Gly Thr His Thr Val Asn Ser Asp Arg Leu His Thr Pro Ser Ser Lys 325 330 335 Thr Phe Ser Pro Ala Phe Phe Ser Leu Val Gln Leu Cys Leu Gln Gln 340 345 350 Asp Pro Glu Lys Arg Pro Ser Ala Ser Ser Leu Leu Ser His Val Phe 355 360 365 Phe Lys Gln Met Lys Glu Glu Ser Gln Asp Ser Ile Leu Ser Leu Leu 370 375 380 Pro Pro Ala Tyr Asn Lys Pro Ser Ile Ser Leu Pro Pro Val Leu Pro 385 390 395 400 Trp Thr Glu Pro Glu Cys Asp Phe Pro Asp Glu Lys Asp Ser Tyr Trp 405 410 415 Glu Phe 100 311 DNA Homo sapiens 100 tcaacaggga cgattacgag ctgcaggagg tgatcgggag tggagcaact gctgtagtcc 60 aagcagctta ttgtgcccct aaaaaggaga aagtggcaat caaacggata aaccttgaga 120 aatgtcaaac tagcatggat gaactcctga aagaaattca agccatgagt caatgccatc 180 atcctaatat tgtatcttac tacacatctt ttgtggtaaa agatgagctg tggcttgtca 240 tgaagctgct aagtggaggt tctgttctgg atattattaa gcacattgtg gcaaaagggg 300 aacacaaaag t 311 101 103 PRT Homo sapiens 101 Asn Arg Asp Asp Tyr Glu Leu Gln Glu Val Ile Gly Ser Gly Ala Thr 1 5 10 15 Ala Val Val Gln Ala Ala Tyr Cys Ala Pro Lys Lys Glu Lys Val Ala 20 25 30 Ile Lys Arg Ile Asn Leu Glu Lys Cys Gln Thr Ser Met Asp Glu Leu 35 40 45 Leu Lys Glu Ile Gln Ala Met Ser Gln Cys His His Pro Asn Ile Val 50 55 60 Ser Tyr Tyr Thr Ser Phe Val Val Lys Asp Glu Leu Trp Leu Val Met 65 70 75 80 Lys Leu Leu Ser Gly Gly Ser Val Leu Asp Ile Ile Lys His Ile Val 85 90 95 Ala Lys Gly Glu His Lys Ser 100 102 2806 DNA Homo sapiens 102 cgggagtgtc cgcggtggtg gcggtgcaag agagctgaag gaggcgcgag ggcgcggagt 60 tccaggccga gcagttaggc cgcgagcgac tgcggcgccg agccgatgag taacccgaag 120 cccctagagg agtggtcacc tgcctgaggg cacttctgtc ccaccagcat cagaccaggc 180 cgcaccgagt ccccggcacc atgtttggga agaggaagaa gcgggtggag atctccgcgc 240 cgtccaactt cgagcaccgc gtgcacacgg gcttcgacca gcacgagcag aagttcacgg 300 ggctgccccg ccagtggcag agcctgatcg aggagtcggc tcgccggccc aagcccctcg 360 tcgaccccgc ctgcatcacc tccatccagc ccggggcccc caagaccatc gtgcggggca 420 gcaaaggtgc caaagatggg gccctcacgc tgctgctgga cgagtttgag aacatgtcgg 480 tgacacgctc caactccctg cggagagaca gcccgccgcc gcccgcccgt gcccgccagg 540 aaaatgggat gccagaggag ccggccacca cggccagagg gggcccaggg aaggcaggca 600 gccgaggccg gttcgccggt cacagcgagg cgggtggcgg cagtggtgac aggcgacggg 660 cggggccaga gaagaggccc aagtcttcca gggagggctc agggggtccc caggagtcct 720 cccgggacaa acgccccctc tccgggcctg atgtcggcac cccccagcct gctggtctgg 780 ccagtggggc gaaactggca gctggccggc cctttaacac ctacccgagg gctgacacgg 840 accacccatc ccggggtgcc cagggggagc ctcatgacgt ggcccctaac gggccatcag 900 cggggggcct ggccatcccc cagtcctcct cctcctcctc ccggcctccc acccgagccc 960 gaggtgcccc cagccctgga gtgctgggac cccacgcctc agagccccag ctggcccctc 1020 cagcctgcac ccccgccgcc cctgctgttc ctgggccccc tggcccccgc tcaccacagc 1080 gggagccaca gcgagtatcc catgagcagt tccgggctgc cctgcagctg gtggtggacc 1140 caggcgaccc ccgctcctac ctggacaact tcatcaagat tggcgagggc tccacgggca 1200 tcgtgtgcat cgccaccgtg cgcagctcgg gcaagctggt ggccgtcaag aagatggacc 1260 tgcgcaagca gcagaggcgc gagctgctct tcaacgaggt ggtaatcatg agggactacc 1320 agcacgagaa tgtggtggag atgtacaaca gctacctggt gggggacgag ctctgggtgg 1380 tcatggagtt cctggaagga ggcgccctca ccgacatcgt cacccacacc aggatgaacg 1440 aggagcagat cgcggccgtg tgccttgcag tgctgcaggc cctgtcggtg ctccacgccc 1500 agggcgtcat ccaccgggac atcaagagcg actcgatcct gctgacccat gatggcaggg 1560 tgaagctgtc agactttggg ttctgcgccc aggtgagcaa ggaagtgccc cgaaggaagt 1620 cgctggtcgg cacgccctac tggatggccc cagagctcat ctcccgcctt ccctacgggc 1680 cagaggtaga catctggtcg ctggggataa tggtgattga gatggtggac ggagagcccc 1740 cctacttcaa cgagccaccc ctcaaagcca tgaagatgat tcgggacaac ctgccacccc 1800 gactgaagaa cctgcacaag gtgtcgccat ccctgaaggg cttcctggac cgcctgctgg 1860 tgcgagaccc tgcccagcgg gccacggcag ccgagctgct gaagcaccca ttcctggcca 1920 aggcagggcc gcctgccagc atcgtgcccc tcatgcgcca gaaccgcacc agatgaggcc 1980 cagcgccctt cccctcaacc aaagagcccc cccgggtcac ccccgcccca ctgaggccag 2040 tagggggcca ggcctcccac tcctcccagc ccgggagatg ctccgcgtgg caccaccctc 2100 cttgctgggg gtagatgaga ccctactact gaactccagt tttgatctcg tgacttttag 2160 aaaaacacag ggactcgtgg gagcaagcga ggctcccagg acccccaccc tctgggacag 2220 gccctccccc atgttcttct gtctccagga agggcagcgg ccctcccatc actggaagtc 2280 tgcagtgggg gtcgctgggg gtggagagaa cactaagagg tgaacatgta tgagtgtgtg 2340 cacgcgtgtg agtgtgcatg tgtgtgtgtg tgcaaaggtc cagccacccc gtcctccagc 2400 ccgcaagggg tgtctggcgc cttgcctgac acccagcccc ctctccccct gagccattgt 2460 gggggtcgat catgaatgtc cgaagagtgg ccttttcccg tagccctgcg ccccctttct 2520 gtggctggat ggggagacag gtcagggccc cccaccctct ccagcccctg cagcaaatga 2580 ctactgcacc tggacagcct cctcttttct agaagtctat ttatattgtc attttataac 2640 actctagccc ctgcccttat tgggggacag atggtccctg tcctgcgggg tggccctggc 2700 agaaccactg cctgaagaac caggttcctg cccggtcagc gcagccccag cccgcccacc 2760 cctgcctcga gttagtttta caattaaaac attgtcttgt tttgtg 2806 103 591 PRT Homo sapiens 103 Met Phe Gly Lys Arg Lys Lys Arg Val Glu Ile Ser Ala Pro Ser Asn 1 5 10 15 Phe Glu His Arg Val His Thr Gly Phe Asp Gln His Glu Gln Lys Phe 20 25 30 Thr Gly Leu Pro Arg Gln Trp Gln Ser Leu Ile Glu Glu Ser Ala Arg 35 40 45 Arg Pro Lys Pro Leu Val Asp Pro Ala Cys Ile Thr Ser Ile Gln Pro 50 55 60 Gly Ala Pro Lys Thr Ile Val Arg Gly Ser Lys Gly Ala Lys Asp Gly 65 70 75 80 Ala Leu Thr Leu Leu Leu Asp Glu Phe Glu Asn Met Ser Val Thr Arg 85 90 95 Ser Asn Ser Leu Arg Arg Asp Ser Pro Pro Pro Pro Ala Arg Ala Arg 100 105 110 Gln Glu Asn Gly Met Pro Glu Glu Pro Ala Thr Thr Ala Arg Gly Gly 115 120 125 Pro Gly Lys Ala Gly Ser Arg Gly Arg Phe Ala Gly His Ser Glu Ala 130 135 140 Gly Gly Gly Ser Gly Asp Arg Arg Arg Ala Gly Pro Glu Lys Arg Pro 145 150 155 160 Lys Ser Ser Arg Glu Gly Ser Gly Gly Pro Gln Glu Ser Ser Arg Asp 165 170 175 Lys Arg Pro Leu Ser Gly Pro Asp Val Gly Thr Pro Gln Pro Ala Gly 180 185 190 Leu Ala Ser Gly Ala Lys Leu Ala Ala Gly Arg Pro Phe Asn Thr Tyr 195 200 205 Pro Arg Ala Asp Thr Asp His Pro Ser Arg Gly Ala Gln Gly Glu Pro 210 215 220 His Asp Val Ala Pro Asn Gly Pro Ser Ala Gly Gly Leu Ala Ile Pro 225 230 235 240 Gln Ser Ser Ser Ser Ser Ser Arg Pro Pro Thr Arg Ala Arg Gly Ala 245 250 255 Pro Ser Pro Gly Val Leu Gly Pro His Ala Ser Glu Pro Gln Leu Ala 260 265 270 Pro Pro Ala Cys Thr Pro Ala Ala Pro Ala Val Pro Gly Pro Pro Gly 275 280 285 Pro Arg Ser Pro Gln Arg Glu Pro Gln Arg Val Ser His Glu Gln Phe 290 295 300 Arg Ala Ala Leu Gln Leu Val Val Asp Pro Gly Asp Pro Arg Ser Tyr 305 310 315 320 Leu Asp Asn Phe Ile Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys 325 330 335 Ile Ala Thr Val Arg Ser Ser Gly Lys Leu Val Ala Val Lys Lys Met 340 345 350 Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val 355 360 365 Ile Met Arg Asp Tyr Gln His Glu Asn Val Val Glu Met Tyr Asn Ser 370 375 380 Tyr Leu Val Gly Asp Glu Leu Trp Val Val Met Glu Phe Leu Glu Gly 385 390 395 400 Gly Ala Leu Thr Asp Ile Val Thr His Thr Arg Met Asn Glu Glu Gln 405 410 415 Ile Ala Ala Val Cys Leu Ala Val Leu Gln Ala Leu Ser Val Leu His 420 425 430 Ala Gln Gly Val Ile His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu 435 440 445 Thr His Asp Gly Arg Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln 450 455 460 Val Ser Lys Glu Val Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr 465 470 475 480 Trp Met Ala Pro Glu Leu Ile Ser Arg Leu Pro Tyr Gly Pro Glu Val 485 490 495 Asp Ile Trp Ser Leu Gly Ile Met Val Ile Glu Met Val Asp Gly Glu 500 505 510 Pro Pro Tyr Phe Asn Glu Pro Pro Leu Lys Ala Met Lys Met Ile Arg 515 520 525 Asp Asn Leu Pro Pro Arg Leu Lys Asn Leu His Lys Val Ser Pro Ser 530 535 540 Leu Lys Gly Phe Leu Asp Arg Leu Leu Val Arg Asp Pro Ala Gln Arg 545 550 555 560 Ala Thr Ala Ala Glu Leu Leu Lys His Pro Phe Leu Ala Lys Ala Gly 565 570 575 Pro Pro Ala Ser Ile Val Pro Leu Met Arg Gln Asn Arg Thr Arg 580 585 590 104 3684 DNA Homo sapiens 104 atggcgggac ctgggggctg gagggacagg gaggtcacgg atctgggcca cctgccggat 60 ccaactggaa tattctcact agataaaacc attggccttg gtacttatgg cagaatctat 120 ttgggacttc atgagaagac tggtgcattt acagctgtta aagtgatgaa cgctcgtaag 180 gatgaggaag aggatctcag gactgaactc aaccttctga ggaagtactc tttccacaaa 240 aacattgtgt ccttctatgg agcatttttc aagctgagtc cccctggtca gcggcaccaa 300 ctttggatgg tgatggagtt atgtgcagca ggttcggtca ctgatgtagt gagaatgacc 360 agtaatcaga gtttaaaaga agattggatt gcttatatct gccgagaaat ccttcagggc 420 ttagctcacc ttcacgcaca ccgagtaatt caccgggaca tcaaaggtca gaatgtgctg 480 ctgactcata atgctgaagt aaaactggtt gattttggag tgagtgccca ggtgagcaga 540 actaatggaa gaaggaatag tttcattggg acaccatact ggatggcacc tgaggtgatt 600 gactgtgatg aggacccaag acgctcctat gattacagaa gtgatgtgtg gtctgtggga 660 attactgcca ttgaaatggc tgaaggagcc cctcctctgt gtaaccttca acccttggaa 720 gctctcttcg ttattttgcg ggaatctgct cccacagtca aatccagcgg atggtcccgt 780 aagttccaca atttcatgga aaagtgtacg ataaaaaatt tcctgtttcg tcctacttct 840 gcaaacatgc ttcaacaccc atttgttcgg gatataaaaa atgaacgaca tgttgttgag 900 tcattaacaa ggcatcttac tggaatcatt aaaaaaagac agaaaaaaga acaggcacgg 960 gagaaaaaat caaaagtttc tactctgagg caagcactgg caaaaagact atcaccaaag 1020 aggttcaggg caaagtcatc atggagacct gaaaagcttg aactctcgga tttagaagcc 1080 cgcaggcaaa ggcgccaacg cagatgggaa gatatcttta atcagcatga ggaagaattg 1140 agacaagttg ataaagacaa agaagatgaa tcatcagaca atgatgaagt atttcattcg 1200 attcaggctg aagtccagat agagccattg aagccataca tttcaaatcc taaaaaaatt 1260 gaggttcaag agagatctcc ttctgtgcct aacaaccagg atcatgcaca tcatgtcaag 1320 ttctcttcaa gcgttcctca gcggtctctt ttggaacaag ctcagaagcc cattgacatc 1380 agacaaagga gttcgcaaaa tcgtcaaaat tggctggcag catcaggtga ttcaaagcac 1440 aaaattttag caggcaaaac acagagctac tgtttaacaa tttatatttc agaagtcaag 1500 aaagaagaat ttcaagaagg aatgaatcaa aagtgtcagg gagcccaagt aggattagga 1560 cctgaaggcc attgtatttg gcaattgggt gaatcttctt ctgaggaaga aagtcctgtg 1620 actggaagga ggtctcagtc atcaccacct tattctacta ttgatcagaa gttgctggtt 1680 gacatccatg ttccagatgg atttaaagta ggaaaaatat caccccctgt atacttgaca 1740 aacgaatggg taggctataa tgcactctct gaaatcttcc ggaatgattg gttaactccg 1800 gcacctgtca ttcagccacc tgaagaggat ggtgattatg ttgaactcta tgatgccagt 1860 gctgatactg atggtgatga tgatgatgag tctaatgata cttttgaaga tacctatgat 1920 catgccaatg gcaatgatga cttggataac caggttgatc aggctaatga tgtttgtaaa 1980 gaccatgatg atgacaacaa taagtttgtt gatgatgtaa ataataatta ttatgaggcg 2040 cctagttgtc caagggcaag ctatggcaga gatggaagct gcaagcaaga tggttatgat 2100 ggaagtcgtg gaaaagagga agcctacaga ggctatggaa gccatacagc caatagaagc 2160 catggaggaa gtgcagccag tgaggacaat gcagccattg gagatcagga agaacatgca 2220 gccaatatag gcagtgaaag aagaggcagt gagggtgatg gaggtaaggg agtcgttcga 2280 accagtgaag agagtggagc ccttggactc aatggagaag aaaattgctc agagacagat 2340 ggtccaggat tgaagagacc tgcgtctcag gactttgaat atctacagga ggagccaggt 2400 ggtggaaatg aggcctcaaa tgccattgac tcaggtgctg caccgtcagc acctgatcat 2460 gagagtgaca ataaggacat atcagaatca tcaacacaat cagatttttc tgccaatcac 2520 tcatctcctt ccaaaggttc tgggatgtct gctgatgcta actttgccag tgccatctta 2580 tacgctggat tcgtagaagt acctgaggaa tcacctaagc aaccctctga agtcaatgtt 2640 aacccactct atgtctctcc tgcatgtaaa aaaccactaa tccacatgta tgaaaaggag 2700 ttcacttctg agatctgctg tggttctttg tggggagtca atttgctgtt gggaacccga 2760 tctaatctat atctgatgga cagaagtgga aaggctgaca ttactaaact tataaggcga 2820 agaccattcc gccagattca agtcttagag ccactcaatt tgctgattac catctcaggt 2880 cataagaaca gacttcgggt gtatcatctg acctggttga ggaacaagat tttgaataat 2940 gatccagaaa gtaaaagaag gcaagaagaa atgctgaaga cagaggaagc ctgcaaagct 3000 attgataagt taacaggctg tgaacacttc agtgtcctcc aacatgaaga aacaacatat 3060 attgcaattg ctttgaaatc atcaattcac ctttatgcat gggcaccaaa gtcctttgat 3120 gaaagcactg ctattaaagt atttccaaca cttgatcata agccagtgac agttgacctg 3180 gctattggtt ctgaaaaaag actaaagatt ttcttcagct cagcagatgg atatcacctc 3240 atcgatgcag aatctgaggt tatgtctgat gtgaccctgc caaagaatcc cctggaaatc 3300 attataccac agaatatcat cattttacct gattgcttgg gaattggcat gatgctcacc 3360 ttcaatgctg aagccctctc tgtggaagca aatgaacaac tcttcaagaa gatccttgaa 3420 atgtggaaag acataccatc ttctatagct tttgaatgta cacagcgaac cacaggatgg 3480 ggccaaaagg ccattgaagt gcgctctttg caatccaggg ttctggaaag tgagctgaag 3540 cgcaggtcaa ttaagaagct gagattcctg tgcacccggg gtgacaagct gttctttacc 3600 tctaccctgc gcaatcacca cagccgggtt tacttcatga cacttggaaa acttgaagag 3660 ctccaaagca attatgatgt ctaa 3684 105 1227 PRT Homo sapiens 105 Met Ala Gly Pro Gly Gly Trp Arg Asp Arg Glu Val Thr Asp Leu Gly 1 5 10 15 His Leu Pro Asp Pro Thr Gly Ile Phe Ser Leu Asp Lys Thr Ile Gly 20 25 30 Leu Gly Thr Tyr Gly Arg Ile Tyr Leu Gly Leu His Glu Lys Thr Gly 35 40 45 Ala Phe Thr Ala Val Lys Val Met Asn Ala Arg Lys Asp Glu Glu Glu 50 55 60 Asp Leu Arg Thr Glu Leu Asn Leu Leu Arg Lys Tyr Ser Phe His Lys 65 70 75 80 Asn Ile Val Ser Phe Tyr Gly Ala Phe Phe Lys Leu Ser Pro Pro Gly 85 90 95 Gln Arg His Gln Leu Trp Met Val Met Glu Leu Cys Ala Ala Gly Ser 100 105 110 Val Thr Asp Val Val Arg Met Thr Ser Asn Gln Ser Leu Lys Glu Asp 115 120 125 Trp Ile Ala Tyr Ile Cys Arg Glu Ile Leu Gln Gly Leu Ala His Leu 130 135 140 His Ala His Arg Val Ile His Arg Asp Ile Lys Gly Gln Asn Val Leu 145 150 155 160 Leu Thr His Asn Ala Glu Val Lys Leu Val Asp Phe Gly Val Ser Ala 165 170 175 Gln Val Ser Arg Thr Asn Gly Arg Arg Asn Ser Phe Ile Gly Thr Pro 180 185 190 Tyr Trp Met Ala Pro Glu Val Ile Asp Cys Asp Glu Asp Pro Arg Arg 195 200 205 Ser Tyr Asp Tyr Arg Ser Asp Val Trp Ser Val Gly Ile Thr Ala Ile 210 215 220 Glu Met Ala Glu Gly Ala Pro Pro Leu Cys Asn Leu Gln Pro Leu Glu 225 230 235 240 Ala Leu Phe Val Ile Leu Arg Glu Ser Ala Pro Thr Val Lys Ser Ser 245 250 255 Gly Trp Ser Arg Lys Phe His Asn Phe Met Glu Lys Cys Thr Ile Lys 260 265 270 Asn Phe Leu Phe Arg Pro Thr Ser Ala Asn Met Leu Gln His Pro Phe 275 280 285 Val Arg Asp Ile Lys Asn Glu Arg His Val Val Glu Ser Leu Thr Arg 290 295 300 His Leu Thr Gly Ile Ile Lys Lys Arg Gln Lys Lys Glu Gln Ala Arg 305 310 315 320 Glu Lys Lys Ser Lys Val Ser Thr Leu Arg Gln Ala Leu Ala Lys Arg 325 330 335 Leu Ser Pro Lys Arg Phe Arg Ala Lys Ser Ser Trp Arg Pro Glu Lys 340 345 350 Leu Glu Leu Ser Asp Leu Glu Ala Arg Arg Gln Arg Arg Gln Arg Arg 355 360 365 Trp Glu Asp Ile Phe Asn Gln His Glu Glu Glu Leu Arg Gln Val Asp 370 375 380 Lys Asp Lys Glu Asp Glu Ser Ser Asp Asn Asp Glu Val Phe His Ser 385 390 395 400 Ile Gln Ala Glu Val Gln Ile Glu Pro Leu Lys Pro Tyr Ile Ser Asn 405 410 415 Pro Lys Lys Ile Glu Val Gln Glu Arg Ser Pro Ser Val Pro Asn Asn 420 425 430 Gln Asp His Ala His His Val Lys Phe Ser Ser Ser Val Pro Gln Arg 435 440 445 Ser Leu Leu Glu Gln Ala Gln Lys Pro Ile Asp Ile Arg Gln Arg Ser 450 455 460 Ser Gln Asn Arg Gln Asn Trp Leu Ala Ala Ser Gly Asp Ser Lys His 465 470 475 480 Lys Ile Leu Ala Gly Lys Thr Gln Ser Tyr Cys Leu Thr Ile Tyr Ile 485 490 495 Ser Glu Val Lys Lys Glu Glu Phe Gln Glu Gly Met Asn Gln Lys Cys 500 505 510 Gln Gly Ala Gln Val Gly Leu Gly Pro Glu Gly His Cys Ile Trp Gln 515 520 525 Leu Gly Glu Ser Ser Ser Glu Glu Glu Ser Pro Val Thr Gly Arg Arg 530 535 540 Ser Gln Ser Ser Pro Pro Tyr Ser Thr Ile Asp Gln Lys Leu Leu Val 545 550 555 560 Asp Ile His Val Pro Asp Gly Phe Lys Val Gly Lys Ile Ser Pro Pro 565 570 575 Val Tyr Leu Thr Asn Glu Trp Val Gly Tyr Asn Ala Leu Ser Glu Ile 580 585 590 Phe Arg Asn Asp Trp Leu Thr Pro Ala Pro Val Ile Gln Pro Pro Glu 595 600 605 Glu Asp Gly Asp Tyr Val Glu Leu Tyr Asp Ala Ser Ala Asp Thr Asp 610 615 620 Gly Asp Asp Asp Asp Glu Ser Asn Asp Thr Phe Glu Asp Thr Tyr Asp 625 630 635 640 His Ala Asn Gly Asn Asp Asp Leu Asp Asn Gln Val Asp Gln Ala Asn 645 650 655 Asp Val Cys Lys Asp His Asp Asp Asp Asn Asn Lys Phe Val Asp Asp 660 665 670 Val Asn Asn Asn Tyr Tyr Glu Ala Pro Ser Cys Pro Arg Ala Ser Tyr 675 680 685 Gly Arg Asp Gly Ser Cys Lys Gln Asp Gly Tyr Asp Gly Ser Arg Gly 690 695 700 Lys Glu Glu Ala Tyr Arg Gly Tyr Gly Ser His Thr Ala Asn Arg Ser 705 710 715 720 His Gly Gly Ser Ala Ala Ser Glu Asp Asn Ala Ala Ile Gly Asp Gln 725 730 735 Glu Glu His Ala Ala Asn Ile Gly Ser Glu Arg Arg Gly Ser Glu Gly 740 745 750 Asp Gly Gly Lys Gly Val Val Arg Thr Ser Glu Glu Ser Gly Ala Leu 755 760 765 Gly Leu Asn Gly Glu Glu Asn Cys Ser Glu Thr Asp Gly Pro Gly Leu 770 775 780 Lys Arg Pro Ala Ser Gln Asp Phe Glu Tyr Leu Gln Glu Glu Pro Gly 785 790 795 800 Gly Gly Asn Glu Ala Ser Asn Ala Ile Asp Ser Gly Ala Ala Pro Ser 805 810 815 Ala Pro Asp His Glu Ser Asp Asn Lys Asp Ile Ser Glu Ser Ser Thr 820 825 830 Gln Ser Asp Phe Ser Ala Asn His Ser Ser Pro Ser Lys Gly Ser Gly 835 840 845 Met Ser Ala Asp Ala Asn Phe Ala Ser Ala Ile Leu Tyr Ala Gly Phe 850 855 860 Val Glu Val Pro Glu Glu Ser Pro Lys Gln Pro Ser Glu Val Asn Val 865 870 875 880 Asn Pro Leu Tyr Val Ser Pro Ala Cys Lys Lys Pro Leu Ile His Met 885 890 895 Tyr Glu Lys Glu Phe Thr Ser Glu Ile Cys Cys Gly Ser Leu Trp Gly 900 905 910 Val Asn Leu Leu Leu Gly Thr Arg Ser Asn Leu Tyr Leu Met Asp Arg 915 920 925 Ser Gly Lys Ala Asp Ile Thr Lys Leu Ile Arg Arg Arg Pro Phe Arg 930 935 940 Gln Ile Gln Val Leu Glu Pro Leu Asn Leu Leu Ile Thr Ile Ser Gly 945 950 955 960 His Lys Asn Arg Leu Arg Val Tyr His Leu Thr Trp Leu Arg Asn Lys 965 970 975 Ile Leu Asn Asn Asp Pro Glu Ser Lys Arg Arg Gln Glu Glu Met Leu 980 985 990 Lys Thr Glu Glu Ala Cys Lys Ala Ile Asp Lys Leu Thr Gly Cys Glu 995 1000 1005 His Phe Ser Val Leu Gln His Glu Glu Thr Thr Tyr Ile Ala Ile Ala 1010 1015 1020 Leu Lys Ser Ser Ile His Leu Tyr Ala Trp Ala Pro Lys Ser Phe Asp 1025 1030 1035 1040 Glu Ser Thr Ala Ile Lys Val Phe Pro Thr Leu Asp His Lys Pro Val 1045 1050 1055 Thr Val Asp Leu Ala Ile Gly Ser Glu Lys Arg Leu Lys Ile Phe Phe 1060 1065 1070 Ser Ser Ala Asp Gly Tyr His Leu Ile Asp Ala Glu Ser Glu Val Met 1075 1080 1085 Ser Asp Val Thr Leu Pro Lys Asn Pro Leu Glu Ile Ile Ile Pro Gln 1090 1095 1100 Asn Ile Ile Ile Leu Pro Asp Cys Leu Gly Ile Gly Met Met Leu Thr 1105 1110 1115 1120 Phe Asn Ala Glu Ala Leu Ser Val Glu Ala Asn Glu Gln Leu Phe Lys 1125 1130 1135 Lys Ile Leu Glu Met Trp Lys Asp Ile Pro Ser Ser Ile Ala Phe Glu 1140 1145 1150 Cys Thr Gln Arg Thr Thr Gly Trp Gly Gln Lys Ala Ile Glu Val Arg 1155 1160 1165 Ser Leu Gln Ser Arg Val Leu Glu Ser Glu Leu Lys Arg Arg Ser Ile 1170 1175 1180 Lys Lys Leu Arg Phe Leu Cys Thr Arg Gly Asp Lys Leu Phe Phe Thr 1185 1190 1195 1200 Ser Thr Leu Arg Asn His His Ser Arg Val Tyr Phe Met Thr Leu Gly 1205 1210 1215 Lys Leu Glu Glu Leu Gln Ser Asn Tyr Asp Val 1220 1225 106 2962 DNA Homo sapiens 106 cgaagccaca gcccgagccc gagcccgagc ccgagccggc gccaccgcgc ccccggccat 60 ggcttttgcc aatttccgcc gcatcctgcg cctgtctacc ttcgagaaga gaaagtcccg 120 cgaatatgag cacgtccgcc gcgacctgga ccccaacgag gtgtgggaga tcgtgggcga 180 gctgggcgac ggcgccttcg gcaaggttta caaggccaag aataaggaga cgggtgcttt 240 ggctgcggcc aaagtcattg aaaccaagag tgaggaggag ctggaggact acatcgtgga 300 gattgagatc ctggccacct gcgaccaccc ctacattgtg aagctcctgg gagcctacta 360 tcacgacggg aagctgtgga tcatgattga gttctgtcca gggggagccg tggacgccat 420 catgctggag ctggacagag gcctcacgga gccccagata caggtggttt gccgccagat 480 gctagaagcc ctcaacttcc tgcacagcaa gaggatcatc caccgagatc tgaaagctgg 540 caacgtgctg atgaccctcg agggagacat caggctggct gactttggtg tgtctgccaa 600 gaatctgaag actctacaga aacgagattc cttcatcggc acgccttact ggatggcccc 660 cgaggtggtc atgtgtgaga ccatgaaaga cacgccctac gactacaaag ccgacatctg 720 gtccctgggc atcacgctga ttgagatggc ccagatcgag ccgccacacc acgagctcaa 780 ccccatgcgg gtcctgctaa agatcgccaa gtcggaccct cccacgctgc tcacgccctc 840 caagtggtct gtagagttcc gtgacttcct gaagatagcc ctggataaga acccagaaac 900 ccgacccagt gccgcgcagc tgctggagca tcccttcgtc agcagcatca ccagtaacaa 960 ggctctgcgg gagctggtgg ctgaggccaa ggccgaggtg atggaagaga tcgaagacgg 1020 ccgggatgag ggggaagagg aggacgccgt ggatgccgcc tccaccctgg agaaccatac 1080 tcagaactcc tctgaggtga gtccgccaag cctcaatgct gacaagcctc tcgaggagtc 1140 accttccacc ccgctggcac ccagccagtc tcaggacagt gtgaatgagc cctgcagcca 1200 gccctctggg gacagatccc tccaaaccac cagtccccca gtcgtggccc ctggaaatga 1260 gaacggcctg gcagtgcctg tgcccctgcg gaagtcccga cccgtgtcaa tggatgccag 1320 aattcaggta gcccaggaga agcaagttgc tgagcagggt ggggacctca gcccagcagc 1380 caacagatct caaaaggcca gccagagccg gcccaacagc agcgccctgg agaccttggg 1440 tggggagaag ctggccaatg gcagcctgga gccacctgcc caggcagctc cagggccttc 1500 caagagggac tcggactgca gcagcctctg cacctctgag agcatggact atggtaccaa 1560 tctctccact gacctgtcgc tgaacaaaga gatgggctct ctgtccatca aggacccgaa 1620 actgtacaaa aaaaccctca agcggacacg caaatttgtg gtggatggtg tggaggtgag 1680 catcaccacc tccaagatca tcagcgaaga tgagaagaag gatgaggaga tgagatttct 1740 caggcgccag gaactccgag agcttcggct gctccagaaa gaagagcatc ggaaccagac 1800 ccagctgagt aacaagcatg agctgcagct ggagcaaatg cataaacgtt ttgaacagga 1860 aatcaacgcc aagaagaagt tctttgacac ggaattagag aacctggagc gtcagcaaaa 1920 gcagcaagtg gagaagatgg agcaagacca tgccgtgcgc cgccgggagg aggccaggcg 1980 gatccgcctg gagcaggatc gggactacac caggttccaa gagcagctca aactgatgaa 2040 gaaagaggtg aagaacgagg tggagaagct cccccgacag cagcggaagg aaagcatgaa 2100 gcagaagatg gaggagcaca cgcagaaaaa gcagcttctt gaccgggact ttgtagccaa 2160 gcagaaggag gacctggagc tggccatgaa gaggctcacc accgacaaca ggcgggagat 2220 ctgtgacaag gagcgcgagt gcctcatgaa gaagcaggag ctccttcgag accgggaagc 2280 agccctgtgg gagatggaag agcaccagct gcaggagagg caccagctgg tgaagcagca 2340 gctcaaagac cagtacttcc tccagcggca cgagctgctg cgcaagcatg agaaggagcg 2400 ggagcagatg cagcgctaca accagcgcat gatagagcag ctgaaggtgc ggcagcaaca 2460 ggaaaaggcg cggctgccca agatccagag gagtgagggc aagacgcgca tggccatgta 2520 caagaagagc ctccacatca acggcggggg cagcgcagct gagcagcgtg agaagatcaa 2580 gcagttctcc cagcaggagg agaagaggca gaagtcggag cggctgcagc aacagcagaa 2640 acacgagaac cagatgcggg acatgctggc gcagtgcgag agcaacatga gcgagctgca 2700 gcagctgcag aatgaaaagt gccacctcct ggtagagcac gaaacccaga aactgaaggc 2760 cctggatgag agccataacc agaacctgaa ggaatggcgg gacaagcttc ggccgcgcaa 2820 gaaggctctg gaagaggatc tgaaccagaa gaagcgggag caggagatgt tcttcaagct 2880 gagcgaggag gcggagtgcc caaacccctc caccccaagc aaggccgcca agttcttccc 2940 ctacagctct ggggatgctt cc 2962 107 968 PRT Homo sapiens 107 Met Ala Phe Ala Asn Phe Arg Arg Ile Leu Arg Leu Ser Thr Phe Glu 1 5 10 15 Lys Arg Lys Ser Arg Glu Tyr Glu His Val Arg Arg Asp Leu Asp Pro 20 25 30 Asn Glu Val Trp Glu Ile Val Gly Glu Leu Gly Asp Gly Ala Phe Gly 35 40 45 Lys Val Tyr Lys Ala Lys Asn Lys Glu Thr Gly Ala Leu Ala Ala Ala 50 55 60 Lys Val Ile Glu Thr Lys Ser Glu Glu Glu Leu Glu Asp Tyr Ile Val 65 70 75 80 Glu Ile Glu Ile Leu Ala Thr Cys Asp His Pro Tyr Ile Val Lys Leu 85 90 95 Leu Gly Ala Tyr Tyr His Asp Gly Lys Leu Trp Ile Met Ile Glu Phe 100 105 110 Cys Pro Gly Gly Ala Val Asp Ala Ile Met Leu Glu Leu Asp Arg Gly 115 120 125 Leu Thr Glu Pro Gln Ile Gln Val Val Cys Arg Gln Met Leu Glu Ala 130 135 140 Leu Asn Phe Leu His Ser Lys Arg Ile Ile His Arg Asp Leu Lys Ala 145 150 155 160 Gly Asn Val Leu Met Thr Leu Glu Gly Asp Ile Arg Leu Ala Asp Phe 165 170 175 Gly Val Ser Ala Lys Asn Leu Lys Thr Leu Gln Lys Arg Asp Ser Phe 180 185 190 Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Met Cys Glu Thr 195 200 205 Met Lys Asp Thr Pro Tyr Asp Tyr Lys Ala Asp Ile Trp Ser Leu Gly 210 215 220 Ile Thr Leu Ile Glu Met Ala Gln Ile Glu Pro Pro His His Glu Leu 225 230 235 240 Asn Pro Met Arg Val Leu Leu Lys Ile Ala Lys Ser Asp Pro Pro Thr 245 250 255 Leu Leu Thr Pro Ser Lys Trp Ser Val Glu Phe Arg Asp Phe Leu Lys 260 265 270 Ile Ala Leu Asp Lys Asn Pro Glu Thr Arg Pro Ser Ala Ala Gln Leu 275 280 285 Leu Glu His Pro Phe Val Ser Ser Ile Thr Ser Asn Lys Ala Leu Arg 290 295 300 Glu Leu Val Ala Glu Ala Lys Ala Glu Val Met Glu Glu Ile Glu Asp 305 310 315 320 Gly Arg Asp Glu Gly Glu Glu Glu Asp Ala Val Asp Ala Ala Ser Thr 325 330 335 Leu Glu Asn His Thr Gln Asn Ser Ser Glu Val Ser Pro Pro Ser Leu 340 345 350 Asn Ala Asp Lys Pro Leu Glu Glu Ser Pro Ser Thr Pro Leu Ala Pro 355 360 365 Ser Gln Ser Gln Asp Ser Val Asn Glu Pro Cys Ser Gln Pro Ser Gly 370 375 380 Asp Arg Ser Leu Gln Thr Thr Ser Pro Pro Val Val Ala Pro Gly Asn 385 390 395 400 Glu Asn Gly Leu Ala Val Pro Val Pro Leu Arg Lys Ser Arg Pro Val 405 410 415 Ser Met Asp Ala Arg Ile Gln Val Ala Gln Glu Lys Gln Val Ala Glu 420 425 430 Gln Gly Gly Asp Leu Ser Pro Ala Ala Asn Arg Ser Gln Lys Ala Ser 435 440 445 Gln Ser Arg Pro Asn Ser Ser Ala Leu Glu Thr Leu Gly Gly Glu Lys 450 455 460 Leu Ala Asn Gly Ser Leu Glu Pro Pro Ala Gln Ala Ala Pro Gly Pro 465 470 475 480 Ser Lys Arg Asp Ser Asp Cys Ser Ser Leu Cys Thr Ser Glu Ser Met 485 490 495 Asp Tyr Gly Thr Asn Leu Ser Thr Asp Leu Ser Leu Asn Lys Glu Met 500 505 510 Gly Ser Leu Ser Ile Lys Asp Pro Lys Leu Tyr Lys Lys Thr Leu Lys 515 520 525 Arg Thr Arg Lys Phe Val Val Asp Gly Val Glu Val Ser Ile Thr Thr 530 535 540 Ser Lys Ile Ile Ser Glu Asp Glu Lys Lys Asp Glu Glu Met Arg Phe 545 550 555 560 Leu Arg Arg Gln Glu Leu Arg Glu Leu Arg Leu Leu Gln Lys Glu Glu 565 570 575 His Arg Asn Gln Thr Gln Leu Ser Asn Lys His Glu Leu Gln Leu Glu 580 585 590 Gln Met His Lys Arg Phe Glu Gln Glu Ile Asn Ala Lys Lys Lys Phe 595 600 605 Phe Asp Thr Glu Leu Glu Asn Leu Glu Arg Gln Gln Lys Gln Gln Val 610 615 620 Glu Lys Met Glu Gln Asp His Ala Val Arg Arg Arg Glu Glu Ala Arg 625 630 635 640 Arg Ile Arg Leu Glu Gln Asp Arg Asp Tyr Thr Arg Phe Gln Glu Gln 645 650 655 Leu Lys Leu Met Lys Lys Glu Val Lys Asn Glu Val Glu Lys Leu Pro 660 665 670 Arg Gln Gln Arg Lys Glu Ser Met Lys Gln Lys Met Glu Glu His Thr 675 680 685 Gln Lys Lys Gln Leu Leu Asp Arg Asp Phe Val Ala Lys Gln Lys Glu 690 695 700 Asp Leu Glu Leu Ala Met Lys Arg Leu Thr Thr Asp Asn Arg Arg Glu 705 710 715 720 Ile Cys Asp Lys Glu Arg Glu Cys Leu Met Lys Lys Gln Glu Leu Leu 725 730 735 Arg Asp Arg Glu Ala Ala Leu Trp Glu Met Glu Glu His Gln Leu Gln 740 745 750 Glu Arg His Gln Leu Val Lys Gln Gln Leu Lys Asp Gln Tyr Phe Leu 755 760 765 Gln Arg His Glu Leu Leu Arg Lys His Glu Lys Glu Arg Glu Gln Met 770 775 780 Gln Arg Tyr Asn Gln Arg Met Ile Glu Gln Leu Lys Val Arg Gln Gln 785 790 795 800 Gln Glu Lys Ala Arg Leu Pro Lys Ile Gln Arg Ser Glu Gly Lys Thr 805 810 815 Arg Met Ala Met Tyr Lys Lys Ser Leu His Ile Asn Gly Gly Gly Ser 820 825 830 Ala Ala Glu Gln Arg Glu Lys Ile Lys Gln Phe Ser Gln Gln Glu Glu 835 840 845 Lys Arg Gln Lys Ser Glu Arg Leu Gln Gln Gln Gln Lys His Glu Asn 850 855 860 Gln Met Arg Asp Met Leu Ala Gln Cys Glu Ser Asn Met Ser Glu Leu 865 870 875 880 Gln Gln Leu Gln Asn Glu Lys Cys His Leu Leu Val Glu His Glu Thr 885 890 895 Gln Lys Leu Lys Ala Leu Asp Glu Ser His Asn Gln Asn Leu Lys Glu 900 905 910 Trp Arg Asp Lys Leu Arg Pro Arg Lys Lys Ala Leu Glu Glu Asp Leu 915 920 925 Asn Gln Lys Lys Arg Glu Gln Glu Met Phe Phe Lys Leu Ser Glu Glu 930 935 940 Ala Glu Cys Pro Asn Pro Ser Thr Pro Ser Lys Ala Ala Lys Phe Phe 945 950 955 960 Pro Tyr Ser Ser Gly Asp Ala Ser 965 108 11 PRT Homo sapiens MOD_RES (2) Any amino acid 108 Leu Xaa Leu Xaa Leu Xaa Leu Xaa Leu Xaa Leu 1 5 10 109 20 DNA Artificial Sequence Description of Artificial Sequence Primer 109 gcagcaagtg gagaagatgg 20 110 22 DNA Artificial Sequence Description of Artificial Sequence Primer 110 ggaagcatcc ccagagctgt ag 22 111 12 PRT Homo sapiens 111 Glu Lys Phe Gln Lys Cys Ser Ala Asp Glu Ser Pro 1 5 10 112 16 PRT Homo sapiens 112 Ser Ile Ser Asn Ser Glu Leu Phe Pro Thr Thr Asp Pro Val Gly Thr 1 5 10 15 113 9 PRT Homo sapiens 113 Leu Asp Phe Pro Lys Glu Asp Tyr Arg 1 5 114 12 PRT Homo sapiens 114 His Gly Asp Pro Arg Pro Glu Pro Arg Pro Thr Gln 1 5 10 115 14 PRT Homo sapiens 115 Pro Ser Thr Asn Arg Ala Gly Ser Leu Lys Asp Pro Glu Cys 1 5 10 116 19 PRT Homo sapiens 116 Asp Pro Arg Thr Arg Ala Ser Asp Pro Gln Ser Pro Pro Gln Val Ser 1 5 10 15 Arg His Lys 117 16 PRT Homo sapiens 117 Cys Leu Val Pro Leu Ile Gln Leu Tyr Arg Lys Gln Thr Ser Thr Cys 1 5 10 15 118 9 PRT Homo sapiens 118 Pro Leu Met Arg Gln Asn Arg Thr Arg 1 5 119 16 PRT Homo sapiens 119 Ser Gly Asp Arg Arg Arg Ala Gly Pro Glu Lys Arg Pro Lys Ser Ser 1 5 10 15 120 16 PRT Homo sapiens 120 Cys Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu 1 5 10 15 121 15 PRT Homo sapiens 121 Arg Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Pro Tyr 1 5 10 15 122 15 PRT Homo sapiens 122 Lys Arg Lys Ser Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu 1 5 10 15 123 15 PRT Homo sapiens 123 Lys Arg Asn Thr Phe Val Gly Thr Pro Phe Trp Met Ala Pro Glu 1 5 10 15 124 15 PRT Homo sapiens 124 Pro Ala Asn Ser Phe Val Gly Thr Pro Tyr Trp Met Ala Pro Glu 1 5 10 15 125 15 PRT Homo sapiens 125 Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu 1 5 10 15 126 15 PRT Homo sapiens 126 Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu 1 5 10 15 127 18 PRT Homo sapiens 127 Arg Asn Lys Val Arg Lys Thr Phe Val Gly Thr Pro Cys Trp Met Ala 1 5 10 15 Pro Glu 128 22 DNA Homo sapiens 128 ctcccatttc ctagcaaaat ca 22 129 22 DNA Homo sapiens 129 agaggcagta ttgtcagatg ta 22 130 22 DNA Homo sapiens 130 ccacacatgc gtatctctgt tg 22 131 24 DNA Homo sapiens 131 ttgctagaat tcacatcagg taca 24 132 22 DNA Homo sapiens 132 atccctggat cacactgctt ct 22 133 22 DNA Homo sapiens 133 caaggtgttc tttgcctctg tt 22 134 21 DNA Homo sapiens 134 agatggactg tactgggagg g 21 135 22 DNA Homo sapiens 135 agaagagcac ttggcactta tc 22 136 20 DNA Homo sapiens 136 catcatgaac tggtgacggg 20 137 23 DNA Homo sapiens 137 ccagtgaaat caaaccagta aaa 23 138 24 DNA Homo sapiens 138 caaaacctgg ccgtctcttc tatt 24 139 23 DNA Homo sapiens 139 atttgtgcta ctgggattct gtg 23 140 24 DNA Homo sapiens 140 gaatagcggt accatgatag aata 24 141 23 DNA Homo sapiens 141 taccaaaaag agccaaaagt gtg 23 142 23 DNA Homo sapiens 142 ctcagtattc tctccaaaga ttg 23 143 23 DNA Homo sapiens 143 gatgttctct ccattctgta aag 23 144 21 DNA Homo sapiens 144 catcactgga agtctgcagt g 21 145 20 DNA Homo sapiens 145 caggtgcagt agtcatttgc 20 146 20 DNA Artificial Sequence Description of Artificial Sequence Primer 146 ggagctgtcg tattccagtc 20 147 21 DNA Artificial Sequence Description of Artificial Sequence Primer 147 aacccctcaa gacccgttta g 21 148 4 PRT Artificial Sequence Description of Artificial Sequence Synthetic motif 148 Pro Xaa Xaa Pro 1 149 50 PRT Artificial Sequence Description of Artificial Sequence Synthetic leucine zipper 149 Leu Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Leu 50 150 9 PRT Artificial Sequence Description of Artificial Sequence Synthetic Cdc42/Rac-binding motif 150 Ser Pro Xaa Xaa Xaa His Xaa Xaa His 1 5 151 787 PRT Homo sapiens 151 Ile Ile Glu Leu Ala Glu Arg Lys Pro Pro Leu Phe Asn Met Asn Ala 1 5 10 15 Met Ser Ala Leu Tyr His Ile Ala Gln Asn Glu Ser Pro Thr Leu Gln 20 25 30 Ser Asn Glu Trp Ser Asp Tyr Phe Arg Asn Phe Val Asp Ser Cys Leu 35 40 45 Gln Lys Ile Pro Gln Asp Arg Pro Thr Ser Glu Glu Leu Leu Lys His 50 55 60 Ile Phe Val Leu Arg Glu Arg Pro Glu Thr Val Leu Ile Asp Leu Ile 65 70 75 80 Gln Arg Thr Lys Asp Ala Val Arg Glu Leu Asp Asn Leu Gln Tyr Arg 85 90 95 Lys Met Lys Lys Leu Leu Phe Gln Glu Ala His Asn Gly Pro Ala Tyr 100 105 110 Glu Ala Gln Glu Glu Glu Glu Glu Gln Asp His Gly Val Gly Arg Thr 115 120 125 Gly Thr Val Asn Ser Val Gly Ser Asn Gln Ser Ile Pro Ser Met Ser 130 135 140 Ile Ser Ala Ser Ser Gln Ser Ser Ser Val Asn Ser Leu Pro Asp Val 145 150 155 160 Ser Asp Asp Lys Ser Glu Leu Asp Met Met Glu Gly Asp His Thr Val 165 170 175 Met Ser Asn Ser Ser Val Ile His Leu Lys Pro Glu Glu Glu Asn Tyr 180 185 190 Arg Glu Glu Gly Asp Pro Arg Thr Arg Ala Ser Asp Pro Gln Ser Pro 195 200 205 Pro Gln Val Ser Arg His Lys Ser His Tyr Arg Asn Arg Glu His Phe 210 215 220 Ala Thr Ile Arg Thr Ala Ser Leu Val Thr Arg Gln Met Gln Glu His 225 230 235 240 Glu Gln Asp Ser Glu Leu Arg Glu Gln Met Ser Gly Tyr Lys Arg Met 245 250 255 Arg Arg Gln His Gln Lys Gln Leu Met Thr Leu Glu Asn Lys Leu Lys 260 265 270 Ala Glu Met Asp Glu His Arg Leu Arg Leu Asp Lys Cys Leu Glu Thr 275 280 285 Gly Arg Asn Asn Phe Ala Ala Glu Met Glu Lys Leu Ile Lys Lys His 290 295 300 Gln Ala Ala Met Glu Lys Glu Ala Lys Val Met Ser Asn Glu Glu Lys 305 310 315 320 Lys Phe Gln Gln His Ile Gln Ala Gln Gln Lys Lys Glu Leu Asn Ser 325 330 335 Phe Leu Glu Ser Gln Lys Arg Glu Tyr Lys Leu Arg Lys Glu Gln Leu 340 345 350 Lys Glu Glu Leu Asn Glu Asn Gln Ser Thr Pro Lys Lys Glu Lys Gln 355 360 365 Glu Trp Leu Ser Lys Gln Lys Glu Asn Ile Gln His Phe Gln Ala Glu 370 375 380 Glu Glu Ala Asn Leu Leu Arg Arg Gln Arg Gln Tyr Leu Glu Leu Glu 385 390 395 400 Cys Arg Arg Phe Lys Arg Arg Met Leu Leu Gly Arg His Asn Leu Glu 405 410 415 Gln Asp Leu Val Arg Glu Glu Leu Asn Lys Arg Gln Thr Gln Lys Asp 420 425 430 Leu Glu His Ala Met Leu Leu Arg Gln His Glu Ser Met Gln Glu Leu 435 440 445 Glu Phe Arg His Leu Asn Thr Ile Gln Lys Met Arg Cys Glu Leu Ile 450 455 460 Arg Leu Gln His Gln Thr Glu Leu Thr Asn Gln Leu Glu Tyr Asn Lys 465 470 475 480 Arg Arg Glu Arg Glu Leu Arg Arg Lys His Val Met Glu Val Arg Gln 485 490 495 Gln Pro Lys Ser Leu Lys Ser Lys Glu Leu Gln Ile Lys Lys Gln Phe 500 505 510 Gln Asp Thr Cys Lys Ile Gln Thr Arg Gln Tyr Lys Ala Leu Arg Asn 515 520 525 His Leu Leu Glu Thr Thr Pro Lys Ser Glu His Lys Ala Val Leu Lys 530 535 540 Arg Leu Lys Glu Glu Gln Thr Arg Lys Leu Ala Ile Leu Ala Glu Gln 545 550 555 560 Tyr Asp His Ser Ile Asn Glu Met Leu Ser Thr Gln Ala Leu Arg Leu 565 570 575 Asp Glu Ala Gln Glu Ala Glu Cys Gln Val Leu Lys Met Gln Leu Gln 580 585 590 Gln Glu Leu Glu Leu Leu Asn Ala Tyr Gln Ser Lys Ile Lys Met Gln 595 600 605 Ala Glu Ala Gln His Asp Arg Glu Leu Arg Glu Leu Glu Gln Arg Val 610 615 620 Ser Leu Arg Arg Ala Leu Leu Glu Gln Lys Ile Glu Glu Glu Met Leu 625 630 635 640 Ala Leu Gln Asn Glu Arg Thr Glu Arg Ile Arg Ser Leu Leu Glu Arg 645 650 655 Gln Ala Arg Glu Ile Glu Ala Phe Asp Ser Glu Ser Met Arg Leu Gly 660 665 670 Phe Ser Asn Met Val Leu Ser Asn Leu Ser Pro Glu Ala Phe Ser His 675 680 685 Ser Tyr Pro Gly Ala Ser Gly Trp Ser His Asn Pro Thr Gly Gly Pro 690 695 700 Gly Pro His Trp Gly His Pro Met Gly Gly Pro Pro Gln Ala Trp Gly 705 710 715 720 His Pro Met Gln Gly Gly Pro Gln Pro Trp Gly His Pro Ser Gly Pro 725 730 735 Met Gln Gly Val Pro Arg Gly Ser Ser Met Gly Val Arg Asn Ser Pro 740 745 750 Gln Ala Leu Arg Arg Thr Ala Ser Gly Gly Arg Thr Glu Gln Gly Met 755 760 765 Ser Arg Ser Thr Ser Val Thr Ser Gln Ile Ser Asn Gly Ser His Met 770 775 780 Ser Tyr Thr 785 152 338 PRT Homo sapiens MOD_RES (2) Any amino acid 152 His Xaa Glu Tyr Val Pro Val Arg Arg Ile Asn Leu Glu Ala Cys Ser 1 5 10 15 Asn Glu Met Val Thr Ser Cys Arg Ala Ser Cys Met Phe Gln Thr Leu 20 25 30 Asn His Pro Asn Ile Val Pro Tyr Arg Ala Thr Leu Ile Ala Asp Asn 35 40 45 Glu Leu Trp Val Val Thr Ser Phe Met Ala Tyr Gly Ser Ala Lys Asp 50 55 60 Leu Ile Cys Thr His Phe Met Asp Gly Met Asn Glu Leu Ala Ile Ala 65 70 75 80 Tyr Ile Leu Gln Gly Val Leu Lys Ala Leu Asp Tyr Ile His His Asn 85 90 95 Gly Tyr Val His Arg Ser Val Lys Ala Ser His Ile Leu Ile Ser Val 100 105 110 Asp Gly Lys Val Tyr Leu Ser Gly Leu Arg Ser Asn Leu Ser Met Ile 115 120 125 Ser His Gly Gln Arg Gln Arg Val Val His Asp Phe Pro Lys Tyr Ser 130 135 140 Val Lys Val Leu Pro Trp Leu Ser Pro Glu Val Leu Gln Gln Asn Leu 145 150 155 160 Gln Gly Tyr Asp Ala Lys Ser Asp Ile Tyr Ser Val Gly Ile Thr Ala 165 170 175 Cys Glu Leu Ala Asn Gly His Val Pro Phe Lys Asp Met Pro Ala Thr 180 185 190 Gln Met Leu Leu Glu Lys Leu Asn Gly Thr Val Pro Cys Leu Leu Asp 195 200 205 Thr Ser Thr Ile Pro Ala Glu Glu Leu Thr Met Ser Pro Ser Arg Ser 210 215 220 Val Ala Asn Ser Gly Leu Ser Asp Ser Leu Thr Thr Ser Thr Pro Arg 225 230 235 240 Pro Ser Asn Gly Asp Ser Pro Ser His Pro Tyr His Arg Thr Phe Ser 245 250 255 Pro His Phe His His Phe Val Glu Gln Cys Leu Gln Arg Asn Pro Asp 260 265 270 Ala Arg Pro Ser Ala Ser Thr Leu Leu Asn His Ser Phe Phe Lys Gln 275 280 285 Ile Lys Arg Arg Ala Ser Glu Ala Leu Pro Glu Leu Leu Arg Pro Val 290 295 300 Thr Pro Ile Thr Asn Phe Glu Gly Ser Gln Ser Gln Asp His Ser Gly 305 310 315 320 Ile Phe Gly Leu Val Thr Asn Leu Glu Glu Leu Glu Val Asp Asp Trp 325 330 335 Glu Phe 153 546 PRT Homo sapiens 153 Met Ala Glu Pro Ser Gly Ser Val His Val Gln Leu Pro Gln Gln Ala 1 5 10 15 Ala Pro Val Thr Ala Ala Ala Ala Ala Ala Pro Ala Ala Ala Thr Ala 20 25 30 Ala Pro Ala Pro Ala Ala Pro Ala Ala Pro Ala Pro Ala Pro Ala Pro 35 40 45 Ala Pro Ala Ala Gln Ala Val Gly Trp Pro Ile Cys Arg Asp Ala Tyr 50 55 60 Glu Leu Gln Glu Val Ile Gly Ser Gly Ala Thr Ala Val Val Gln Ala 65 70 75 80 Ala Leu Cys Lys Pro Arg Gln Glu Arg Val Ala Ile Lys Arg Ile Asn 85 90 95 Leu Glu Lys Cys Gln Thr Ser Met Asp Glu Leu Leu Lys Glu Ile Gln 100 105 110 Ala Met Ser Gln Cys Ser His Pro Asn Val Val Thr Tyr Tyr Thr Ser 115 120 125 Phe Val Val Lys Asp Glu Leu Trp Leu Val Met Lys Leu Leu Ser Gly 130 135 140 Gly Ser Met Leu Asp Ile Ile Lys Tyr Ile Val Asn Arg Gly Glu His 145 150 155 160 Lys Asn Gly Val Leu Glu Glu Ala Ile Ile Ala Thr Ile Leu Lys Glu 165 170 175 Val Leu Glu Gly Leu Asp Tyr Leu His Arg Asn Gly Gln Ile His Arg 180 185 190 Asp Leu Lys Ala Gly Asn Ile Leu Leu Gly Glu Asp Gly Ser Val Gln 195 200 205 Ile Ala Asp Phe Gly Val Ser Ala Phe Leu Ala Thr Gly Gly Asp Val 210 215 220 Thr Arg Asn Lys Val Arg Lys Thr Phe Val Gly Thr Pro Cys Trp Met 225 230 235 240 Ala Pro Glu Val Met Glu Gln Val Arg Gly Tyr Asp Phe Lys Ala Asp 245 250 255 Met Trp Ser Phe Gly Ile Thr Ala Ile Glu Leu Ala Thr Gly Ala Ala 260 265 270 Pro Tyr His Lys Tyr Pro Pro Met Lys Val Leu Met Leu Thr Leu Gln 275 280 285 Asn Asp Pro Pro Thr Leu Glu Thr Gly Val Glu Asp Lys Glu Met Met 290 295 300 Lys Lys Tyr Gly Lys Ser Phe Arg Lys Leu Leu Ser Leu Cys Leu Gln 305 310 315 320 Lys Asp Pro Ser Lys Arg Pro Thr Ala Ala Glu Leu Leu Lys Cys Lys 325 330 335 Phe Phe Gln Lys Ala Lys Asn Arg Glu Tyr Leu Ile Glu Lys Leu Leu 340 345 350 Thr Arg Thr Pro Asp Ile Ala Gln Arg Ala Lys Lys Val Arg Arg Val 355 360 365 Pro Gly Ser Ser Gly His Leu His Lys Thr Glu Asp Gly Asp Trp Glu 370 375 380 Trp Ser Asp Asp Glu Met Asp Glu Lys Ser Glu Glu Gly Lys Ala Ala 385 390 395 400 Phe Ser Gln Glu Lys Ser Arg Arg Val Lys Glu Glu Asn Pro Glu Ile 405 410 415 Ala Val Ser Ala Ser Thr Ile Pro Glu Gln Ile Gln Ser Leu Ser Val 420 425 430 His Asp Ser Gln Gly Pro Pro Asn Ala Asn Glu Asp Tyr Arg Glu Ala 435 440 445 Ser Ser Cys Ala Val Asn Leu Val Leu Arg Leu Arg Asn Ser Arg Lys 450 455 460 Glu Leu Asn Asp Ile Arg Phe Glu Phe Thr Pro Gly Arg Asp Thr Ala 465 470 475 480 Asp Gly Val Ser Gln Glu Leu Phe Ser Ala Gly Leu Val Asp Gly His 485 490 495 Asp Val Val Ile Val Ala Ala Asn Leu Gln Lys Ile Val Asp Asp Pro 500 505 510 Lys Ala Leu Lys Thr Leu Thr Phe Lys Leu Ala Ser Gly Cys Asp Gly 515 520 525 Ser Glu Ile Pro Asp Glu Val Lys Leu Ile Gly Phe Ala Gln Leu Ser 530 535 540 Val Ser 545 154 966 PRT Murine sp. 154 Met Ala Phe Ala Asn Phe Arg Arg Ile Leu Arg Leu Ser Thr Phe Glu 1 5 10 15 Lys Arg Lys Ser Arg Glu Tyr Glu His Val Arg Arg Asp Leu Asp Pro 20 25 30 Asn Asp Val Trp Glu Ile Val Gly Glu Leu Gly Asp Gly Ala Phe Gly 35 40 45 Lys Val Tyr Lys Ala Lys Asn Lys Glu Thr Gly Ala Leu Ala Ala Ala 50 55 60 Lys Val Ile Glu Thr Lys Ser Glu Glu Glu Leu Glu Asp Tyr Ile Val 65 70 75 80 Glu Ile Glu Ile Leu Ala Thr Cys Asp His Pro Tyr Ile Val Lys Leu 85 90 95 Leu Gly Ala Tyr Tyr Tyr Asp Gly Lys Leu Trp Ile Met Ile Glu Phe 100 105 110 Cys Pro Gly Gly Ala Val Asp Ala Ile Met Leu Glu Leu Asp Arg Gly 115 120 125 Leu Thr Glu Pro Gln Ile Gln Val Val Cys Arg Gln Met Leu Glu Ala 130 135 140 Leu Asn Phe Leu His Gly Lys Arg Ile Ile His Arg Asp Leu Lys Ala 145 150 155 160 Gly Asn Val Leu Met Thr Leu Glu Gly Asp Ile Arg Leu Ala Asp Phe 165 170 175 Gly Val Ser Ala Lys Asn Leu Lys Thr Leu Gln Lys Arg Asp Ser Phe 180 185 190 Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Leu Cys Glu Thr 195 200 205 Met Lys Asp Ala Pro Tyr Asp Tyr Lys Ala Asp Ile Trp Ser Leu Gly 210 215 220 Ile Thr Leu Ile Glu Met Ala Gln Ile Glu Pro Pro His His Glu Leu 225 230 235 240 Asn Pro Met Arg Val Leu Leu Lys Ile Ala Lys Ser Asp Pro Pro Thr 245 250 255 Leu Leu Thr Pro Ser Lys Trp Ser Val Glu Phe Arg Asp Phe Leu Lys 260 265 270 Ile Ala Leu Asp Lys Asn Pro Glu Thr Arg Pro Ser Ala Ala Gln Leu 275 280 285 Leu Gln His Pro Phe Val Ser Arg Val Thr Ser Asn Lys Ala Leu Arg 290 295 300 Glu Leu Val Ala Glu Ala Lys Ala Glu Val Met Glu Glu Ile Glu Asp 305 310 315 320 Gly Arg Glu Asp Gly Glu Glu Glu Asp Ala Val Asp Ala Val Pro Pro 325 330 335 Leu Val Asn His Thr Gln Asp Ser Ala Asn Val Thr Gln Pro Ser Leu 340 345 350 Asp Ser Asn Lys Leu Leu Gln Asp Ser Ser Thr Pro Leu Pro Pro Ser 355 360 365 Gln Pro Gln Glu Pro Val Asn Gly Pro Cys Ser Gln Pro Ser Gly Asp 370 375 380 Gly Pro Leu Gln Thr Thr Ser Pro Ala Asp Gly Leu Ser Lys Asn Asp 385 390 395 400 Asn Asp Leu Lys Val Pro Val Pro Leu Arg Lys Ser Arg Pro Leu Ser 405 410 415 Met Asp Ala Arg Ile Gln Met Asp Glu Glu Lys Gln Ile Pro Asp Gln 420 425 430 Asp Glu Asn Pro Ser Pro Ala Ala Ser Lys Ser Gln Lys Ala Asn Gln 435 440 445 Ser Arg Pro Asn Ser Ser Ala Leu Glu Thr Leu Gly Gly Glu Ala Leu 450 455 460 Thr Asn Gly Gly Leu Glu Leu Pro Ser Ser Val Thr Pro Ser His Ser 465 470 475 480 Lys Arg Ala Ser Asp Cys Ser Asn Leu Ser Thr Ser Glu Ser Met Asp 485 490 495 Tyr Gly Thr Ser Leu Ser Ala Asp Leu Ser Leu Asn Lys Glu Thr Gly 500 505 510 Ser Leu Ser Leu Lys Gly Ser Lys Leu His Asn Lys Thr Leu Lys Arg 515 520 525 Thr Arg Arg Phe Val Val Asp Gly Val Glu Val Ser Ile Thr Thr Ser 530 535 540 Lys Ile Ile Ser Glu Asp Glu Lys Lys Asp Glu Glu Met Arg Phe Leu 545 550 555 560 Arg Arg Gln Glu Leu Arg Glu Leu Arg Leu Leu Gln Lys Glu Glu His 565 570 575 Arg Asn Gln Thr Gln Leu Ser Ser Lys His Glu Leu Gln Leu Glu Gln 580 585 590 Met His Lys Arg Phe Glu Gln Glu Ile Asn Ala Lys Lys Lys Phe Tyr 595 600 605 Asp Val Glu Leu Glu Asn Leu Glu Arg Gln Gln Lys Gln Gln Val Glu 610 615 620 Lys Met Glu Gln Asp His Ser Val Arg Arg Lys Glu Glu Ala Lys Arg 625 630 635 640 Ile Arg Leu Glu Gln Asp Arg Asp Tyr Ala Lys Phe Gln Glu Gln Leu 645 650 655 Lys Gln Met Lys Lys Glu Val Lys Ser Glu Val Glu Lys Leu Pro Arg 660 665 670 Gln Gln Arg Lys Glu Ser Met Lys Gln Lys Met Glu Glu His Ser Gln 675 680 685 Lys Lys Gln Arg Leu Asp Arg Asp Phe Val Ala Lys Gln Lys Glu Asp 690 695 700 Leu Glu Leu Ala Met Arg Lys Leu Thr Thr Glu Asn Arg Arg Glu Ile 705 710 715 720 Cys Asp Lys Glu Arg Asp Cys Leu Ser Lys Lys Gln Glu Leu Leu Arg 725 730 735 Asp Arg Glu Ala Ala Leu Trp Glu Met Glu Glu His Gln Leu Gln Glu 740 745 750 Arg His Gln Leu Val Lys Gln Gln Leu Lys Asp Gln Tyr Phe Leu Gln 755 760 765 Arg His Asp Leu Leu Arg Lys His Glu Lys Glu Arg Glu Gln Met Gln 770 775 780 Arg Tyr Asn Gln Arg Met Met Glu Gln Leu Lys Val Arg Gln Gln Gln 785 790 795 800 Glu Lys Ala Arg Leu Pro Lys Ile Gln Arg Ser Asp Gly Glu Thr Arg 805 810 815 Met Ala Met Tyr Lys Lys Ser Leu His Ile Asn Gly Ala Gly Ser Ala 820 825 830 Ser Glu Gln Arg Glu Lys Ile Lys Gln Phe Ser Gln Gln Glu Glu Lys 835 840 845 Arg Gln Lys Ala Glu Arg Leu Gln Gln Gln Gln Lys His Glu His Gln 850 855 860 Met Arg Asp Met Val Ala Gln Cys Glu Ser Asn Met Ser Glu Leu Gln 865 870 875 880 Gln Leu Gln Asn Glu Lys Cys Tyr Leu Leu Val Glu His Glu Thr Gln 885 890 895 Lys Leu Lys Ala Leu Asp Glu Ser His Asn Gln Ser Leu Lys Glu Trp 900 905 910 Arg Asp Lys Leu Arg Pro Arg Lys Lys Ala Leu Glu Glu Asp Leu Asn 915 920 925 Gln Lys Lys Arg Glu Gln Glu Met Phe Phe Lys Leu Ser Glu Glu Ala 930 935 940 Glu Pro Arg Pro Thr Thr Pro Ser Lys Ala Ser Asn Phe Phe Pro Tyr 945 950 955 960 Ser Ser Gly Asp Ala Ser 965 155 968 PRT Homo sapiens 155 Met Ala Phe Ala Asn Phe Arg Arg Ile Leu Arg Leu Ser Thr Phe Glu 1 5 10 15 Lys Arg Lys Ser Arg Glu Tyr Glu His Val Arg Arg Asp Leu Asp Pro 20 25 30 Asn Glu Val Trp Glu Ile Val Gly Glu Leu Gly Asp Gly Ala Phe Gly 35 40 45 Lys Val Tyr Lys Ala Lys Asn Lys Glu Thr Gly Ala Leu Ala Ala Ala 50 55 60 Lys Val Ile Glu Thr Lys Ser Glu Glu Glu Leu Glu Asp Tyr Ile Val 65 70 75 80 Glu Ile Glu Ile Leu Ala Thr Cys Asp His Pro Tyr Ile Val Lys Leu 85 90 95 Leu Gly Ala Tyr Tyr His Asp Gly Lys Leu Trp Ile Met Ile Glu Phe 100 105 110 Cys Pro Gly Gly Ala Val Asp Ala Ile Met Leu Glu Leu Asp Arg Gly 115 120 125 Leu Thr Glu Pro Gln Ile Gln Val Val Cys Arg Gln Met Leu Glu Ala 130 135 140 Leu Asn Phe Leu His Ser Lys Arg Ile Ile His Arg Asp Leu Lys Ala 145 150 155 160 Gly Asn Val Leu Met Thr Leu Glu Gly Asp Ile Arg Leu Ala Asp Phe 165 170 175 Gly Val Ser Ala Lys Asn Leu Lys Thr Leu Gln Lys Arg Asp Ser Phe 180 185 190 Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Val Met Cys Glu Thr 195 200 205 Met Lys Asp Thr Pro Tyr Asp Tyr Lys Ala Asp Ile Trp Ser Leu Gly 210 215 220 Ile Thr Leu Ile Glu Met Ala Gln Ile Glu Pro Pro His His Glu Leu 225 230 235 240 Asn Pro Met Arg Val Leu Leu Lys Ile Ala Lys Ser Asp Pro Pro Thr 245 250 255 Leu Leu Thr Pro Ser Lys Trp Ser Val Glu Phe Arg Asp Phe Leu Lys 260 265 270 Ile Ala Leu Asp Lys Asn Pro Glu Thr Arg Pro Ser Ala Ala Gln Leu 275 280 285 Leu Glu His Pro Phe Val Ser Ser Ile Thr Ser Asn Lys Ala Leu Arg 290 295 300 Glu Leu Val Ala Glu Ala Lys Ala Glu Val Met Glu Glu Ile Glu Asp 305 310 315 320 Gly Arg Asp Glu Gly Glu Glu Glu Asp Ala Val Asp Ala Ala Ser Thr 325 330 335 Leu Glu Asn His Thr Gln Asn Ser Ser Glu Val Ser Pro Pro Ser Leu 340 345 350 Asn Ala Asp Lys Pro Leu Glu Glu Ser Pro Ser Thr Pro Leu Ala Pro 355 360 365 Ser Gln Ser Gln Asp Ser Val Asn Glu Pro Cys Ser Gln Pro Ser Gly 370 375 380 Asp Arg Ser Leu Gln Thr Thr Ser Pro Pro Val Val Ala Pro Gly Asn 385 390 395 400 Glu Asn Gly Leu Ala Val Pro Val Pro Leu Arg Lys Ser Arg Pro Val 405 410 415 Ser Met Asp Ala Arg Ile Gln Val Ala Gln Glu Lys Gln Val Ala Glu 420 425 430 Gln Gly Gly Asp Leu Ser Pro Ala Ala Asn Arg Ser Gln Lys Ala Ser 435 440 445 Gln Ser Arg Pro Asn Ser Ser Ala Leu Glu Thr Leu Gly Gly Glu Lys 450 455 460 Leu Ala Asn Gly Ser Leu Glu Pro Pro Ala Gln Ala Ala Pro Gly Pro 465 470 475 480 Ser Lys Arg Asp Ser Asp Cys Ser Ser Leu Cys Thr Ser Glu Ser Met 485 490 495 Asp Tyr Gly Thr Asn Leu Ser Thr Asp Leu Ser Leu Asn Lys Glu Met 500 505 510 Gly Ser Leu Ser Ile Lys Asp Pro Lys Leu Tyr Lys Lys Thr Leu Lys 515 520 525 Arg Thr Arg Lys Phe Val Val Asp Gly Val Glu Val Ser Ile Thr Thr 530 535 540 Ser Lys Ile Ile Ser Glu Asp Glu Lys Lys Asp Glu Glu Met Arg Phe 545 550 555 560 Leu Arg Arg Gln Glu Leu Arg Glu Leu Arg Leu Leu Gln Lys Glu Glu 565 570 575 His Arg Asn Gln Thr Gln Leu Ser Asn Lys His Glu Leu Gln Leu Glu 580 585 590 Gln Met His Lys Arg Phe Glu Gln Glu Ile Asn Ala Lys Lys Lys Phe 595 600 605 Phe Asp Thr Glu Leu Glu Asn Leu Glu Arg Gln Gln Lys Gln Gln Val 610 615 620 Glu Lys Met Glu Gln Asp His Ala Val Arg Arg Arg Glu Glu Ala Arg 625 630 635 640 Arg Ile Arg Leu Glu Gln Asp Arg Asp Tyr Thr Arg Phe Gln Glu Gln 645 650 655 Leu Lys Leu Met Lys Lys Glu Val Lys Asn Glu Val Glu Lys Leu Pro 660 665 670 Arg Gln Gln Arg Lys Glu Ser Met Lys Gln Lys Met Glu Glu His Thr 675 680 685 Gln Lys Lys Gln Leu Leu Asp Arg Asp Phe Val Ala Lys Gln Lys Glu 690 695 700 Asp Leu Glu Leu Ala Met Lys Arg Leu Thr Thr Asp Asn Arg Arg Glu 705 710 715 720 Ile Cys Asp Lys Glu Arg Glu Cys Leu Met Lys Lys Gln Glu Leu Leu 725 730 735 Arg Asp Arg Glu Ala Ala Leu Trp Glu Met Glu Glu His Gln Leu Gln 740 745 750 Glu Arg His Gln Leu Val Lys Gln Gln Leu Lys Asp Gln Tyr Phe Leu 755 760 765 Gln Arg His Glu Leu Leu Arg Lys His Glu Lys Glu Arg Glu Gln Met 770 775 780 Gln Arg Tyr Asn Gln Arg Met Ile Glu Gln Leu Lys Val Arg Gln Gln 785 790 795 800 Gln Glu Lys Ala Arg Leu Pro Lys Ile Gln Arg Ser Glu Gly Lys Thr 805 810 815 Arg Met Ala Met Tyr Lys Lys Ser Leu His Ile Asn Gly Gly Gly Ser 820 825 830 Ala Ala Glu Gln Arg Glu Lys Ile Lys Gln Phe Ser Gln Gln Glu Glu 835 840 845 Lys Arg Gln Lys Ser Glu Arg Leu Gln Gln Gln Gln Lys His Glu Asn 850 855 860 Gln Met Arg Asp Met Leu Ala Gln Cys Glu Ser Asn Met Ser Glu Leu 865 870 875 880 Gln Gln Leu Gln Asn Glu Lys Cys His Leu Leu Val Glu His Glu Thr 885 890 895 Gln Lys Leu Lys Ala Leu Asp Glu Ser His Asn Gln Asn Leu Lys Glu 900 905 910 Trp Arg Asp Lys Leu Arg Pro Arg Lys Lys Ala Leu Glu Glu Asp Leu 915 920 925 Asn Gln Lys Lys Arg Glu Gln Glu Met Phe Phe Lys Leu Ser Glu Glu 930 935 940 Ala Glu Cys Pro Asn Pro Ser Thr Pro Ser Lys Ala Ala Lys Phe Phe 945 950 955 960 Pro Tyr Ser Ser Gly Asp Ala Ser 965 

What is claimed is:
 1. An isolated, enriched, or purified nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence that: (a) encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, or SEQ ID NO:107; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide; (d) encodes a kinase polypeptide having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, or SEQ ID NO:107, except that it lacks one or more, but not all, of the following segments of amino acid residues: 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489 or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 1-22, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (e) is the complement of the nucleotide sequence of (d); (f) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, or SEQ ID NO:107 from amino acid residues 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489 or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, or 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (g) is the complement of the nucleotide sequence of (f); (h) encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, or SEQ ID NO:107, except that it lacks one or more, but not all, of the domains selected from the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a proline-rich region, a coiled-coil structure region, and a C-terminal tail; or (i) is the complement of the nucleotide sequence of (h).
 3. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.
 4. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.
 5. The nucleic acid molecule of claim 4, wherein said mammal is a human.
 6. A nucleic acid probe for the detection of nucleic acid encoding a kinase polypeptide in a sample, wherein said polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 7. The probe of claim 6, wherein said polypeptide is a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, or SEQ ID NO:107.
 8. A recombinant cell comprising a nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 9. The cell of claim 8, wherein said polypeptide is a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, or SEQ ID NO:107.
 10. An isolated, enriched, or purified kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 11. The polypeptide of claim 10, wherein said polypeptide is a fragment of the protein encoded by the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107.
 12. The polypeptide of claim 10, wherein said polypeptide comprises: (a) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107; (b) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more, but not all, of the following segments of amino acid residues: 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489 or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 1-22, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-668, 669-872, or 873-1227 of SEQ ID NO:105, or 1-33, 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; (c) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107 from amino acid residues 1-21, 22-274, or 275-416 of SEQ ID NO:5, 1-31, 32-308, 309-489, or 490-516 of SEQ ID NO:6, 1-178 or 179-414 of SEQ ID NO:7, 23-289, 290-526, 527-640, 641-896, or 897-1239 of SEQ ID NO:13, 1-255, 256-442, 443-626, 627-954, or 955-1297 of SEQ ID NO:14, 1-255, 256-476, 477-680, 681-983, or 984-1326 of SEQ ID NO:15, 1-13, 14-273, 274-346, 347-534, or 535-894 of SEQ ID NO:18, 1-21, 22-277, 278-427, 428-637, 638-751, or 752-898 of SEQ ID NO:22, 1-66, 67-215, 216-425, 426-539, 540-786, or 787-887 of SEQ ID NO:23, 1-25, 26-273, 274-422, 423-632, or 633-748 of SEQ ID NO:24, 1-51, 52-224, 225-393, 394-658, or 659-681 of SEQ ID NO:29, 1-25, 26-281, 282-430, 431-640, 641-754, 755-901, or 902-1001 of SEQ ID NO:31, 1-10, 11-321, or 322-373 of SEQ ID NO:97, 1-57, 58-369, or 370-418 of SEQ ID NO:99, 1-52, 53-173, 174-307, 308-572, or 573-591 of SEQ ID NO:103, 1-24, 25-289, 290-397, 398-628, 629-668, 669-872, or 873-1227 of SEQ ID NO:105, or 34-294, 295-337, 338-472, 473-724, or 725-968 of SEQ ID NO:107; or (d) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:105, or SEQ ID NO:107, except that it lacks one or more, but not all, of the domains selected from the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a proline-rich region, a coiled-coil structure region, and a C-terminal tail.
 13. The kinase polypeptide of claim 10, wherein said polypeptide is isolated, purified, or enriched from a mammal.
 14. The kinase polypeptide of claim 13, wherein said mammal is a human.
 15. The kinase polypeptide of claim 10, wherein said polypeptide is a STLK2, STLK3, STLK4, STLK5, STLK6, STLK7 polypeptide.
 16. The kinase polypeptide of claim 10, wherein said polypeptide is a ZC1, ZC2, ZC3, or ZC4 polypeptide.
 17. The kinase polypeptide of claim 10, wherein said polypeptide is a KHS2 polypeptide.
 18. The kinase polypeptide of claim 10, wherein said polypeptide is a SULU1 or SULU3 polypeptide.
 19. The kinase polypeptide of claim 10, wherein said polypeptide is a GEK2 polypeptide.
 20. The kinase polypeptide of claim 10, wherein said polypeptide is a PAK4 or PAK5 polypeptide.
 21. An antibody or antibody fragment having specific binding affinity to a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5 or a kinase domain polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 22. A hybridoma which produces an antibody having specific binding affinity to a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 23. A method for identifying a substance that modulates kinase activity comprising the steps of: (a) contacting a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5 with a test substance; (b) measuring the activity of said polypeptide; and (c) determining whether said substance modulates the activity of said polypeptide.
 24. A method for identifying a substance that modulates kinase activity in a cell comprising the steps of: (a) expressing a kinase polypeptide in a cell, wherein said polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5; (b) adding a test substance to said cell; and (c) monitoring a change in cell phenotype or the interaction between said polypeptide and a natural binding partner.
 25. A method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5.
 26. The method of claim 25, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer.
 27. The method of claim 25, wherein said substance modulates kinase activity in vitro.
 28. The method of claim 27, wherein said substance is a kinase inhibitor.
 29. A method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises: (a) contacting said sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, said probe comprising the nucleic acid sequence encoding said polypeptide, fragments thereof, or the complements of said sequences and fragments; and (b) detecting the presence or amount of the probe:target region hybrid as an indication of said disease.
 30. The method of claim 29, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer.
 31. A method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises: (a) comparing a nucleic acid target region encoding said kinase polypeptide in a sample, wherein said kinase polypeptide is selected from the group consisting of STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, or one or more fragments thereof, with a control nucleic acid target region encoding said kinase polypeptide, or one or more fragments thereof; and (b) detecting differences in sequence or amount between said target region and said control target region, as an indication of said disease or disorder.
 32. The method of claim 31, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer. 